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ABSTRACT
Abstract
Background- With coronary artery disease set to become the world’s leading cause of mortality 
by 2020, there is an urgent requirement for novel treatment strategies which protect the 
myocardium against ischaemia-reperfusion injury, in order that patient morbidity and mortality 
can be improved and the global burden of this disease can be alleviated. This thesis examined 
the role of the mitochondrial permeability transition pore (mPTP) as a novel target for two major 
strategies for myocardial protection: (1) Interventions applied at the time of reperfusion, which 
protect the heart against lethal reperfusion injury, and (2) Myocardial Preconditioning, a process 
which renders the myocardium more resistant to subsequent ischaemia-reperfusion injury. 
Methods and Results- Using an isolated perfused rat model of ischaemia-reperfusion injury, 
we demonstrated that the opening of the mPTP at the time of reperfusion is a critical 
determinant of myocyte death, and we have shown that inhibiting its opening, by administering 
pharmacological agents at the time of reperfusion, is cardio-protective. Using experimental 
models for inducing and detecting mPTP opening in adult rat mitochondria and myocytes, we 
demonstrated that myocardial preconditioning protects the heart by inhibiting mPTP opening, 
and that the pro-survival kinases Akt and Erk1/2, may act to mediate the preconditioning- 
induced inhibition of mPTP opening at the time of reperfusion. Finally, we found that the mPTP 
may also act as a mediator of the preconditioning signal. In this scenario, transient (low- 
conductance) opening of the mPTP, which does not lead to cell death, may paradoxically 
contributed to protective mechanisms recruited by myocardial preconditioning and 
mitochondrial-uncoupling, indicating a dual role for the mPTP in myocardial preconditioning. 
Conclusion- We have demonstrated that inhibiting the opening of the mitochondrial 
permeability transition pore at the time of reperfusion, presents a common target for myocardial 
protection, irrespective of whether protection is mediated by myocardial preconditioning or by 
interventions applied solely at the time of reperfusion. Therefore, interventions which target and 
inhibit mPTP opening, at the time of reperfusion, may improve morbidity and mortality from 
coronary artery disease, in the clinical settings of ischaemia-reperfusion injury such as 
thrombolysis following an acute myocardial infarction, heart surgery and percutaneous 
transluminal coronary angioplasty. Furthermore, we found that transient (low-conductance) 
opening of the mPTP mediates both preconditioning and mitochondrial uncoupling-induced 
protection by acting as a channel for the mitochondrial release of reactive oxygen species.
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1.1 Coronary Artery Disease
Coronary artery disease and its many sequelae is currently the leading cause of mortality and 
morbidity in the Western World, and by the year 2020, it is poised to become the leading cause 
of mortality in the World.(1) Therefore, the magnitude of the problem and the global burden it 
imposes now and in the immediate future, necessitates a concerted research effort both in the 
areas of primary prevention and secondary p revention of coronary a rtery d isease. Ischaemic 
heart disease encompasses a continuum of disease states ranging from sub-clinical coronary 
artery disease to chronic stable angina, through to unstable angina, right up to an acute 
myocardial infarction, and its incumbent consequences such as congestive cardiac failure. 
Targeting the different stages of this disease process remains a common goal for researchers 
based in the basic laboratory as well as those in the clinical environment. Importantly, it is the 
translation of basic research findings made in the laboratory setting (the so-called ‘bench to the 
bedside’ approach), which will make the largest impact on tackling the consequences of 
coronary artery disease, in the clinical arena.
The serious and often fatal consequence of coronary artery disease culminate from the 
rupture of an unstable atherosclerotic plaque, which results in the formation of a thrombotic plug 
which occludes one of the major coronary arteries, and presents clinically as an acute 
myocardial infarction.(2;3) In this scenario, the best hope of salvaging myocardium for the two 
thirds of patients presenting with an acute myocardial infarction that make it alive to the 
hospital,(4) is the timely restoration of coronary blood flow to the ischaemic myocardium, by 
either thrombolysis or primary percutaneous transluminal coronary angioplasty (PTCA). By 
limiting the size of an evolving myocardial infarct, through the employment of these reperfusion 
strategies, the ultimate goal is to maintain and optimise left ventricular function, since it is the 
residual left ventricular function, which determines the patient’s prognosis.
Therefore, in order to realise an improvement in the mortality and morbidity of this 
disease, it is necessary to discover novel treatment strategies which provide protection to the 
myocardium from ischaemia-reperfusion injury. Treatment strategies which protect the 
myocardium from the myocyte injury that results from an acute coronary artery occlusion, can 
be broadly classified into two categories:
(1) Treatment strategies that intervene before the index ischaemic event: these are difficult to 
apply in the clinical arena, given the unpredictable onset of an acute coronary artery occlusion.
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(2) Treatment strategies which intervene after the onset of ischaemia but before or at the time 
of therapeutic reperfusion: these protect the heart against lethal reperfusion injury, and are 
easier to apply, as the onset of reperfusion is under the control of the operator. In this scenario 
the intervention can be administered as an adjunct to current reperfusion therapy.
One of the most powerful mechanisms for protecting the myocardium before the acute 
coronary artery occlusion occurs, is to ischaemically precondition the myocardium, a 
phenomenon which was first described in the seminal study by Murry and colleagues in 1986.(5) 
This manoeuvre renders the myocardium more resistant to the ensuing lethal ischaemic period, 
by inducing an innate cellular adaptation response to stress. This approach, however depends 
crucially on intervening before the ischaemic event, which is difficult, given the unpredictable 
timing of an acute coronary artery occlusion.
The restoration of coronary blood flow, following an acute coronary artery occlusion is 
essential for myocardial salvage, but paradoxically, it is also accompanied by injury to the 
myocardium, termed lethal reperfusion injury.(6) Therefore, protecting the myocardium against 
the lethal reperfusion injury, which results from opening the occluded coronary artery, offers an 
alternative clinically amenable target for cardio-protection, given that the onset of reperfusion is 
predictable, and is under the control of the operator.
This thesis explores both these mechanisms of protecting the myocardium from 
ischaemia-reperfusion injury. Despite being separated in terms of the timing of the intervention 
and the conceived mechanisms of action, these cardio-protective strategies may both converge 
on the main subject of this thesis, the mitochondrial permeability transition pore (mPTP), which 
was first described in the late 1970’s by the pioneering studies of Haworth and Hunter.(7'10) The 
mPTP is emerging as a key player in the arena of myocardial protection, and it is the aim of this 
thesis to explore its critical role in ischaemia-reperfusion injury, and to examine its contribution 
to the setting of ischaemic preconditioning.
An acute myocardial infarction is accompanied by abrupt biochemical and metabolic 
changes, which occur during the ischaemic period as well as at the time of reperfusion, when 
the occluded coronary artery is opened. An appreciation of the biochemical changes which take 
place during ischaemia-reperfusion injury provides the context for understanding the 
mechanisms involved in the cardio-protective strategies explored in this thesis.
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1.2 Myocardial Ischaemia-Reperfusion Injury
An acute coronary artery occlusion results in a critical reduction in coronary blood flow and 
deprivation of oxygen and nutrients to the affected area of myocardium, and reduces the 
clearance of waste metabolites, subjecting myocytes to the abrupt metabolic and biochemical 
changes associated with myocardial ischaemia. If blood flow is restored to the affected area by 
the removal of the coronary artery occlusion, the ischaemic myocytes are then exposed to the 
further metabolic and biochemical changes associated with the reperfusion process. The 
combined injury sustained by the myocardium during these processes is termed myocardial 
ischaemia-reperfusion injury, and the sequential metabolic and biochemical perturbations that 
occur during this process are reviewed in this section and presented diagrammatically in figure 
1.1.
Figure 1.1: The Metabolic and Biochemical Changes Which Occur During Ischaemia and 
Reperfusion. During myocardial ischaemia there is an increase in intracellular Ca2+, Ph Na+, 
reactive oxygen species (ROS), NADH, H+ and a fall in both ATP levels and the mitochondrial
membrane potential (__,*). At reperfusion there is repolarisation of th e  m and restoration of
ATP production, a further increase in Ca2+, Pj, ROS, oxidation of NADH and restoration of 
physiological pH.
Na+/Ca2+
NADH
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1.2.1 Metabolic and Biochemical Consequences of Myocardial Ischaemia
Deprivation of oxygen during ischaemia impairs oxidative phosphorylation by reducing electron 
flow through the electron transport chain, leading to an accumulation of NADH and FADH and 
cessation of ATP production^11) The m itochondrial membrane potential collapses as it is no 
longer maintained by the electrochemical gradient maintained across the inner m itochondrial 
membrane.(12) Intracellular creatine phosphate is depleted with a concomitant rise in 
intracellular Pj, resulting in mitochondria accumulating Pj.(13) Residual reserves of ATP are 
hydrolysed by FoFrATPase in an attempt to restore the mitochondrial membrane potential,(14:15) 
resulting in catalytic metabolites such as hypoxanthine which are oxidised to release free 
radicals. The activity of the adenine nucleotide translocase is reduced impairing oxidative 
phosphorylation still further.(16)
The reduced availability of ATP and oxygen drives anaerobic glycolysis which results in 
lactic acid accumulation, leading to a decrease in intracellular pH.(11) The fall in pH activates the 
Na+/H+ exchanger in an effort to remove cytosolic protons, which causes the entry of N a \ The 
Na+/K+-ATPase which normally removes excess Na+ is inhibited because of the reduced 
availability of ATP and the increase in intracellular phosphate. This causes a rise in intracellular 
Na+ which triggers the Na+/Ca2+ exchanger to function in reverse, in order to remove cytosolic 
Na+ (17)- however, this occurs at the expense of an increase in intracellular Ca2+. The rise in 
cytosolic Ca2+ results in the mitochondrial accumulation of Ca2+via the mitochondrial Na+/Ca2+ 
exchanger.(18) The onset of rigour contracture, which times with the depletion of ATP,(19) is 
followed by cellular Ca2+ overload.(20)
Therefore, following an episode of sustained myocardial ischaemia, the metabolic and 
biochemical derangements include: a low intracellular pH (<7.0), high intracellular [Ca2+] and [PJ, 
and ATP depletion (see figure 1.1). However, these conditions are drastically changed once the 
ischaemic myocardium is reperfused.
1.2.2 Metabolic and Biochemical Consequences of Myocardial Reperfusion
Reperfusion of an ischaemic myocardium has several important consequences: (1) re- 
energisation of the myocyte which causes repolarisation of the mitochondrial membrane 
potential; (2) reoxygenation of a reduced mitochondrial respiratory chain resulting in the
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production of reactive oxygen species and oxidation of NADH/FADH (3) a drop in intracellular 
Ca2+ but a further influx of Ca2+ into mitochondria via the Ca2+-uniporter driven by the recovered 
mitochondrial membrane potential;(20'22) (4) the wash-out of lactic acid, which in combination 
with the reactivation of the Na+/H+ exchanger, acts to restore a physiological pH. The changes 
which occur at the time of reperfusion are discussed in more detail in section 1.4.1 in the 
context of lethal reperfusion injury. Many of the biochemical and metabolic changes which take 
place during the first few minutes of reperfusion can mediate cell death by inducing the opening 
of the mitochondrial permeability transition pore (mPTP), which is discussed later in section 1.5.
Therefore, the ultimate aim of any cardio-protective strategy which is designed to 
protect the myocyte against the combined effect of ischaemic and reperfusion injury, is to 
preserve cellular energetic and ionic homeostasis during this insult. In this regard, by rendering 
the myocardium more resistant to the effects of ischaemia-reperfusion injury, ischaemic 
preconditioning presents a powerful cardio-protective strategy and is reviewed in the following 
section.
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1.3 Myocardial Protection by Ischaemic Preconditioning
Following the discovery in 1984, that repeated brief episodes of myocardial ischaemia did not 
produce cumulative deficits in either adenine nucleotide content(23) or contractile function,(24) 
Reimer and colleagues went on to demonstrate that four 10 minute episodes of myocardial 
ischaemia did not induce myocardial necrosis or cause a cumulative loss in ATP, when 
compared to a sustained 40 minute period of ischaemia.(25) Based on these findings, Reimer 
and colleagues embarked on a study, the findings of which would go on to make a major impact 
in the field of myocardial protection^5) In what has become a seminal study, these investigators 
demonstrated, using a canine model of ischaemia-reperfusion injury, that four 5 minute 
alternate episodes of circumflex coronary artery occlusion and reperfusion, applied before a 
sustained 40 minute occlusion, reduced infarct size to 25% of that observed in the control 
group.(5) The investigators termed this protection, ischaemic preconditioning (IPC), and 
suggested that this protective effect appeared to delay cell death, as the protective effect was 
lost if sustained ischaemia was extended to 3 hours.(5) An alternative explanation may be, that 
timely reperfusion is still a pre-requisite for limiting infarct size. They also demonstrated that IPC 
resulted in a permanent reduction in infarct size, as the protection was still present after 4 days 
of reperfusion.(5)
The clinical potential of such a powerful protective phenomenon has generated 
enormous interest in identifying the underlying intracellular signalling pathways, and has 
resulted in the publication of nearly 4000 studies over the last 17 years, leading some 
commentators to describe ischaemic preconditioning as “the strongest form of in vivo protection 
against myocardial ischemia other than early reperfusion”.(26) Despite the magnitude of this 
research effort the exact mechanism through which ischaemic preconditioning protects the 
heart against a subsequent lethal ischaemic episode is not completely understood.
Characteristics of Ischaemic Preconditioning
The phenomenon of ischaemic preconditioning exerts robust and reproducible protection and 
appears to be a ubiquitous endogenous protective mechanism that has been observed: (a) in 
the heart of every species tested, including rat,(27) mice,(28) pig,(29) rabbit,(30) ferret,(31) guinea 
pig,(32) sheep(33) and man(34); (b) at the cellular level (reviewed in reference ( 35)); (c) at the
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mitochondrial level;(36) (d) in other organs such as liver,(37) kidney,(38) gut,(39) skeletal tissue,(40) 
urinary bladder(41) and brain.(42)
The cardio-protective effect of ischaemic preconditioning disappears if the time interval 
between the preconditioning ischaemic episode and the subsequent sustained lethal ischaemic 
episode is extended beyond 3-4 hours,(43) suggesting that the protection induced by ischaemic 
preconditioning is transient. In rat hearts, 5 minutes of ischaemia is required to induce the 
preconditioning effect, whereas in the rabbit and canine hearts, 2 minutes of ischaemia may be 
sufficient to elicit a preconditioning-induced reduction in infarct size.(43) This early transient form 
of ischaemic preconditioning-induced protection has been termed classical preconditioning.
In 1993, two laboratories independently described the reappearance of preconditioning- 
induced protection in terms of a reduction in infarct size, 24 hours after the onset of the 
preconditioning stimulus, in rabbit(44) and canine(45) myocardium, a phenomenon that has been 
termed the second window of protection (SWOP) or delayed preconditioning^44)
Indicators of IPC-lnduced Protection
The original end-point used to assess the protection induced by ischaemic preconditioning was 
the reduction in infarct size.(5) However, ischaemic preconditioning has also been demonstrated 
to protect against ventricular arrhythmias,(46) and improve the recovery of post-ischaemic 
contractile function in isolated hearts.(47) Whether IPC protects against the phenomenon of 
myocardial stunning, which describes the impairment of left ventricular contractile function 
induced by a sub-lethal episode of ischaemia (usually less than 15 minutes), is unresolved 
(reviewed in reference (48)).
To aid the identification of the intracellular pathways implicated in ischaemic 
preconditioning, investigators have developed various models which simulate the phenomenon 
of ischaemic preconditioning at the tissue and cellular level. In these models ischaemia is 
simulated by: (a) subjecting the cells to hypoxia (which is achieved by either using an hypoxic 
chamber(49) or by centrifuging the cells into an ischaemic pellet and covering the cells with a 
layer of mineral oil(50:51)), or (b) by subjecting the cells to metabolic inhibition^52) By applying a 
brief episode of the simulated ischaemia prior to the period of simulated lethal ischaemia, these 
investigators have demonstrated ‘preconditioning-like’ protection, in terms of enhanced viability, 
assessed either morphologically or by measuring the reduction in staining with either propidium 
iodide or trypan blue (markers of necrotic cell death). Preconditioning has also been
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demonstrated in isolated rabbit ventricular trabeculae, in which a brief exposure of simulated 
ischaemia, reproduced by superfusing with hypoxic buffer, can protect the tissue against a 
sustained hypoxic period, as evidence by an improved recovery of contractile function.(53)
1.3.1 Classical Preconditioning
Despite on-going intensive investigation, the actual mechanism of protection associated with 
IPC remains unknown. However, the components which make up the signal transduction 
pathway involved in protection have been thoroughly explored, and will be reviewed first, 
followed by the possible mechanisms of protection that have been postulated to mediate IPC.
The signal transduction pathway can be conceptually classified into triggers (these are 
factors which act before the index ischaemic episode and activate downstream signalling 
mechanisms, and convey the ‘memory’ effect of preconditioning) or mediators/end-effectors 
(these are factors which act during or after the index ischaemic episode and mediate the 
protective effect). This separation is not rigid as certain components have been demonstrated to 
act as both triggers and mediators/effectors.
1.3.2 Triggers of Classical Preconditioning
1.3.2.1 G-Protein Coupled Receptor Ligands
In 1991, Downey’s group examined the role of adenosine, which is generated during myocardial 
ischaemia from the hydrolysis of ATP, as a potential trigger of preconditioning^30) They 
demonstrated that the protection associated with IPC could be abolished by the pre-treatment of 
an adenosine antagonist, and that a 5 minute intra-coronary infusion of adenosine followed by 
10 minutes of wash-out, could reproduce IPC-induced protection^30) The important implications 
from these findings included: (1) IPC-induced protection could be mimicked by pharmacological 
agents, with these agents acting as triggers of preconditioning (so-called pharmacological 
preconditioning); and (2) the endogenous activation of a G-protein coupled receptor (GPCR), 
was an essential component of IPC-induced protection , that is IPC was a receptor-mediated 
phenomenon.
Several studies followed, providing support for the involvement of GPCR activation as 
an essential trigger of preconditioning-induced protection, using other ligands, such as
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bradykinin^5* 55) opioids,(56) acetylcholine,(57) catecholamines,(58) angiotensin II,(59) and 
endothelin-1 ,(60) some of which are released by the heart during ischaemia.
Interestingly, Goto and colleagues(55) demonstrated that, pharmacologically blocking 
the bradykinin receptor could abrogate protection from a single cycle of preconditioning but not
from m ultiple cycles, suggesting that ischaemic preconditioning via the GPCR, was a highly
redundant phenomenon. Therefore, the blockade of a single receptor type served only to raise 
the ischaemic threshold required to trigger protection, rather than completely blocking it.(55) The 
simultaneous activation of these GPCR’s during brief ischaemia-reperfusion suggested that the 
preconditioning signal converged on a downstream target. Protein kinase C (PKC) was 
proposed to be the downstream target, based on the finding that: (a) PKC was phosphorylated 
by the activation of the GPCR’s; (58;59) and (b) that the protection associated with bradykinin,(55) 
adenosine,(61) and opioids,(62) could aII be blocked by PKC inhibitors. The role of PKC as a 
mediator of preconditioning is reviewed later in section 1.3.3.1. PKC has also been 
demonstrated to be a downstream target of reactive oxygen species (ROS),(63) a non-receptor 
trigger of preconditioning which is reviewed in the next section.
1.3.2.2 Reactive Oxygen Species
Reactive oxygen species (ROS), when present in low concentrations, in contrast to higher 
concentrations which are pro-injurious, can modify cellular activities and participate in cell 
signalling (reviewed in reference (*)). In 1988, Murry and colleagues(65) first demonstrated that 
antioxidants could abolish the preconditioning effect, implicating for the first time a role for ROS 
as a trigger of preconditioning, a finding which was later supported by several studies,(63:66:67) 
but not all.(68'70) The disparity in findings between these studies has been attributed to the type 
of antioxidant and the number of preconditioning cycles used in the different studies.(63)
Tritto and colleagues(71) were the first to demonstrate directly, that a low dose of ROS 
could act as a preconditioning trigger and mimic IPC-induced protection. Subsequently, Vanden 
Hoek and colleagues(49) demonstrated, using chick neonatal myocytes, that hypoxic 
preconditioning produced a burst of ROS (mainly H20 2), as measured by dichlorofluorescin 
fluorescence, from complex III of the mitochondrial electron transport chain, which appeared to 
exit mitochondria via the inner membrane anion channel (IMAC). The mechanism by which 
preconditioning results in the mitochondrial generation of ROS is unclear but recent studies
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implicate the involvement of the mitochondrial ATP-sensitive K + (K At p ) channel (see section 
1.3.2.4).(72*74)
Once released into the cytosol, mitochondrial-derived ROS are believed to activate 
protein kinases such as PKC,(63) Erk1/2,(75) p38 MAPK,(76) which then act as mediators of the 
preconditioning signal (see section 1.3.3). The modulation of ROS production at the time of 
reperfusion in IPC also implicates ROS as a potential end-effector of IPC-induced protection, in 
addition to its proposed role as a trigger of preconditioning (see section 1.3.4.4).(77'79)
The actual intracellular pathway through which an IPC stimulus received at the cell 
membrane results in the mitochondrial release of ROS is also unclear, although the activation of 
the phosphatidyl inositol 3-OH kinase (PI3K)-Akt cascade has been implicated.(80)
1.3.2.3 The PI3K-Akt Kinase Cascade
Recent studies have implicated signalling through the pro-survival, phosphatidyl inositol 3-OH 
kinase (PI3K)-Akt cascade, during the preconditioning phase before the index ischaemic 
episode, in IPC-induced protection. Tong and colleagues(81) were the first to demonstrate that 
IPC activates the PI3K-Akt kinase cascades prior to the index ischaemic episode, and they 
showed that inhibiting Akt activity, using the PI3K inhibitor, wortmannin, abolished IPC-induced 
protection, using the recovery of function as the end-point. Yellon’s group(82) confirmed these 
findings in the isolated perfused rat heart infarct model. Interestingly, an earlier study by Baines 
and colleagues,(83) had demonstrated that insulin-induced preconditioning also required the 
activation of the PI3K-Akt kinase cascade prior to the index ischaemic episode.
Activation of the GPCR by the preconditioning mimetic, acetylcholine, has been 
demonstrated to activate the PI3K-Akt kinase cascade prior to the index ischaemic period, 
suggesting that the GPCR may be the upstream activator of the PI3K-Akt kinase cascade, in 
the setting of IPC.(74:80:84) Activation of the PI3K-Akt kinase was demonstrated to occur via the 
activation of Src tyrosine kinase and the epidermal growth factor receptor.(85)
Tong and colleagues(86) have demonstrated that signalling through the PI3K-Akt kinase 
cascade results in the phosphorylation and inactivation of glycogen synthase kinase 3p, an 
enzyme originally identified for its role in regulating glycogen synthesis in response to 
insulin.(87;88) Inactivation of this enzyme has been demonstrated to reduce apoptosis and 
enhance cell survival.(89) The anti-apoptotic effects of the PI3K-Akt kinase cascades are
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described in more detail in the context of protecting the heart against lethal reperfusion injury 
(see section 1.4.3.2).
Downey’s laboratory(74:80) have implicated the PI3K-Akt signalling cascade as a trigger 
of preconditioning, such that it relays the preconditioning signal from the GPCR at the cell 
membrane to the mitochondrial K At p  channel, where the opening of the latter mediates the 
mitochondrial release of ROS. The intracellular signalling pathway through which the activation 
of the PI3K-Akt kinase cascade results in the opening of the mitochondrial K At p  channel is not 
clear although nitric oxide has been implicated (see section 1.3.2.4.b).(90) Interestingly, insulin- 
mediated recruitment of the PI3K-Akt did not appear to signal to the mitochondrial KATP channel 
or PKC, suggesting an alternative pathway of protection in this setting.(83)
Many of these trigger mechanisms converge on the mitochondria, and they appear to 
target the mitochondrial K ATp  channel in particular, which is reviewed in the next section.
1.3.2.4 The KATP Channel and Cardio-Protection
The role of the KATP channel in ischaemic preconditioning-induced protection has had an 
interesting and often controversial history. In 1983, Noma first identified an ATP-sensitive 
potassium (K ATp ) channel in isolated guinea pig ventricular myocytes.(91) In this landmark 
discovery, Noma hypothesised that the opening of this channel in response to hypoxia or 
ischaemia, would protect the heart by enhancing the shortening of the action potential duration 
(APD), thereby providing a repolarising K+ current, the effect of which would be to reduce 
cellular Ca2+ loading during ischaemia-reperfusion.(91) Cole and colleagues(92) provided the 
evidence for this proposition, by demonstrating that glibenclamide (a non-specific KATP channel 
blocker) attenuated the ADP shortening observed during ischaemia, and that pinacidil (a K ATp 
channel opener) accelerated ADP shortening and improved myocardial recovery in function, 
following ischaemia-reperfusion.
The Katp channel has been shown to comprise an octomeric complex consisting of four 
Kir (an inwardly-rectifying K+ channel) subunits and four SUR (sulphonylurea receptor) 
subunits.(93,94) The Kir forms the K+ conductance pore of the channel and the SUR confers the 
channel’s sensitivity to ATP and sulphonylureas, and is a member of the ATP-binding cassette 
protein family (ABC family).(93:94) Currently it is believed that Kir6.2 and SUR2 make up the 
sarcolemmal KATP channel.(93)
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Gross and colleagues(95:96) were the first to link the opening of the K Atp  channel with 
IPC-induced protection, from studies in which they demonstrated that IPC-induced protection 
could be abolished by the K ATp channel blockers, glibenclamide or 5-hydroxydecanoic acid (5- 
HD). At this time, IPC-induced protection in this setting was attributed to APD shortening.(97'99) 
However, from 1994, several studies appeared which suggested that the cardio-protection 
associated with K ATP channel opening was independent of APD shortening,(100:101) a finding 
which appeared to also apply to IPC-induced protection^50) This suggested that the 
sarcolemmal K ATp channel may not be responsible for the cardio-protection associated with K ATP 
channel openers and IPC, which resulted in the hunt for an intracellular site of protection, which 
culminated in the identification and characterisation of a K ATP channel in the mitochondrial inner 
membrane, the source of much interest and controversy in the field of cardio-protection.
1.3.2.4.a The Mitochondrial KA TP channel and Cardio-Protection
The existence of an ATP-sensitive potassium channel in the mitochondrial membrane was first 
suggested by Inoue and colleagues in 1991 ,(102) In patch-clamp experiments of giant mitoplasts, 
fused from rat liver mitochondria, they demonstrated a K+-selective channel sensitive to ATP, 
glibenclamide and 4-aminopyridine.(102) Garlid’s group then purified from the inner mitochondrial 
membranes of rat liver and bovine heart mitochondria, a fraction containing mitochondrial KATP 
channel activity, and found that this channel shared some pharmacological properties with the 
sarcolemmal KATP channel, while possessing a distinct profile.(103)
In 1997, Garlid’s group first demonstrated a role for the mitochondrial KATP channel in 
cardio-protection.(104) In that study, inner mitochondrial membrane proteins comprising the 
mitochondrial KATP channel were reconstituted into proteoliposomes and were demonstrated to 
be 2000 times m ore sensitive to diazoxide, than the sarcolemmal KATP channel, in terms of 
inducing a K+ current.(104) Furthermore, at concentrations (30-100 pmol/l) that did not activate 
the sarcolemmal KATP channel or shorten the APD, diazoxide was demonstrated to cardio- 
protect the isolated perfused rat heart subjected to ischaemia-reperfusion, as evidenced by an 
improvement in the recovery of left ventricular contractile function and attenuated lactate 
dehydrogenase (LDH) release.(104) The effects of diazoxide were blocked by the non-specific 
Katp channel blocker, glibenclamide (with a Kj of 1-6 pmol/l) and 5-hydroxydecanoic acid (with a 
Kj of 45-85 pmol/l),(104) which is believed to be a mitochondrial KATP channel specific blocker,(104' 
106) although this has recently been disputed (see section 1.3.2.4.d).(107)
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In the same year, Marban’s group(108) provided further evidence for the role of the 
mitochondrial K At p  channel in cardio-protection, using rabbit ventricular myocytes, in which 
diazoxide (at 100 pmol/l) was demonstrated to: (1) induce a reversible increase in flavoprotein 
oxidation which was considered an indirect indicator of mitochondrial K At p  channel opening, 
based on the premise that the opening of the mitochondrial KATP channel induces flavoprotein 
oxidation through mitochondrial uncoupling of oxidative phosphorylation. This effect of diazoxide 
was blocked by 5 -HD using a concentration of 500 pmol/l but not at 1 00 pmol/l, which is in 
contrast to the study by Garlid’s group, in which the Kj of 5HD was demonstrated to be 45-85 
pmol/l;(104) (2) protect the myocytes against simulated ischaemia-reperfusion injury; and (3) not 
induce opening of the sarcolemmal KATP channel.(108) However, Standen’s group(109) who were 
able to demonstrate cardio-protection in rat ventricular myocytes subjected to simulated 
ischaemia-reperfusion, were unable to reproduce the flavoprotein oxidation and mitochondrial 
membrane depolarisation induced by diazoxide, as observed by Marban’s group.(108) It has now 
transpired, that to demonstrate the flavoprotein oxidation in response to diazoxide, the cells had 
been kept overnight in substrate-free medium, which would have de-energised them, allowing 
diazoxide to exert an uncoupling effect.(110) The flavoprotein oxidation induced by diazoxide 
may also be d ue t o i n p art t o a n on-specific e ffect o f t his d rug o n m itochondrial r espiration, 
which occurs independently of the mitochondrial KATP channel, an issue which is discussed in 
section 1.3.2.4.d.
Because of the studies demonstrating that IPC-induced protection was sensitive to 5- 
HD, a presumed mitochondrial KATP channel blocker, and because of the studies demonstrating 
that opening of the mitochondrial KATP channel mediated cardio-protection,(104;108) the next aim 
was to determine the role of the mitochondrial KATP channel in IPC-induced protection.
1.3.2.4.b The Mitochondrial KATP Channel as a Trigger of Preconditioning 
The mitochondrial KATP channel was originally proposed to be the end-effector of IPC-induced 
protection^104’108) and this aspect is discussed in section 1.3.4.3, along with the possible 
mechanisms through which opening of the mitochondrial KATP channel is believed to mediate 
protection.
The role of the mitochondrial KATP channel as a trigger of preconditioning is a relatively 
recent development, first proposed by Downey’s group.(72) They and others(72;11i) have 
demonstrated that the transient opening of the mitochondrial KATP channel (for 5 minutes
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followed by wash-out of the drug) could induce a preconditioned state for up to 30 minutes, after 
the application of the drug. They next demonstrated that both IPC and diazoxide-induced 
protection could only be abrogated if the K At p  channel blockers were administered early to 
bracket the preconditioning stimulus.(72) If the K At p  channel blockers were given late, that is 
after the preconditioning stimulus but prior to the index ischaemic period, both IPC and 
diazoxide-induced protection was maintained, suggesting that the opening of the mitochondrial 
K a tp  channel was acting as a trigger of preconditioning, or in other words it was inducing the 
‘memory effect’ associated with IPC.(72) The role of the mitochondrial KATP channel as a 
preconditioning trigger has been questioned by several investigators who have proposed that 
the mitochondrial K ATp  channel may act as both a trigger and mediator/end-effector of 
preconditioning^112'115)
The Relationship Between the Mitochondrial KATP Channel and ROS
Early studies had implicated ROS as a potential trigger of preconditioning (65_67;71) and complex 
III of the mitochondrial electron transport chain had been demonstrated to be the source of the 
ROS generated in response to a preconditioning stimulus (see section 1 .3.2.2).(49;90) Forbes 
and colleagues(116) were the first to link mitochondrial ROS release with diazoxide-induced 
protection, thereby implicating the mitochondrial KATP channel in this scheme. They 
demonstrated in adult rat myocytes that the protection induced by diazoxide against hypoxia- 
reoxygenation injury, was dependent on mitochondrial ROS production, assessed using 
dichlorofluorescin fluorescence.(116) This effect of diazoxide was abolished in the presence of 
the mitochondrial KATP channel blocker, 5-HD, and the free radical scavengers, N-acetylcysteine 
or N-mercaptopropionylglycine.(116) In this paradigm, the opening of the mitochondrial KATP 
channel results in the production of ROS from the electron transport chain, which are released 
into the cytosol, where they activate downstream mediators of the preconditioning signal such 
as PKC.(49:117'119)
However, a recent study has demonstrated that the opening of the mitochondrial KATP 
channel using diazoxide may actually reduce ROS production prior to the index ischaemic 
period, which is in direct contrast to the findings of studies implicating a trigger role for ROS in 
preconditioning^120) However, this study was conducted on isolated mitochondria, whereas the 
studies demonstrating the production of ROS with diazoxide were undertaken in myocytes, 
which may explain the disparity in findings. In another study, again using isolated mitochondria,
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Terzic’s group demonstrated that diazoxide reduced mitochondrial ROS release from complex II 
of the electron transport chain.(121)
Downey’s group,(73:74:84:85:90) have extensively studied the signal transduction pathways 
that mediate the preconditioning stimulus applied at the GPCR to the mitochondrial K Atp  
channel (figure 1.2 is a cartoon representation of their current working model). They and others 
have demonstrated that the activation of the GPCR, using either acetylcholine, opioids, 
bradykinin or noradrenaline opens the mitochondrial K At p  channel and generates mitochondrial 
ROS.(73:9°) Activation o f t he G PCR h as b een d emonstrated t o activate t he e pidermal g rowth 
factor receptor (EGFR),(85) via a matrix metalloproteinase. The EGFR in conjunction with Src 
tyrosine kinase,(74:84;85) then activates the PI3K-Akt pathway.(74:80:85) Activation of Akt then 
phosphorylates and activates endothelial nitric oxide synthase (eNOS),(90) which activates 
guanylate cyclase,(90) via nitric oxide. Guanylate cyclase then activates protein kinase G 
(PKG),(90) via (cyclic guanine-5-monophosphate) cGMP. Finally, PKG via some unknown 
mechanism opens the mitochondrial KATP channel,(90) which results in the mitochondrial release 
of ROS that then activate the mediators of preconditioning such as PKC (see figure 1.2).
The requirement for nitric oxide (NO) as a trigger in classical preconditioning suggested 
by the scheme in figure 1.2 is controversial with some studies demonstrating a role for NO(122'124) 
but others do not, including a study by Downey’s own group.(125) The discrepancy has been 
attributed to the concentration of N w-nitro-L-arginine methyl ester (L-NAME, the nitric oxide 
synthase inhibitor) used in the different models.(90)
Interestingly, the activation of the GPCR by adenosine has been demonstrated by 
Downey’s group, to not signal through this pathway but appears to activate PKC directly without 
the requirement for either PI3K-Akt pathway, the mitochondrial KATP channel or ROS,(73:126) 
although this is in contradiction to a study by the same group which did implicate the PI3K-Akt 
pathway in adenosine-induced protection^85)
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Figure 1.2: The Signal Transduction Pathway Recruited by Preconditioning Triggers 
Which Act Via the GPCR: Activation of the G-protein coupled receptor (GPCR) leads to the 
trans-activation of the epidermal growth factor receptor (EGRF), which then activates the PI3K- 
Akt pathway in an Src kinase dependent manner. Signalling through the PI3K-Akt pathway 
results in the phosphorylation and activation of endothelial nitric oxide synthase (eNOS) which 
then activates guanylate cyclase (GC) via nitric oxide (NO). Guanylate cyclase then activates 
protein kinase G (PKG) via cyclic guanine-5-monophosphate (cGMP). PKG is then postulated to 
open the mitochondrial K Atp  channel (m K ATp) via an unknown mechanism. Opening of the 
mKATp channel then results in the mitochondrial release, possibly via the inner membrane anion 
channel (IMAC), of reactive oxygen species (ROS), generated from the electron transport chain 
(ETC), which then activate the mediators of preconditioning.
Acetylcholine, Bradykinin, 
Opioids, Noradrenaline
f  cGMP
Extracellular
nmmmmnmmmmmm
Intracellular
Mediators of Preconditioning 
such as PKC, p38 MAPK, Erk1/2
PROTECTION
Mitochondria
Upstream Activators of the Mitochondrial K a t p  Channel
The hypothetical scheme, recently proposed by Downey’s group, which is depicted in figure 1.2, 
postulates that PKG may act as the upstream activator of the mitochondrial IWp channel^90) In 
support of this proposition, Han and colleagues(127) demonstrated that the guanylyl cyclase- 
cGMP-PKG pathway could phosphorylate the sarcolemmal K ATp channel, and Marban’s 
group(128) have reported that nitric oxide can open the mitochondrial KaTP channel, using 
flavoprotein oxidation in rabbit myocytes, to indicate channel opening.
Evidence from previous studies have postulated that PKC may be responsible for 
regulating the mitochondrial Katp channel in IPC.(129;13°) The role of PKC in the setting of IPC is 
reviewed in section 1.3.3.1.
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Interestingly, Lebuffe and colleagues(124) have recently demonstrated that ROS may 
contribute a t m ultiple s teps d uring the preconditioning p hase, b y a ctivating t he mitochondrial 
K a tp  channel, as well as being generated as a consequence of mitochondrial K At p  channel 
opening. In support of this finding, an earlier study by Zhang and colleagues(131) had 
demonstrated superoxide activation of bovine heart mitochondrial K At p  channels reconstituted 
into planar lipid bilayers.
How Does Mitochondrial KATP Channel Opening Generate Mitochondrial ROS?
The mechanism through which the opening of the mitochondrial KATP channel using diazoxide or 
pinacidil generates mitochondrial ROS in unclear but several mechanisms have been proposed:
(1) Garlid’s laboratory(110;132) have proposed that the opening of the mitochondrial K ATp channel 
causes K+ influx into the mitochondrial matrix coupled with H+ efflux out of the mitochondria. The 
increase in matrix pH is accompanied by the influx of anions such as Pj, but because of the 
relatively low cytosolic concentration of Pj, the net effect of K+ influx into the mitochondrial matrix 
on opening of the mitochondrial KATP channel is matrix alkanisation.(132) In separate 
experiments, Garlid’s group have demonstrated in isolated mitochondria that matrix alkanisation 
can increase ROS production^133) However, it has not been demonstrated directly that opening 
of the mitochondrial KATP channel generates mitochondrial ROS via causing matrix alkanisation.
(2) Inhibition of mitochondrial respiration generates ROS from the electron transport chain 
(ETC).(134) During the brief ischaemic episode of an IPC stimulus one may expect that the 
transient inhibition of the ETC that occurs may be sufficient to generate ROS. Furthermore, the 
short reperfusion period that is required as part of the IPC-stimulus, may be expected to further 
produce ROS, by re-oxygenating a mildly inhibited ETC. In this regard, it is interesting to note 
that some of the pharmacological preconditioning agents such as diazoxide and pinacidil that 
are believed to generate ROS via the opening of the mitochondrial KATP channel, can inhibit the 
ETC at complex II.(78;135;136) Therefore, the wash-out of the preconditioning agent (which forms 
part of the experimental protocol when using these drugs) could potentially release the inhibitory 
effect on the ETC, and generate ROS, without invoking the opening of the mitochondrial KATP 
channel. This issue is discussed in section 1.3.2.4.d, which addresses some of the 
controversies surrounding the mitochondrial KATP channel, which have arisen from not knowing 
the molecular identity of the channel.
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1.3.2.4.C The Identity of the Mitochondrial KA TP Channel
Despite being described nearly 14 years ago,(102) and despite being thoroughly characterised 
by Garlid’s group,(103:132:137'139) the molecular composition of the mitochondrial K At p  channel 
remains unknown. Because the cardiac sarcolemmal K At p  channel was demonstrated to 
comprise the Kir6.2 (about 40 kDa) and SUR2A (about 140 kDa) subunits,(93;14°) the initial 
attempts at identifying the mitochondrial KATP channel were aimed at detecting Kir or SUR 
subunits within mitochondrial membranes. Suzuki and colleagues(141) demonstrated that 
mitochondria immuno-stained with antibodies, that had been generated to bind to part of the 
Kir6.1 subunit. However, evidence from Garlid’s group(142) found that this antibody did not react 
with any protein in the reconstitutively active purified fraction of the mitochondrial KATP channel. 
Furthermore, Marban’s group(143) demonstrated that rabbit myocytes with dominant negative 
constructs of Kir6.1 and Kir6.2, still possessed mitochondrial KATP channel activity as 
determined by changes in flavoprotein oxidation. Binding studies have failed to identify a 
conventional SUR within mitochondrial membranes, suggesting instead that mitochondrial SUR 
may be smaller proteins ranging from 28 to 63 kDa in size.(142:144) Garlid’s group(142) have 
identified a 55 kD channel protein (which they have termed mitoKir) and a 63 kDa sulphonylurea 
receptor (which they have termed mitoSUR) as potential components of the mitochondrial KATP 
channel. They(142) have postulated that the 63 kDa protein, may turn out to be an half ABC 
protein, called mitochondrial ATP binding cassette protein-2 (M-ABC2), which has been 
identified in mitochondrial membranes and proposed to be part of the mitochondrial K ATp 
channel.(145)
Recently, Marban’s group(146) have proposed a new model for the mitochondrial KATP 
channel, using a novel approach to identifying its components. Based on the premise that 
diazoxide, an opener of the mitochondrial KATP channel, also inhibits succinate dehydrogenase 
(SDH), using pull-down columns they determined which mitochondrial membrane proteins were 
complexed to SDH.(146) Interestingly, they identified adenine nucleotide translocase (ANT), an 
ATPase, M-ABC1 and a phosphate carrier. They demonstrated that K+ fluxes through this 
complex were regulated by diazoxide and 5-HD. However, they could not identify which of these 
components formed the K+ conductance pore. Interestingly, the ANT has also been proposed to 
form part of the mitochondrial permeability transition pore (mPTP), discussed in section 1.5. It is 
intriguing to speculate on the possibility that the mPTP may be masquerading as the 
mitochondrial KATP channel. Against the ANT forming the K+ conductance pore of this new
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proposed model of the mitochondrial KATP channel, the complex was demonstrated to be 
insensitive to atractyloside, which would have been expected to change the ANT into a pore- 
forming configuration, if the ANT had been responsible for the K+ conductance property.(146)
To add to the confusion over the identity of the mitochondrial K At p  channel, Brian 
O’Rourke’s group(147) have recently identified a Ca2+-activated K+ channel in cardiac inner 
mitochondrial membrane that can mediate protection against ischaemia-reperfusion injury.
Therefore, because the molecular composition of the m itochondrial KATP channel still 
remains unknown, the evidence concerning its existence and actions have been inferred by the 
pharmacological manipulation of the channel using agents such as diazoxide and 5-HD, which 
not surprisingly has generated the controversy surrounding the channel’s actual existence, a 
subject which is reviewed in the next section.
1.3.2.4.d The Controversies Surrounding the MitochondriaI KATP Channel 
The Non-Specific Effects of Drugs Used to Investigate the Mitochondrial KATP Channel 
The controversies that surround the mitochondrial KATP channel relate to the fact that the 
molecular identity of the mitochondrial KATP channel is unknown. Therefore, the existence of the 
channel can only in the most part be inferred by the presumed actions of pharmacological 
agents on the channel. However, these drugs, which include diazoxide, pinacidil and 5- 
hydroxydecanoic acid have been demonstrated to exert effects on mitochondria, independent of 
their effect on the mitochondrial KATP channel, which may in part explain their capacity to 
influence IPC-induced protection.
For example, diazoxide and 5-hydroxydecanoic acid (5-HD) have been demonstrated to 
be a specific opener and blocker of the mitochondrial KATP channel, respectively.(104:106:108:138) 
However, diazoxide has been demonstrated to inhibit succinate dehydrogenase, which forms 
part of the FADH-linked electron transport carrier | |(107;121;135;136;148:149) ancj may induce cardio- 
protection i ndependent of the m itochondrial KATP channel.(78;15°) Terzic’s g roup d emonstrated 
that diazoxide inhibits SDH with an IC50 of 32 pmol/l.(121) Inhibition of SDH could also account 
for the observed flavoprotein oxidation observed with diazoxide by Marban’s group.(108)
These studies would suggest that the inhibition of the ETC may induce preconditioning­
like protection. Interestingly, Kukreja’s group(151) showed that inhibiting SDH, using low dose 3- 
nitropropionic acid (3-NPA, an irreversible inhibitor of SDH), protected in vivo rabbit hearts from 
infarction, an effect abolished by 5-HD. This study demonstrated that inhibiting SDH directly
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could mediate cardio-protection, a finding supported by Terzic’s group,(78) who demonstrated 
that the SDH inhibitor, malonate, could mimic the protective effect induced by either diazoxide 
or nicorandil against ischaemia-reperfusion injury. Furthermore, they demonstrated that the K+ 
ionophore, valinomycin could also mimic protection, suggesting that a non-specific K+ 
conductance was sufficient to induce preconditioning-like protection^78) In neuronal tissue, 
chemical preconditioning using 3-NPA has been demonstrated in several studies to be neuro- 
protective.(152*156)
The mechanism by which the inhibition of SDH induces cardio-protection may be via 
mitochondrial ROS release, which may then mediate the protection observed with these 
preconditioning m imetics ( see s ection 1.3.2.2). In t his r egard, t he S DH i nhibitor, 3 -NPA, h as 
been shown to induce a burst of free radicals, albeit in cerebral tissue.(157)
In addition, pinacidil, another cardio-protective agent was demonstrated to inhibit NADH 
oxidation.(107) Hanley and colleagues also demonstrated that 5-HD, the presumed archetypal 
mitochondrial K At p  channel blocker, is converted to 5-HD-CoA, the (3-metabolites of which can 
cause metabolic effects which can antagonize the beneficial effects of preconditioning.(107:149;158) 
This may provide a mitochondrial KATP channel-independent mechanism by which 5-HD 
antagonises the effects of diazoxide and pinacidil, suggesting that these drugs can modify IPC- 
induced protection independent of the mitochondrial KATP channel.
The Method for Detecting Mitochondrial Swelling
Another controversial issue is the effect of diazoxide and 5-HD on mitochondrial matrix volume 
as assessed by light scattering. Garlid’s group(159;16°) have demonstrated that diazoxide-induces 
an ATP-sensitive decrease in light scattering, indicating mitochondrial matrix swelling secondary 
to a K+ influx. However, Halestrap’s group(161) were unable to demonstrate a diazoxide or 5-HD 
induced change in mitochondrial matrix volume, by measuring light scattering. Instead they 
attributed the changes in light scattering observed by Garlid’s group on ATP/ADP-induced 
conformational changes in mitochondria rather than changes in volume. Therefore, both groups 
agree that diazoxide induces a K+-dependent increase in mitochondrial matrix volume, but the 
dispute revolves around the technique used for demonstrating this increase, and whether the 
mitochondrial matrix expansion is mediated by an ATP-sensitive K+ channel or not.(149;159'161)
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1.3.2.4.d The Renaissance of the Sarcolemmal KATP Channel
While various laboratories continue to debate the role of the mitochondrial K At p  channel in 
ischaemic preconditioning, several other groups have been re-investigating the role of the 
sarcolemmal K At p  channel as a component of preconditioning-induced protection. The 
contribution of this channel to ischaemic preconditioning had been more or less overlooked 
since its mitochondrial counterpart entered the scene in 1997>(104,108) and it was demonstrated 
that agents which opened cardiac KATP channels were able to protect the heart without affecting 
the aPD.(50:100:101)
However, several studies have been published demonstrating that the protection 
associated with opening of the sarcolemmal K ATp  channel was dependent on APD 
shortening.(97‘" )  Terzic’s group(162;163) have demonstrated that transfection of KATp-deficient 
cells with Kir6.2/SUR2A (components of the sarcolemmal K ATp  channel) genes resulted in a 
pinacidil sensitive K+ current and mediated protection against hypoxia-reoxygenation injury, 
implicating a role for the sarcolemmal K ATp  channel in cardio-protection.
A recent study published in 2002 by Suzuki and colleagues(164) provides strong 
evidence that the sarcolemmal K ATp  channel is important for IPC-induced protection. Using 
transgenic mice lacking Kir6.2 (a component of the sarcolemmal KATP channel), these 
investigators failed to demonstrate a reduction in infarct size with IPC.(164) However, the fast- 
beating murine heart is likely to be more sensitive to changes in APD when compared to other 
animal models. Rajasharee and colleagues(165) demonstrated that isolated perfused murine 
hearts, taken from mice expressing a mutant Kir6.2 subunit, were insensitive to IPC, using 
protection against myocardial stunning as the end-point. However, in the isolated perfused heart, 
IPC may reduce infarct size without improving the recovery of contractile function.(166)
A further study by the same group demonstrated that diazoxide had no protective effect 
against myocardial stunning in transgenic mice lacking Kir6.2, and that the diazoxide-induced 
protection provided in wild-type mice was associated with APD shortening and was blocked by 
HMR1098 (the specific sarcolemmal K ATp  channel blocker), but not 5-HD (a presumed 
mitochondrial K ATp  channel blocker).(167) A recent study by Terzic’s group(168) demonstrated that 
the inability to ischaemically precondition the hearts from Kir6.2-knockout mice was related to 
the critical role the sarcolemmal KATP channel plays in mediating preservation of myocardial 
energetics during ischaemia-reperfusion.
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Therefore, these recent studies add further confusion to the role of K Atp  channels in IPC, 
and suggest a role for the sarcolemmal K At p  channel in IPC-induced protection. This confusion 
is compounded by studies suggesting that both channel types may be involved in IPC.(169'171)
1.3.3 Mediators (Signal Transduction) of Classical Preconditioning
1.3.3.1 Protein Kinase C
Studies by Ytrehus and colleagues in the rabbit,(172) and Yellon’s group in the rat,(173) were the 
first to demonstrate that the activation of protein kinase C (PKC) was required for IPC-induced 
protection, using PKC analogues such as phorbol 12-myristate 13-acetate, and diacylglycerol to 
induce protection. PKC is a serine/threonine kinases of which there are 12 isoforms divided into 
3 groups: conventional (a, pi, pNand y), novel (5, e, q, 9) and atypical (£, i, A, p).(174)
Later studies demonstrated that PKC was a downstream element of the signal 
transduction p athway of p reconditioning, s ince t he p rotection a ssociated with p reconditioning 
triggers such as bradykinin,(55) adenosine,(61) opioids,(62) and ROS,(63) could all be blocked by 
PKC inhibitors. Furthermore, the redundancy effect observed with the GPCR ligands in 
mediating IPC-induced protection could be correlated to the extent of kinase activity of PKC.(55) 
Activation of PKC requires the translocation from the cytosol to the particulate fraction 
which includes the membranes and cytoskeleton. Translocation is dependent on isoform- 
specific binding of PKC to receptors of activated C kinase (RACKs).(175:176) Localisation of the 
isozyme specific PKC-RACK complex can determine different cellular functions. It has been 
demonstrated that IPC induces the translocation of PKC-5 and PKC-e in rats hearts.(177'179) Ping 
and colleagues demonstrated translocation of PKC-e and PKC-q in rabbit hearts.(18°)
The role of PKC as a mediator of IPC-induced protection was suggested by Downey’s 
group(181) when they demonstrated that IPC-induced protection was only abolished by the PKC 
inhibitor, staurospaurine, if the latter was given during the index ischaemic period, and not if it 
was given during the preconditioning phase. The same group postulated that it was the 
relatively slow translocation of PKC induced by the preconditioning triggers, which provided the 
memory of IPC.(182) Further studies using isozyme-specific inhibitors for PKC-e, have implicated 
this particular isozyme in IPC-induced protection at least in rabbit hearts.(183)
Interestingly, Mochly-Rosen’s group(184:185) have recently demonstrated that the PKC-5 
isoform may contribute to ischaemia-reperfusion injury. They demonstrated that inhibiting the
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PKC-5 isoform, protected the isolated perfused rat heart against ischaemia-reperfusion 
injury.(184) Furthermore, they demonstrated that the protection associated with the inhibition of 
PKC-5 and the activation of PKC-e was additive.(185) Further studies by the same group in the 
open chest pig demonstrated that PKC-6 may act as a mediator of lethal reperfusion
The mechanism by which PKC induces cardio-protection is unclear but it may relate to 
either their activation of the mitogen-activated protein kinases (see section 1.3.3.3), or the 
mitochondrial K At p  channel.(129:13°) Another mediator of IPC-induced protection is tyrosine 
kinase which is reviewed next.
Tyrosine kinases can be divided into: (1) receptor tyrosine kinases which may act as 
preconditioning triggers by activating PKC and (2) cytosolic receptor tyrosine kinases which may 
act as preconditioning mediators by acting downstream or in parallel with PKC. Activation of 
receptor tyrosine kinases can take place in response to GPCR-ligand binding.(186) Recent 
studies by Downey’s group suggest that Src tyrosine kinase in conjunction with the epidermal 
growth factor receptor may be required to activate the PI3K-Akt pathway, a kinase cascade 
recently implicated in IPC-induced protection.(74;84;85)
Maulik and colleagues(187) were the first to demonstrate that genistein, the tyrosine 
kinase inhibitor could block IPC-induced protection in rat hearts, and Downey’s group(188) 
determined that cytosolic tyrosine kinase activation was required d uring the index ischaemic 
period, and was likely to be downstream of PKC, at least in rabbit myocardium. Studies in swine 
hearts have suggested that tyrosine kinase may act in parallel to PKC,(189) suggesting 
redundant parallel pathways in the porcine myocardium.
The mechanism by which the receptor tyrosine kinases induce cardio-protection is 
unclear but it may relate to their activation of the mitogen-activated protein kinases.
1.3.3.3 Mitogen-Activated Protein Kinases (MAPK’s)
The MAPK’s encompass 4 major kinase cascades in the heart, the p38 MAPK, the c-Jun NHP2 
terminal kinase (JNK), the 42 and 44-kDa extracellular signal-regulated (Erk1/2) MAPK, and the 
big MAPkinasel (BMK1 or Erk5).(190*192) These 4 major kinase pathways exhibit the same 
conserved three-tier module of a MAPKKK/MKKK (MEKK) phosphorylating a MAPK kinase
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big MAP kinase 1 (BMK1 or Erk5).(190"192) These 4 major kinase pathways exhibit the same 
conserved three-tier module of a MAPKKK/MKKK (MEKK) phosphorylating a MAPK kinase 
(MKK or MEK) which then activates, the MAPK which comprises the JNK, p38, BMK1 or Erk1/2 
MAP kinases. These kinase cascades are activated in response to stress such as ischaemia- 
reperfusion and receptor protein tyrosine kinases, GPCR’s and PKC (see figure 1.3 for 
scheme).(192)
Figure 1.3: Schematic Representation of the four Major Classes of MAPK Family. Each 
major class of MAPK, Erk1/2, BMK1, JNK1/2 and p38 comprises a well-conserved three tier 
module of a MKKK-MKK-MAPK. These MAPK’s are activated in response to ischaemia- 
reperfusion and can be activated in response to an IPC stimulus (with G-protein coupled 
receptors, GPCR’s or receptor tyrosine kinases, RTK’s). These MAPK’s phosphorylate their 
substrates (in green-see text for details) which mediate protection recruiting anti-apoptotic 
protective mechanisms or regulating gene expression.
Stress such as Ischaemia -Reperfusion
Stabilise cytoskeleton 
Anti-apoptoticGene ExpressionAnti-apoptotic
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Erk1/2 MAP Kinase
Whether Erk1/2 MAPK contributes to cardio-protection associated with classical preconditioning 
is unclear, with studies demonstrating that it is activated prior to the index ischaemic 
period,(82;193'195) but not all of them show these MAPK’s contributing to IPC-induced 
protection.(193;194) In contrast there are studies reporting no change in Erk1/2 activity in the 
setting of IPC.(196;197) A recent study suggests that diazoxide-induced mitochondrial ROS 
release may activate Erk1/2.(75) This is interesting given the findings of a study by Baines and 
colleagues,(198) which demonstrated that PKC-e modules can form complexes with Erk1/2-BAD, 
p38 and JNK at the mitochondria. In this scenario, PKC-e phosphorylated both Erk1/2 and p38 
MAPK but down-regulated JNK.(198) Erk1/2 can mediate cellular protection by phosphorylating 
recruiting several anti-apoptotic mechanisms (see section 1.4.3).
p38 MAP Kinase
The role of p38-MAPK in IPC-induced protection is also controversial with studies 
demonstrating increased activation of p38-MAPK during the index ischaemia in preconditioned 
isolated rabbit and rat hearts,(174;199‘201) and rabbit cardiomyocytes,(202) as well as activation of 
MAPKAPK2, a downstream substrate of p38-MAPK.(203) In contrast, several studies have 
reported that the p38-MAPK activation that occurs during the index ischaemia is transient and 
does not correlate with the preconditioning effect.(196:204) To complicate matters further, studies 
have also shown that p38-MAPK activity is attenuated in preconditioned rabbit(205) and rat 
hearts,(206:207) suggesting that p38-MAPK activation is pro-injurious, a finding which is supported 
by studies demonstrating that inhibiting p38-MAPK, using SB203580, protects the heart against 
ischaemia-reperfusion injury.(208*210) In contrast other studies have demonstrated that inhibiting 
p38-MAPK abrogated preconditioning-induced protection,(200;211) but only if the p38-MAPK 
inhibitor was present during the index ischaemic episode.(212)
The discrepancy in results may be attributed in part to the different p38-MAPK isoforms 
that exist, with p38a contributing to myocyte death, and p38(3 responsible for cell survival.(195:213) 
Marber’s group(195) have demonstrated that preconditioning decreased p38a MAPK activity 
during the index ischaemia, suggesting that this isoform was responsible for mediating 
ischaemia-reperfusion injury. In further studies Marber’s group(214) demonstrated that the nitric 
oxide donor, S-nitro N-acetyl penicillamine (SNAP) could delay the ischaemia-induced 
activation of p38a in myocytes subjected to hypoxia-reoxygenation.
45
Derek J Hausenloy Chapter 1: General Introduction
JNK MAP Kinase
The JNK MAPK family comprise two isoforms, the 46 kDa JNK1 and the 54 kDa JNK2, both of 
which are present in the heart.(215) Clerk and colleagues(215;216) have demonstrated that both 
JNK1 and JNK2 are activated upon reperfusion but are not affected by ischaemia, whereas 
other reports suggested that ischaemia-reperfusion may also activate JNK.(217;218) In the context 
of IPC, Takeishi and colleagues(197) found that IPC resulted in a more rapid activation of JNK 
during the index ischaemic period, although the significance of this to IPC-induced protection is 
unclear. Iliodromitis and colleagues(201) found that IPC induced an increase in both JNK1 and 
JNK2, confirming the findings of Ping and colleagues(219) who also demonstrated a PKC- 
dependent activation of both JNK’s during IPC in conscious rabbits. In contrast, Downey’s group 
reported no change in JNK activation when isolated rabbit hearts were subjected to IPC.(203)
Big MAP Kinase
Recently a new member of the MAPK family has been described, called the big MAP kinase 
(BMK1 or Erk5).(190:191) This MAPK is anti-apoptotic and it may mediate cellular responses by 
regulating expression of the gene c-jun,(220;22i) the expression of which has been shown to 
occur during ischaemia or hypoxia.(218:222) BMK1 is activated by MEK5 and also results in the 
phosphorylation of MEF2A and MEF2C, transcription factors that belong to the myocyte 
enhancing factor-2 (MEF2) family, which are involved in cardiac gene expression^221)
Takeishi and colleagues^3) have demonstrated activation of this MAPK during 
ischaemia reperfusion, and have reported that preconditioning in rabbit hearts increased the 
ischaemic-induced activation of BMK1,(197) though the importance of this MAPK to protection is 
unclear at present.
In summary, the contribution of the MAPK’s to IPC-induced protection is shrouded with 
confusion. Disparity between the different studies may in part be due to presence of different 
isoforms with contrasting actions or the use of different experimental model and species.
1.3.3.4 The JAK-STAT Pathway
The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is a 
stress-responsive mechanism that transduces signals for the cell membrane to the nucleus, 
where gene expression is modulated (reviewed in reference (224)). The JAK-STAT pathway is
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activated in response to ischaemia-reperfusion and has been demonstrated to mediate 
apoptosis (STAT1)(225) and myocardial dysfunction (STAT5A, STAT6).(226) In contrast STAT3 
was demonstrated to contribute to IPC-induced protection in a study by Hattori and 
colleagues.(227) They found that IPC produced an early activation of JAK2 and STAT3 in 
isolated rat hearts.(227) IPC reduced infarct size and attenuated apoptotic cell death concurrent 
with up-regulation of the anti-apoptotic protein BCI2and down-regulation of the pro-apoptotic 
protein BAX. The presence of the JAK inhibitor, AG-490 abolished JAK2 and STAT3 
phosphorylation and abrogated the IPC-mediated reduction in infarct size and apopotosis, 
suggesting an important role for STAT 3 in IPC-induced protection^227)
1.3.4 End-Effectors of Classical Preconditioning: Mechanisms of Protection
1.3.4.1 Mitochondrial Function
The survival and recovery of myocytes following an episode of ischaemia-reperfusion injury 
depends critically on maintaining mitochondrial function during this insult. Therefore, optimizing 
mitochondrial function with respect to energy production and ionic homeostasis is crucial if 
myocytes are to survive ischaemia-reperfusion. Murry and colleagues(5) in the first study 
describing IPC, postulated that the protection-induced by IPC may be the result of reduced ATP 
depletion and/or reduced catabolite accumulation.
Later studies have demonstrated that IPC protects by: (1) Attenuating ATP hydrolysis 
during ischaemia;(228) (2) Increasing creatine phosphate and reducing ATP consumption^229'231)
(3) Reducing demand for high energy phosphates because of lower mitochondrial ATPase 
activity;(232) (4) Preserving mitochondrial energy production at reperfusion;(231:233) and (5) 
Increasing ATP synthesis.(234) In contrast, Kolocassides and colleagues(235) demonstrated that 
IPC-treated rat hearts went into contracture earlier and had lower ATP levels during the index 
ischaemic period.
Recent studies have demonstrated that modest uncoupling of mitochondrial oxidative 
phosphorylation can mimic preconditioning-induced protection.(236;23?) Furthermore, 
mitochondrial uncoupling has been demonstrated to be a critical event in IPC-induced 
protection^150) The mechanism by which mitochondrial uncoupling protects the heart from 
ischaemia-reperfusion injury is unknown but it may relate to a reduction in intracellular(238) and
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mitochondrial Ca2+ loading,(239) and this effect has been linked to opening of the mitochondrial 
Katp channel (see section 1.3.4.3).(239)
1.3.4.2 Protection Against the Apoptotic Component of Cell death
Recent advances in our understanding of cell death during ischaemia-reperfusion have 
implicated two forms of cell death in the pathology of a myocardial infarction, namely necrosis 
and apoptosis.(240) Apoptosis is a regulated, energy-dependent process which results in 
chromatin condensation, DNA fragmentation and apoptotic body formation, preserved cell 
membrane integrity, without an associated inflammatory response.(241) In contrast, necrosis is 
characterised by membrane disruption, massive cell swelling, cell lysis and fragmentation, with 
an associated acute inflammatory response. The exact contribution of these two forms of cell 
death in the setting of ischaemia-reperfusion injury is unclear, as are the factors which 
determine whether the apoptotic or necrotic death pathway is recruited (this subject is 
discussed in section 1.4.2).
Piot and colleagues,(242) using the open chest rat model, were the first to report a 
reduction in the apoptotic component of myocyte death, as measured by a reduction in DNA 
fragmentation. Later studies have confirmed this finding, using the same model, concurrent with 
a reduction in the pro-apoptotic protein, BAX expression^243) A reduction in apoptosis has also
been reported i n i solated p erfused rat hearts,(244:245) with an associated i ncrease in the a nti-
apoptotic protein, B-cell lymphoma 2 gene (BCI2).(244)
IPC may reduce the apoptotic component of cell death by: (1) inhibiting the generation 
of ROS;(246) (2) preserving vascular endothelium;(247;248) (3) up-regulating the anti-apopototic 
protein BCI2,(244) or down-regulating the pro-apoptotic proteins BAX,(243) and p53;(249,250) (4) 
reducing mitochondrial cytochrome C release;(239:251:252) (5) reducing caspase activity;(253,254) or 
by (6) opening of the mitochondrial K At p  channel.
1.3.4.3 The Mitochondrial KATp  Channel
The finding that mitochondrial K At p  channel opening could protect the heart against ischaemia- 
reperfusion injury(104:108) and that 5-hydroxydecanoic acid (the presumed mitochondrial KATP 
channel blocker) could abolish IPC-induced protection,(95:96) led investigators to propose the 
mitochondrial KATP channel as the mediator/end-effector of IPC-induced protection,(50;104;108) 
with several studies demonstrating that the mitochondrial K ATp  channel has to be open during
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the index ischaemic period.(169;255:256) Several hypotheses have been proposed to account for 
the protection induced by mitochondrial K At p  channel opening, and include the following:
1.3.4.3. a Reduction in Mitochondrial Ca2+ Load due to Mitochondrial Membrane
Depolarisation
Accumulation of mitochondrial Ca2+ during ischaemia-reperfusion is detrimental to mitochondrial 
funotion.(21;22) Studies have suggested that mitochondrial K At p  channel opening can reduce 
mitochondrial Ca2+ loading, by inducing mitochondrial membrane depolarisation, which would in 
turn reduce the electrochemical gradient for Ca2+ entry.(257;258) However, these studies have 
attracted controversy because of the high concentrations of diazoxide and pinacidil used, and 
over whether mitochondrial K ATp channel opening actually i nduces a significant m itochondrial 
membrane depolarisation.(109:159;160:259) At high concentrations, diazoxide and pinacidil can 
uncouple mitochondria, independent of mitochondrial KATP channel opening.(160:26°) In support of 
an uncoupling action being critical for preconditioning-induced protection, Sack’s group(150) 
have demonstrated that diazoxide protects by inducing mitochondrial uncoupling. Furthermore, 
pharmacological-induced mitochondrial uncoupling can mimic preconditioning-induced 
protection.(236;237)
Studies in other laboratories have noted that IPC and diazoxide protect against 
ischaemia-reperfusion injury by causing reduction in mitochondrial Ca2+ load.(52:239;261:262) 
Crestanello and colleagues(263'265) found that IPC and mitochondrial KATP channel openers 
preserved mitochondrial function and rendered mitochondria more tolerant to mitochondrial Ca2+ 
loading, compared to control mitochondria.
However, one problem with this suggested role for mitochondrial KATP channel opening 
is that during myocardial ischaemia, the mitochondrial membrane potential is reduced, and so 
the role of mitochondrial KATP channel openers in reducing mitochondrial calcium loading by 
depolarising the mitochondrial membrane potential may not be of great significance. This would 
suggest an alternative mechanism for reducing calcium load during ischaemia. The 
mitochondrial permeability transition pore (mPTP) has been demonstrated to act as a 
mitochondrial Ca2+ release channel, and some studies have demonstrated that diazoxide may 
induce mitochondrial Ca2+ efflux via this route (see section 1.5.6.3.a).(257;258:266)
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1.3.4.3.b Improved Energy Production During Ischaemia-Reperfusion
Preserving mitochondrial energy production is vital to myocyte survival during ischaemic- 
reperfusion injury. Opening of the mitochondrial K At p  channel has been demonstrated to 
increase ATP synthesis,(234), preserve mitochondrial energy production^267) decrease ATP 
hydrolysis,(159) and improve energy transfer at reperfusion.(159)
Garlid’s laboratory(159) have proposed that during myocardial ischaemia, the opening of 
the mitochondrial K At p  channel increases mitochondrial matrix volume thereby preserving the 
integrity of the intermembranous space which facilitates energy transfer and reduces ATP 
hydrolysis.
At the time of reperfusion, opening of the mitochondrial KATP channel preserves the 
impermeability of the mitochondrial outer membrane to cytochrome C and adenine 
nucleotides.(159) In support of a role for mitochondrial K ATp  channel opening at the time of 
reperfusion, several studies have demonstrated that activating the mitochondrial KATP channel at 
reperfusion can protect the myocardium from lethal reperfusion injury(79;169;268:269) Other studies 
however, have failed to show cardio-protection with the pharmacological activation of the 
mitochondrial KATP channel using either diazoxide(256) or nicorandil.(270:271)
1.3.4.3.C Reduced Apoptotic Cell Death
Ashrafs group(272) have demonstrated that mitochondrial KATP channel opening can reduce the 
apoptotic component of myocyte death following ischaemia-reperfusion injury. The same group 
demonstrated that this protective effect was related to the ability of mitochondrial KATP channel 
opening to m aintain the mitochondrial m embrane p otential following a s imulated episode of 
ischaemia-reperfusion.(273) This finding was confirmed by Marban’s group using the purported 
mitochondrial KATP channel openers, diazoxide,(274) pinacidil(274) or nicorandil.(275) Garlid’s 
group(159) demonstrated that mitochondrial KATP channel opening could preserve the 
impermeability of the outer mitochondrial membrane to cytochrome C during ischaemia- 
reperfusion, thereby preventing the translocation of mitochondrial cytochrome C into the cytosol 
and avoiding apoptosis.
1.3.4.4 Reducing the Generation of Reactive Oxygen Species
Reactive oxygen species generated on reperfusion of ischaemic myocardium, are a major 
cause of I ethal reperfusion i njury ( see s ection 1.4.1.1 ).(79:276;277) T herefore reducing oxidative
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stress at the time of reperfusion offers protection against lethal reperfusion injury. In this regard, 
Crestanello and colleagues(278) were the first to demonstrate that IPC reduces the production of 
ROS, as measured by chemiluminescence, at the time of reperfusion. Vanden Hoek’s group(79) 
reported in chick myocytes that preconditioning using either hypoxia or adenonsine protected 
the cells by reducing oxidative stress at reoxygenation, a finding that has been confirmed by 
another group.(77) The K At p  channel openers, diazoxide and nicorandil have also been 
demonstrated to protect by attenuating ROS production at the time of reoxygenation, using 
isolated mitochondria.(78) Interestingly, the protective effect was also mimicked by malonate (an 
inhibitor of succinate dehydrogenase) and the K+ ionophore, valinomycin, suggesting that the 
protective effects of these drugs were independent of their opening of a K At p  channel (see 
section 1.3.2.4.d). The mechanism by which preconditioning results in less oxidative stress at 
the time of reperfusion is unknown, but Terzic and colleagues speculate that it is due to the 
reduction in electron flow into the coenzyme Q cycle,(78) a critical component in ROS generation.
1.3.4.5 Gap Junctions
Gap junctions in the myocardium, which comprise connexin (Cx) 43,(279) interconnect myocytes 
into a functional syncytium. During ischaemia, dephosphorylation of Cx43 occurs which allows 
communication between the cells via these junctions. During reperfusion, gap junction 
communication allows cell-to-cell spread of Na+ which mediates hypercontracture and cell 
death,(280,28i) and therefore, inhibiting this communication using heptanol, a gap-junction 
inhibitor, can reduce cell death.(280)
A recent study has demonstrated that transgenic mice deficient in Cx43 could no longer 
be protected by IPC, suggesting the requirement for gap junctions to mediate IPC-induced 
protection^282) In contrast, Saltman and colleagues(283) have demonstrated that closing gap 
junctions can mimic IPC-induced protection, presumably by preventing the propagation of 
hypercontracture and cell necrosis via the gap junctions. In support of this study, Schulz and 
colleagues(284) have demonstrated that in anaesthetised pigs, IPC can phosphorylate Cx43 
(keeping gap junctions closed) via p38 MAP kinase and PKC. Another study confirms that IPC 
maintains the phosphorylation state of Cx43 via the KATP channel.(285) In direct contrast, another 
study suggests that opening gap junctions are essential for IPC-induced protection, as a 
possible route for some unknown ‘survival’ factor.(286)
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1.3.4.6 The Na*-hT Exchanger
The activation of the Na+-H+ exchanger (NHE)(287) in response to an increase in intracellular pH 
during the index ischaemic period (via the activation of NHE kinases such as Erk1/2 MAP 
kinase)(288), is detrimental to cellular and mitochondrial function as it results in both cytosolic 
and therefore mitochondrial Ca2+ loading. Therefore, inhibiting the Na+-H+ exchanger using 
either amiloride(289) or a class of NHE inhibitors(290) during ischaemia-reperfusion offers a 
potential target for cardio-protection and can preserve cellular and mitochondrial ionic 
homeostasis at this crucial time.(291:292) In this regard, several studies have reported protection 
against ischaemia-reperfusion injury with this class of drugs and demonstrated that these drugs 
are most effective when given prior to ischaemia or after the onset of ischaemia,(291:292) and in 
some cases the protection demonstrated with this class of drugs may be greater than ischaemic 
preconditioning^293* 94)
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1.3.5 The Second Window of Protection (Delayed Preconditioning)
The protection induced by ischaemic preconditioning the myocardium is a biphasic 
phenomenon with an early phase of protection (classical preconditioning) that develops within 
minutes and lasts 2 to 3 hours,(5) and a delayed phase of protection (also known as delayed 
preconditioning, the second window of protection or late preconditioning) manifests 12-24 hours 
later,(44;45) and I asts up to 72 hours.(295) Kuzuya a nd colleagues(45) demonstrated u sing the 
open-chest dog model, that four-5 minute cycles of left anterior descending (LAD) arterial 
occlusion protected the heart subjected to sustained lethal ischaemia-reperfusion injury, as 
measured by a reduction in infarct size, 24 hours but not 3 or 12 hours later, demonstrating that 
classical preconditioning wanes after 3 hours and re-appears 24 hours later. 
Contemporaneously and independently, Marber and colleagues(44) demonstrated using the 
open-chest rabbit model that a preconditioning stimulus or sub-lethal thermal stress, protected 
the heart 24 hours later, concurrent with up-regulation of HSP 72, and they termed this the 
Second Window of Protection (SWOP).
Following the initial description of delayed preconditioning in dog(45) and rabbit,(44) the 
phenomenon has been observed in pig,(296) mouse,(297:298) and rat,(299) and has been 
reproduced in other organ tissue, such as brain,(30°) intestine,(301) kidney,(302) and liver.(37) In 
addition to infarct size, delayed preconditioning also protects against arrhythmias,(303) 
myocardial stunning,(304) apoptosis,(305) and endothelial dysfunction,(306) and has been 
reproduced at the cellular level in response to simulated ischaemia-reperfusion,(307'309) including 
human myocytes,(310;311) and human atrial tissue.(312)
1.3.5.1 Mechanisms of Protection in Delayed Preconditioning
Since the original description of delayed preconditioning in 1993,(44;45) the current paradigm of 
delayed preconditioning conceptually classifies the components of delayed preconditioning into 
‘triggers’ (molecular species generated during the preconditioning stimulus) that activate 
‘mediators’ such as protein kinases, which in turn mediate the transcription of distal mediators 
and effectors 24-72 hours later, thereby manifesting the protection (see figure 1.4).
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Figure 1.4: Schematic Representation of Components of Delayed Preconditioning.
Conceptually, the components of delayed preconditioning are classified into triggers, mediators 
and distal mediators/effectors. Triggers of preconditioning are released in response to cellular 
stress. Delayed preconditioning can be mimicked by pharmacological agents such as reactive 
oxygen species (ROS), nitric oxide (NO) donors. These triggers or agents then activate the 
mediators of delayed preconditioning which include the protein kinases, protein kinase C-_ 
(PKCJ, tyrosine kinases (TK such as Src/Lck), mitogen activated protein kinases (MAPK’S). 
These kinases then activate transcription factors such NF-_B and the JAK-STAT pathway, 
which transcribe the distal effector mediators and proteins on days 2-4, which then mediate the 
protection against the index ischaemia-reperfusion episode. These distal mediators and 
effectors include heat shock proteins (HSP’s), inducible nitric oxide synthase (iNOS), 
manganese superoxide dismutase (MnSOD), Katp channels.
DAY 1
Triggers
NO, ROS. Adonosins, 
Brady kin in. Opioids
V
Mediators
Kinases: PKC ?,TK's,MAPK's
Transcription Factors
NF-7B, JAK-STAT
Gene Transcription
DAYS 2-4
Distal Mediators and Effectors
HSP's,iNOS,MnSOD,K ATP,COX-2,
Aldose reductase
1.3.5.2 Triggers of Delayed Preconditioning
1.3.5.2. a Adenosine
Adenosine, released in response to the sublethal episode of ischaemia-reperfusion that 
comprises a preconditioning stimulus, may act as a trigger, initiating a myocardial phenotype 
more resistant to a further ischaemic insult. Yellon’s group(313) were the first to demonstrate the 
role of adenosine as a trigger of delayed preconditioning. Using the open-chest rabbit model, 
they demonstrated that the presence of a non-specific adenosine antagonist, 8-p- 
sulphonyphenyl theophylline (SPT) during the IPC protocol abrogated the reduction in infarct
size 24 hours later. Conversely, they found that administering the adenosine A1-receptor
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agonist, 2-chloro-N6-cyclopentyladenosine (CCPA) induced a delayed preconditioning- 
protective effect.(313) Subsequent studies have confirmed the involvement of A1 adenosine 
receptor, and have also implicated the A3 adenosine receptor as a trigger of delayed 
preconditioning^314)
1.3.5.2.b Reactive Oxygen Species (ROS)
Sun and colleagues,(315) using the open chest pig model, demonstrated that a combination of 
antioxidants (MPG, OSD and catalase) abolished delayed preconditioning protection against 
stunning, suggesting that sublethal oxidative stress acts as a trigger of delayed preconditioning. 
This finding has been confirmed using: (1) different end-points of protection: infarct size,(316) 
protection against arrhythmias(316) and protection against endothelial injury;(306) (2) different 
inducers of protection: heat stress,(316) and exercise;(317) and (3) at the cellular level.(309) The 
source for the ROS is currently unknown.
1.3.5.2.C Nitric Oxide
Bolli’s group were the first to demonstrate that nitric oxide (NO), which is generated during 
ischaemia, could act as a trigger of delayed preconditioning protection against first stunning,(318) 
and then infarction.(319) The non-specific nitric oxide synthase (NOS) inhibitor, N^-nitro-L- 
arginine, abolished delayed preconditioning protection,(318) and infusion of NO donors induced 
delayed cardio-protection.(320) The endothelial NOS was implicated as the source of NO in this 
setting.(321) Because NO-induced delayed cardio-protection was not abolished by ODQ (the 
guanylate cyclase inhibitor) but by MPG,(320) NO is now believed to induce protection by 
generating a peroxynitrite anion (from NO and *02’), instead of signalling through a cGMP- 
dependent pathway.(320)
1.3.5.2.C Brady kin in
Yellon’s group(322) were the first to demonstrate that bradykinin could act as a trigger of delayed 
preconditioning. They demonstrated that administering bradykinin to a rat reduced infarct size 
24 hours later via a NO-dependent mechanism. The same laboratory(296) demonstrated that a 
sub-threshold IPC stimulus could be augmented by the presence of an Angiotensin Converting 
Enzyme Inhibitor (ACE-I, which would increase bradykinin levels) to induce delayed
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preconditioning in the open-chest pig model. Whether endogenous bradykinin acts as a trigger 
for protection is unknown at present.
1.3.5.2M Opioids
Pharmacological activation of the 6-opioid receptor has been demonstrated to induce delayed 
cardio-protection in the rat.(323)
1.3.5.3 Mediators of Delayed Preconditioning
1.3.5.3. a Protein Kinase C
Yamashita and colleagues(308) were the first to demonstrate that inhibition of PKC using 
staurospaurine abolished the protection associated with hypoxic delayed preconditioning in 
myocytes. Y ellon’s group(324) were the first to report, using the i n vivo rabbit model, that the 
PKC inhibitor, chelerythrine, abolished the delayed protection using infarct size as the end-point. 
Subsequently, the same group demonstrated that a PKC agonist could mimic delayed 
ischaemic preconditioning^325) Translocation of the PKCe and PKCq isoforms have been 
implicated in mediating protection.(122:180;219:326'328) PKC once activated is able to phosphorylate 
other kinase mediators.
1.3.5.3.b Tyrosine Kinase
The tyrosine kinase inhibitor, genistein has been demonstrated to abolish both the protection 
against stunning(329) and infarction,(33°) induced by delayed preconditioning. Ping and 
colleagues(328) subsequently established that src and Ick tyrosine kinases are activated 
downstream of PKC and required for delayed cardio-protection.
1.3.5.3.C Mitogen Activated Protein Kinases (MAPK’s)
An IPC protocol capable of inducing delayed cardio-protection v ia P KC can activate 3 major 
members of the MAPK family, Erk1/2, p38 and JNK MAP kinases.(219;327)
Punn and colleagues(307) demonstrated that delayed preconditioning in myocytes was 
PKC but not Erk1/2-dependent. In contrast, Gross’ group(331) demonstrated that 
pharmacological activation of the 6-opioid receptor induced delayed cardio-protection via the 
p38 MAPK and Erk1/2. Furthermore, a recent study implicates ROS-induced Erk1/2 activation in
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delayed preconditioning induced by pharmacological openers of the sarcolemmal and 
mitochondrial K Atp  channels.(332)
Yellon’s group(333) demonstrated that the delayed preconditioning effect induced by the 
adenosine A1 -receptor a gonist, C CPA, r esulted i n t he a ctivation o f p 38 M APK via P KC a nd 
tyrosine kinase. Kukreja’s group(334) subsequently reported abrogation of delayed cardio- 
protection using SB203580, the p38 MAPK inhibitor. The same group later demonstrated that 
the pharmacological activation of p38 MAPK, using anisomycin induced delayed cardio- 
protection in the mouse via activation of NF-kB and iNOS, distal mediators/effectors of delayed 
preconditioning^335)
1.3.5.3.d The PI3K-Akt Pathway
Recently, Yellon’s group(336) have demonstrated that the PI3K-Akt-p70S6K kinase cascade is 
required to mediate the delayed preconditioning-induced reduction in infarct size in the in vivo 
rabbit model. However, the downstream mechanisms involved in mediating the delayed 
preconditioning effect in this setting are currently unknown.
1.3.5.3.e Cardiac KATp  Channels
Studies have implicated the sarcolemmal K Atp  and mitochondrial KATP channels as mediators of 
delayed preconditioning induced by ischaemia,(337) heat stress,(338) opioids,(339) bradykinin,(322) 
adenosine,(311;34°) or diazoxide (the putative mitochondrial KATP channel opener),(272:341) The 
contribution of the different types of K ATp channel to delayed preconditioning is unclear, but a 
recent study by Gross’ group(339) suggests that sarcolemmal KATP channel activation may act as 
a trigger and mitochondrial KATP channel activation may act as a mediator/effector of delayed 
preconditioning-induced protection. A recent study has suggested that the KATP channel openers, 
P-1075and diazoxide, induced d elayed cardio-protection by activating both the sarcolemmal 
and mitochondrial KATP channels, since the protection was abolished by 5-HD (the presumed 
mitochondrial KATP channel blocker) and HMR1098 (the sarcolemmal KATP channel blocker). In 
contrast, the KATP channel opener, BMS-191095, induced a delayed preconditioning effect 
which was not abolished by HMR1098, suggesting that it is more specific for the mitochondrial 
K a tp  channel, than either diazoxide or P-1075.(332) The protection induced by all three KATP 
channel openers was demonstrated to be dependent on both ROS and Erkl^.f332)
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1.3.5.3.f Transcription Factors in Delayed Preconditioning
Recruitment of the kinases results in the activation of transcription factors, the most important 
one of which is nuclear factor-KB (NF-kB), which is expressed constitutively and is activated by 
preconditioning. It is known to regulate various distal mediators/effectors of delayed 
preconditioning (see section 1.3.5.4) such as iNOS, COX-2 and aldose reductase. Xuan and 
colleagues(342) demonstrated that the activation of NF-kB occurred in response to a IPC 
stimulus or NO donors, and a non-specific inhibitor of NF-kB could abolish the delayed 
protective effect of preconditioning. Furthermore, inhibiting certain triggers/mediators such as 
NOS, PKC, tyrosine kinase, free radicals abolished the early activation of NF-kB, suggesting 
that the latter was a common downstream target of these triggers/mediators^342) Activation of 
NF-kB results from the phosphorylation of IkB (an inhibitory protein) by a distal MAP kinase 
called IKK. Maulik and colleagues^3) demonstrated that IPC resulted in the phosphorylation of 
IkB by IKK, via a PKC-dependent mechanism. PKCe along with Erk1/2/JNK have been 
implicated in activating NF-kB in delayed preconditioning^344)
There are probably other transcription factors involved in delayed preconditioning which 
are yet to be identified. One potential candidate is activating protein-1 (AP-1) which has been 
found to be activated in response to a brief ischaemia in rats.f344)
1.3.5.3.f The JAK-STAT Pathway
The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is a 
stress-responsive mechanism that transduces signals from the cell membrane to the nucleus, 
where gene expression is modulated (reviewed in reference (224)). The JAK-STAT pathway is 
activated in response to an IPC stimulus and has been demonstrated to result in the 
transcriptional upregulation of iNOS(345) and COX-2,(346) known distal mediators/effectors of 
delayed preconditioning. Of the 4 JAK isoforms that have been described, JAK1 and JAK2, and 
of the 7 STAT isoforms that have been described, STAT1 and STAT3 have been implicated in 
delayed preconditioning^224)
1.3.5.4 Distal Mediators and End-Effectors of Delayed Preconditioning
The temporal characteristics of delayed preconditioning obviate the requirement for the 
synthesis de novo of proteins which act as distal mediators/effectors, possibly under the 
regulatory control of transcription factors such as NF-kB and the JAK-STAT pathway. As such
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these new proteins (for which the most evidence supports iNOS and COX-2) mediate their 
effect, 2-4 days following the original preconditioning stimulus. One study has reported that 
cycloheximide, a protein synthesis inhibitor, abolished delayed preconditioning in vivo.(347)
1.3.5.4.a Nitric Oxide Synthase
Vegh and colleagues^8) were the first to postulate that delayed preconditioning against 
arrhythmias in dogs may require inducible nitric oxide synthase (iNOS) and/or cyclo-oxygenase 
(COX), following the finding that dexamethasone (which would inhibit NOS and COX) abolished 
the effect of delayed preconditioning. Subsequently, Bolli’s group^9) demonstrated an 
obligatory role for iNOS, as a distal mediator/effector in delayed preconditioning. L-NAME given 
just prior to the index ischaemic period, 24 hours after the IPC stimulus, abolished the delayed 
protective effect against both infarction^349) and stunning.(350) Selective iNOS inhibitors 
produced the same effect.(351) Guo and colleagues(352) demonstrated up-regulation of iNOS but 
not endothelial NOS (eNOS), and found that transgenic iNOS-knockout mice abrogated the 
delayed infarct-sparing effect.
Therefore, NO appears to play a dual role in delayed preconditioning, with NO 
generated from eNOS following the IPC stimulus acting as a trigger, and NO generated from 
iNOS 24 hours after the IPC stimulus acting as a distal mediator^321) Besides ischaemia, iNOS 
has been implicated in delayed preconditioning induced by diazoxide,C341) but whether iNOS is 
required for CCPA-induced delayed preconditioning is unclear.(353:354)
1.3.5.4.b Cyclo-Oxygenase-2
Shinmura and colleagues(355) demonstrated that COX-2 protein expression and myocardial 
levels of prostaglandin (PG) E2 and /or PGI2 were increased 24 hours following an IPC stimulus, 
and that inhibiting COX-2 24 hours after the IPC stimulus abolished the cardio-protective effects 
of delayed preconditioning. Subsequent studies demonstrated that COX-2 was downstream of 
iNOS in the preconditioned heart,(356) and that the JAK-STAT pathway may mediate the up- 
regulation of COX-2.(346) Recently, COX-2 was implicated in delayed preconditioning induced by 
heat stress.(357)
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1.3.5.4.C Aldose Reductase
Aldose reductase (AR), is a member of the aldo-keto reductase family that has been shown to 
metabolise toxic aldehydes generated by lipid peroxidation. The protein expression of AR was 
demonstrated to be increased 24 hours after an IPC stimulus in conscious rabbits and the 
protective effect of delayed preconditioning was abolished if aldose reductase was inhibited.(358)
1.3.5.4.d Antioxidant Enzymes (MnSOD)
Studies have demonstrated an increase in the protein expression of manganese superoxide 
dismutase, 24 hours after a preconditioning stimulus using ischaemia,(359) heat stress,(316)
exercise,(317) or CCPA.(360) In contrast, some studies found no increase in antioxidant enzymes
24 hours after the PC stimulus,(361) so the role of antioxidants as a distal mediator is not clear.
1.3.5.4.d Heat Shock Proteins
Dillman’s group(362) reported that ischaemia induced the expression of mRNA for HSP72, and 
Knowlton and colleagues(363) demonstrated an increase in HSP70 mRNA immediately following 
an IPC stimulus but also 24 hours after the stimulus. In Marber and colleagues’ first description 
of delayed preconditioning, the elevation of HSP72 was noted 24 hours after the preconditioning 
stimulus.(44) Subsequently, Yellon’s group(333) have implicated HSP27 in the delayed 
preconditioning effect induced by CCPA.
1.3.6 Other Forms of Preconditioning
1.3.6.1 Remote Preconditioning
Remote preconditioning describes a less recognised phenomenon, in which preconditioning of a 
region or an organ protects neighbouring tissues or remote organs, and was first described by 
Przyklenk and colleagues,(364) in a study in which they demonstrated that a brief circumflex 
artery occlusion could precondition an area of myocardium served by the left anterior 
descending artery. Subsequently it has been demonstrated that ischaemia of many different 
organs such as kidney, mesentery, intestine and brain can protect the heart.(365"370) The 
mechanisms involved in this phenomenon appear similar to that of classical preconditioning and 
involve adenosine, bradykinin, nitric oxide, PKC, inducible nitric oxide synthase, (365'370) Further
60
Derek J Hausenloy Chapter 1: General Introduction
work is needed to elucidate the mechanisms involved and to evaluate the clinical potential of 
this form of preconditioning.
1.3.6.2 Calcium Preconditioning
Calcium-preconditioning (CPC) describes the phenomenon in which a transient small increase 
in intracellular [Ca2+], triggers a preconditioning-like effect.(371'373) Ashrafs group postulated that 
the transient rise in intracellular [Ca2+] leads to a rapid adaptation of [Ca2+] homeostasis and that 
the Ca2+ can activate different signalling pathways implicated in IPC-induced protection 
including PKC,(172;272) and MAP kinases.(187:20°) It is likely, that CPC utilises the same signalling 
pathways as IPC, since the brief ischaemic episode of an IPC protocol would be expected to 
produce a transitory increase in intracellular [Ca2+]. Studies have implicated PKC (a known 
mediator of IPC)(172,272) as a mediator of CPC,(374:375) but the role of the mitochondrial K Atp  
channel in CPC, however, is unclear.(376:377) Calcium-preconditioning has also been 
demonstrated in human myocardium and was shown to be mediated by PKC.(378)
1.3.7 Preconditioning the Human Myocardium
In order to translate the wealth of data available on myocardial preconditioning in animal hearts 
to the clinical arena of ischaemia-reperfusion injury (such as acute myocardial infarction, 
cardiac surgery, and percutaneous transluminal coronary angioplasty), an obligatory step is to 
demonstrate that the human myocardium can be protected by myocardial preconditioning, 
followed by the evaluation of these preconditioning strategies in large well-conducted 
randomised placebo-controlled clinical trials.
1.3.7.1 In Vitro Studies
Ikonomidis and colleagues(379) were the first to demonstrate that hypoxic preconditioning could 
protect human ventricular myocytes against hypoxia-reoxygenation injury, as evidenced by 
reduced trypan blue uptake and attenuated LDH release. The same group went on to implicate 
a role for adenosine and PKC using the same model.(380) Arstall and colleagues(310) 
subsequently demonstrated that a period of hypoxia could elicit a delayed preconditioning effect 
in foetal human myocytes.
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Yellon’s group(381) have demonstrated that human adult atrial trabeculae harvested at 
the time of cardiac surgery can be hypoxically preconditioned, using the recovery of baseline 
contractile function as the end-point. Using this model, they have demonstrated that adenosine 
A1 and A3(382) and 5-opioid(383) activation can act as triggers of preconditioning, and have 
implicated PKC and the mitochondrial K At p  channel as mediators of preconditioning.(384,385) 
Preconditioning using this model has been confirmed by another laboratory.(386,387)
Galinanes group have demonstrated hypoxic preconditioning, in slices of human adult 
atrial appendage harvested at the time of cardiac surgery, using the release of creatine kinase
■ _i- . r  • /312:388-392\as an indicator of necrosis.( )
1.3.7.2 In Vivo Studies
It has been suggested that warm-up angina (which describes the phenomenon in which a 
patient can exercise for longer without symptoms, following an episode of angina) may be due 
to a preconditioning-like effect,(393'398) rather than due to the recruitment of collateral vessels as 
previously thought. However, certain components normally associated with myocardial 
preconditioning such as adenosine(399) and K ATp  channels(40CM02) do not appear to be implicated 
in t he p henomenon o f w arm-up a ngina, s uggesting t hat t he m echanism may n ot a ctually be 
preconditioning.
From retrospective analyses of patients who have had an acute myocardial infarction, 
the presence of pre-infarction angina has been associated with an attenuated release of 
creatine kinase, improved left ventricular function, reduced ventricular arrhythmias, reduced 
incidence of congestive cardiac failure, and reduced mortality,(403-410) and even a smaller infarct 
size.(411) Other studies however, have reported no benefit with angina, antecedent to primary 
PTCA for myocardial infarction.(412) Whether this apparent protective effect is due to myocardial 
preconditioning is unknown,(413) but studies suggest that pre-infarction angina is only protective 
if it occurs within 24-72 hours of the myocardial infarction,(403;407:4i1) which interestingly 
corresponds to the time-frame of delayed preconditioning-induced protection.
A surrogate model for myocardial preconditioning has been demonstrated in the setting 
of percutaneous transluminal coronary angioplasty (PTCA). Studies have demonstrated 
that an intracoronary inflation lasting longer than 60-90 seconds, can improve indicators of 
myocardial ischaemia for subsequent inflations, independent of collateral vessel recruitment. 
These indices of myocardial ischaemia include chest pain, abnormalities of left ventricular
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regional wall motion, S-T segment elevation, ventricular ectopic activity, lactate release and 
CKMB release^414"418) Interestingly, the mechanisms implicated in this protective effect are 
those known to mediate classical preconditioning and include K At p  channels,(419;42°) 
adenosine,(421_423) opioids,(424) and bradykinin.(425)
With respect to delayed preconditioning, Bolli’s group(426) demonstrated that an 
intravenous infusion of nitroglycerin, 24 hours prior to the PTCA procedure, attenuated the 
symptoms of chest pain, attenuated S-T segment elevation and improved regional ventricular 
wall motion compared to control patients. Marber’s group(427) have recently demonstrated that 
an exercise tolerance test (ETT) can confer a myocardial adaptive effect 24 hours later, with an 
improved exercise tolerance and less ventricular ectopics during an ETT and attenuated S-T 
segment elevation at the time of PTCA.
Another surrogate model for myocardial preconditioning of the human myocardium is at 
the time of cardiac surgery, during which time the heart is subject to sustained periods of 
global ischaemia induced by aortic cross-clamping, for the insertion of coronary artery bypass 
grafts. Yellon’s group and others have demonstrated that intermittent cross-clamping of the 
aorta prior to the sustained episode of global ischaemia protected the human hearts as 
evidenced by the preservation of ATP levels,(428) and attenuated troponin T release^429-431) 
However, applying this preconditioning protocol when using either hypothermia or cardioplegic 
arrest or a combination of both to protect the heart has produced mixed results, with some 
studies reporting a beneficial effect^431-433) but others not.(434;435) Pharmacological 
preconditioning using adenosine produced a negative result,(436) and in another study ischaemic 
preconditioning was more beneficial that an adenosine A1 agonist.(430)
Preconditioning in cardiac surgery has met with resistance because intermittent cross­
clamping may prolong surgery by 15-30 minutes and represents an embolic risk, and has not 
been examined in terms of mortality and morbidity. In addition, ischaemic preconditioning in 
cardiac surgery may offer no more protection than that obtained by the drugs used for pre­
medication (opioids)(383) and anaesthesia (isoflurane),(436) cardiopulmonary bypass(33), all 
interventions which in themselves may protect the heart.
Therefore preconditioning in cardiac surgery will only become an important and 
widespread technique if a pharmacological alternative to intermittent cross-clamping can be 
demonstrated to be an effective preconditioning strategy in large-scale clinical trials.
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1.3.7.3 Preconditioning in the Clinicai Arena
The evidence suggests that the human myocardium can be preconditioned but in the clinical 
settings of ischaemia-reperfusion injury such as acute myocardial i nfarction, cardiac surgery, 
and PTCA, preconditioning by an episode of antecedent ischaemia is not clinically feasible, and 
pharmacological agents which have been demonstrated in animal models to precondition the 
myocardium need to be examined in large scale clinical trials. Another issue is the patient group 
which i s I ikely to b enefit f rom s uch a n intervention a nd the I ogistics of a pplying a n effective 
preconditioning strategy, g iven the unpredictable onset of an acute myocardial i nfarction, the 
patients likely to benefit from a preconditioning strategy, which by definition needs to be 
instituted prior to the ischaemic insult, will be high-risk unstable coronary artery disease patients 
and those undergoing cardiac surgery. Otherwise, the putative preconditioning agent would 
have to be administered to patients with chronic stable coronary artery d isease which would 
raise the issue of tachyphylaxis, although a recent study by Yellon’s group(437) suggests that the 
intermittent treatment of a known preconditioning agent, an A1 adenosine receptor agonist may 
be able to maintain a preconditioned state over several days.
Nicorandil, a putative mitochondrial K At p  channel opener has been examined as a 
potential preconditioning agent in the clinical setting in patients with unstable coronary artery 
disease and was demonstrated to attenuate myocardial ischaemia and ischaemia-induced 
arrhythmias.(438) The Impact Of Nicorandil on Angina (IONA) study examined nicorandil in 
patients with chronic stable coronary artery disease and demonstrated a small but significant 
reduction in major coronary events.(439) However, in both these studies the vasodilatory 
property of this drug cannot be discounted from the apparent protective effect.
This section has reviewed the phenomenon of myocardial preconditioning, a 
mechanism of myocardial protection which needs to be instituted before the index ischaemic 
episode to be effective. The next section reviews an alternate treatment strategy for myocardial 
protection which allows intervention at the time of reperfusion, following the index ischaemic 
episode.
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1.4 Myocardial Protection by Intervening at Reperfusion
1.4.1 Targeting Lethal Reperfusion Injury
Following an acute myocardial infarction, re-establishing coronary blood flow with the rapid use 
of reperfusion strategies such as thrombolysis or primary angioplasty, is a pre-requisite to 
myocardial salvage. However, the restoration of coronary blood flow to the ischaemic 
myocardium carries with it an inherent risk, in that paradoxically, the process of reperfusion can 
itself result in myocyte death-a phenomenon termed lethal reperfusion injury.(6) The non-lethal 
forms of reperfusion injury which comprise myocardial stunning and reperfusion arrhythmias will 
not be dealt with in this section.
Lethal reperfusion injury is defined as injury caused by restoration of blood flow after an 
ischaemic episode leading to death of cells that were only reversibly injured during that 
preceding ischaemic episode.(440) The existence of lethal reperfusion injury as an entity 
separate from ischaemic injury is controversial and has been debated over the years, with some 
commentators suggesting that reperfusion only exacerbates the cellular injury sustained during 
the ischaemic period.(441)
However, other studies have demonstrated that reperfusion can exacerbate the necrotic 
component of cell death as evidenced by an extension in infarct size, following a fixed period of 
ischaemia.(442;443) Other studies, on the other hand, indicate that the oxidative stress and abrupt 
metabolic changes that accompany reperfusion can initiate cellular injury in the absence of 
ischaemia.(444;445)
In order to prove the existence of lethal reperfusion injury as an independent cause of 
cell death it is necessary to demonstrate that myocytes which are viable immediately prior to 
reperfusion, are irreversibly injured by the act of reperfusion. Because the progress of necrosis 
following an episode of ischaemia-reperfusion is difficult to follow accurately, the most 
convincing means of demonstrating the existence of lethal reperfusion injury has been to show 
that myocyte death can be modified by interventions administered at the time of reperfusion. 
The definitive evidence of lethal reperfusion injury requires a reproducible, controlled study in 
which an intervention given at the time of reperfusion (and subsequently withdrawn) results in a 
significant and sustained improvement in infarct size, cardiac function and cardiac metabolism, 
when assessed 4 or more days after a period of ischaemia.(446) Of course many studies do not
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conform to all these rigorous criteria, which may in part explain the disparity and confusion in 
findings from studies investigating the contribution of lethal reperfusion injury. This section 
explores interventions that have been demonstrated to protect the heart against lethal 
reperfusion injury, by modifying factors that have been implicated as critical determinants of 
lethal reperfusion injury, such as reactive oxygen species, calcium overload, and pH changes. 
Finally, the role of the survival kinase cascades PI3K-Akt and MEK1/2-Erk1/2, that have been 
demonstrated to mediate protection against lethal reperfusion injury are examined.
1.4.1.1 Reactive Oxygen Species as Mediators of Lethal Reperfusion Injury
Free radicals such as superoxide anion ( 0 2.), hydrogen peroxide (H20 2) and hydroxyl radical 
( OH), are produced on reperfusion of ischaemic myocardium and represent a major cause of 
lethal reperfusion injury.(79;276:277) The source of the free radicals generated during the 
reperfusion phase include xanthine oxidase,(447;448) and the mitochondrial respiratory chain.(449) 
The catalytic breakdown products ADP and AMP which result from the ATP hydrolysis that 
takes place during ischaemia, are converted to hypoxanthine, which is oxidised to produce 
oxygen free radicals.(447) The reoxygenation of a reduced mitochondrial respiratory chain has 
been d emonstrated t o b e am  ajor s ource o f free r adicals i n t he t ransition f rom i schaemia t o 
reperfusion.(450) In particular, ubiquinone is believed to be the site of ROS generation^449)
Free radicals cause damage to cell membrane phospholipids and cellular proteins 
resulting in metabolic and structural changes. Free radicals induce lipid peroxidation, generating 
lipid peroxides which can induce damage to both cellular and membranous proteins.(451) The 
oxidation of membranous thiol groups can induce the opening of the mitochondrial permeability 
transition pore (mPTP), which leads to irreversible cell injury (see section 1.5.2.1 .b).(452;453) 
Therefore, the pro-injurious effects associated with the burst of free radicals which are produced 
at the time of reperfusion offer a target for protection against lethal reperfusion injury.
In this regard, in 1984, Jolly and colleagues,(454) were the first to demonstrate, that 
scavenging free radicals at the time of reperfusion protected the myocardium against lethal 
reperfusion injury, as evidenced by a reduction in infarct size. Using a canine model subjected 
to 90 minutes of left circumflex coronary artery occlusion, they demonstrated that infusing 
superoxide dismutase (SOD) and catalase into the left atrium 15 minutes before reperfusion, 
reduced infarct size by 50%, although free radical scavengers given 40 minutes after the onset 
of reperfusion were ineffective, underlining the importance of intervening during the early
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reperfusion phase.(454) Other studies however, have failed to show any infarct limitation using 
the same model of ischaemia-reperfusion.(455'457) Variations in collateral flow,(458) and the 
techniques used for measuring infarct size,(459) have been suggested explanations for the 
conflicting results. Studies which fail to assess collateral flow (pertinent in the canine heart 
where collateral flow can vary from 5% to 80%) often give false-negative results.(458) Measuring 
infarct size by tetrazolium staining can detect necrotic tissue not detected by normal histological 
techniques.(459) Studies using transgenic mice over-expression SOD endured 50% smaller 
infarct sizes compared to non-transgenic control, following ischaemia-reperfusion.(46°)
1.4.1.2 Calcium Overload
In the first few minutes of reperfusion there is an abrupt accumulation of cytosolic calcium which 
in turn activates phospholipases, proteases and nucleases. In 1972, Shen & Jennings,(21;22) 
using the canine heart, were the first to demonstrate the accumulation of calcium overload on 
reperfusion of ischaemic myocardium. In addition, the rise in cytosolic calcium enters the 
mitochondria via the Ca2+-uniporter driven by the repolarised mitochondrial membrane potential, 
and can trigger the opening of the mPTP, which can mediate cell death.(452)
Therefore, preventing the calcium overload that occurs at the time of reperfusion is 
another target for protecting the heart against lethal reperfusion injury. In this regard, studies 
have demonstrated that calcium antagonists administered at the time of reperfusion can protect 
against lethal reperfusion injury.(461-463) Using the swine model of ischaemia-reperfusion, 
Herzog and colleagues(463) found that diltiazem given for the first 12 minutes of reperfusion 
reduced infarct size. In the same model, Klein and colleagues(461) demonstrated a reduction in 
infarct size with the intracoronary infusion of either nifedipine or verapamil, and Hatori and 
colleagues(462) found that coronary venous retroperfusion with felodipine reduced infarct size.
The influx of calcium into mitochondria at the time of reperfusion can be targeted 
directly, by using ruthenium red, an inhibitor of the Ca2+-uniporter. Several studies have 
demonstrated protection against lethal reperfusion/reoxygenation injury with this agent, using 
the in vivo porcine heart(464), and the isolated perfused rat heart,(465), Miyamae and 
colleagues(466) demonstrated directly in the isolated perfused rat heart that ruthenium red 
inhibited the increase in mitochondrial Ca2+ at the time of reperfusion, and improved post- 
ischaemic recovery in contractile function.
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1.4.1.3 The pH Paradox and Na*/H+ Exchanger Inhibitors
The intracellular acidification (pH<7.0) which occurs during ischaemia has been demonstrated 
to be protective.(467;468) Therefore its abrupt reversal at the time of reperfusion to neutral pH due 
to wash-out of lactic acid and the activation of the Na+/H+ exchanger, contributes to the cell 
death from lethal reperfusion injury-termed the pH paradox.(469) Furthermore, the action of the 
Na+/H+ exchanger to extrude H+ results in the activation of the Na+/Ca2+ exchanger, which in 
turn causes calcium overload at the expense of Na+ extrusion. Intracellular acidosis is believed 
to protect the myocardium by inactivating phospholipases and proteases as well as inhibiting 
mPTP opening.(469) Lemaster’s group(470) have demonstrated that the reoxygenation of hypoxic 
myocytes with acidic buffer can protect the cells against lethal reoxygenation injury by inhibiting 
mPTP opening.
Maintaining a low intracellular pH during the first few minutes of reperfusion may 
therefore be a target for protection against lethal reperfusion injury. In this regard, administering 
a Na+/H+ exchanger inhibitor, such as HOE 694,(47i) cariporide (HOE 642),(472) or EMD- 
85131 ,(473) at the time of reperfusion has been demonstrated to protect against lethal 
reperfusion injury. However, there are studies that report no protective effective associated with 
Na+/H+ exchanger inhibitors against lethal reperfusion injury^474-476) which supports the general 
notion that these class of drugs are most effective when administered prior to or after the onset 
of the index ischaemic period.(477)
1.4.1.4 Nitric Oxide
In the first few minutes of reperfusion, the endothelial production of nitric oxide (NO) is impaired 
in response to the inactivation of NO by superoxide, resulting in endothelial dysfunction.(478) On 
this basis, the restoration of NO at the time of reperfusion offers a potential target for protecting 
against lethal reperfusion injury. In this regard, the presence of exogenous nitric oxide, in the 
form of NO dissolved in aqueous medium or NO donors can reduce infarct size in various 
models of ischaemia-reperfusion^479^ 81) Transgenic mice lacking the gene for endothelial nitric 
oxide synthase (eNOS) sustain larger infarcts when subjected to ischaemia-reperfusion.(28;482) 
Cardio-protective mechanisms of NO at reperfusion include: attenuation of neutrophil 
infiltration,(483) the inactivation of superoxide radicals,(484) or the improved coronary blood flow 
secondary to NO-induced vasodilation.(485)
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However, there are studies that report the contrary, that NO is detrimental at 
reperfusion,(486:487) and one study reported that functional recovery following ischaemia- 
reperfusion was improved in eNOS-knockout mice when compared to non-transgenic 
controls(488) The dichotomous role of NO may be due to the concentration of NO and the source 
of NO, whether it is produced by eNOS or inducible nitric oxide synthase (iNOS). With regard to 
the former, this may have implications on mPTP opening at the time of reperfusion, with small 
quantities of NO inhibiting mPTP opening and larger amounts inducing mPTP opening.(489) In 
this regard, Lemasters and colieagues have demonstrated that the NO donor SNAP 
administered to rat myocytes at the time of reoxygenation can protect against lethal 
reoxygenation injury by inhibiting mPTP opening (unpublished data).
1.4.1.5 Adenosine
In addition to acting as a trigger for classical preconditioning, adenosine has been demonstrated 
to mediate protection against lethal reperfusion injury, although there are studies reporting the 
contrary. The intracoronary i nfusion of adenosine in a canine model of myocardial i nfarction, 
given at the onset of reperfusion reduced infarct size.(490) Agonists for the adenosine A1, A2, 
and A3 receptor sub-types have been demonstrated to protect against lethal reperfusion injury, 
when given at the time of reperfusion.(491_493) The adenosine A1/A2a receptor agonist, AMP 579, 
has been observed in various animal models of ischaemia-reperfusion to protect against lethal 
reperfusion injury, when administered at the time of reperfusion.(494_497) However, there have 
also been several studies reporting no protection with adenosine given at the time of 
reperfusion.(498;499)
The mechanism of adenosine-induced protection at the time of reperfusion has been 
attributed to attenuation of neutrophil infiltration, reduced superoxide generation and attenuated 
endothelial dysfunction,(493) and in the case of the adenosine agonist, AMP 579, the MEK1/2- 
Erk1/2 pathway(494) has been implicated.
1.4.1.6 The Renin-Angiotensin System
Angiotensin II type 1 receptor blockers such as candesartan(500) and losartan have been 
demonstrated to protect against lethal reperfusion injury by potentiating bradykinin stimulation at 
the bradykinin B2 receptors^1) and releasing nitric oxide.(502)
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1.4.2 The Contribution of Apoptosis to Lethal Reperfusion Injury
Apoptotic cell death in the rat heart has been demonstrated to be induced by a prolonged 
episode of ischaemia alone, in the absence of reperfusion.(503;504) Some studies have 
suggested that reperfusion accelerates the apoptotic death process initiated during 
ischaemia^503’505-507) In contrast, several studies suggest that the apoptotic component of cell 
death is triggered at the time of reperfusion, and does not manifest during the ischaemic 
period.(508) Therefore, the evidence suggests that the apoptotic component of cell death is 
either triggered or accelerated during the reperfusion phase. The fact that apoptosis is an 
energy-dependent process and ATP levels are depleted during ischaemia and replenished on 
reperfusion, may explain why the apoptotic component of cell death is associated with 
reperfusion.(509)
The relationship between apoptotic and necrotic cell death in the setting of ischemia- 
reperfusion injury is also unresolved, with some commentators suggesting that there may be 
considerable overlap in terms of early signalling events between these two pathways, an 
observation that may be useful in terms of developing therapeutic targets for clinical use. Zhao 
and colleagues(510) have characterised, using a canine model of ischaemia-reperfusion injury, 
the contribution of necrotic and apoptotic cell death. They demonstrated that these two forms of 
cell death occur simultaneously during the reperfusion phase, with necrotic cell death peaking 
after 24 hours reperfusion, and apoptotic cell death increasing up to 72 hours of reperfusion.(510) 
Other studies have demonstrated that the pharmacological inhibition of the apoptotic signalling 
cascade during the reperfusion phase, is able to attenuate both the apoptotic and necrotic 
components of cell death,(511'514) suggesting that the apoptotic death process can evolve into 
necrotic cell death. As well as the apoptotic component of cell death contributing to the 
extension of infarct size during reperfusion, a study by Zhao and colleagues, (514) demonstrated 
that pharmacologically inhibiting the reperfusion-induced apoptotic component of cell death also 
resulted in improved contractile function of ischaemic canine hearts.
However, although it is fair to state that the majority of evidence supports the role of 
apoptosis in ischaemia-reperfusion injury, because of unresolved issues surrounding the 
contribution of apoptosis to the pathophysiology of ischaemia-reperfusion injury, several authors 
still question the significance of apoptosis in this setting.(515) For example, methodological 
issues concerning the detection of apoptosis in the heart, were questioned in a study by Ohno
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and colleagues,(516;517) in which immunogold electron microscopy and in situ nick end labelling, 
revealed that coronary artery occlusion in the rabbit resulted in detection of necrotic and not 
apoptotic cell death, andTaimor and colleagues(518) could only demonstrate the induction of 
necrosis but not apoptosis in isolated rat myocytes subjected to hypoxia-reoxygenation.
These studies suggest that targeting the reperfusion-induced apoptotic component of 
cell death can impact on both the apoptotic and necrotic components of cell death, the 
consequences of which are a reduction in infarct size and improved contractile function. Yellon’s 
laboratory(519) have been investigating the role of specific pro-survival signalling kinase 
cascades at the time of reperfusion, which protect the heart against lethal reperfusion injury by 
targeting the apoptotic component of cell death.
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1.4.3 The Reperfusion Injury Salvage Kinase Pathway: The RISK-Pathway
Yellon’s laboratory(519) formulated and tested the hypothesis that the pharmacological activation 
of the signalling kinase pathways, phosphatidylinositol-3-OH kinase (PI3K)-Akt, and p42/p44 
extra-cellular signal-regulated kinases (Erk 1/2), at the time of reperfusion protects the 
myocardium against lethal reperfusion injury. Activation of these kinase cascades (which have 
been termed the Reperfusion Injury Salvage Kinase Pathway [The RISK-Pathway]),(52°) 
protects the heart by recruiting several anti-apoptotic pathways of cellular survival (see figure
1.5).
1.4.3.1 Protecting the Heart Against Lethal Reperfusion Injury by Activating the (RISK)-
Pathway at Time of Reperfusion 
A number of growth factors and other agents have been shown to induce cardio-protection in 
the setting of ischaemia-reperfusion injury. This section will focus on those that have been 
shown to protect the heart when given during the early reperfusion phase, and whose 
mechanism of protection has been linked to activation of these pro-survival kinase cascades. 
Table 1.1, provides a summary of these agents which have been demonstrated to protect 
against lethal reperfusion injury, by activating either the PI3K-Akt and/or Raf1-MEK1/2-Erk1/2 
kinase cascades, when given at the time of reperfusion.
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Table 1.1: Summary of Agents Which Protect at Reperfusion by Activating Akt/Erk1/2. These agents protect at the time of r eperfusion via 
activating the: G-protein coupled receptor (GPCR), NO receptor (NR), glycoprotein 130 (gp130) receptor, the tyrosine kinase (TK) receptor or serine 
threonine kinase receptor, which then activates either the Akt or Erk1/2 of the Reperfusion Injury Salvage Kinase (RISK) pathway.
Protective Agent Receptor RISK-Pathway 
Akt Erk1/2
Model Reference
AMP579 GPCR S In vivo rabbit model Kis 2004(521)
Atorvastatin NR v' s Isolated mouse heart Bell 2003(522) Efthymiou(523)
Bradykinin GPCR
s
Isolated mouse heart 
In vivo rabbit model
Bell 2003(524)
Downey (unpublished)
CT-1 gp130 S
S
Isolated rat heart 
Adult rat myocytes
Liao 2002(525) 
Brar 2001 (526;527)
FGF TK s In vivo rat heart Cuevas 1997,1999(528:529)
Insulin TK Isolated rat heart 
In vivo rat heart
Jonassen 2001 (53°) 
Gao 2002(531)
IGF-1 TK Isolated rat heart 
In vivo mouse heart
Otani 2000(532) 
Yamashita 2001 (533)
TGF-P1 Ser Thr 
Kinase
s
s
Isolated rat heart 
Adult rat myocytes
Baxter 2001 (534) 
Baxter 2001 (534)
Urocortin TK s
s
In vivo rat heart 
Isolated rat heart 
Adult rat myocytes
Schulman 2002(535)
Schulman 2002(535)Brar 2000(536) 
Brar 2000,2002(536:537)
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1.4.3.1.a Insulin
Jonassen and colleagues(538) demonstrated using an in vivo rat heart model of ischaemia- 
reperfusion injury, a reduction in infarct size associated with the administration of glucose- 
insulin-potassium (GIK) at the time of reperfusion. In studies using rat cardiomyocytes subjected 
to hypoxia, Yellon’s laboratory(539) demonstrated that insulin given, at the time of reoxygenation, 
attenuated the apoptotic and necrotic components of cell death. In order to determine the 
mechanism of insulin-induced protection at the time of reperfusion, Yellon’s group(530) 
demonstrated using the isolated perfused rat heart, that administering insulin at the time of 
reperfusion activated the PI3K-Akt-p70S6K-BAD pathway, and that inhibitors of this pathway 
such as wortmannin (the PI3K inhibitor), and rapamycin (the p70S6K inhibitor), abrogated 
insulin-induced protection. Administering insulin at the time of reperfusion activated this kinase 
cascade.(530) The early perfusion of insulin was essential for protection, as delaying its 
administration to 15 minutes after the onset of reperfusion, was not associated with protection, 
suggesting that the protection via the PI3-Akt kinase cascade was mediated in the first few 
minutes of reperfusion.(53°) U sing an i n vivo rat h eart m odel of i schaemia-reperfusion i njury, 
Gao and colleagues(531) have also implicated eNOS, another downstream target of Akt 
phosphorylation, in insulin-mediated cardio-protection at reperfusion.
1.4.3.1.b Insulin-Like Growth Factor-1 (IGF-1)
IGF-1 is a serum factor implicated in cellular survival and growth that has been shown to reduce 
apoptosis in a wide variety of cells in response to a diverse array of stimuli. IGF-1 has been 
demonstrated to protect the heart against ischaemia-reperfusion injury, by attenuating both 
apoptotic and necrotic cell death.(533;54°) in a manner that is dependent on the PI3K-Akt and Erk 
1/2 signalling cascades.(541;542)
In the isolated perfused rat heart, the administration of IGF-1 at reperfusion protected 
the heart against lethal reperfusion-injury in a wortmannin-sensitive manner, suggesting the 
involvement of the PI3K-Akt pathway.(532) Studies in transgenic mice over-expressing IGF-1, 
displayed protection against ischaemia-reperfusion injury, and were found to have a higher 
basal activation of Akt, and interestingly, at reperfusion the level of Akt activation was amplified 
even further.(533) Downstream of the these kinase cascades, Bad.f543) Bax, caspase 3A544) and 
p70S6K have been implicated in IGF-1 induced cellular protection.
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1.4.3.1.C Transforming Growth Factor-pi
Transforming Growth Factor-f31 (TGF-(31) is a cytokine that regulates cell growth and 
differentiation and modulates apoptosis in many cell types. The cardio-protective properties of 
TGF-p1 were first investigated in the early 1990’s by Lefer and colleagues who demonstrated 
protection against ischaemia-reperfusion injury in the rat heart ex vivo and in vivo.(478)
Yellon’s group(534) were the first to study the effect of TGF-01 when given at the point of 
reoxygenation/reperfusion in rat myocytes and in the isolated perfused rat heart, respectively. In 
this study, TGF-p1 given during the reoxygenation phase following an episode of lethal hypoxia, 
was shown to be protective, demonstrated by attenuated trypan blue uptake and a reduction in 
the apoptotic component of cell death (assessed by a reduction in TUNEL and annexin V- 
positive cells) and in the isolated perfused rat heart, treatment with TGF-p1 for the first 15 
minutes of reperfusion, following an episode of lethal ischaemia, was associated with a 
significant reduction in infarct size. In both these cases TGF-p1 -induced protection was 
demonstrated to be dependent on the Erk 1/2 cascade.(534)
1.4.3.1.d Cardiotrophin-1
Cardiotrophin-1 (CT-1) is a member of the interleukin 6 family of cytokines, which was originally 
isolated for its ability to induce a hypertrophic response in isolated cardio-myocytes^545) by 
signalling through the gp130 trans-membrane protein.(546) CT-1 has since been shown to be 
cardio-protective, exerting an anti-apoptotic effect in response to serum withdrawal in cardiac 
myocytes via an Erk 1/2-dependent pathway.(547) Using the isolated rat myocyte and the 
isolated perfused rat heart models, Yellon’s group demonstrated that, when given at point of 
reoxygenation/reperfusion, CT-1 induced protection against lethal reperfusion injury via 
activation of the MEK1/2-Erk 1/2 (525;526) and the PI3K-Akt path ways. (527)
1.4.3.1.e Urocortin
Urocortin, a peptide related to hypothalamic corticotrophin releasing factor, is released by 
myocytes in response to stressful stimuli such as ischaemia.(548) Using neonatal rat myocytes, 
Brar and colleagues (536) demonstrated that after a prolonged episode of hypoxia, the presence 
of urocortin, at the time of reoxygenation, prevented cell death, by an anti-apoptotic action 
(represented as a reduction in annexin V and TUNEL staining). Yellon’s laboratory went on to
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demonstrate, in the isolated perfused rat heart and in-vivo rat heart subjected to prolonged 
ischaemia, that urocortin given at the time of reperfusion reduces infarct size by activating the 
MEK1/2-Erk1/2 kinase cascades.(535;536) Brar and colleagues also demonstrated in neonatal rat 
myocytes that urocortin induced the expression of HSP90 in a MEK1/2-dependent manner^549)
In a further study Brar and colleagues demonstrated that urocortin-mediated protection 
against hypoxia-reoxygenation injury was abrogated in rat myocytes treated with the specific 
PI3K-inhibitors, wortmannin or LY294002, implicating the PI3K-Akt kinase cascade in urocortin- 
induced cardio-protection.(537) In addition, urocortin-induced protection in the same setting was 
abrogated in neonatal rat myocytes possessing a dominant negative mutation of PI3K-Akt.(537)
1 A. 3.1.f Fibroblast Growth Factor
Fibroblast growth factor-2 (also known as basic fibroblast growth factor, FGF) is a polypeptide 
growth factor, which has been shown to modulate cell proliferation, survival and apoptosis.(550) 
FGF has been demonstrated to protect against lethal reperfusion injury, when administered 
during the reperfusion phase in an in vivo rat heart model of myocardial infarction by increasing 
iNOS,(529;551) and has been associated with attenuation of apoptotic cell death.(528) Studies have 
implicated PKC and the Erk1/2 pathway in FGF-mediated cardio-protection.(552,553) Jiang and 
colleagues(554) demonstrated cardio-protection in the isolated perfused rat heart when FGF was 
given during the first 12 minutes of reperfusion, following 30 min of global ischaemia, and 
protection was shown to be PKC-dependent. The fact that FGF-mediated cardio-protection has 
been shown to be dependent on PKC and possibly KATP channels,(555) suggests that FGF may 
protect via a similar mechanism to ischaemic preconditioning.
1.4.3.1.g Other Cardio-Protective Growth Factors
Several other growth factors including vascular endothelial growth factor(556) and hepatic growth 
factor(557;558) have been shown to cardio-protect against ischaemia-reperfusion injury but have 
not been examined at the time of reperfusion. Hepatic growth factor was demonstrated to 
induce activation of Erk 1/2 kinase, but the contribution of this kinase to cellular protection was 
not examined in this study.(558)
Other growth factors such as epidermal growth factor,(559) nerve growth factor(560) and 
platelet-derived growth factor,(56°) have been shown to be protective but have not yet been 
investigated in cardiac tissue. One can postulate that if these growth factors activate the pro-
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survival kinases cascades of the RISK-pathway, in myocardial tissue, one might expect them to 
also protect the heart against lethal reperfusion injury.
1.4.3.1.h HMG-CoA Reductase Inhibitors
The hydroxyl-3-methylglutaryl (HMG)-co-enzyme A (CoA) reductase inhibitors or “statins” have 
been shown to be cardio-protective in large-scale primary (561) and secondary prevention clinical 
studies.(562) In addition to its cholesterol-lowering effect, this class of drugs has been associated 
with many pleiotropic effects, many of which mediate their cardio-protective effect.(563) HMG- 
CoA reductase inhibitors have also been shown to up-regulate the PI3K-Akt kinase cascade, in 
endothelial cell lines.(564)
Yellon’s group,(522) using the isolated perfused mouse heart model, demonstrated that 
the HMG-CoA reductase inhibitor, atorvastatin, administered during the early reperfusion phase, 
limited infarct size via recruitment of the PI3K-Akt kinase pathway. Furthermore, the 
downstream activation of eNOS was also implicated in atorvastatin-induced cardio-protection at 
reperfusion, based on the finding that atorvastatin provided no cardio-protection in mice with a 
targeted deletion of the eNOS gene.(522)
Recently, this group have also demonstrated that atorvastatin administered at the time 
of reperfusion in the isolated perfused mouse heart, protects against lethal reperfusion injury as 
evidenced by a reduction infarct size, via the activation of the MEK1/2-Erk1/2 kinase 
cascade.(523)
1.4.3.1.i Bradykinin
Treatment with angiotensin-converting enzyme inhibitors (ACE-I) have been I inked to cardio- 
protection in the setting of ischaemia-reperfusion injury.(565) Studies have demonstrated that 
ACE-I induced cardio-protection is mediated by bradykinin (acting at the B2 receptor) and is 
dependent on nitric oxide.(566) Interestingly, it has been shown that Gq-protein receptors, such 
as the bradykinin B2 receptor signal through the PI3K pathway in the guinea pig heart.(567)
Based upon this, Yellon’s group(524) demonstrated for the first time a link between G 
protein coupled receptor activation at reperfusion, using bradykinin, and cardio-protection via 
recruitment of the PI3K-Akt pathway. Using the isolated perfused mouse heart model, they 
found that bradykinin administered during the first few minutes of reperfusion, limited infarct size 
via recruitment of the PI3K-Akt kinase pathway.(524) Furthermore, bradykinin-induced cardio-
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protection was shown to be eNOS dependent, as bradykinin provided no cardio-protection in 
transgenic eNOS knockout mice.(524)
Interestingly, a recent study in bovine aortic endothelial cells has shown that bradykinin 
can activate Erk 1/2 and eNOS activation, independent of the PI3-Akt pathway.(568) This 
suggests that the Erk 1/2 kinase pathway may also contribute to bradykinin-mediated cardio- 
protection at reperfusion. This is supported by the recent findings of Downey and colleagues 
who found that administering bradykinin or NECA at the time of reperfusion protected the in vivo 
rabbit heart against lethal reperfusion injury via the MEK1/2-Erk1/2 cascade (unpublished data).
1.4.3.1 .j Adenosine agonists
Xu and colleagues demonstrated that AMP579 (an adenosine A1/A2a receptor agonist) given 
during the reperfusion phase limited infarct size using the in vivo rabbit heart model of 
ischaemia-reperfusion injury.(496) Interestingly, activation of the adenosine A1, A2 and A3 
receptor has been associated with phosphorylation of the Erk 1/2 kinase cascade in Chinese 
Hamster ovary cells.(569) Using the in vivo rabbit heart model of ischaemia-reperfusion injury, 
Yellon’s group found that AMP579-induced protection at reperfusion, was abrogated in the 
presence of PD 98059 (the MEK 1/2 inhibitor).(521)
1.4.3.2 The PI3K-Akt Kinase Signalling Cascade
The activation of the pro-survival PI3K-Akt and MEK 1/2-Erk 1/2 cascades at the time of 
reperfusion, by ligands to growth factor or G-protein coupled receptors, protects the heart 
against lethal reperfusion injury. The protective mechanisms induced by these kinase cascades 
are mediated by the diverse array of substrates which these kinases phosphorylate.
The PI3K-Akt kinase signalling cascade is activated in response to the activation of a 
wide range of receptors, including those for growth factors and G-protein coupled receptors.(57°) 
In response to ligand-receptor binding, the p85 regulatory subunit of PI3K is phosphorylated,
which results in the activation of the p110 catalytic subunit of PI3K, which in turn phosphorylates
the membrane lipid, phosphatidylinositol 3,4-biphosphate(571) to phosphatidylinositol 3,4,5- 
triphosphate,(572) which then recruits Akt (also known as PKB) to the membrane. Upstream 
kinases such as 3-phosphoinositide-dependent protein kinases 1 and 2 (PDK1 and 2) then 
phosphorylate and activate Akt at Thr-308 and Ser-473.(573)
78
Derek J Hausenloy Chapter 1: General Introduction
Figure 1.5: Scheme Outlining the Mechanisms by Which the Activation of the PI3K-Akt 
and Raf1-MEK1/2-Erk1/2 Kinase Cascades Protect Against Lethal Reperfusion Injury, at 
the Time of Reperfusion. Agents which protect at the time of reperfusion bind to receptors, 
which via the small G-protein, RAS, activate the PI3K-Akt and Raf1-MEK1/2-Erk1/2 kinase 
cascades, which together comprise the Reperfusion Injury Salvage Kinase (RISK)-pathway. 
Protection against lethal reperfusion injury is then mediated by the: (1) phosphorylation and 
inactivation of pro-apoptotic factors, caspases 3 and 9, BIM, BAX, BAD and p53, one 
consequence of which is to prevent the release of mitochondrial cytochrome C in response to 
an apoptotic stimulus (shown by dashed arrows); (2) phosphorylation and activation of eNOS 
(endothelial nitric oxide synthase), producing nitric oxide which may protect by inhibiting 
opening of the mitochondrial permeability transition pore (mPTP); (3) phosphorylation and 
activation of p70S6K and p90S6K which can protect by inactivating BAD or regulating protein 
transcription/translation; and (4) regulating the expression of genes concerned with cellular 
survival.
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The activation of Akt phosphorylates a diverse array of substrates, influencing numerous 
cellular processes, many of which are anti-apoptotic in action. Downstream targets of PI3K-Akt 
which mediate anti-apoptotic effects include (see figure 1.5):
1. Pro-apoptotic factors: Akt can phosphorylate and inactivate several pro-apoptotic factors 
including BAD,(574) Bax,(575:576) BIM,(577) p53,(578) and pro-caspase 9;(579)
2. Mitochondrial cytochrome C release: It has been demonstrated that signalling through the 
PI3K-Akt kinase cascade can inhibit apoptosis by preventing mitochondrial cytochrome C 
release;(580)
3. p70S6K: Akt can phosphorylate and activate this kinase which can in turn phosphorylate and 
inactivate the pro-apoptotic factor, BAD(581)
4. Mitochondrial Raf-1: Akt via PKC can activate mitochondrial Raf-1 which has been shown to 
phosphorylate and inactivate BAD.(582)
5. Gene transcription factors: Akt phosphorylates and activates IKK-a, which leads to the 
activation and translocation of NF-kB to the nucleus, where it acts as a transcription factor for a 
variety of survival pathways.(583) Akt can phosphorylate and inhibit Forkhead transcription 
factor-1 mediated transcription of death-inducing genes such as Fas ligands.(584)
Other downstream targets of PI3K-Akt include (see figure 1.5):
1. Endothelial nitric oxide synthetase (eNOS): Akt phosphorylates and activates eNOS, 
which has been implicated in cellular protection^585)
2. Glycogen synthase kinase-3^: phosphorylation and inactivation of glycogen synthase 
kinase-3p has been implicated in preconditioning-induced protection^86)
3. GLUT4 vesicles: Matsui and colleagues(586) have demonstrated that the constitutive over­
expression of Akt enhanced sarcolemmal expression of Glut-4 and increased glucose uptake.
4. Protein kinase C (PKC): Akt can phosphorylate and activate PKC, which has been 
implicated in preconditioning-induced protection^587)
1.4.3.3 The Raf-MEK1/2-Erk1/2 Kinase Signalling Cascade
The Raf-MEK1/2-Erk1/2 kinase cascade is a member of the mitogen-activated protein kinases 
(MAPKs), a family of serine-threonine kinases concerned with regulation of cell proliferation, 
differentiation and survival. Raf-1 is a serine threonine kinase which is activated in response to 
a variety of extra-cellular stimuli which target receptor tyrosine kinases and G-protein coupled
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receptors.(192) Activated Raf-1 then phosphorylates and activates the MEK1/2-Erk1/2 kinase 
cascade. (588)
The activation of Erk1/2, like Akt, can phosphorylate a diverse array of substrates, 
influencing numerous cellular processes, some of which are anti-apoptotic in action. 
Downstream targets of MEK1/2-Erk1/2 which mediate anti-apoptotic effects include (see figure
1.5):
1. Pro-apoptotic factors: Erk1/2 can phosphorylate and inactivate several pro-apoptotic factors 
including BAD,(574) Bax,(577) BIM,(577) and caspase 3,(589)
2. Inhibiting cytochrome C-induced apoptosis: It has been demonstrated that Erk 1/2 
rendered cells resistant to cytochrome C-induced apoptosis.(590)
3. p70S6K: Erk1/2 can phosphorylate and activate this kinase which in turn can phosphorylate 
and inactivate the pro-apoptotic factor, BAD,(591)
4. p90RSK: Erk1/2 can phosphorylate and activate this kinase which in turn can phosphorylate 
and inactivate the pro-apoptotic factor, BAD.(592) Furthermore, p90RSK has been linked to the 
regulation of the gene expression of: (1) cAMP-response element-binding protein, which 
transcribes genes concerned with cellular survival;(593) (2) regulation of protein synthesis by 
phosphorylation of polyribosomal proteins and glycogen synthase kinase-3; and (3) stimulation 
of the Na+-H+ exchanger.(594)
From the available evidence therefore, it appears that BAD, BAX, p70S6K and eNOS appear to 
be the downstream components responsible for mediating the protection associated w ith the 
activation of these kinase cascades at the time of reperfusion.
1.4.3.4 Agents which precondition versus those which protect at reperfusion: Do the
P13K-Akt and Erk1/2 cascades constitute a common pathway of protection?
It is interesting to note that these kinase cascades have also been implicated in mediating the 
protection associated with the phenomenon of ischaemic preconditioning^81,82,194) In this 
scenario, the activation of the kinase cascades occurs prior to the ischaemic insult and acts as 
a preconditioning trigger and/or mediator for cardio-protection.(595)
In the light of this evidence, one can propose that these kinase cascades may constitute 
a common pathway of cardio-protection, mediating the protection associated with both IPC and 
the RISK-pathway. Evidence in support of this proposition, is provided by the fact that agents
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which precondition, such as bradykinin and AMP579,(596;597) also confer protection when given 
at reperfusion.(494;524). Conversely, agents which have been demonstrated to protect at 
reperfusion by activating the RISK-pathway, such as insulin, urocortin and CT-1 have also been 
shown to precondition the myocardium.(83;391;598)
The evidence would tend to suggest that the pro-survival kinase cascades may 
therefore constitute a common pathway, mediating the cardio-protection induced by IPC on the 
one hand, as well as protecting the myocardium through their recruitment at the time of 
reperfusion, on the other hand. However, the only direct evidence for this rests with insulin- 
induced cardio-protection, and therefore more research is needed to elucidate whether the pro­
survival kinase cascades actually constitute the common pathway for cardio-protection in these 
two settings.
1.4.3.5 Cross-Talk Between the PI3K-Akt and Raf1-MEK1/2-Erk 1/2 kinase cascades 
The previous section demonstrates that the activation of the kinase cascades which comprise 
the RISK-pathway, at the time of reperfusion, can protect the heart against lethal reperfusion 
injury. The exact interplay that exists between the PI3K-Akt and Raf-MEK1/2-Erk1/2 kinase 
cascades in mediating their protective effect at reperfusion is unclear, and their interaction at 
this time has not been previously examined. In various immortal cell lines, these kinase 
cascades have been demonstrated to exhibit a variety of complex, sometimes contradictory, 
interactions which enable mutual amplification or inhibition of the signal.
For example: (i) The small G-protein Ras can stimulate both the PI3K-Akt and Raf- 
MEK1/2-Erk1/2 kinase cascades;(599) (ii) It has been demonstrated that the PI3k-Akt cascade 
can both inhibit(600:601) and facilitate^02-604) the Raf-MEK1/2-Erk1/2 kinase cascade; (iii) The 
Raf-MEK1/2-Erk1/2 pathway can activate the PI3K-Akt-p70S6K cascade;(605:606) and (iv) 
Signalling through these kinases cascades may converge on a distal target, such as the pro- 
apoptotic protein, BAD.(607;608)
The phenomenon of ‘cross-talk’ observed between the kinase cascades, in which the 
inhibition of one kinase cascade results in the activation of the other and vice versa, has been 
observed in other organ tissue, including the lens(609) and neuronal cells.(603) In previous 
studies, using immortal cell lines, it has been demonstrated that Akt inhibits the Raf-MEK1/2- 
Erk1/2 kinase cascade by phosphorylation and inactivation of Raf at Ser259 ^ 6001601) and this 
inhibitory pathway may be recruited at different stages of cell development^600) or vary
82
Derek J Hausenloy Chapter 1: General Introduction
according to the concentration and type of ligand exposure.(604) Therefore, the inhibition of the 
PI3K-Akt pathway may activate the Raf-MEK1/2-Erk1/2 cascade, providing a form of 
‘compensatory regulation’.
1.4.4 ‘Ischaemic Post-Conditioning’
At the Hatter Institute 3rd International Workshop on Cardio-protection, in August 2001,(6i0) 
Jakob Vinten-Johansen first introduced the concept of ‘ischaemic post-conditioning’,(611) a 
phenomenon which describes the myocardial protection against lethal reperfusion injury, 
obtained from applying brief intermittent episodes of ischaemia/reperfusion immediately after 
the index ischaemic period.(611) Using the in vivo canine model of ischaemia-reperfusion injury, 
Vinten-Johansen and colleagues(611) demonstrated that immediately following a 3 hour period of 
left anterior descend artery occlusion, the application of three 30 second episodes of alternate 
left anterior descend artery re-occlusion and reperfusion, produced a significant reduction in 
infarct size from 25±3% to 14±2%, an effect comparable to ischaemic preconditioning. 
Furthermore, neutrophil accumulation, lipid peroxidation (an indicator of oxidant stress injury), 
and endothelial dysfunction were all attenuated in the ‘ischaemic post-conditioned’ group.(611)
Interestingly, the concept of ‘ischaemic post-conditioning’ may not be an entirely novel 
phenomenon, as it may simply constitute a variation of controlled reperfusion, which several 
previous studies have demonstrated can protect the myocardium against lethal reperfusion 
injury.(612'614) In 1986, Okamato and colleagues,(612) demonstrated using the canine in vivo 
model of ischaemia-reperfusion, that graded low-pressure reperfusion could protect against 
lethal reperfusion injury as shown by a reduction in infarct size and improved contractile 
functional recovery. Peng and colleagues,(613) using an in vivo pig model of ischaemia- 
reperfusion found that controlled reperfusion preserved certain parameters of mitochondrial 
function such as mitochondrial oxidative phosphorylation. The Vinten-Johansen group(614) 
demonstrated in the canine experimental model that following the index ischaemic event, 
gradual reperfusion could protect the myocardium against lethal reperfusion injury as evidenced 
by a reduction in infarct size and attenuation of endothelial dysfunction.
Since its first description, the phenomenon of ‘ischaemic post-conditioning’ has been 
reproduced by other laboratories and in other animal experimental models and the mechanism 
of protection is currently being investigated with preliminary data having been presented at the
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last AHA 2003 Scientific Sessions. Downey’s laboratory(615) reproduced ‘ischaemic post­
conditioning’ in the in vivo rabbit model of ischaemia-reperfusion injury, and found the protection 
to be sensitive to PD 98059 (the MEK1/2 inhibitor) and L-NAME (the antagonist of nitric oxide 
synthase), which may suggest a role for both the MEK1/2-Erk1/2 kinase cascade and nitric 
oxide in mediating the protection.
Vinten-Johansen’s group(616) were able to reproduce ‘ischaemic post-conditioning’ in 
the in vivo rat model, in which they demonstrated that the ‘ischaemic post-conditioning’ had to 
be applied at the immediate onset of reperfusion, as delaying to after 1 minute reperfusion was 
ineffective. The protection observed in the in vivo rat model was smaller than in the other animal 
models with ‘ischaemic post-conditioning’ reducing infarct size from 52% to 40%, and the 
protection was shown to be associated with an attenuation in the production of ROS at 
reperfusion.(616)
Interestingly, the same group demonstrated the phenomenon of ‘ischaemic post­
conditioning’ in neonatal rat myocytes by applying an ‘hypoxic post-conditioning’ protocol 
following a 3 hr episode of lethal hypoxia.(617) This resulted in less necrotic cell death, 
attenuated ROS production and reduced mitochondrial calcium loading.(617)
The term ‘ischaemic post-conditioning’ is probably a misnomer, as the word 
conditioning implies that the process prepares the myocardium for the index ischaemic event, 
as in ischaemic preconditioning. The term modification of lethal reperfusion injury, may be more 
appropriate as it may transpire that ‘ischaemic post-conditioning’ protects the myocardium 
against lethal reperfusion injury, by recruiting the same mechanisms outlined i n the previous 
sections such as attenuating ROS production and reducing mitochondrial calcium load.(617)
1.4.5 Protecting the Human Myocardium Against Ischaemia-Reperfusion Injury
Several clinical studies have examined the potential benefits of the use of various cardio­
protective pharmacological agents as adjuncts to current reperfusion strategies such as 
thrombolysis and cardiac surgery.
1.4.5.1 Insulin
In 1962, Sodi-Pallares and colleagues first introduced the concept that glucose-insulin- 
potassium (GIK) may offer cardio-protection in response to ischaemia-reperfusion injury.(618)
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Several inconclusive studies followed in the 1960’s and 1970’s, and the use of GIK as a cardio­
protective strategy fell out of favour. However, attention was again directed to the benefits of 
GIK therapy in ischaemia-reperfusion injury, following the publication in the late 1 990’s of: a 
meta-analysis reporting a 21% significant reduction in mortality,(619) and the DIGAMI clinical trial 
in which glucose and insulin therapy demonstrated a 29% significant reduction in mortality;(620) 
as well as the ECLA clinical trial which reported a 66% reduction in mortality in diabetic patients 
reperfused following an acute myocardial infarction.(621) Recent data has also suggested that 
GIK therapy in the setting of coronary artery bypass graft (CABG) surgery, may also be cardio­
protective^622)
However, in the light of both experimental (623) and clinical (624) studies that have 
reported findings to the contrary, and in the absence of large-scale clinical trial data, the routine 
use of GIK therapy in the setting of an acute myocardial infarction is currently only 
recommended in d iabetics.(625) A large randomised clinical trial (called GIK II) which aims to 
recruit up to 10,000 patients is now underway examining the potential benefits of GIK therapy 
following an acute myocardial infarction.(626) Whether the mechanism of insulin-induced 
protection is due to the activation of the pro-survival kinases as outlined in section 1.4.3.1.a is 
unclear at present.
1.4.5.2 Magnesium
Several studies have reported that iv magnesium can protect the animal heart against 
ischaemia-reperfusion injury.(627_629) However, clinical studies have produce mixed results with 
the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) trial(630) reporting a 
benefit but the larger fourth International Study of Infarct Survival (ISIS-IV) trial(631) reporting no 
benefit with intravenous magnesium given as an adjunctive therapy to thrombolysis. The 
disparity between the two studies may relate to the timing of the intravenous magnesium 
infusion which was instituted before thrombolysis in the LIMIT-2 trial but was given after 
thrombolysis in ISIS-IV.
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1.4.5.3 Adenosine
The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) demonstrated that the 
administration of adenosine as an adjunct to thrombolysis resulted in a 67% relative reduction in 
infarct size in patients with anterior myocardial infarction, as determined by technetium 
sestamibi single-photon emission computed tomography (SPECT) imaging.(632)
1.4.5.4 Na+-H+ Exchanger Inhibitors
Initial studies with the use of Na+-H+ exchanger as an adjunct to primary PTCA in patients with 
an acute myocardial infarction were positive reporting attenuated CKMB release, improved 
ejection fraction and improved regional left ventricular wall motion.(633) A subsequent larger 
study called the ESCAMI trial (Evaluation of the Safety and Cardio-protective Effects of 
Eniporide in Acute Myocardial Infarction), however reported no attenuation in CKMB release in 
patients given the Na+-H+ exchanger inhibitor, eniporide as an adjunct to reperfusion therapy for 
an acute myocardial infarction.(634) In retrospect, the negative outcome of these studies may 
have been anticipated on the basis that most of the experimental studies demonstrating a 
protective effect with this class of drug, had administered the Na+-H+ exchanger inhibitor either 
before or after the onset of ischaemia.(477)
In this regard the GUARDIAN (Guard during ischaemia against necrosis) trial(635) 
reported that in three groups of patients at risk of a myocardial infarction (unstable angina, 
PTCA, and cardiac surgery) the treatment with the Na+-H+ exchanger inhibitor, cariporide, 
produced a reduction in the combined end-point of death and Ml, in the sub-group of patients 
awaiting cardiac surgery only. The absence of a beneficial effect in the other two patient groups 
may be due to the fact that the reperfusion therapy in these groups was not instituted in a timely 
manner.(477)
1.4.5.5 Activating the Mitochondrial KATP Channel at the Time of Reperfusion
Pharmacological opening of the mitochondrial KATP channel at the time of reperfusion, following 
an episode of lethal ischaemia has been shown in the in vivo canine(268:269) and swine(636) 
models of ischaemia-reperfusion injury to reduce infarct size. Based on a retrospective study by 
Sugimoto and colleagues,(637) demonstrating reduced cardiac events, with intravenous 
nicorandil (a mitochondrial KATP channel opener) given at the time of primary PTCA for 
myocardial infarction, the same investigators have embarked on a prospective study
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investigating the benefits of opening the mitochondrial K At p  channel at the time of reperfusion 
termed the J-WIND trial.
1.4.5.6 Free Radical Scavengers
Clinical studies investigating the role of oxidative stress as a mediator of lethal reperfusion injury 
in man have been largely disappointing. Human recombinant superoxide dismutase when used 
as an adjunct to reperfusion therapy in patients presenting with an acute myocardial infarction 
resulted in no improvement in left ventricular function or outcome.(638) Large scale clinical trials 
of antioxidants have produced mixed results.f639-642)
In this section, the factors that mediate lethal reperfusion injury and the interventions 
that provide protection against lethal reperfusion injury have been reviewed. Many of these 
factors have a direct effect on the subject of the next section, the mitochondrial permeability 
transition pore (mPTP).
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1.5 The Mitochondrial Permeability Transition Pore (mPTP)
1.5.1 The Discovery of the mPTP
The mitochondrial permeability transition pore (mPTP) denotes the term given to the 
proteinaceous pore of the inner mitochondrial membrane which on opening mediates the 
mitochondrial permeability transition (mPT), which describes the abrupt increase in permeability 
of the inner mitochondrial membrane, which takes place in response to various inducing 
factors. (7’1°)
The c oncept of a n a ctual i nner m itochondrial m embrane p roteinaceous p ore ( mPTP) 
was first made in the late 1970’s in the seminal studies by Haworth and Hunter,(7'10) and was 
originally described as a “Ca2+-lnduced Membrane Transition in Mitochondria.” But the 
description of the phenomenon that would later become known as the mPT, preceded that by 
almost 30 years, with the study by Potter in 1947, who identified Ca2+ as an inhibitory factor of Pj 
uptake (indicating ATP production) in kidney homogenates^643) However, it was not until 1955 
that Hunter and Fordf644) a scribed the loss of mitochondrial membrane impermeability to the 
mPT, in order to explain the various phenomena previous investigators had observed that 
mitochondria underwent when exposed to certain conditions, such as: (1) swelling in isotonic 
media; (2) Ca2+-induced: uncoupling, ATPase activity, swelling, inhibition of site I respiration; (3) 
protection by ethylene diamine tetracetic acid (EDTA); (4) Ppinduced uncoupling and swelling;
(5) Permeation by sucrose; (6) Loss of K+; (7) Loss of adenine and pyridine nucleotides;(8) Loss 
of Kreb’s cycle intermediates;(9) Loss of Co-enzyme A.
1.5.2 Characterisation of the Mitochondrial Permeability Transition Pore
By 1980, Haworth and Hunter had already discovered and characterised many of the key 
features of the mPTP.(7‘10:645) In 1976, they demonstrated that the mPTP was unselectively 
permeable to H+, Ca2+ Mg2+, choline, glucose, sucrose, and NAD(P)H.(7;9) They also 
demonstrated that mPTP opening was a reversible process, in that the open mPTP could be 
completely re-sealed by adding ATP plus Mg2+ or by chelating Ca2+ with Ethylene Glycol-Tetra 
Acetate (EGTA).(7:9) They determined that mPTP opening could be activated by the allosteric 
binding of Ca2+ at the matrix side of the pore, and could be inhibited by ADP and Mg2+.(9:645) The 
redox couples NAD(P)+/NAD(P)H(7*10) and pH(9) were shown to modulate mPTP opening.
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Based on the finding that the mPTP could be opened by atractyloside(8) and closed by 
bongekrekic acid,(8) both known inhibitors of the adenine nucleotide translocase (ANT), and that 
mPTP opening was s ensitive t o ADP,(7'10) they proposed t hat t he ANT might be part of the 
mPTP. They also anticipated that the mPTP may form at contact sites between the inner and 
outer mitochondrial membranes.(10) Subsequent studies have demonstrated in both these 
cases that their postulations on the components of the mPTP to be true (see section 1.5.3).
Using dextrans of different molecular weight, they determined the molecular cut-off to 
be <1500 Da,(9) consistent with the induction of a large pore of discrete size. Subsequent 
studies by Crompton’s group examining the permeability of the mPTP to [14C] solute fluxes, 
calculated that the mPTP had a diameter of 2.0-2.6 nm.(452;646) There is evidence for a lower- 
conductance state of the mPTP,(647:648) which was also anticipated by Hunter and Haworth.(9;1°) 
The transient (low-conductance) opening of the mPTP is discussed in section 1.5.6.
Since the initial discovery of the mPTP, an ever increasing number of inducers and 
inhibitors of mPTP opening have been described. Tables 1.2 and 1.3, list the important known 
inducers and inhibitors along with their mechanisms of action if known.
Table 1.2: List of Important mPTP Inducers. Please see text for details.
Important mPTP Inducers Mechanism of Action (if known)
Ca2+ Binding to Ca2+-activating sites on the ANT induce mPTP 
opening
Pi Increases Ca2+ loading and prevents matrix acidification.
Oxidative Stress and 
Thiol Agents
Cross-linking of inner membrane protein thiol groups 
induces mPTP opening
Pyridine Nucleotides NAD+ and NADP induce mPTP opening
Fatty Acids Mitochondrial uncoupling effect induces mPTP opening
ANT Ligands
Atractyloside
Carboxyatractyloside
These ligands inhibit ANT and favour the ‘c’ conformation 
which induces mPTP opening
Mitochondrial Uncouplers Collapse of the mitochondrial membrane potential or ROS 
induce mPTP opening
Mitochondrial Membrane 
Depolarisation
Collapse of the mitochondrial membrane potential induces 
mPTP opening as the mPTP is voltage-sensitive
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Table 1.3: List of Important mPTP Inhibitors. Please see text for details.
Important mPTP Inhibitors Mechanism of Action (if known)
Pharmacological Agents
Cyclosporin-A
Sanglifehrin-A
Trifluoperazine 
3-aminoketone derivatives
By binding to cyclophilin D it prevents the interaction of the 
latter with the ANT
This drug inhibits the cis-trans isomerase activity of 
cyclophilin D such that it does not modulate ANT 
conformation.
? Modification of voltage-sensitivity of the mPTP 
Inhibition of mPTP opening by targeting VDAC ?mechanism
Cations
Mg2\  Sr2*, Mn2+, Ba2+ These divalent ions compete for the Ca2+-binding sites 
thereby inhibiting mPTP opening
Protons Acidic matrix pH (<7.0) inhibits mPTP opening by reversible 
protonation of histidine residues
Pyridine Nucleotides NADH and NADPH inhibits mPTP opening
Adenine Nucleotides 
AD P/ATP Binding of ATP (to the cytosolic side of the ANT) and ADP 
(to the matrix side of the ANT) inhibits mPTP opening
ANT Ligands
Bongkrekic acid This ligand inhibits ANT and favours the ‘ m’ conformation 
which inhibits mPTP opening
Ubiquinine Analogues By partially inhibiting electron flow through complex I of the 
electron transport chain they inhibit mPTP opening
1.5.2.1 Inducers of mPTP Opening
1.5.2.1. a Calcium and Phosphate
Mitochondrial matrix Ca2+, which is a critical pre-requisite for mPTP opening, is believed to 
induce mPTP opening by b inding to two activating sites on the matrix side of the pore.(9:649) 
Ca2+-induced mPTP opening can be facilitated in the presence of mPTP inducers such as Pj, a 
weak acid which allows the accumulation of mitochondrial Ca2+up-take,(650) and prevents matrix 
acidification.(651)
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1.5.2.1.b Oxidative Stress
Opening of the mPTP can be induced by: (1) Reactive oxygen species generated by the 
mitochondrial electron transport chain, xanthine oxidase, and NADPH oxidase; (2) Exogenous 
sources of ROS;(652) and (3) Oxidising agents such as t-butylhydroperoxide.(653)
Oxidative stress induces mPTP opening by:
(1) oxidising critical thiol groups of the inner mitochondrial membrane (IMM) to form thiol 
crosslinkage.(654;655) Bernardi’s group(654;655) have identified one thiol group which is sensitive to 
the oxidation of glutathione and another thiol group which is regulated by the redox state of 
NAD(P). Because of the role of thiol groups in regulation of mPTP opening, thiol agents such as 
phenylarsenine oxide,(656) hydroperoxides(653) and diamide(657) induce mPTP opening by cross- 
linking inner membrane thiol groups. One candidate protein of the IMM which may have to be 
cross-linked for mPTP opening is the adenine nucleotide translocase (ANT).
(2) oxidising NAD(P)+H and NAD(P)H, antagonises the inhibitory effect of these pyridine 
nucleotides on mPTP opening.(9)
Also, oxidative stress can induce leakiness of the IMM, independent of the mPTP, by causing 
lipid peroxidation of the membrane.
1.5.2.1.c Thiol Agents
Thiol agents such as diamide and phenylarsenine oxide induce mPTP opening by cross-linking 
critical thiol groups present on the ANT.(655) Halestraps’ group(658) have postulated that these 
agents induce mPTP opening by cross-linking Cys160 and Cys257 of the ANT.
1.5.2.1.d Pyridine Nucleotides
Oxidation of the mitochondrial NAD(P)H pool induces mPTP opening.(8;659) NADH is believed to 
act synergistically with ADP to inhibit mPTP opening^645) and therefore its oxidation removes 
this inhibitory effect on mPTP opening.
1.5.2.1.d Fatty Acids
Fatty acids diffuse into the mitochondria as the protonated electroneutral form, thereby 
effectively uncoupling mitochondria,(66°) the effect of which would be to induce mPTP opening, 
as the latter is voltage-sensitive.(661)
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1.5.2.1.e Adenine Nucleotide Translocator Ligands
ANT ligands such as atractyloside and carboxyatractyloside,(9) which stabilise the ANT in the ‘c’ 
conformation (with the adenine nucleotide binding site facing the cytosol) favour mPTP 
opening.(662) Conversely, ANT ligands such as bongkrekate and acyl-CoA’s, which stabilise the 
ANT in the ‘m’ conformation (with the adenine nucleotide binding site facing the matrix) inhibit 
mPTP opening.(9;662)
1.5.2.1.e Mitochondrial Uncouplers and Mitochondrial Membrane Depolarisation
Haworth and Hunter were the first to demonstrate that mitochondrial uncoupling could induce 
mPTP opening,(8) providing the first clue that mPTP opening may be regulated by voltage. 
Mitochondrial uncouplers induce mPTP opening by collapsing the mitochondrial membrane 
potential. The mPTP is believed to be voltage-sensitive and Bernardi’s group(651;661) have 
proposed that the modulation of the mPTP by matrix Ca2+, ADP, protons, Mg2+, fatty acids, and 
cross-linking of thiol groups may all be mediated by the shifting of the voltage sensitivity of the 
mPTP to opening. They demonstrated that the rate of mPTP opening in response to different 
doses of the uncoupler, FCCP, could be modified by agents known to modulate mPTP
/651;661\opemng.( ’ )
1.5.2.2 Inhibitors
1.5.2.2. a Cyclosporin-A
In 1987, Fournier and colleagues,(663) while examining the effect of the immunosuppressive 
agent, cyclosporin-A (CsA) on mitochondrial function discovered that this agent could inhibit 
mitochondrial Ca2+ efflux and allowed mitochondria to accumulate large amounts of Ca2+. 
Crompton’s group(664) and Pfeiffer’s group(665) both realised the significance of these findings 
and proceeded to demonstrate that CsA was a potent inhibitor of mPTP opening a year later. 
This discovery would have a major impact on the research into this area, especially in terms of 
elucidating the molecular composition of the mPTP (see section 1.5.3.).
Using a chromatography affinity binding column, Halestrap’s group(666) demonstrated 
that a fusion protein between cyclophilin D and glutathione-S-transferase (GST) bound to ANT 
in response to the thiol, diamide, and binding was inhibited by CsA, suggesting that CsA 
inhibited mPTP opening by preventing the binding of cyclophilin D to ANT.(666)
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CsA can inhibit mPTP opening caused by a variety of mPTP inducers but its inhibition is 
not absolute.(667;668) Furthermore, CsA-induced inhibition of mPTP opening can be overcome by 
high mitochondrial [Qa2*]^649;669-672) supporting the proposition by Lemaster’s group of the 
existence of an unregulated CsA-insensitive form of mPTP opening (see section 1.5.3).(673)
In addition, as well as inhibiting mPTP opening it can inhibit the protein phosphatase, 
calcineurin through its binding to cyclophilin A, which has resulted in the use of CsA analogues 
such as N-methyl 4-valine CsA(674) and N-methyl-4-iosleucine-CsA (NIM811),(675) which inhibit 
mPTP opening without inhibiting calcineurin. In this regard, a new mPTP inhibitor called 
sanglifehrin-A has been described which also inhibits mPTP opening without inhibiting 
calcineurin.(676)
1.5.2.2.b Sanglifehrin-A
Halestrap’s group(676) have recently characterised a new mPTP inhibitor called sanglifehrin-A 
(SfA), which is a newly described immunosuppressant which differs from CsA in that it does not 
inhibit calcineurin.(677;678) Halestrap’s group(676) demonstrated that the mechanism of mPTP 
inhibition also differed from that of CsA. SfA was demonstrated to bind to and inhibit the PPIase 
activity of cyclophilin D (K j of about 2.2 nmol/l) but unlike CsA,(666) SfA did not prevent the 
binding of cyclophilin D with ANT.(676) Using the isolated perfused rat heart they demonstrated 
that inhibiting mPTP opening using SfA (at 1.0 pmol/l) protected the heart against ischaemia- 
reperfusion injury, as evidenced by attenuated LDH release and improved recovery of left 
ventricular contractile function.(676)
1.5.2.2.C Trifluoperazine
The phenothiazine, trifluoperazine was originally thought to inhibit mPTP opening by competing 
with Ca2+ for its binding site on the mPTP.(679) However, it also has many non-specific effects 
which include inhibition of calmodulin and it also inhibits the FiFoATPase^680) Later studies 
have suggested that it may modify the voltage sensitivity of the mPTP.(681)
1.5.2.2.d A New Class of VDAC Inhibitors: the fi-aminoketone derivatives
Bernardi’s group(682) have recently described a new class of mPTP inhibitors, called j8- 
aminoketone derivatives, which appear to target the VDAC. The most potent mPTP inhibitor of
93
Derek J Hausenloy Chapter 1: General Introduction
this class of compounds was Ro 68-3400, with a potency comparable to that of CsA.(682) The 
mechanism by which they inhibit mPTP opening is currently unknown and is under investigation.
1.5.2.2.e Divalent Cations
Divalent cations such as Mg2+, Sr2\  Mn2+, Ba2+ can inhibit mPTP opening by competing with 
Ca2+ for its activating site on the mPTP.(679:683) Alternatively, these ions may inhibit mPTP 
opening by binding to an alternative site on the cytosolic side of the mPTP.(679)
1.5.2.2. f Protons
The protective effect of protons against mPTP opening was first recognised in 1953, when it 
was demonstrated that mitochondrial swelling did not take place at pH<6.0.(684) Haworth and 
Hunter demonstrated that protons inhibited mPTP opening by competing for the Ca2+ activating 
site on the mPTP,(9) a finding which was later confirmed.(685) A later study by Bernardi’s group 
suggested that the proton-mediated inhibition of mPTP opening was due to the protonation of 
histidyl residues on the matrix side of the mPTP.(686)
1.5.2.2.g Adenine Nucleotides
The binding of ATP (to the cytosolic side of the ANT) and the binding of ADP (to the matrix side 
of the ANT) inhibits mPTP opening. Binding of ADP competes for the Ca2+-activating site on the 
mPTP.(9)
1.5.2.2.h Ubiquinone Analogues
Bernardi’s group(687'689) have demonstrated that substrates which increase electron flow through 
the complex I of the electron transport chain compared to complexes II and IV, sensitise the 
mPTP to Ca2+, and therefore ubiquinone analogues which act to inhibit electron flow through 
complex I can inhibit mPTP opening.
1.5.2.2.i Pyruvate and Propofol
Halestrap’s group have demonstrated that both pyruvate (possibly by lowering intracellular pH 
and scavenging free radicals)(690) and propofol (a free radical scavenger)(691) protected the 
isolated perfused rat heart against ischaemia-reperfusion injury by inhibiting mPTP opening, as 
assessed by the mitochondrial 2-deoxyglucose entrapment technique.
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The concept of a proteinaceous pore of the inner mitochondrial membrane mediating the 
mitochondrial permeability transition (mPT), was first postulated in studies by Haworth and 
Hunter, in which they demonstrated the all-or-nothing nature of the mPT, and in which they 
suggested the opening of a pore in the inner membrane mediated the mPT.(8;9) The discovery 
by Crompton’s group that mPTP opening could be immediately interrupted by EGTA(452:692_694) 
and that it could be inhibited by cyclosporin-A(664) added support to this hypothesis. Until that 
point, the mPT was believed to be due to membrane permeability defects upon accumulation of 
lysophospholipids.(695) In 1989, definitive evidence for the existence of a pore was provided 
from electrophysiological patch-clamp studies which identified a large 1.3 nS (in 150 mmol/l KCI) 
multi-state channel in the mitochondrial inner membrane-the mitochondrial megachannel 
(MMC),(696:697) which was later identified as the mPTP.
The actual molecular composition of the mPTP is currently unknown but the most 
popular working model suggests that it comprises three core components: the adenine 
nucleotide translocase (ANT) of the inner mitochondrial membrane (IMM), the voltage- 
dependent anion channel (VDAC) of the outer mitochondrial membrane (VDAC) and cyclophilin 
D of the m itochondrial matrix. The m PTP is believed to form when these three components 
associate, which has been demonstrated to occur at contact points between the OMM and IMM. 
Figure 1.6 is a cartoon demonstrating the basic structure of the mPTP, and its interaction with 
the various inducing and inhibitory agents as well as the pro- and anti-apoptotic members of the 
Bcl-2 family (see later section). Hunter and Haworth had postulated that the mPTP may form at 
fusion points between the OMM and IMM.(645)
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Figure 1.6: Schematic Representation of the Mitochondrial Permeability Transition Pore.
The mPTP, which comprises the core components of the voltage-dependent anion channel 
(VDAC) of the outer mitochondrial membrane (OMM), the adenine nucleotide translocase (ANT) 
of the inner mitochondrial membrane (IMM), cyclophilin D (CY-D) of the mitochondrial matrix, is 
under the regulatory control of a multitude of factors. The mPTP can be regulated by additional 
components such as the creatine kinase (CK) of the intermembranous space and the 
mitochondrial benzodiazepine receptor (MBR) and hexokinase (HK). mPTP opening can be 
induced by the pro-apoptotic members of the Bcl-2 family, BAX and BAK. In addition, BAX and 
truncated BID (t-BID) may form pores in the OMM and cause the release of pro-apoptotic 
factors such as cytochrome C, pro-caspases 2, 3 and 9, apoptosis-inducing factor (AIF), 
Smac/DIABLO, high temperature requirement A2 (HtrA2), and endonuclease G (Endo G), 
independent of mPTP opening. The anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl- 
XL are believed to inhibit mPTP opening and stabilise the OMM. Inducers of mPTP opening 
include Ca2+, Pit oxidative stress and thiol agents (which cross-link thiol groups on ANT), 
uncouplers, and atractyloside (which inhibits ANT). Inhibitors of mPTP opening include 
cyclosporine-A and sanglifehrin-A (which inhibit cyclophilin D activity), bongkrekate (which 
inhibits ANT), divalent cations, Mg2+, Sr2*, Mn2+, Ba2+, protons (which protonate histidyl residues 
on the ANT), ADP/ATP and NADH, and VDAC inhibitors.
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1.5.3.1 Components of the mPTP
1.5.3.1. a Adenine Nucleotide Translocase
When Haworth and Hunter described the mPTP for the first time in 1979, they proposed that the 
ANT might be part of the mPTP, based on their findings that mPTP opening was sensitive to 
ADP, and the ANT inhibitors atractyloside and bongkrekic acid.(7'10645) In 1988, Le Quoc and
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Le Quoc(662;698) confirmed the involvement of the ANT in mPTP formation and proposed that 
mPTP inducers such as atractyloside, carboxyatractyloside, a high NADP/NADPH ratio, and 
fatty acids stabilised the ‘c’ conformation (where the nucleotide-binding site is on the cytosolic 
side) of the ANT and mPTP inhibitors such as bongkrekic acid and matrix ADP stabilised the ‘m’ 
conformation (where the nucleotide-binding site is on the matrix side)^66* 698) Modulation of thiol 
groups on the ANT were demonstrated to mediate transitions between the two 
conformations^698)
The studies appeared to suggest that the ‘c’ conformation of ANT could deform into a 
non-selective pore under high [Ca2+].(698) In 1990, Halestrap’s group(699) first proposed and 
have subsequently demonstrated that cyclophilin D induces the conformational change in ANT 
to form the mPTP (see section 1.5.3.1 .b).
In 1996, Brustovetsky & Klingenberg,(700) demonstrated that reconstituting purified ANT 
into liposomes created a selective anti-porter, which converted to a non-selective pore under 
high [Ca2+], that possessed features in common with the mPTP. For example, it was 
demonstrated to be sensitive to pH (with half-maximal activity at pH 6.2), voltage (sensitivity 
over the range 150-180mV), bongkrekic acid and ADP. Interestingly, however, it was found to 
be insensitive to carboxyatractyloside.(700)
1.5.3.1.b Cyclophilin D
The finding that CsA could inhibit mPTP opening in 1988,(664;665) suggested the involvement of 
cyclophilin in the formation of the mPTP. In 1990, Halestrap’s group(699) were the first to 
propose that cyclophilin D may mediate the conformational change in the ANT to form the 
mPTP. Cyclophilin D is a cis-trans peptidyl prolyl transisomerase (PPIase) which can mediate 
conformational changes in proteins. Evidence confirming the role of cyclophilin D in mPTP 
formation include:
(1) Mitochondria have been demonstrated to contain a CsA-sensitive PPIase,(699) which has 
been purified and cloned.(701‘703)
(2) The relative potencies of cyclosporin-A, G and H as inhibitors of PPIase correlate with their 
ability to inhibit mPTP opening.(699;704:705)
(3) Similar amounts of bound CsA (approximately 50 pmol/mg of mitochondrial protein) are 
needed to block the mPTP and to inhibit the PPIase activity of cyclophilin d .(699:706)
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(4) Cyclophilin D has been demonstrated to bind to the IMM in response to thiols and oxidative 
stress, factors known to induce mPTP opening.(670:671) Interestingly, an increased mitochondrial 
volume was demonstrated to increase cyclophilin D binding to the inner mitochondrial 
membrane in response to Ca2+, though the significance of this finding is unclear.(671)
In contrast, there is evidence to suggest that cyclophilin D is not required for m PTP 
opening at very high mitochondrial [Ca2+], such that mPTP opening is no longer inhibited by 
CsA (649;669'672:704:707)
1.5.3.1.c Interaction Between the ANT and Cyclophilin D
Using a chromatography affinity binding column, Halestrap’s group(666) demonstrated that a 
fusion protein between cyclophilin D and glutathione-S-transferase (GST) bound to ANT in 
response to the thiol, diamide, and binding was inhibited by CsA. However, a similar study by 
Crompton’s group demonstrated binding of cyclophilin D with both VDAC and ANT, and that the 
binding was not inhibited by CsA,(708), wherein lies the reason for disparate views between the 
two groups concerning the actual composition of the mPTP, with Crompton’s group supporting a 
role for VDAC in the formation of the mPTP, and Halestrap’s group holding the contrary view.
In view of the findings by Bernardi’s group(655) that mPTP opening is regulated by 
cross-linking of critical thiol groups on the inner mitochondrial membrane, Halestrap’s group(658) 
have been investigating the cross-linking of three thiol groups (Cys57, Cys160 and Cys257) 
present on the matrix side of ANT, which may regulate mPTP opening. They demonstrated that 
PAO and diamide induce mPTP opening by cross-linking the thiols, Cys160 and Cys257, present 
on the matrix side of ANT, causing inhibition of ADP binding to the mPTP.(658)
Halestrap’s group(699) postulated that cyclophilin D binds to the ANT via Pro62, a proline 
residue present on the matrix side of ANT, adjacent to Cys57. In apparent support of this 
proposition, this proline residue is not present in yeast mitochondrial ANT and mPTP opening in 
this setting is not sensitive to CsA.(672)
1.5.3.1.d Voltage-Dependent Anion Channel
The VDAC, first characterised in 1979,(709) is a membrane protein that forms an aqueous 
channel in the OMM. At voltages <30 mV, it displays a high conductance formation (4 nS at 1M 
KCI) with a diameter of 4 nm, and is anion selective. At voltages >30 mV, it displays a lower 
conductance of 2 nS with a diameter of 2 nm and the ion selectivity changes to cations. (709;710)
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The mPTP has been proposed to form at contact sites between the IMM and OMM.(645) 
Studies have demonstrated the increased presence of VDAC and ANT at these contact 
sites.(711'713) Crompton’s group demonstrated that the fusion protein between cyclophilin D and 
GST bound a 1:1 VDAC-ANT complex.(700) This cyclophilin D-VDAC-ANT complex was 
incorporated into lysosomes and demonstrated mPTP activity in response to Ca2+ and Pj which 
was blocked by CsA.(708)
1.5.3.1.e Other Components of the mPTP
Several other components have been postulated to form part of the mPTP, but the evidence 
suggests that these additional components probably contribute to the other mitochondrial roles 
the VDAC-ANT complexes at the contacts sites are involved in. For example, hexokinase(714) is 
bound to the junctional complexes to facilitate the entry of mitochondrial generated ATP into the 
first step of glycolysis.(715) Creatine phosphokinase (present in the intermembranous space) 
associates with the junctional complexes to facilitate energy transfer between ADP (which is 
poorly diffusible in the cytosol) and the more diffusible creatine-creatine-phosphate couple in the 
cytosol.(714) Furthermore, creatine kinase can form octamers which by binding to the VDAC- 
ANT channel can suppress m PTP opening.(716;717) This finding may be of importance in the 
setting of ischaemia-reperfusion injury, in which Garlid has proposed that preserving the 
integrity of the mitochondrial intermembranous space, during myocardial ischaemia and 
maintaining the octameric structure of CK, is critical to the protection induced by opening the 
mitochondrial K At p  channel.(159) It has been postulated that the VDAC and ANT can interact in 
such a way that these cytosolic kinases can communicate with ANT and regulate oxidative 
phosphorylation.(718) The benzodiazepine receptor may also associate with the VDAC to 
facilitate the transfer of cholesterol across the mitochondrial membranes.(719) Members of the 
Bcl-2 family such as Bcl-2 and BAX have also been demonstrated to be associated with 
components of the mPTP and are discussed in section 1.5.4.2.a.
Recently, Lemaster’s group(673) have proposed a new model for the mPTP which 
dispenses with the concept of a pore and postulates that the mPTP is formed by aggregation 
and misfolded integral membrane proteins damaged by oxidants and other stresses, which are 
blocked by chaperone proteins. In this scenario, the mPTP displays both a regulated Ca2+- 
dependent CsA-sensitive opening as well as an unregulated Ca2+-independent CsA-insensitive 
opening.(673) In support, of this model which does not implicate a role for the ANT, mPTP
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conductance has been reported in triple ANT knockout yeast,(720) and high conductance pores 
can be induced in the absence of ANT by other mitochondrial carrier proteins such as the 
aspartate/glutamate and phosphate carriers.(721:722)
1.5.4 Consequences of mPTP Opening
The conditions required to induce mPTP opening are usually encountered when the cell is 
subjected to stress such as during ischaemia-reperfusion injury. In this setting, mPTP opening 
occurs, and results in both apoptotic and necrotic cell death. In this scenario, the mPTP opening 
that occurs is a high-conductance non-selective opening, in contrast to the transient low- 
conductance mPTP opening which can occur under physiological conditions. The latter is 
discussed in section 1.5.6, whereas this section will focus on the high-conductance non- 
selective opening which results in cell death.
1.5.4.1 Necrotic Cell Death and the mPTP
Under aerobic conditions, the oxidation of pyruvate in the tricarboxylic acid cycle in the 
mitochondrial matrix generates reduced coenzymes (NADH and FADH), which transfer their 
electrons into the electron transport chain. The electron flow through the electron transport 
chain releases energy, which is used to translocate protons from the mitochondrial matrix via 
the electron transport carriers (I, III and IV) and into the intermembranous space. This creates 
an electrochemical gradient into the mitochondria which drives protons back into the matrix. The 
only entry route into the mitochondria is via the FoFi-ATPase complex, which utilises the energy 
to phosphorylate ADP, producing ATP. Therefore, maintaining the relative impermeability of the 
inner mitochondrial membrane is critical to ATP production, as it permits the generation of this 
electro-chemical gradient which drives ATP phosphorylation-the chemiosmotic hypothesis first 
described by Mitchell & Moyle, in the 1960’s.(723)
Therefore, the abrupt permeation of the IMM that occurs on opening of the mPTP, 
creates a bypass circuit for the entry of protons into the mitochondrial matrix, which dissipates 
the proton-mediated mitochondrial membrane potential. This halts ATP production and results 
in ATP hydrolysis as the FoF^ATPase complex breaks down ATP in an attempt to maintain the 
mitochondrial membrane potential. Therefore, if mPTP opening is prolonged and is not reversed, 
ATP depletion results followed by necrotic cell death. Opening of the mPTP is associated with
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loss of matrix Ca2+, depletion of reduced glutathione, depletion of NADPH, and the 
hypergeneration of superoxide anion. Prolonged opening of the mPTP in the setting of 
ischaemia-reperfusion results in necrotic cell death and is dealt with in section 1.5.5.
1.5.4.2 Apoptotic Cell Death and Mitochondria
Another major consequence of mPTP opening is apoptotic cell death. Apoptosis is an 
evolutionary conserved ATP-dependent process that permits the selective removal of cells 
through an intrinsic cell-suicide program, and is characterised by DNA fragmentation, cell 
shrinkage without loss of membrane integrity or inflammation.(724) Apoptosis is orchestrated by 
caspases (cysteinyl-aspartate-specific-proteinases) that are constitutively inactive and become 
activated after proteolytic cleavage. Until 1996, caspase activation was believed to occur only 
via a receptor-mediated pathway.(725) However, it is now clear that there exists a mitochondria- 
dependent pathway of caspase activation.
A pivotal study by Liu and colleagues in 1996,(728) first demonstrated that mitochondria 
played a role in apoptosis. They showed that caspase activation by apoptosis protease-inducing 
factor-1 (APAF-1) in a cell-free system required both dATP and mitochondrial cytochrome C.(726) 
Since this publication, several other pro-apoptotic proteins have been demonstrated to be 
present in the mitochondrial intermembranous space including pro-caspases 2, 3 and 9,(727:728) 
apoptosis-inducing factor (AIF, which mediates DNA fragmentation)^729) second mitochondrial 
activator of caspases (Smac, which inhibits cytosolic inhibitors of apoptosis [IAP’s])(730) also 
known as direct lAP-binding protein with low pi (DIABLO),(731) high temperature requirement A2 
(HtrA2, a serine protease that binds to and inhibits IAP’s),(732) and endonuclease G (mediates 
DNA fragmentation)^733)
The cytochrome C released into the cytosol binds to APAF-1 and procaspase 9 to form 
an apoptosome, which then cleaves caspase 9 into its active form, thereby setting off the 
caspase cascade and apoptosis.(734:735)
However, the mechanism by which mitochondrial cytochrome C and the other pro- 
apoptotic factors translocate from the mitochondrial intermembranous space into the cytosol is 
currently under debate, since the process would require large holes or breaks in the OMM-so 
called mitochondrial membrane permeabilisation (MMP). Two mechanisms have been 
postulated: (1) Pro-apoptotic and anti-apoptotic members of the Bcl-2 family interact with
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components of the mPTP to mediate MMP; and (2) Pro-apoptotic members of the Bcl-2 family 
mediate MMP, independent of the mPTP.
The Bcl-2 family contains both: (1) pro-apoptotic members comprising (a) the Bax 
subfamily, Bax, Bak and Bok and (b) the BH3-only proteins, Bid, Bad and Bim; and (2) anti- 
apoptotic family members Bcl-2 and Bcl-xL.(736) The anti-apoptotic proteins Bcl-2 and Bcl-xL 
reside at the mitochondria and stabilise the OMM, thereby preventing MMP. The pro-apoptotic 
proteins Bax, Bid, Bim and Bad reside in the cytosol and in response to an apoptotic stimulus 
they translocate to the mitochondria where they interact with the OMM to induce MMP.(736’737) 
Bid is activated by caspase 8 into truncated Bid (t-Bid)(738) which then induces the 
oligomerisation and activation of both Bax(739’740) and Bak,(741) and all three are then able to 
insert into the OMM to induce MMP and apoptosis. At the mitochondria, Bim(742) and Bad(743) 
induce apoptosis by interacting with both Bcl-2/Bcl-xL to antagonise their anti-apoptotic activity 
and Bax/Bak.(744) Bid is believed to induce MMP independently of the mPTP(745) but whether 
Bax and Bak act via the mPTP or not is still a matter of debate.(746,747)
1.5.4.2. a The mPTP is Required to Mediate Apoptotic Cell Death 
In response to an apoptotic stimulus the opening of the mPTP renders the IMM non-selectively 
permeable to molecules up to 1500 Da. Matrix proteins larger than this size remain in the 
mitochondria and exert a colloidal osmotic pressure, which results in the influx in water and 
mitochondrial matrix swelling. The IMM, because it is folded into cristae has a larger surface 
area when compared to the OMM, so the IMM can accommodate the increase in matrix volume, 
whereas the OMM ruptures, releasing the pro-apoptotic factors that reside in the mitochondrial 
intermembranous space-also called mitochondrial membrane permeabilisation (MMP)(748) 
Therefore, in this model pro-apoptotic factors such as Bax and Bak are believed to induce MMP 
via interacting with components of the mPTP.
Evidence in support of this model includes:
(1) Inhibiting MMP using mPTP inhibitors such as cyclosporin-A or bongkrekic acid have been 
demonstrated to inhibit apoptotic cell death,(749'752) suggesting that mPTP opening is an 
obligatory mediator of apoptosis.
(2) Ultrastructural evidence for matrix swelling and rupture of the OMM has been obtained in 
many models of cell death.(750) However, mitochondrial swelling and OMM rupture is not a
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universal feature of apoptosis suggesting alternative mechanisms of OMM (see next 
section).(740:741;753:754)
(3) In isolated mitochondria, Bax or Bak can induce MMP which is sensitive to mPTP inhibitors 
such as CsA and bongkrekate.(755‘757) Interestingly, at low doses Bax was demonstrated to 
induce permeabilisation of the OMM only, though at higher doses it also induced the 
permeabilisation of the IMM.(755)
(4) In cells, apoptotic death induced by BNIP3 could be inhibited by CsA and bongkrekate.(758)
(5) N arita and colleagues(757) have d emonstrated that Bax a nd Bak can b ind to VDAC, and 
induce mPTP opening which is sensitive to CsA and bongkrekic acid. Shimizu and 
colleagues(759) showed that Bax and Bak could induce opening of the VDAC, thereby allowing 
the exit of mitochondrial cytochrome C, whereas the anti-apoptotic protein, Bcl-xL acts to close 
the VDAC and suppress apoptosis. Furthermore, VDAC-1 deficient cells were resistant to 
Bax/Bak induced apoptosis.(759) The pore formed by the interaction between B ax and VDAC 
had a conductance four and ten times greater than those of VDAC or Bax channel, 
respectively.(76°) Crompton’s group have also demonstrated co-immunoprecipitation of Bax with 
VDAC and ANT.(761)
(6) In other studies Bax has been demonstrated to co-immunoprecipitate with ANT,(762) and Bax 
and ANT reconstituted into synthetic lipid bilayers have been found to generate channels.(762) 
Furthermore, the channel formed by the interaction between Bax and ANT was larger than that 
formed by the mPTP alone.(763)
(7) Several viral and bacterial proteins which induce apoptosis interact with components of the 
mPTP such as: (a) Vpr from HIV-1 and vMIA/UL37 from cytomegalovirus both of which bind to 
ANT;(764:765) and (b) hepatitis virus BX-protein and porin B from Neisseria meningitidis both of 
which bind to VDAC.(766;767)
(8) An interesting recent study by Ichas’ group demonstrated that ‘flickering’ of the mPTP and 
cytochrome C release, signals for Bax translocation to the mitochondria.(768)
The problem with this model is that mPTP opening in this setting will result in ATP 
depletion which would be expected to halt the energy-dependent apoptotic process, so it 
appears counter-intuitive to have mPTP opening in apoptotic cell death. Furthermore, 
mitochondrial swelling and OMM rupture does not always occur in apoptotic cells, and 
mitochondrial cytochrome C release can occur independent of mPTP opening.(741:753:754;769)
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Therefore, MMP may occur by a direct action of pro-apoptotic protein on the OMM, independent 
of the mPTP.
1.5.4.2.b The mPTP is Not Required to Mediate Apoptotic Cell Death 
Recombinant Bax and Bid can form ion channels in artificial membranes.(770) It has been 
demonstrated that Bax forms pores in liposome that are large enough to release cytochrome 
C.(771) Recombinant t-BID added to isolated mitochondria, has been reported to cause MMP 
without inducing mitochondrial membrane depolarisation and the MMP was not affected by 
mPTP inhibitors.(772) In support of this cytochrome C can be released from mitochondria that 
have a preserved ultrastructure and conserved mitochondrial membrane potential.(740:754:769)
Therefore, under pathological conditions the opening of the mPTP may result in both 
apoptotic and necrotic cell death. One such pathological condition is in the setting of ischaemia- 
reperfusion where the mPTP has been demonstrated to be a critical determinant of cell death.
1.5.5 The Role of the mPTP in Ischaemia-Reperfusion Injury
Crompton’s group were the first to postulate a role for the mPTP in the setting of ischaemia- 
reperfusion injury.(694) Evidence supporting the role of the mPTP in ischaemia-reperfusion 
comprises three lines of investigation: (1) The major known inducers of mPTP opening, 
mitochondrial [Ca2+] and [PJ, oxidative stress, and ATP depletion are all present in the setting of 
ischaemia-reperfusion; (2) Studies have demonstrated mPTP occurring in the setting of 
ischaemia-reperfusion injury; and (3) Inhibiting mPTP opening in the setting of ischaemia- 
reperfusion using pharmacological mPTP inhibitors such as CsA can protect the heart against 
ischaemia-reperfusion injury.
1.5.5.1 Metabolic and Biochemical Changes During Ischaemia-Reperfusion Predispose
to mPTP Opening
The adenine nucleotides, ATP and ADP are known to inhibit mPTP opening and therefore in the 
setting of ischaemia,(9;645) when there is a depletion of adenine nucleotides, the reduction in 
ATP and ADP level removes the inhibitory effect of these adenine nucleotides on mPTP
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opening. ATP is the more potent mPTP inhibitor than ADP,(773) and cells become vulnerable to 
mPTP opening when more than two-thirds of cellular ATP has been lost.
During ischaemia, the rise in cytosolic Ca2+ begins when about two-thirds of cellular 
ATP has been depleted. A study(774) has demonstrated that providing the cellular Ca2+ does not 
exceed 1-2 pmol/l during the a noxic/ischaemic period, mitochondrial function can recover on 
reoxygenation/reperfusion. However, if this threshold is exceeded then cell death and presumed 
mPTP opening occurs. This limit is close to the set-point of 1-3 pmol/l at which cytosolic Ca2+ 
results in mitochondrial Ca2+ loading and mPTP opening,(775) suggesting that the mitochondrial 
[Ca2+] is a critical determinant of mPTP opening and cell death.(466) Concomitant with ATP 
depletion, mitochondrial Ca2+ loading results in mPTP opening.
1.5.5.2 Timing of mPTP Opening in Ischaemia-Reperfusion injury
Studies have demonstrated that despite the prevailing factors for mPTP induction being present 
during the index ischaemic period, it is during the first few minutes of reperfusion that mPTP 
opening is most likely to occur.(52:470;776;777) It is believed that during the index ischaemic period, 
mPTP opening is inhibited by the lactate-induced acidic pH, and high levels of ADP and Mg2\  
Several events then take place at reperfusion that induce mPTP opening in the first few minutes 
of reperfusion: (1) with washout of the lactate and activation of the Na+-H+ exchanger, the pH 
returns to physiological levels and mPTP opening is no longer inhibited by the acidic conditions;
(2) there is a burst of oxidative stress from within the mitochondria due to reoxygenation of a 
reduced electron transport chain; (3) repolarisation of the mitochondrial membrane drives the 
influx of Ca2+ into the mitochondria.
Halestrap’s group(776) demonstrated using the isolated perfused rat heart that mPTP 
opening (measured by the mitochondrial entrapment of 2-deoxyglucose-see section 1.5.7.3) 
occurs in the first few minutes of reperfusion. Di Lisa’s group(777) demonstrated the same finding 
using the CsA-sensitive loss of mitochondrial NAD+, that occurred during the first few minutes 
of reperfusion to indicate mPTP opening. However, it must be borne in mind, that damage to 
cellular and mitochondrial membranes induced during necrotic cell death at the time of 
reperfusion may result in the release of mitochondrial NAD+, independent of mPTP opening.
At the cellular level, Le Masters’ group(470) demonstrated mPTP opening occurring at 
the time of reoxygenation, in hepatocytes subjected to period of simulated ischaemia. In this 
model mPTP opening was indicated by the entry of the membrane-impermeant fluorescent dye
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calcein (see section 1.5.7.2.a) and mitochondrial membrane depolarisation.(470) Marban’s 
group(52) demonstrated a CsA-sensitive increase in mitochondrial Ca2+ (indicating mPTP 
opening), occurring at the time of reoxygenation, in myocytes exposed to a sustained period of 
simulated ischaemia.
In contrast to these findings a recent study by Brown’s group s uggested that m PTP 
opening occurred during the index ischaemic period.(778) However, in this study mPTP opening 
was not assessed directly, and was only implied by the CsA-sensitive mitochondrial cytochrome 
C release that occurred during ischaemia.
1.5.5.3 Inhibiting mPTP Opening During ischaemia-Reperfusion Using CsA
Opening of the mPTP during ischaemia-reperfusion is a critical determinant of cell death, a fact 
which is supported by the studies demonstrating that pharmacologically inhibiting its opening is 
protective.
Following the discovery that CsA acted as a potent inhibitor of mPTP opening in 
1988,(664) studies have demonstrated that inhibiting mPTP opening in the setting of ischaemia- 
reperfusion using CsA can protect against cell death. In 1991, Crompton’s group(779) 
demonstrated using rat myocytes subjected to anoxia-reoxygenation injury, that cyclosporin-A 
at a concentration of 0.2 pmol/l protected the cell against necrotic cell death (assessed by 
Trypan-blue exclusion and LDH release) and protected against the loss of ATP. Importantly, 
they discovered that the protection by CsA was dependent on the concentration, with the best 
protective effect demonstrated at concentrations between 0.2-0.4 pmol/l, and a concentration 
>1.0 pmol/l conferring no protection^779) This dose-dependent response to CsA has been 
observed in subsequent studies.(780) The mechanism for the variation in response to CsA 
according to the concentration is unknown, but may relate to the non-specific effects of CsA 
such as the inhibition of other cellular cyclophillins. Halestrap’s group(780) demonstrated using 
the isolated perfused rat heart that CsA could protect the heart against ischaemia-reperfusion 
injury (as measured by LDH release and recovery of left ventricular contractile function) and 
could preserve the ATP/ADP ratio even if CsA was given at the time of reperfusion. Several 
subsequent studies have demonstrated that inhibiting mPTP opening using CsA is cardio- 
protective.(236;773:781'784)
Studies have demonstrated that CsA can protect hepatocytes subjected to high Ca2+ 
and oxidative stress^785*787) This was confirmed in studies by Le Master’s group, (47°) who
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demonstrated that CsA administered at the time of reoxygenation protection hepatocytes 
against anoxic-reoxygenation injury by inhibiting mPTP opening. Subsequently, Ashrafs 
group(251) demonstrated that CsA could protect neonatal rat myocytes subjected to anoxia- 
reoxygenation injury against both apoptotic and necrotic cell death.
In 1992, Shiga and colleagues(788) first demonstrated that CsA could protect the brain 
against ischaemia-reperfusion injury. This finding has been confirmed in several subsequent 
studies in protection against ischaemia-reperfusion injury,(789‘793) and protection against 
hypoglycaemic damage.(794;795) Yoshimoto and colleagues(796) reported that the protection 
induced by CsA was more marked if it was given at the time of reperfusion of ischaemic brain, 
and protection was also associated with preservation of Akt phosphorylation.
CsA has also been recently demonstrated to protect human atrial muscle harvested at 
the time of cardiac surgery, subjected to hypoxia-reoxygenation,(797) and has been 
demonstrated to protect skeletal muscle against ischaemia-reperfusion injury.(798)
Recent studies have suggested that CsA may protect against ischaemia-reperfusion 
injury by mechanisms other than via inhibition of mPTP opening. For example, Chen and 
colleagues(799) demonstrated that CsA protected against oxidative stress-induced apoptosis by 
producing ROS, and up-regulating HSP70 and iNOS, factors that have been associated with 
preconditioning-induced protection. Niemann and colleagues(800) have demonstrated that the 
reduction in infarct s ize i nduced by pre-treating rats with CsAfor 3 days prior to ischaemia- 
reperfusion correlated with a dose-dependent reduction in myocardial energy metabolism. A 
recent study attributes the protection of CsA against ischaemia-reperfusion injury to its ability to 
attenuate the cell volume increase induced by ischaemia.(801) Furthermore, Downey’s group(802) 
demonstrated that CsA could protect the isolated perfused rabbit heart against ischaemia- 
reperfusion injury by inhibiting calcineurin.
Therefore, because of the non-specific effects of CsA, it is necessary to evaluate the 
effect of other mPTP inhibitors in ischaemia-reperfusion injury. In this regard, CsA analogues 
such as N-methylvaline 4-CsA, which does not inhibit calcineurin but does inhibit mPTP opening 
have been demonstrated to protect the cell against both apoptotic and necrotic cell 
death. (674:705:776)
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1.5.5.4 Inhibiting mPTP Opening During fschaemia-Reperfusion Using Other Agents
Halestrap’s group(676) have characterised and investigated the effect of sanglifehrin-A (SfA) on 
mPTP opening in the setting of ischaemia-reperfusion injury. This mPTP inhibitor does not 
inhibit calcineurin and was demonstrated to protect the isolated perfused rat heart against 
ischaemia-reperfusion injury (as measured by LDH release and recovery of left ventricular 
contractile function).(676) Furthermore, SfA given at the time of reperfusion was demonstrated to 
protect the isolated perfused rat heart subjected to ischaemia-reperfusion injury by inhibiting 
mPTP opening, detected by the mitochondrial 2-deoxyglucose technique.(803)
The phenothiazine, trifluoperazine, a known mPTP inhibitor has been demonstrated to 
protect the heart^04-808) and brain(809;81°) against ischaemia-reperfusion injury but these studies 
did not demonstrate directly that the protection was due to inhibition of mPTP opening. Le 
Master’s group(653) did demonstrate that oxidative stress-induced mPTP and cell death could be 
prevented by trifluoperazine.
Halestrap’s group have also demonstrated that inhibition of mPTP opening (detected by 
the mitochondrial entrapment of 2-deoxyglucose) using either pyruvate(690) or probofol(811) 
protected the isolated perfused rat heart against ischaemia-reperfusion injury.
1.5.5.4 Inhibiting mPTP Opening During Ischaemia-Reperfusion: the pH Paradox 
Opening of the mPTP during the ischaemic period is inhibited by the prevailing acidic conditions. 
On reperfusion, with the restoration of physiological pH at the time of reperfusion, cell death 
ensues probably secondary to mPTP opening. Studies have demonstrated that reperfusing with 
acidic buffer can protect the heart against lethal reperfusion injury-the so-called pH 
paradox.(469:47°)
1.5.6 Transient (Low-Conductance) mPTP Opening
Studies from the mid-1980’s appeared to suggest that the mPTP may exist in two different open 
configurations: (1) The high-conductance (<1500 Da) non-selective state of mPTP opening as 
discussed in the previous section;(9) and (2) a low-conductance (<300 Da) ion-selective (Ca2+, 
H+ and K+) state of mPTP opening (also called transient mPTP opening or ‘mPTP flicker’), which 
is the less well known of the two, and which may occur under physiological 
circumstances.^648*812)
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Naturally, in 1979, the pioneers of the mPTP, Haworth and Hunter had already 
anticipated the existence of mPTP ‘flicker’: “the Ca2+-induced permeability is discontinuous in 
time: t he t reated m itochondria m ust b e c ontinuously s witching b etween a permeable a nd an 
impermeable state".(9) Furthermore, they had observed a sub-conductance state of the mPTP, 
when they found that mitochondria impermeable to sucrose could still release Ca2+ at a fast rate, 
in a ruthenium-red insensitive manner, and in the absence of Na+.(10)
1.5.6.1 Characteristics of Transient (Low-Conductance) mPTP Opening
Early studies suggested that in the presence of Ca2+ and P„ mitochondria exhibited an initial H+- 
specific mitochondrial permeability increase, followed by a non-selective mitochondrial 
permeability increase^64* 6931813) Interestingly, numerous studies had described a Na+ and 
ruthenium red-insensitive pro-oxidant-induced Ca2+-efflux, which may represent the low- 
conductance form of mPTP opening.(812:814)
Ichas & Mazat confirmed that the transitory low-conductance mPTP opening was 
permeable to Ca2\  H+ and K+ but was impermeable to sucrose (suggesting a molecular cut-off 
of 300 Da), and did not cause mitochondrial swelling^647* 15) They demonstrated that mPTP 
opening resulted in a transitory depolarisation of mitochondrial potential and mitochondrial Ca2+ 
efflux, followed by mitochondrial repolarisation and reaccumulation of Ca2+, indicating that 
mPTP opening was transitory^647) The low-conductance state of mPTP opening has been 
demonstrated to precede the high-conductance mPTP opening in several studies^64* 816)
In e lectrophysiological s tudies, it h as b een d emonstrated t hat t he m PTP c an d isplay 
several sub-conductance levels, including a half-conductance state of 500 pS mPTP 
flicker,(817:818) which may correspond to the transient low-conductance mPTP open configuration.
Balakirev & Zimmer(819) described in rat liver mitochondria, that the mPTP opening 
induced by phenylarsenine oxide occurred gradually, with an electrogenic K+ influx initially, 
followed by a permeability to protons. Interestingly, the K+ influx was demonstrated to not be 
sensitive to glibenclamide.
Brustovetsky & Dubinsky(820) demonstrated in isolated brain mitochondria that a Ca2+ 
challenge induced two forms of mPTP opening depending on the substrate. When energized 
with succinate plus glutamate, a Ca2+ challenge induced mitochondrial membrane 
depolarisation and an increase in mitochondrial Ca2+ and an increase in matrix volume, though 
when energized with succinate alone, the mitochondrial accumulated Ca2+ without mitochondrial
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swelling. Interestingly, the latter form of mPTP opening was sensitive to CsA but neither form of 
mPTP opening was sensitive to carboxyatractyloside nor bongkrekic acid, suggesting that the 
ANT was not involved. (820)
However, some studies have described low conductance channels in the inner 
membrane which do not appear to be due to mPTP opening. Broekemeier and colleagues(821) 
have described a small pore of the inner mitochondrial membrane which is proton-selective and 
is insensitive to CsA, and so whether it forms part of the mPTP is unclear at present. 
Furthermore, Kushnareva & Sokolove(822) have described a pro-oxidant Ca2+-sensitive induced 
low-conductance inner membrane channel which was permeable to Ca2+ and not H+, and was 
insensitive to the normal mPTP inhibitors, CsA, trifluoperazine, and Mg2+.
1.5.6.2 Regulation of Transient (Low-Conductance) mPTP Opening
Transient (low-conductance) mPTP opening is inhibited by CsA, acidic pH, and is activated by 
matrix Ca2+, alkaline pH, mitochondrial membrane depolarisation and oxidative stress.(647;659,815) 
Ichas & Mazat have postulated a mechanism for transitory mPTP opening in the context of 
mitochondrial calcium induced calcium release (rnCICR), that appears to be pH-operated: A 
Ca2+ signal reaches the mitochondria and Ca2+ entry occurs driven by the electrochemical 
potential, which increases matrix pH (mediated by charge compensation via the respiratory 
chain), which triggers mPTP opening, resulting in mitochondrial membrane depolarisation. This 
results in mitochondrial calcium efflux via the mPTP and matrix acidification, which closes the 
mPTP, allowing restoration of the mitochondrial membrane repolarisation and Ca2+entry, and so 
the cycle continues resulting in mPTP flickering^647)
Vercesi’s group(659;823;824) demonstrated that the oxidation of NADH, using acetoacetate 
induced a CsA-sensitive mitochondrial Ca2+efflux in the absence of any change in respiration or 
mitochondrial membrane potential suggesting induction of the low-conductance form of mPTP 
opening.
1.5.6.3 Detecting Transient (Low-Conductance) mPTP Opening
1.5.6.3. a Mitochondria
In the original description of the mPTP, Hunter & Haworth observed a spontaneous release of 
Ca2+ from mitochondria that was inhibited by Mg2+, Sr2", ADP and BSA, suggesting opening of 
the mPTP under steady state conditions,(10) which may well have been due to transient (low-
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conductance) mPTP opening. Crompton’s group(692;693) demonstrated that under steady state 
conditions sucrose entered mitochondria, suggesting mPTP opening occurring under basal 
conditions and under the control of matrix [Ca2+]. Huser & Blatter(825) demonstrated mPTP 
‘flicker’ in mitochondria fixed to coverslips and loaded with the fluorescent dye, tetramethyl- 
rhodamine methyl ester (TMRM). The TMRM accumulates in the mitochondria according to the 
mitochondrial membrane potential, and on confocal laser-illumination, mitochondria undergo 
CsA-sensitive mPTP ‘flicker’ represented by cycles of depolarisation and repolarisation, as the 
mPTP opens and closes, respectively^825)
Electrophysiological studies of the mPTP, in which patch-clamp measurements are 
made on mitochondrial mitoplasts, have demonstrated mPTP ‘flicker’ with various conductances 
across the mPTP.(826)
1.5.6.3.b Cells
Using the same TMRM model, Huser and Blatter(827) demonstrated that the mitochondria in 
myocytes loaded with TMRM undergo mPTP ‘flicker’. This phenomenon has also been 
observed in Duchen’s laboratory in myocytes(828;829) and astrocytes,(83°) and by Fall & Bennet in 
neuroblastoma cells.(831) The finding that mPTP opening occurs under physiological conditions 
was observed in a study by Di Lisa’s group(832) in which they demonstrated in hepatocytes, the 
mitochondria of which had been loaded with the fluorescent dye, calcein, that there was a 
spontaneous reduction in mitochondrial calcein fluorescence, indicating transient mPTP 
opening, which was sensitive to CsA. This finding has been confirmed in myocytes.(266)
1.5.6.3.C Whole Heart
In the mitochondrial 2-DOG entrapment technique, devised by Halestrap’s group(690;776;803;811:833) 
for detecting mPTP opening in the isolated perfused heart (in which mPTP opening is indicated 
by the mitochondrial entrapment of 2-DOG), the entry of 2-DOG into mitochondria was noted 
under basal conditions in several studies. This may have suggested that transient mPTP 
opening was occurring under physiological conditions, although this was not supported by the 
fact that it was demonstrated to be insensitive to cyclosporin-A.(690:776:803;811;833)
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1.5.6.4 Proposed Physiological Roles of the mPTP
Several physiological roles have been suggested for transient (low-conductance) mPTP 
opening:
Gunter & Pfeiffer(834) proposed that mPTP opening under physiological conditions could act as 
an energetically favourable mechanism for ridding mitochondria of excess solutes including 
Ca2+, and may also provide a pathway for uptake of essential components from the cytosolic 
compartment without a requirement for specific transport processes. In support of its role in 
mediating Ca2+ efflux, Altschuld and colleagues(835) demonstrated that cyclosporin-A inhibited 
mitochondrial efflux in adult rat myocytes under normal conditions, suggesting that Ca2+-efflux 
via mPTP opening occurs under physiological conditions. In this scenario, a rise in 
mitochondrial [Ca2+], which triggers mPTP opening, caused mitochondrial membrane 
depolarisation (allowing Ca2+ efflux via the mPTP), and the mPTP then closes once 
mitochondrial [Ca2+] had returned below threshold levels, allowing repolarisation to occur.(674)
1.5.6.3.b Role in Calcium Signalling
Evtodienko(836) observed in Ehrlich ascites tumour cells, that Ca2+ induced mitochondrial 
oscillatory changes in respiration, mitochondrial membrane potential, pH and Ca2+ efflux 
consistent with transient flickering of the mPTP. Subsequently, in a series of publications Ichas 
& Maza^5201647;648;815;®37-839) established a role for mitochondrial Ca2+-induced Ca2+ release 
(rnCICR) dependent on transitory opening of the mPTP operating in a low-conductance mode in 
conveying electrical and calcium signals. Initial studies demonstrated that Ca2+ loading induced 
a CsA-sensitive mitochondrial Ca2+ spike via transitory opening of the mPTP which rendered the 
inner mitochondrial membrane permeable to Ca2+, H+, and K+,(815) causing a mitochondrial 
depolarisation spike (mDPS)^647) Importantly, Ichas & Mazat demonstrated that a locally 
induced mDPS/mCICR could propagate throughout a population of mitochondria, and in this 
way propagate an electrical or calcium signal from one part of the cell to another^647) In the 
context of signalling, they demonstrated that during inositol 1,4,5-triphosphate (IP3)-induced 
mobilisation of Ca2+ from the endoplasmic reticulum, the rnCICR amplified the cytosolic Ca2+ 
transients.(647) The phenomenon of rnCICR has also been demonstrated in liver mitochondria 
by another laboratory.(816)
1.5.6.3.a As a Calcium Release Channel
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1.5.6.3.C To Mediate Mitochondrial ROS Release
Zorov and colleagues(840) have demonstrated that laser-induced generation of mitochondrial 
ROS, via photosensitisation of the fluorescent dye, TMRM, induces mPTP opening and 
subsequent ROS generation-termed ROS-induced ROS release.
1.5.6.3.d To Mediate Apoptotic Signalling Within the Cell
Transitory opening of the mPTP may release mitochondrial cytochrome C,(841) and Ca2+- 
dependent ‘waves’ of mitochondrial depolarization may contribute to propagation of the 
apoptotic signal within the cell.(842) Pacher & Hajnoczky(842) demonstrated that an apoptotic 
stimulus initiates a Ca2+-dependent ‘wave’ of mitochondrial depolarisation which was 
propagated through opening of the mPTP and was associated with cytochrome C release. A 
recent study by De Giorgi and colleagues(768) has demonstrated that mPTP flicker may induce 
mitochondrial cytochrome C release, which signals the mitochondrial translocation of the pro- 
apoptotic protein Bax.
1.5.6.3.e A Role in Learning and Synaptic Plasticity
A recent study suggests that a possible physiological function of the mPTP in the brain is to 
contribute to learning and synaptic plasticity through mitochondrial Ca2+ regulation. They 
observed that either VDAC-deficient mice or mice treated with CsA (at a concentration directed 
to target cyclophilin D) displayed difficulties in learning.(843)
1.5.7 Methods for Detecting mPTP Opening
When studying the role of the mPTP, it is necessary to be able to both induce and detect it 
reproducibly a nd a ccurately. H owever, m ost models w hich d etect m PTP o pening d epend o n 
measuring or detecting a known effect of mPTP opening such as mitochondria membrane 
depolarisation or following the re-distribution of membrane-impermeant molecules such as the 
fluorescent dye calcein (in isolated mitochondria or intact cells) or radio-labelled de-oxyglucose 
(in the whole heart), either into or out of mitochondria, on mPTP opening. Which ever model is 
used it is important to demonstrate that the variable that is being used to represent mPTP 
opening is sensitive to CSA (a potent inhibitor of mPTP opening).
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1.5.7.1 Detecting mPTP Opening in Mitochondria
In isolated mitochondria, the opening of the mPTP leads to:
1. matrix swelling which results in rupture of the outer mitochondrial membrane,
2. the release of pro-apoptotic factors such as cytochrome C from the intermembrane space,
3 . collapse of the mitochondrial membrane potential,
4. the release of small molecules up to 1500 Da from the matrix, including calcium and
fluorescent dyes such as calcein, through the mPTP.(9)
Therefore, detecting mPTP opening in this setting involves monitoring the consequences of 
mPTP opening.
1.5.7.1.a “Large Amplitude Matrix Swelling'  of Isolated Mitochondria
Mitochondrial matrix swelling secondary to mPTP opening is detected as the reduction in 
absorbance (when a spectrophotometer is used) or the increase in 90° light scattering (when a 
spectrofluorimeter is used) at a wavelength of 545 nm.(844) A variation of this technique was 
used by Haworth and Hunter in their original description of the mPTP.(7'10) They first induced 
mPTP opening with Ca2+ and then exposed the mitochondria to polyethylene glycol (PEG) 
which shrunk the mitochondria, and mPTP opening was indicated by the reduction in the light 
scattering that occurs on exposure to PEG.(7'10) The advantage of this technique is that it 
allowed the investigator to modify the mitochondrial matrix, such that the effect of mPTP 
inducers and inhibitors could be examined directly.
1.5.7.1.b Monitoring the Influx/Efflux of Proteins or Ions
Crompton’s group measured the influx of [14C]-sucrose to quantify mPTP opening in isolated 
mitochondria.(693) The loss of soluble proteins such as cytochrome C and apoptotic-inducing 
factor (AIF) which normally reside in the intermembranous space can be measured on induction 
of mPTP opening.(755) On mPTP opening, Ca2+efflux can be measured using Ca2+-sensitive dye 
or electrode^647)
1.5.7.1.C Detecting the Collapse in Mitochondrial Membrane Potential
Opening of the mPTP dissipates the mitochondrial membrane potential which can be detected 
using fluorescent dyes ora TPMP+ electrode. Using flow cytometry or confocal fluorescence 
microscopy,(825) the collapse in mitochondrial membrane potential that occurs on mPTP
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opening is represented by a loss in mitochondrial fluorescence of a lipophilic cationic dye. 
These dyes accumulate in the mitochondrial matrix, according to the electrochemical gradient, 
adhering to the Nernst equation,(845) according to which every 61.5 mV increase in membrane 
potential corresponds to a 10-fold increase in monovalent cation concentration in the matrix. 
Given that the mitochondrial membrane potential is usually -120 to -170mV, the concentration 
of cations is 2 to 3 logs higher in the matrix than in the cytosol.(844)
1.5.7.1.d Monitoring Caicein Efflux
The fluorophore, calcein, is membrane impermeable, although mitochondria can be loaded with 
its membrane-permeable non-fluorescent form, calcein acetoxymethyl ester (calcein-AM). Once 
within the mitochondria, non-specific esterases remove the acetoxymethyl ester group 
generating free calcein, which is fluorescent and becomes trapped within the matrix, as it is 
membrane impermeable. Given the size of calcein (620 Da) it can only leave the matrix if the 
mPTP opens. Therefore mPTP opening is represented by the loss of mitochondrial calcein 
fluorescence, which can be detected either by using flow cytometry or confocal
/755;825;846\microscopy.( ’ ' )
1.5.7.1.e Electrophysiological Studies
Patch clamp studies of excised mitochondrial membranes allows the investigator to a Iter the 
composition of the medium on either side of the membrane and permits measuring of the 
conductance characteristics of the mPTP.(707) Using this technique the Mitochondrial Mega 
Channel (MMC),(697) which has been subsequently identified as the mPTP,(847) was first 
discovered.
1.5.7.2 Detecting mPTP Opening in the Intact Cell
Until the development of these techniques, detecting mPTP opening in situ depended on 
monitoring secondary events such as mitochondrial membrane potential or on pharmacological 
tools such as CsA. However, the use of fluorescent dyes allows the direct assessment of mPTP 
opening, though this technique is not without its problems.(848) Most of these models depend on 
being able to follow the movement of fluorescent dyes in or out of mitochondria on opening of 
the mPTP, and employ the use of confocal fluorescence microscopy.
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1.5.7.2.a Dual Loading with TMRM and Calcein
This technique has been used extensively by Le Master’s group(470;653;849;850,851) to detect mPTP 
opening in both hepatocytes and myocytes. Cells are loaded with both calcein-AM which does 
not appear to enter mitochondria and TMRM which localises to the mitochondrial according the 
mitochondrial membrane potential. Opening of the mPTP is represented by (a) movement of the 
fluorescent dye, calcein, into the mitochondria from the cytosol and (b) loss of TMRM 
fluorescence on collapse of the mitochondrial membrane potential.(470;653;849;850;851)
Controversy surrounds this technique as Di Lisa’s group have been unable to reproduce 
this technique, arguing that the apparent filling defects present when loading with calcein are 
due to quenching of the calcein fluorescent signal by TMRM, and do not indicate 
mitochondria.(832;852) Therefore, on mPTP opening, when TMRM exits the mitochondria because 
of the mitochondrial membrane depolarisation, one would artifactually observe enhanced 
calcein fluorescence in the mitochondria, as the calcein signal is dequenched.(852)
1.5.7.2.b Loading with Calcein and Cobalt Chloride
Di Lisa’s group^321852-854) first described this technique for localising the calcein signal to 
mitochondria. If cells are loaded with calcein-AM alone, the calcein signal is not localised to the 
mitochondria. Therefore, by quenching the cytosolic calcein fluorescence signal using cobalt 
chloride, one can localise the calcein signal to the mitochondria. Opening of the mPTP is 
represented by the reduction in mitochondrial calcein fluorescence. This reproducible and 
reliable technique for detecting mPTP opening has been used by several other 
laboratories. (266:855;856)
The disadvantage of this technique is that cobalt chloride can interfere with Ca2+ uptake 
and slightly decreases respiration.(832) This technique was also demonstrated to detect transient 
(low-conductance) mPTP opening in hepatocytes(832) and myocytes.(266) Di Lisa’s group(832) 
demonstrated that mitochondrial calcein fluorescence declined under steady state conditions in 
a CsA-sensitive manner, indicating the occurrence of mPTP opening under physiological 
conditions.
1.5.7.2.C Loading with Calcein Alone
The mitochondria of cells are selectively loaded with calcein-AM, by using a method of loading 
that allows the cell to ‘pump’ out cytosolic calcein. Opening of the mPTP is represented by the
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movement of calcein out of the mitochondria.(857) The advantage of this technique is that it 
allows the mitochondrial loading of calcein without the use of cobalt chloride.
1.5.7.2.d Pinocytic Loading with Calcein
Cells are pinocytically loaded into the cytosol with free calcein (which is membrane 
impermeable). Opening of the mPTP is represented by movement of calcein into the 
mitochondria.(858)
1.5.7.2.e Detecting the Collapse in Mitochondrial Membrane Potential
In this technique, cells are loaded with the fluorescent dye, tetramethylrhodamine methyl ester 
(TMRM) which localises to mitochondria, according to the mitochondrial membrane potential. 
Laser-illumination of the cells generates reactive oxygen species within the mitochondria, which 
provoke mPTP opening, as detected by mitochondrial membrane depolarisation. This technique 
has been used in a number of different laboratories and represents a reproducible technique for 
inducing and detecting mPTP opening in the intact cell (647;768;827-830;839;840;859;860)
However, there have been studies which suggest that the mitochondrial depolarisations 
observed when u sing T MRM f luorescence d o n ot indicate m PTP o pening, but t hese s tudies 
refer to the physiological oscillations in mitochondrial respiration and membrane potential, in the 
absence of significant oxidative stress^861*863)
1.5.7.3 Detecting mPTP Opening in the Whole Heart
Halestrap’s grOup(666:690:776:783:803;811) have developed a technique for detecting mPTP opening in 
the isolated perfused rat heart. Rat hearts are perfused with titriated 2-deoxyglucose before 
being subjected to ischaemia-reperfusion injury. The 2-DOG loads into the cytosol but can only 
enter the mitochondria if mPTP opening occurs. Therefore, the mitochondrial entrapment of 2- 
DOG is used as a measure of mPTP opening.
Di Lisa’s group(777) devised an alternative method for detecting mPTP opening in the 
isolated perfused rat heart. The mitochondrial loss of NAD+ is used as a measure o f mPTP 
opening. However, because the mitochondrial loss of NAD+ can occur under conditions of 
membrane damage, it may not be specific for mPTP opening. Therefore, this technique would 
have to be used in conjunction with the detection of mitochondrial NAD+ loss from isolated 
mitochondria.
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1.6 Summary and Main Objectives of the Thesis
Mitochondrial permeability transition pore (mPTP) opening is induced under pathological 
conditions such as ischaemia-reperfusion injury, when conditions which predispose to its 
opening prevail. These include a high mitochondrial [Ca2+] and [Pi], ATP depletion and oxidative 
stress. Opening of the mPTP disrupts normal mitochondrial function and is a critical determinant 
of both apoptotic and necrotic cell death. Therefore, inhibiting mPTP opening during ischaemia- 
reperfusion injury offers a powerful target for protecting the heart against ischaemia-reperfusion 
injury.
The main a im o f t his t hesis i s t o d emonstrate that i nhibiting t he m PTP o pening t hat 
occurs at the time of reperfusion, following a lethal period of ischaemia, is a common 
mechanism for cardio-protection whether it be by agents which protect when given at the time of 
reperfusion or by myocardial preconditioning. In Chapter 4, we examine the effect of 
pharmacologically inhibiting mPTP opening during the first few minutes of post-ischaemic 
reperfusion, the time-period when mPTP opening has been demonstrated to occur. In Chapter 5, 
we examine the powerful cardio-protective phenomenon that is myocardial preconditioning, and 
we investigate a novel mechanism of protection in this setting. Specifically we investigate 
whether this form of protection is mediated by the inhibition of mPTP opening at the time of 
reperfusion. In Chapter 6, we examine the pro-survival kinases, Akt and Erk1/2 MAPK, as a 
possible mechanism linking the process of myocardial preconditioning to the inhibition of mPTP 
opening, at the time of reperfusion. Finally, in Chapter 7, we examine the role of the mPTP as a 
potential mediator of myocardial preconditioning. Specifically, we examine the transient (low- 
conductance) form of mPTP opening, which paradoxically, does not lead to cell death and may 
actually benefit cellular function.
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Chapter Two: HYPOTHESES
2.1 HYPOTHESIS ONE
Inhibiting the prolonged (high-conductance) mPTP opening which takes place at 
reperfusion is a common target for cardio-protection: irrespective of whether protection 
is mediated by myocardial preconditioning or by interventions applied solely at the time 
of reperfusion.
This first major hypothesis was divided into 3 parts:
2.1.1 Inhibiting the prolonged (high-conductance) mPTP opening that occurs at the time of 
reperfusion, following a lethal ischaemic insult, protects the heart against ischaemia-reperfusion 
injury.
2.1.2 Myocardial preconditioning protects by inhibiting the prolonged (high-conductance) 
mPTP opening that occurs at time of reperfusion, following a lethal ischaemic insult.
2.1.3 Myocardial preconditioning protects by inhibiting the prolonged (high-conductance) 
mPTP opening that occurs at time of reperfusion, via the activation of the pro-survival kinases 
Akt and Erk1/2.
In section 1.5.5 of the introduction an account was given outlining the role of the prolonged 
(high conductance) opening of the mPTP, which occurs at the time of reperfusion, as a critical 
determinant of cell death in the setting of ischaemia-reperfusion injury. The first objective of the 
study (2.1.1) was to demonstrate that pharmacologically inhibiting its opening at the time of 
reperfusion protects the heart against ischaemia-reperfusion injury (see chapter 4).
The next objective (2.1.2) was to determine whether the powerful protection associated 
with inhibiting the prolonged (high-conductance) mPTP opening at the time of reperfusion, is a 
common mechanism of cardio-protection and whether it contributes to the protection induced by 
the phenomenon of myocardial preconditioning (see chapter 5).
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The next objective (2.1.3) was to explore the potential mechanisms through which 
myocardial preconditioning inhibits mPTP opening at the time of reperfusion. In this regard, the 
role of the pro-survival kinases Akt and Erk1/2 was examined (see chapter 6).
2.2 HYPOTHESIS TWO
Transient (low-conductance) opening of the mPTP mediates both preconditioning and 
mitochondrial uncoupling-induced protection by acting as a channel for mitochondrial 
ROS release.
In section 1.5.6 of the introduction, the transient (low-conductance) form of mPTP opening was 
described. This form of mPTP opening does not lead to cell death and may actually contribute 
to the protective mechanisms associated with myocardial preconditioning, by reducing 
mitochondrial calcium load and facilitating mitochondrial ROS release/signalling. The role of this 
transient (low-conductance) form of mPTP opening in myocardial protection associated with 
ischaemic preconditioning and mitochondrial uncoupling was examined (see chapter 7).
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Male Sprague-Dawley rats were used in this study. All animals were obtained from Charles 
River UK Limited, (Margate, UK), and received humane care in accordance with The Guidance 
on the Operation of the Animals (Scientific Procedures) Act 1986 (The Stationery Office, 
London, UK). Animals were allowed to acclimatise for a minimum of 4-5 days prior to use. They 
were kept in cages of four and had free access to fresh water and standard pellet chow (RM1 
diet) and were subjected to a 12 hour light-dark cycle, and maintained at 19-22°C, and 55±10% 
humidity.
3.2 In Vitro Infarct Model in Rat Heart
The isolated crystalloid-perfused rat heart model of ischaemia-reperfusion was employed for 
this study to simulate the human pathological condition of myocardial ischaemia-reperfusion 
injury for several reasons: (1) it is a highly reproducible robust preparation which permits the 
measurement of: contractile function, biochemical markers of necrosis (such as lactate 
dehydrogenase and creatine kinase), morphological markers (such as infarct size) and 
electrophysiological markers (such as arrhythmias); (2) it allows the study of large numbers in a 
relatively short period of time and provides reproducible data; (3) it allows the examination of 
various pharmacological agents in the setting of ischaemia-reperfusion injury, (4) it removes the 
confounding effects of the systemic circulation (neuro-hormonal factors) and therefore allows 
one to examine the direct effect of interventions on the myocardium.(864)
The disadvantages of this preparation include: (1) the heart being isolated from blood- 
borne factors and neuronal innervation, meaning that it is unable to simulate in vivo conditions; 
(2) the preparation is constantly deteriorating^864)
3.2.1 Langendorff Crystalloid-Perfused Rat Heart Model
In this study, the Langendorff perfused heart model, as first described by Oscar Langendorff in 
1895,(865) was used. Rats were anaesthetised with sodium pentobarbital (55 mg/kg intra- 
peritoneally, Sagatal-Rhone Merieux), and were given heparin sodium (300 IU intra-peritoneally, 
Multiparin CP Pharmaceuticals Ltd.) to prevent thrombus formation in the heart and vessels.
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When the rat was sufficiently anaesthetised, indicated by the loss of the pedal withdrawal reflex, 
a trans-abdominal incision was made and the thoracic cavity was exposed by a bilateral incision 
along the lower rib margin. The anterior thoracic cage was then reflected superiorly, and the 
heart was gently held between the fingers and excised.
Immediately after excision, the heart was immersed in cold perfusion solution (at 4°C to 
limit ischaemic injury and to arrest the heart) and then mounted on a constant hydrostatic 
pressure (at 100 mmHg) Langendorff-perfusion apparatus (represented schematically in figure 
3.1). The time taken from excising the heart to mounting the heart on the Langendorff apparatus 
was kept under one minute, to avoid inadvertently inducing ischaemic preconditioning. The 
constant pressure mode of perfusion was used as it allows auto-regulatory mechanisms 
induced by ischaemia-reperfusion to manifest, whereas a constant flow mode of perfusion, may 
over-ride these mechanisms.(864)
The heart’s aorta was cannulated, allowing retrograde perfusion of crystalloid down the 
vessel, which forces the aortic valves shut and directs the perfusate into the coronary arteries. 
The whole myocardium is therefore perfused, with the perfusate then draining into the right 
atrium. The hearts were perfused with a modified Krebs-Henseleit bicarbonate buffer containing 
(in mmol/l): NaCI 118.5, NaHC03 25.0, KCI 4.8, MgS04 1.2, KH2P04 1.2, CaCI2 1.7, and 
glucose 12.(866) The major modification made to the original composition described by Krebs & 
Henseleit was the reduction in CaCI2from 2.5 to 1.7 mmol/l, as the former concentration does 
not take into account the calcium bound to proteins. All solutions were filtered through a 
Whatman 1.0-pm microfilter to remove particulate impurities and were bubbled with 95% 
0 2/C 02, at a flow which maintained the pH between 7.35-7.40, as measured using a gas 
analyser (ABL 700, Radiometer, Denmark).
Temperature was continuously monitored by a thermo-probe inserted into an incision 
made at the base of the pulmonary artery and was m aintained b etween 37.0°C and 37.5°C 
(figure 3.1). Temperature was controlled by use of a thermostatically-controlled water-jacketed 
system in which all glass reservoirs and the heart perfusion chamber are surrounded by rapidly 
flowing warmed water at 37.0-37.5°C, using a water circulator (figure 3.1).
A latex, fluid-filled, iso-volumic balloon was introduced into the left ventricle via the left 
atrium, through a hole made by removing the left atrial appendage, to monitor contractile 
function of the left ventricle. The balloon was inflated with distilled water to give a left ventricular 
end d iastolic p ressure o f 4 -8 m mHg, w hich was d isplayed o n a c hart r ecorder ( Multitrace 2,
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Lectromed, UK) (see figure 3.1). Left ventricular developed systolic and diastolic pressures, 
heart rate and coronary flow were noted at regular intervals.
A 3/0 Mersilk suture was passed under the left main coronary artery, using a round­
bodied curved surgical needle, and the ends of the suture were passed through a pipette tip to 
form a snare (figure 3.2 depicts a heart in stabilisation). After the 30 minutes stabilisation period, 
the hearts were subjected to 35 minutes regional ischaemia. This was induced by occluding the 
left main coronary artery with the snare, thereby clamping the snare to the epicardial surface 
(figure 3.3 depicts a heart in regional ischaemia). Effective ischaemia was confirmed by a 50% 
reduction in coronary flow rate and rate pressure product.
After 35 minutes of regional ischaemia, reperfusion was initiated by releasing the ends 
of the suture, and the heart was perfused for 120 minutes. An increase in coronary flow upon 
reperfusion was indicative of successful re-flow, but coronary flow subsequently declined in all 
groups during the 120 minutes reperfusion period. In reperfusion the left ventricular developed 
pressure recovered gradually, though never reaching stabilisation values, a feature of “run­
down” in this experimental procedure (864).
In the early part of the study, a standard constant-pressure Langendorff apparatus was 
employed for isolated rat heart perfusion (figure 3.1). However, in the latter part of the study, a 
Langendorff-apparatus (AD Instruments Ltd, Australia) devised by Professor Shattock and 
colleagues was used in which an electrical feedback system monitors the perfusion pressure 
and maintains the delivery of a constant pressure mode of perfusion.(867) In this set-up, 
haemodynamic variables were measured and displayed using a Mac Lab.
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Figure 3.1: Schematic Representation of Langendorff-Perfusion Apparatus. The
isolated rat heart is mounted on a steel aortic cannula and perfused in constant pressure mode 
(100 mmHg) with oxygenated Kreb’s Henseleit buffer which is warmed as it passes through the 
heated water jacket. A fluid-filled latex balloon inserted into the left ventricle monitors the left 
ventricular pressure, which is displayed on the chart recorder. A thermo-probe inserted into the 
pulmonary artery monitors temperature. The coronary effluent is measured as an indicator of 
the coronary flow rate.
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Figure 3.2: Isolated Perfused Rat Heart in Stabilisation: with loose snare and plastic
pipette tip positioned around the left coronary artery.
—  Aortic cannula
—  Silk suture around left main coronary artery
—  Plastic pipette tip snare
—  Heated organ bath
Figure 3.3: Isolated Perfused Rat Heart in Ischaemia: with suture pulled tight and held in
place by plastic pipette tip snare, to induce regional ischaemia.
Plastic pipette tip snare pulled tight to 
induce regional ischaemia
Figure 3.4: Delineation of the Risk Zone of the Isolated Perfused Rat Heart: with the
suture tied-off, the perfused Evan’s blue stains the non-risk area blue, leaving 
the risk area unstained.
™ Unstained risk area
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3.2.2 Determination of Infarct Size
Myocardial Infarct size was determined after 120 minutes reperfusion, using the
triphenyltetrazolium technique, which has been used to quantify infarct size in many
experimental models.(868;869)
At t he e nd o f t he 120 m inute r eperfusion p eriod, t he s nare was p ulled tight a nd t he 
heart was slowly perfused with saline solution containing 0.25% Evans blue (Sigma Chemicals, 
Poole, Dorset), to delineate the non-ischaemic zone of the myocardium as a dark blue area 
(figure 3.4 depicts a heart perfused with Evans blue). After 1 to 4 hours at -20 °C, the hearts 
were sliced into 5 x 2mm-thick transverse sections from apex to base, and incubated in 
triphenyltetrazolium chloride (Sigma Chemicals, Poole, Dorset) solution (1% in phosphate buffer, 
pH 7.4) at 37°C for 15 minutes.
Measuring infarct size using tetrazolium staining depends on the ability of 
dehydrogenase enzymes and cofactors present in viable myocardial tissue reacting with 
tetrazolium salts and forming the red formazan pigment.(870) Dehydrogenase enzymes and 
cofactors are washed out during the phase of reperfusion from the infarcted tissue and therefore 
do not stain with the red formazan pigment and appear as white areas devoid of pigment. In the 
isolated crystalloid-perfused rat heart, it is essential to reperfuse for at least 2 hours to ensure 
adequate wash-out of dehydrogenase enzymes and cofactors. Inadequate wash-out of
dehydrogenase enzymes and cofactors from use of a shorter reperfusion times will
underestimate the infarct size.(868)
The tissue slices were then put in 10% formalin (BDH Laboratory Supplies, Poole, UK) 
for 24 hours, to make the infarcted area easier to distinguish. In the risk zone the viable tissue 
was stained red and the infarcted tissue appeared pale (figure 3.5 depicts heart slices stained 
with tetrazolium). The stained slices were then placed between two clear Perspex plates which 
were held together with spring clamps, and were then traced onto clear acetate and with the 
use of a computerised planimetry package (Summa Sketch III, Summagraphics, Seymour, CT, 
USA), the percentage of infarcted tissue within the volume of myocardium at risk was calculated 
and expressed as infarct-risk volume ratio (l/R%) (figure 3.6 depicts the planimetered heart 
slices).
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Figure 3.5: Tetrazolium-Stained Heart Slices: taken from (a) control hearts (35 minutes of
left main coronary artery occlusion followed by 120 minutes of reperfusion) and (b) ischaemic 
preconditioned (IPC) hearts (which underwent the same ischaemia-reperfusion protocol, 
preceded by an IPC protocol comprising two five minutes coronary occlusions with an 
intervening 10 minutes reperfusion). The slices demonstrate areas of infarction (white), non- 
infarcted risk area (red) and non-risk area (blue). Note the smaller infarct area in preconditioned 
hearts vs the control hearts.
(a) Control Non-risk
(b) Preconditioned
area Risk area
Infarcted area
Figure 3.6: Planimetred Heart Slices: taken from (a) control and (b) ischaemic
preconditioned hearts stained depicting infarcted areas (red), non-infarcted risk area (green) 
and non-risk area (yellow).
(a) Control Non.rjsk area Risk area
(b) Preconditioned
Infarcted area
3.2.3 Exclusion Criteria
Hearts were excluded from the study if after the 30 minutes stabilisation period, the rate 
pressure product (RPP, heart rate multiplied by left ventricular developed pressure) was less 
than 17 mmHg/min or the coronary flow rate was <10 ml/min. Hearts were also excluded if the 
risk volume was either less than 0.3 cm3 or greater than 0.7cm3.
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3.3 Preparation of Adult Rat Mitochondria
The centrifuge was pre-cooled to 4°C by spinning with no samples for 15 minutes at 5800 g. 
Rats were anaesthetised with sodium pentobarbital (55 mg/kg intra-peritoneally, Sagatal-Rhone 
Merieux), and were given heparin sodium (300 III intra-peritoneally, Multiparin CP 
Pharmaceuticals Ltd.) to prevent thrombus formation in the heart and vessels. When the rat 
was sufficiently anaesthetised, indicated by the loss of the pedal withdrawal reflex, a trans­
abdominal incision was made and the thoracic cavity exposed by a bilateral incision along the 
lower rib margin. The anterior thoracic cage was then reflected superiorly, and the heart was 
gently held between the fingers and excised.
Immediately after excision, the heart was immersed in cold perfusion solution (at 4°C to 
limit ischaemic injury) and then mounted on an adapted constant flow (at 14 ml/min) non­
recirculating Langendorff-perfusion apparatus, and perfused for 5 minutes with modified Krebs- 
Henseleit buffer containing (in mmol/l): NaC1118.5, NaHC03 25.0, KCI 4.8, MgS04 1.2, KH2P04
1.2, CaCI21.7, and glucose 12, to displace all the blood.
The heart was then removed from the perfusion apparatus and cut into pieces in a Petri 
dish and placed into a 50 ml falcon tube containing Isolation Buffer 1 which comprised (in 
mmol/l): mannitol 210, sucrose 70, Tris/HC110, fatty acid-free BSA 0.5 mg/ml, and EGTA 1 (pH 
7.3). The heart tissue was then homogenised, using a Polytron model T25 homogeniser (IKA 
Labortechnik T25, Janke & Kunkel GmbH & Co., Germany), for 15 seconds and the solution 
was centrifuged at 450 g for 5 minutes at 4°C. Following this, 35 ml of the supernatant was 
removed and transferred to a reinforced centrifuge tube and spun at 5800 g for 10 minutes at 
4°C. The remaining 15 ml containing the pellet was discarded. The 35 ml supernatant was then 
decanted and discarded and the pellet was re-suspended in 5 ml of Isolation Buffer 2, which 
comprised (in mmol/l): mannitol 210, sucrose 70, Tris/HCI 10. The solution was then spun at 
5800 g for 10 minutes at 4°C. The supernatant was decanted and the pellet was re-suspended 
in 3 ml of Respiratory Buffer 1 which comprised in mmol/l: sucrose 250, HEPES 10, K2HP04 2. 
To this, 3ml of Respiratory Buffer 2 was added, which contained in mmol/l: HEPES 10, KCI 80, 
Mg acetate 2.
After extraction, the mitochondria were kept on ice suspended, in the 6 ml of the 
combined respiratory buffers (at pH 7.5), and were used within 6 hours. To ensure equal 
amounts of mitochondria were used for each experiment the protein content of each
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mitochondrial sample was determined, and 0.5 mg/ml of mitochondrial was used for the 
experiment (see section 3.3.1).
The viability of the isolated mitochondrial sample, was tested by determining the 
mitochondrial membrane potential (an indication of the extent of mitochondrial respiratory 
coupling), using flow cytometrical analysis (see section 3.4).
3.3.1 Protein Quantification
The Bicinchoninic acid-based (BCA™) protein assay reagent system (Pierce, Rockford, USA) 
was used to estimate the protein concentration of the mitochondrial samples. Duplicate 
mitochondrial samples were incubated for 30 minutes at 37°C, with a mixture of Cu2+ and 
bicinchoninic acid (BCA), which is originally green in colour, and forms a purple solution on 
formation of the BCA-Cu2+ complex. The optical density of the solution was determined by 
measuring the absorbance at 562 nm, using a photo-spectrometer (Janway model 6405 UVA/is, 
Dunmow, UK). The relationship between the absorbance and protein content is linear over (20- 
2000 pg/ml), and therefore a standard calibration curve can be obtained by measuring the 
absorbance for duplicate samples containing increasing concentrations of bovine serum albumin 
(BSA): 0, 10, 20, 30, 40 pg/pl. Using the standard curve, the protein content (pg/pl) for each 
mitochondrial sample was then derived from the optical absorbance for that particular sample.
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Flow cytometry is the measurement of cells in a flow system: and applies to instruments which 
focus light on to cells and record their fluorescence and light scattered by them. Typically, five 
parameters can be measured: using blue light (generated by the 488-nm argon laser) for 
excitation, one can record green, orange, and red fluorescence and blue light scattered in a 
forward direction (forward scatter) and at right angles to the laser beam (side-scatter). Cyto- 
fluorometric analysis was performed on a Partec flow cytometer (Partec, Munster, Germany) 
equipped with a 488-nm argon laser (see figure 3.7).
In the present study, the 488-nm laser was used to excite a fluorescent compound 
within mitochondria which absorbs the light and then emits light at a lower energy and therefore 
longer wavelength than the exciting light (see figure 3.8). Much of the light directed at the 
mitochondria is scattered in a forward or sideways direction by the mitochondrial surface (so- 
called forward and side scatter, see figure 3.8 and 3.9). However, some of the light is absorbed 
by the fluorescent compound within the cell and is emitted at a longer wave-length, thereby 
enabling its differentiation from the light scatter. Measurements are made as the mitochondrial 
sample flows through the instrument. The mitochondria are reproducibly delivered to the 
measuring point, using hydrodynamic focusing, which involves introducing a slow stream of 
mitochondria into a quickly moving carrier fluid (which constrains the mitochondria to the centre 
of the tube). The emitted light is directed to the appropriate detector, directed through the use of 
dichroic and band-pass filters. Dichroic filters are selective mirrors which allow the transmission 
of long wavelengths while reflecting short wavelengths (see figure 3.8). Band-pass filters allow 
light of a specific wavelength, or narrow band of wavelengths, to pass through.
To determine the viability of the isolated mitochondrial sample, a 2 ml 0.5 mg/ml sample 
was incubated w ith 200 nmol/l of the fluorometric probe, tetramethyl rhodamine methyl ester 
(TMRM, Molecular Probes Inc., Leiden, The Netherlands), for 2 minutes at room temperature. 
TMRM is a cationic probe which reversibly accumulates in the mitochondria according to the 
negative mitochondrial membrane potential with a Nernstian distribution^845) Using the flow 
cytometer, the TMRM fluorescence (an indicator of mitochondrial membrane potential) was 
measured, both before and after the addition of 1 pmol/l of the ionophore, carbonyl cyanide p- 
(trifluoromethoxy)phenylhydrazone (FCCP, Sigma Chemicals, Poole, Dorset), which by 
uncoupling mitochondrial respiration should result in a reduction in TMRM fluorescence
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(indicating collapse of the mitochondrial membrane potential). Mitochondrial samples were 
excluded if they did not produce these changes in mitochondrial membrane potential, indicating 
that they were not respiratory coupled.
For TMRM fluorescence, the signal was analysed in the FL2 channel equipped with a 
band-pass filter at 580 nm; the photo-multiplier value of the detector was 631 V. The flow 
cytometer counts the number of mitochondria (depicted as ‘Counts’ on the Y scale) at a 
particular fluorescence or light intensity on the logarithmic X scale (see figure 3.9). Arithmetic 
mean values of the median fluorescence intensities were determined for each sample for 
graphic representation.
Figure 3.7: Flow Cytometer
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Figure 3.8: Basic Principles of Flow Cytometry: Light from the 488-nm Argon laser is 
directed at the downward moving mitochondrial sample. Light is absorbed by the fluorescent 
probe contained within the mitochondria, and is emitted at various lower energy longer 
wavelengths, which are then directed by means of the dichroic and band-pass filters to the 
appropriate detector: FL1 for mitochondrial calcein fluorescence and FL2 for mitochondrial 
TMRM fluorescence. Light scattered on the mitochondrial surface is detected as forward and 
side scatter at the same wave-length.
Detectors
FL2 ChannelDichroic Filters
FL1 Channel
Mitochondrial
sample
Band-Pass Filters
Forward Scatter
Waste
Figure 3.9: Representative Flow Cytometric Profile of Unstained Mitochondria: Light 
scattered on the mitochondrial surface is detected as forward (FSC) and side scatter (SSC) at 
the same wave-length, demonstrating a distinct mitochondrial population.
File: SrtMnga Data: 18-01-2002 Time: 12:43:83 Particler 20000 Acq.-Tlw: 101
1000?--------------------------------------------------n SOO-i------------------------------------
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3.5 Preparation of Adult Rat Myocytes
Chapter 3: General Methods
Isolated ventricular myocytes provide a uniform population of a cell type free from neuro- 
hormonal influence in an environment which can be controlled. Rats were anaesthetised with 
sodium pentobarbital (55 mg/kg intra-peritoneally, Sagatal-Rhone Merieux), and were given 
heparin sodium (300 IU intra-peritoneally, Multiparin CP Pharmaceuticals Ltd.) to prevent 
thrombus formation in the heart and vessels. When the rat was sufficiently anaesthetised, 
indicated by the loss of the pedal withdrawal reflex, a trans-abdominal incision was made and 
the thoracic cavity exposed by a bilateral incision along the lower rib margin. The anterior 
thoracic cage was then reflected superiorly, and the heart was gently held between the fingers 
and excised. Immediately after excision, the heart was immersed in cold perfusion solution (at 
4°C to limit ischaemic injury) and then mounted on an adapted constant flow (at 14 ml/min) non­
recirculating Langendorff-perfusion apparatus (figure 3.7).
All buffers were made from autoclaved distilled water and were based on a modified 
calcium-free Krebs-Ringer’s-HEPES (KRH) buffer (in mmol/l): 116.0 NaCI, 5.4 KCI, 0.4 MgS04,
20.0 HEPES, 0.9 Na2HP04, 5.6 glucose (pH 7.4). All solutions were filter-sterilised prior to use. 
The perfusate was bubbled with 100% 0 2 and maintained at 37°C using a thermostatically- 
controlled water-jacketed system in which all glass reservoirs, and the heart perfusion chamber 
are surrounded by rapidly flowing warmed water at 37.0-37.5°C, using a water circulator.
The heart was initially perfused with Buffer 1 comprising KRH buffer containing 1 mg/ml 
BSA and 3.3 pmol/l EGTA (figure 3.7). After 5 min the heart was perfused with Buffer 2 
comprising KRH buffer containing 0.75 mg/ml collagenase (Type II LS004176, Worthington 
Biochemical Corporation, Lakewood, NJ), and 25 pmol/l calcium for 10-15 min (figure 3.7). The 
heart was finally perfused with Buffer 3 comprising KRH buffer containing 50 pmol/l calcium for 
5 minutes (figure 3.7). Following perfusion the heart was removed from the Langendorff 
apparatus and the atria trimmed away. The ventricles were then carefully cut into strips and 
placed in a Petri-dish with collagenase for 10 minutes, and the Petri-dish was gently agitated at 
37°C. Harvested cells were then filtered through a nylon mesh and washed with restoration 
buffer comprising KRH buffer + (in mmol/l) 0.5 Na pyruvate, 5.0 taurine, 2.0 carnitine, 1.0 
creatine + 75 pmol/l calcium + 10 mg/ml BSA, using low speed centrifugation (1000 rpm for 30 
seconds) to sediment the cells. The remaining undigested heart tissue underwent a further 20
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minute collagenase digestion, which usually resulted in complete dispersal of ventricular cells. 
Again these cells were washed in restoration buffer and these were then added to the cells from 
the first collagenase digestion. The calcium concentration was increased in a step-wise manner 
to 1.25 mmol/l, by adding 5 aliquots of 235 pmol/l calcium, with one added every 15 minutes, in 
order to render the cells calcium-tolerant.
After isolation, cell viability was assessed using light microscopy and routinely averaged 
80-90%. Isolations yielding less than 60-70% viable cells were excluded.
Figure 3.10: Langendorff Perfusion Apparatus for Preparing Adult Rat Myocytes: the
isolated rat heart is perfused in sequence with the 3 buffers.
Buffer 1 Buffer 2 Buffer 3
Isolated perfused rat 
heart
135
Derek J Hausenloy
3.6 Preparing Myocytes for Confocal Microscopy
Chapter 3: General Methods
For confocal microscopy, the cells had to be seeded onto 25 mm diameter round glass cover- 
slips. All the following procedures were conducted in a sterile positive-pressure Microbiological 
Safety Cabinet (Walker Safety Cabinets Ltd, Derbyshire, UK). Before use, these cover-slips 
were sterilised with 100% ethanol and were washed in sterilised phosphate buffered saline 
(PBS). Once the cover-slips were dry, 200 p I of laminin (1 mg/ml d iluted in 30 ml of d istilled 
water, Sigma Chemicals, Poole, Dorset), was pipetted onto the centre of the cover-slip and left 
to dry for 1-134 hours. 500 pi of the cell suspension was then carefully placed on the laminin 
residue in the centre of the cover-slip. The cells were left to settle and seed to the cover-slips for 
134-2 hours in an incubator (C02 Incubator, C028IR, New Brunswick Scientific, USA) at 37°C in 
an atmosphere of 95% air/ 5% C 02. After adequate seeding, the restoration buffer was carefully 
replaced with M-199 medium (M7653, Sigma Chemicals, Poole, Dorset) containing 10% foetal 
calf serum (Sigma Cell Chemicals, Poole, Dorset) and 1% penicillin-streptomycin (Sigma 
Chemicals, Poole, Dorset), and the cells were incubated overnight at 37°C in an atmosphere of 
95% air/ 5% C 02. Next day the cells were washed with restoration buffer and kept in the 
incubator until use.
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3.7 Confocal Microscopy
Chapter 3: General Methods
All confocal imaging and analysis was conducted in the Mitochondrial Biology Group, the 
department of Physiology, University College London in collaboration with Professor Michael 
Duchen. The 25 mm round cover-slip containing the seeded myocytes was placed in a custom- 
made chamber with 1 ml of restoration buffer and mounted on the stage of a Zeiss 510 CLSM 
confocal microscope equipped with x40 oil immersion, quartz objective lens (NA 1.3).
For measuring tetramethylrhodamine methyl ester (TMRM) fluorescence, the cells were 
illuminated using the 543 nm emission line of a henna laser. The fluorescence of TMRM was 
collected using a 585 nm long pass filter. For measuring calcein fluorescence, the cells were 
illuminated using the 488 nm emission line of an Argon laser. The fluorescence of calcein was 
collected using a 505 nm long pass filter.
Images were analysed using the Zeiss software (LSM 2.8) and also using Lucida 
(Kinetic Imaging, Wirral) to measure changes in mean and SD of the signals with time.
Figure 3.11: Confocal Microscope With Camera Attached
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3.8 Western Blotting
Chapter 3: General Methods
3.8.1 Collecting Tissue Samples
Hearts were isolated from anaesthetised male Sprague-Dawley rats and mounted on the 
Langendorff-apparatus and subjected to the relevant ischaemia-reperfusion protocols set out in 
Chapter 6. At time points determined by the relevant protocols, coronary flow was terminated 
and the snare, that was used to induce regional ischaemia (see section 3.2.1), was pulled tight 
and the heart was slowly perfused with saline solution containing 0.25% Evans blue (Sigma 
Chemicals, Poole, Dorset), to delineate the ischaemic risk zone of the myocardium as the 
unstained area (figure 3.4). The ischaemic risk zone was excised from the rest of the heart, and 
immediately snap-frozen in liquid nitrogen using pre-cooled tongs. The heart sample was then 
broken into small pieces and stored at -70°C for Western blot analysis.
3.8.2 Protein Extraction
For each collected heart sample (see section 3.8.1), approximately 50 mg of frozen heart tissue 
was used. The tissue was homogenised, using a Polytron model T25 homogeniser (IKA 
Labortechnik T25, Janke & Kunkel GmbH & Co., Germany), on ice in 250 pi of suspension buffer, 
which comprised (in mmol/l): NaCI 100, TRIS 10 (pH 7.6), EDTA 1 (pH 8.0), sodium 
pyrophosphate 2, sodium fluoride 2, p-glycerophosphate 2, phenyl methyl sulphonyl fluoride 
(PMSF) 0.1 pg/ml, and 1 pg/ml each of aprotonin, leupeptin, trypsin inhibitor and protease 
inhibitor. This part of the procedure lyses the cells and releases proteins. The latter constituents 
of the sample buffer are protease inhibitors which prevent protein degradation of the sample.
The homogenised samples were then centrifuged at 10,000 rpm for 10 minutes at 4°C 
and the pellet (containing cellular debris) discarded. The protein content of the supernatant from 
each protein sample was determined using the Bicinchoninic acid-based (BCA™) protein assay 
reagent system (Pierce, Rockford, USA)(see section 3.3.1). The protein sample was then diluted 
in 2x sample buffer, comprising (in mmol/l): Tris 100 (pH 6.8), dithiothreitol (DTT) 200, sodium 
dodecylsulphate (SDS) 2%, bromophenol blue 0.2%, and glycerol 20%) and subsequently 
heated for 10 minutes at 100°C, and then stored at -70°C for later analysis.
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3.8.3 Preparing the Gel and Electrophoresis
For the present study, SDS-PAGE gels were used. The gel was made between two carefully 
cleaned glass plates separated by spacers and combs, and the edges were sealed with agarose 
gel. The gel consisted of:
(1) the 5% stacking gel (comprising 7.0 ml de-ionised H20, 3 ml stacking gel base [comprising 
0.5 M TRIS, 0.4% SDS in de-ionised H20 , pH 6.8], 2 ml 30% acrylamide, 20 pi 8% bromophenol 
blue, 24 pi TEMED and 120 pi 10% ammonium persulphate) and
(2) the 12.5% running gel (comprising 12 ml de-ionised H20, 9 ml stacking gel base [comprising 
1.5M TRIS, 0.4% SDS in de-ionised H20, pH 8.8], 15 ml 30% acrylamide, 40 pi TEMED and 200 
pi 10% ammonium persulphate).
The SDS is the denaturing agent that binds proteins so they become negatively charge 
and therefore separate on the basis of size alone and not on the intrinsic protein charge. The 
APS is a polymerisation catalyst required for gel formation. The TEMED is also a polymerisation 
catalyst, which catalyses the formation of persulphate free radicals from the APS, which in turn 
initiates polymerisation.
For each lane of the stacking gel, 30 pg of protein was loaded into each well. A 
molecular weight Rainbow marker was also loaded (10 pi) onto the gel. The gel was then placed 
in a vertical electrophoresis system containing running buffer (comprising glycine 14.4 g/l, SDS
1.0 g/l, Tris 3.0, distilled H20  1 litre) and the gel was allowed to run for 4-5 hours at 125 V.
3.8.4 Protein Transfer
After electrophoresis, the gel was mounted in a tank transfer system containing transfer buffer 
(200 ml methanol, 700 ml distilled H20, 100 ml of transfer buffer [glycine 14.4 g/l, Tris 3.0 g/l, 
distilled H20  1 litre]). The gel was carefully placed on a Hybond ECL nitrocellulose membrane 
(Amersham, UK), cut to the same shape as the gel. The gel and membrane were then placed 
between two pieces of Whatman paper, and any air bubbles were removed. The proteins were 
then allowed to transfer overnight (12-16 hours) at 140 mA. The gels were stained with 
Coomassie blue to confirm adequate transfer of proteins. After Western blotting, the membrane 
was t hen r emoved a nd a dequate t ransfer o f p roteins w as f urther c onfirmed b y P onceau R ed 
staining of the membranes (Sigma Chemicals, Poole, UK).
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3.8.5 Antibody Probing
The membrane was then placed on a rocking platform and washed for 5 minutes in PBS-Tween 
(comprising Na2HP04 1.6 g/l, NaCI 8.0 g/l, distilled H20  1 litre, Tween-20 500 pi, pH 7.2), before 
being placed in blocking buffer (PBS-Tween with 5% Marvel) for 2 hours. The blocking buffer 
blocks potential binding sites on the membrane, in order to reduce non-specific binding of the 
antibodies onto the membrane. Following this, the membrane was washed 3 times for 5 minutes 
each time in PBS-Tween, and then placed in the primary antibody solution (comprising PBS- 
Tween with the antibody at 1:1000 dilution-*- 3% BSA) for 3 hours.
The membrane was then washed a further three times for 5 minutes each time and then 
subsequently probed with horse-radish peroxidase-conjugated secondary anti-rabbit antibody 
solution (comprising PBS-Tween with antibody at 1:2000 dilution in + 5% Marvel) for 1 hour. The 
membrane was then washed a final three times for 5 minutes each time. The proteins were 
detected using enhanced chemi-luminescence ECL Western blotting detection reagent and the 
bands were visualised by exposing the membrane onto Kodak AR film.
3.8.6 Quantification of Protein Bands
The developed films were scanned on a flat-bed picture/document scanner, and the digital image 
was assessed using the National Institutes of Health (NIH) Shareware program, NIH Image 
(version 1.63). The relative densitometry for individual protein bands was determined by the grey 
scale technique, using the supplied program ‘Gel plotting macro’. The values were corrected if 
required for equal protein loading as determined by probing for p-actin.
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3.9 Statistical Analyses
Chapter 3: General Methods
All results are presented as group means ± standard error of the mean (SEM). For comparison 
between more than two groups, factorial one way analysis of variance (ANOVA) was employed. 
Where a significant F-valuewas obtained, the Fishers protected least significance difference 
(PLSD) post hoc test was applied for between group comparisons. For analysing data recorded 
over a period of time, ANOVA for repeated measures was employed, and where significance 
was found, the Fishers PLSD post hoc test was applied. Results were considered significant 
when P£0.05. All statistical analysis was carried out on a Power Macintosh computer, using 
Statview statistical software (Version 4.5, Abacus Concepts Inc.).
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4.1 Introduction
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
In section 1.5.5, the role of the mitochondrial permeability transition pore (mPTP) during 
ischaemia-reperfusion i njury was reviewed. O pening of the m PTP i n the first few m inutes of 
reperfusion, following an episode of lethal ischaemia, is a critical determinant of cell death in 
ischaemia-reperfusion. The conditions that prevail during the first few minutes of reperfusion act 
in concert to mediate the opening of the mPTP in the transition from ischaemia to reperfusion. 
These conditions which include a high mitochondrial [Ca2+] and [PJ, ATP depletion, oxidative 
stress, correction of the acidic pH, are known inducing factors for mPTP opening.(7;8;452) 
Opening of the mPTP results in both apoptotic and necrotic cell death,(871) and the inhibition of 
its opening during ischaemia-reperfusion injury has been demonstrated to confer protection in 
various experimental models.
A previous study in the isolated perfused rat heart demonstrated that inhibiting mPTP 
opening using cyclosporin-A (CsA), restored the ATP/ADP ratio and AMP to pre-ischaemic 
levels and improved the recovery of LV function following a prolonged length of ischaemia.(780) 
In myocytes subjected to lethal hypoxia-reoxygenation, the presence of CsA improved cell 
viability.(779) A Ithough c yclosporin-A ( CsA) i s a p otent i nhibitor of m PTP o pening, i t also h as 
other actions,(664) which include inhibiting the activity of the protein phosphatase, calcineurin.(674) 
The phosphorylation of the pro-apoptotic protein, BAD, prevents its binding to 1 4-3-3, which 
sequesters it from its mitochondrial target, thereby preventing apoptosis.(743) Being a 
phosphatase, calcineurin acts to dephosphorylate BAD, thereby enhancing apoptosis. 
Therefore, by inhibiting calcineurin, CsA may mediate cardio-protection via this anti-apoptotic 
mechanism rather than inhibiting mPTP opening.
Recently, the novel immunosuppressant, sanglifehrin-A (SfA), has been shown, to also 
act as a potent inhibitor of mPTP opening.(676) This drug has been demonstrated to be a more 
potent inhibitor of mPTP opening than CsA, and in addition SfA does not inhibit 
calcineurin.(676:677) When administered prior to the lethal ischaemic period in the isolated 
perfused heart, SfA was shown to improve recovery of LV function and reduce LDH release.(676) 
In addition, these investigators elucidated that the mechanism of action on the mPTP differed 
between SfA and CsA, with SfA preventing mPTP opening by inhibiting the peptidyl-prolyl cis-
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trans isomerase activity of cyclophilin D, whereas CsA is believed to inhibit mPTP opening by 
preventing the binding of cyclophilin D to the adenine nucleotide translocase.(676)
However, these studies did not examine the effect of inhibiting mPTP opening using 
CsA or SfA at the crucial time of reperfusion alone, when the mPTP has been demonstrated to 
open.(470;776;777) Furthermore, these studies did not examine the effect of inhibiting mPTP 
opening at the time of reperfusion on lethal reperfusion injury, in terms of necrotic cell death as 
measured by infarct size. Therefore the aim of the initial study was to determine whether 
pharmacologically inhibiting mPTP opening at the time of reperfusion, protects the heart against 
lethal reperfusion injury, using infarct size as the measured end-point of necrotic cell death.
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4.2 Hypothesis
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
Opening of the mPTP at the time of reperfusion is a critical determinant of cell death and 
inhibiting its opening protects the heart against lethal reperfusion injury
In this initial part of the study, we set out to examine the role of the mPTP in mediating the cell 
death induced by lethal reperfusion injury. We used cyclosporin-A (the archetypal mPTP 
inhibitor)(664) to inhibit the mPTP opening that has been demonstrated to occur in the first few 
minutes of reperfusion.(470;776;777) In order to exclude any effect that inhibiting calcineurin may 
have in this setting, we examined the effect of a drug called tacrolimus (FK506), an 
immunosuppressant which inhibits calcineurin without affecting mPTP opening.(780) It was 
important to use two different known inhibitors of m PTP opening to examine the role of the 
mPTP in mediating lethal reperfusion injury. Therefore, we also investigated the effect of the 
newly described mPTP inhibitor, sanglifehrin-A, which also does not inhibit calcineurin.(676) 
Importantly, we administered these agents only at the time of reperfusion in order to 
demonstrate that the opening of the mPTP is an important mediator of lethal reperfusion injury. 
We used an isolated Langendorff-perfused rat heart model of ischaemia-reperfusion to 
demonstrate the effect of pharmacological inhibition of mPTP opening at the time of reperfusion 
on the cell death induced by lethal reperfusion injury, using infarct size as the measured end­
point.
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4.3 Aim (1)
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
To determine whether pharmacologically inhibiting mPTP opening at the time of 
reperfusion protects the heart against lethal reperfusion injury
4.3.1 Materials
Cyclosporin-A (Sigma Chemicals, Poole, Dorset), and Tacrolimus (FK506, Fujisawa Ltd., Japan) 
were dissolved in 50% ethanol and added to the Krebs-Henseleit buffer such that the final 
ethanol concentration was less than 0.005%. Sanglifehrin-A (Novartis Pharma AG, Basel) was 
dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset) and added to the 
Krebs-Henseleit buffer such that the final DMSO concentration was less than 0.01%, which has 
no effect on infarct size in the Langendorff perfused rat heart. All other reagents were of 
standard analytical grade.
4.3.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
4.3.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in Figure 4.1. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control h earts were perfused with the vehicles 0.005% ethanol ( n=6), o r 0.01 % D MSO 
(n=6) or Krebs-Henseleit buffer alone (n=6) during the first 15 minutes of reperfusion;
(2) CsA-treatment: hearts (n=6) were perfused with cyclosporin-A (0.2 pmol/l) during the first 
15 minutes of reperfusion. This concentration of CsA has been demonstrated to inhibit mPTP 
opening in the isolated perfused rat heart.(780) In addition, this concentration provided the most 
potent inhibition of mPTP opening in adult rat myocytes.(779)
(3) Delayed CsA-treatment: hearts (n=6) were perfused with Kreb’s-Henseleit buffer alone for 
the first 15 minutes of reperfusion followed by cyclosporin-A (0.2 pmol/L) for the next 15 minutes
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of reperfusion. Therefore, CsA was not given until after the first 15 minutes of reperfusion had 
elapsed;
(4) FK506-treatment: hearts (n=6) were perfused with FK506 (5.0 pmol/l) during the first 15 
minutes of reperfusion. This concentration of FK506 has been used, to show that the inhibition 
of the protein phosphatase, calcineurin, was not the mechanism by which CsA induces cardio- 
protection.(780) At 5 pmol/l, FK506 has been demonstrated to not inhibit mPTP opening.(704) At 
0.2 pmol/l, CSA causes little or no inhibition of calcineurin activity in the heart, whereas 25 
pmol/l of FK506 causes substantial inhibition of calcineurin activity in heart.(872)
(5) SfA-treatment: hearts (n=6) were perfused with sanglifehrin-A (1.0 pmol/l) during the first 15 
minutes of reperfusion. This concentration of SfA has been demonstrated to give the most 
potent inhibition of mPTP opening;(676) and
(6) Delayed SfA-treatment: hearts (n=6) were perfused with Kreb’s-Henseleit buffer alone for 
the first 15 minutes of reperfusion followed by sanglifehrin-A (1.0 pmol/l) for the next 15 minutes 
of reperfusion. Therefore, SfA was not given until after the first 15 minutes of reperfusion had 
elapsed.
Figure 4.1: Experimental Protocols for Investigating the Effect of Inhibiting mPTP
Opening on Infarct Size. CsA-cyclosporin-A, SfA-sanglifehrin-A, TTC- 
tetrazolium.
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4.3.4 Results
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4.3.4.1 Exclusions
We used 52 male Sprague-Dawley rat hearts for the infarct size experiments of which 4 were 
excluded owing to poor function during stabilisation (see section 3.2.3 for exclusion criteria).
4.3.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 4.1). Baseline data relating to cardiac function (assessed by the rate-pressure-product, 
RPP) and coronary flow at the end of the stabilisation period just before the lethal ischaemic 
period, were similar in the experimental groups (see tables 4.2, 4.3). During regional ischaemia, 
coronary flow and RPP decreased to a similar extent in both groups. An increase in cardiac 
function and coronary flow upon reperfusion was indicative of successful re-flow.
The measured end-point, when using the isolated perfused rat heart was the infarct size. 
To measure left ventricular contractile function accurately, it is necessary to use an isolated 
working heart model. The method used to measure the left ventricular function in the isolated 
perfused rat heart is not accurate enough and is not wholly reproducible. In addition, the 
recovery of left ventricular contractile function (as indicated by the rate pressure product, RPP, 
which is the left ventricular developed pressure multiplied by the heart rate) following a period of 
ischaemia-reperfusion, did not always correlate with the reduction in infarct size. The RPP data 
was used as an indicator that effective regional ischaemia had been induced and that adequate 
reperfusion had occurred. In addition, any effects of the drug on haemodynamic function could 
also be monitored.
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Table 4.1 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight
(g)
Risk volume 
(cm3)
1. Control 6 359±19 1.90±0.06 0.411 ±0.017
0.005% ethanol 6 389±38 2.04±0.06 0.405±0.046
2. CsA 6 387±20 1.98±0.07 0.555±0.037
3. Delayed CsA 6 360±12 1.89±0.11 0.490±0.029
4. FK506 6 343±1 1.66±0.04 0.508±0.023
5. SfA 6 339±22 1.72±0.11 0.485±0.046
6. Delayed SfA 6 351 ±5 2.16±0.07 0.505±0.033
Table 4.2 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 29.8±2.0 27.412.3 13.311.7 13.812.2 12.812.1 10.111.3
0.005% ethanol 37.3±1.0* 33.511.0* 15.113.1 17.314.8 9.711.7 6.211.4
2. CsA 36.411.0* 32.112.1 12.512.0 18.9H.4 12.110.9 10.811.6
3. Delayed-CsA 22.110.6* 23.612.2 6.411.1 9.311.0 10.612.4 8.210.4
4. FK506 33.011.1 30.910.6 7.613.5 13.010.8 17.510.8 10.310.3
5. SfA 26.511.9 26.411.8 5.811.1 14.613.0 14.710.5 15.411.4
6. Delayed SfA 20.412.0* 23.011.8 8.412.2 14.912.0 16.111.8 11.810.6
Table 4.3 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 14.611.1 12.611.2 7.210.9 6.010.8 8.811.4 5.210.7
0.005% ethanol 15.712.3 15.712.3 8.711.5 6.710.9 6.710.7 5.310.9
2. CsA 15.811.4 13.610.7 7.210.9 6.010.5 7.011.0 5.010.6
3. Delayed-CsA 19.310.9 19.010.6* 8.310.3 7.310.3 10.711.3 6.011.2
4. FK506 18.311.2 18.311.2* 8.710.7 7.010.6 9.013.6 6.211.9
5. SfA 15.511.9 16.011.7 8.010.4 7.310.9 9.811.3 8.510.6
6. Delayed SfA 21.012.4 20.012.2* 1011.2 1111.9 13.011.5 8.311.6
Values are meaniSEM. *P<0.05 compared with control.
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4.3.4.3 Infarct Size Data
Infarct size is presented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. The presence of CsA for the first 15 minutes o f reperfusion reduced infarct size from 
44.7±2.0% in control hearts (40.1±1.4% in ethanol control hearts) to 24.6±1.9% with CsA- 
treatment (P<0.0001; figure 4.2). However, when CsA was omitted for the first 15 minutes of 
reperfusion, and only given after 15 minutes of reperfusion had elapsed, there was no influence 
on infarct size (40.6±2.8% with delayed-CsA vs 44.7±2.0% in control; P=NS; figure 4.2), which 
suggests that CsA needs to be present during the first 15 minutes of reperfusion to exert its 
cardio-protective effect. The presence of FK506 at reperfusion did not influence infarct size 
(43.1 ±3.5% with FK506-treatment vs 44.7±2.0% in control hearts; P=NS; figure 4.2), suggesting 
that the inhibition of calcineurin at the time of reperfusion is not cardio-protective. The presence 
of sanglifehrin-A for the first 15 minutes of reperfusion, reduced infarct size from 44.7±2.0% in 
control hearts to 23.8±4.2% with SfA-treatment (P<0.001; figure 4.2). However, when SfA was 
omitted for the first 15 minutes of reperfusion, and only given after 15 minutes of reperfusion 
had elapsed, there was no influence on infarct size (43.8±5.7% with delayed-SfA given vs 
44.7±2.0% in control; P=NS; figure 4.2), which suggests that SfA needs to be present during the 
first 15 minutes of reperfusion to exert its cardio-protective effect.
Figure 4.2: Inhibiting mPTP Opening at the Time of Reperfusion Protects the Heart 
Against Lethal Reperfusion Injury. Pharmacologically inhibiting mPTP opening for the first 15 
minutes of reperfusion using either cyclosporin-A (CsA) or sanglifehrin-A (SfA) reduced infarct 
size, although inhibiting mPTP opening after the first 15 minutes of reperfusion was not cardio­
protective (delayed CsA and delayed SfA). Inhibiting calcineurin for the first 15 minutes of 
reperfusion, using tacrolimus (FK506) did not influence infarct size.*P<0.001 compared to 
control.
SfA Delayed 
SfA
Control Ethanol CsA Delayed FK506
CsA
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4.3.5 Discussion
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
In this part of the study we demonstrated that pharmacologically inhibiting mPTP opening for 
the first 15 minutes of reperfusion, following a lethal period of ischaemia, using either 
cyclosporin-A (CsA) or sanglifehrin-A (SfA), protected the heart against lethal reperfusion injury, 
as evidenced by a reduction in infarct size. Importantly, the known mPTP inhibitors were only 
given at the time of reperfusion, to target the time period when mPTP opening has been 
demonstrated to occur.(470:776:777)
Furthermore, we demonstrated that targeting the first 15 minutes of reperfusion is 
crucial to the protective effect of these agents, since the administration of these agents after the 
first 15 minutes of reperfusion had elapsed, did not protect the heart against lethal reperfusion 
injury. This suggests that to mediate cardio-protection these drugs have to be present at the 
immediate onset of reperfusion and for the first 15 minutes of reperfusion, which corresponds to 
the time-period during which mPTP opening has been demonstrated to occur.(776;777) 
Presumably, these drugs are ineffective at reducing infarct size if given after the first 15 minutes 
of reperfusion because irreversible mPTP opening had already occurred by that stage of 
reperfusion, in response to the mPTP-inducing factors present at this time (see figure 4.3 a,b). 
Therefore, providing these agents were administered in a timely manner, they were able to 
inhibit mPTP opening despite the presence of the mPTP-inducing factors that prevail in the first 
few minutes of reperfusion (see figure 4.3 a-c).
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Figure 4.3 a-c: Modulation of mPTP Opening in Ischaemia-Reperfusion Injury, (a) During 
ischaemia mPTP opening is inhibited by the acidic matrix pH and NADH despite the presence 
of Ca2+ and Pj and ATP depletion, (b) At reperfusion there is a further rise in mitochondrial Ca2+, 
a burst of oxidative stress, oxidation of NADH, restoration of physiological pH and cyclophilin D 
associates with adenine nucleotide translocase (ANT). These factors act in concert to induce 
mPTP opening at the time of reperfusion, thereby causing cell death, (c) The presence of either 
cyclosporin-A or sanglifehrin-A at the time of reperfusion inhibits mPTP opening mediating cell 
survival, despite the presence of the mPTP-inducing factors that prevail during the first few 
minutes of reperfusion. VDAC-voltage dependent anion channel.
(c) A t  Reperfus ion  in the Presence o f  mPTP Inh ib i to rs
Cytosol
m PTP Closed
i
Cell Surv iva l
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The fact that FK506, when given at the time of reperfusion, provided no protection against lethal 
reperfusion injury, suggests that the inhibition of calcineurin for the first 15 minutes of 
reperfusion does not mediate cardio-protection. Therefore, the reduction in infarct size induced 
by CsA at reperfusion was not due to its effect on calcineurin but was most likely due to its 
suppression of mPTP opening. In support of this, we also demonstrated protection against 
lethal reperfusion injury using sanglifehrin-A, which does not inhibit calcineurin.(677;678) In the 
previous study by Griffiths and colleagues,(78°) the effect of CsA at the time of reperfusion was 
previously examined and inhibiting mPTP opening at this time was demonstrated to restore 
ATP/ADP and AMP to pre-ischaemic levels and improved the recovery of left ventricular 
contractile function. However, necrotic cell death as measured by infarct size was not 
determined in this study. Other studies which have investigated the effect of CsA in ischaemia- 
reperfusion injury have given the drug either before the index ischaemic period or after the 
onset of ischaemia.(236;800:802) Interestingly, CsA has been demonstrated to protect the brain 
when given at the time of reperfusion following a two hour occlusion of the middle cerebral 
artery, as evidenced by a reduction in infarct size.(796) Although SfA has been previously 
investigated in the setting of ischaemia-reperfusion injury, the drug was administered both prior 
to index global ischaemia and for a further 10 minutes of reperfusion.(676) Furthermore, in that 
study the end-points of post-ischaemic recovery of left ventricular function and LDH release 
were used. As such, it is difficult to interpret whether this agent was only having its effect during 
the reperfusion phase, given that the drug was administered prior to the lethal ischaemic 
episode. In addition, necrotic cell death as measured by infarct size was not determined in this 
previous study.
In conclusion, we have demonstrated that pharmacologically inhibiting mPTP opening 
during the first few minutes of reperfusion protects the heart against lethal reperfusion injury.
From the results of this part of the study, it appears that the opening of the mPTP at the time of 
reperfusion m ediates I ethal reperfusion injury, a nd m ay be responsible f or u p to 50% of the 
infarct size, sustained in this setting. The first few minutes of reperfusion therefore represent a 
‘window of opportunity’ for interventions directed to attenuating lethal reperfusion injury, via 
inhibition of mPTP opening. In this regard we next examined the newly described phenomenon 
of ‘ischaemic post-conditioning’ which has been demonstrated to protect the heart against lethal 
reperfusion injury,(61i) with the intention of demonstrating that protection occurs via inhibition of 
mPTP opening.
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4.4 Aim (2):
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
To d etermine w hether i schaemic p ost-conditioning p rotects a gainst I ethal reperfusion 
injury by inhibiting mPTP opening at the time of reperfusion
The mechanism associated with the phenomenon of ‘ischaemic post conditioning’ as first 
described by Vinten-Johansen in 2001 (and outlined in section 1.4.4), is unknown but based on 
previous studies, (612_614) the controlled gradual reperfusion of ischaemic myocardium may be 
central to the protective effect. In this regard, we hypothesised that the protection at the time of 
reperfusion may be mediated via the inhibition of mPTP opening. Opening of the mPTP in the 
first few minutes of reperfusion in response to the prevailing conditions (which include a high 
mitochondrial [Ca2+], [PJ, ATP depletion, oxidative stress and a corrected pH), is a critical 
determinant of cell death in lethal reperfusion injury (see sections 1.5.5 and 4.3). One may 
envisage that the application of brief intermittent episodes of ischaemia/reperfusion (‘ischaemic 
post conditioning’) or the gradual controlled reperfusion employed in the previous studies,(612‘614) 
may allow the homeostatic mechanisms which govern normal cellular and mitochondrial 
function to acclimatise to the abrupt metabolic and biochemical conditions associated with the 
reperfusion phase (listed above), thereby acting to reduce the opening probability of the mPTP 
at the time of reperfusion.
The data from Downey’s laboratory suggest that the MEK1/2-Erk1/2 kinase cascade (a 
component of the RISK-pathway-see section 1.4.3) may be implicated in the protection 
associated with ‘ischaemic post conditioning’. On this basis, we were therefore interested, to 
test whether the PI3K-Akt kinase cascade (the other component of the RISK-pathway) is also 
involved in mediating the protective effect.
We wanted to determine whether the phenomenon of ‘ischaemic post-conditioning’ 
could be reproduced in the in vitro Langendorff-perfused rat heart and go on to explore the 
potential mechanisms involved.
4.4.1 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of
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reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
4.4.2. Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in Figure 4.4. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts,
(2) 0.5 minute ischaemic post-conditioning: hearts (n=6) were subjected to 35 minutes of 
lethal ischaemia, and then received six alternate episodes of 0.5 minute global ischaemia and 
reperfusion, and were then reperfused for a further 117 minutes, making the total reperfusion 
time 120 minutes. This ischaemic post-conditioning protocol had been previously demonstrated 
to protect the in vivo canine heart.(611)
(3) 1 minute ischaemic post-conditioning: hearts (n=6) were subjected to 35 minutes of lethal 
ischaemia, and then received six alternate episodes of 1 minute global ischaemia and 
reperfusion, and were then reperfused for a further 114 minutes, making the total reperfusion 
time 120 minutes.
Figure 4.4: Experimental Protocols Investigating Ischaemic Post-Conditioning.
TTC-tetrazolium.
Time (min)
30 min 
stabilisation
Group 1: Control
Group 2: 0.5 min —
Ischaemic post-conditioning
Group 3 :1.0 min __
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30 65 185
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t
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155
Derek J Hausenloy
4.4.3 Results
Chapter 4: The mPTP in Ischaemia-Reperfusion Injury
4.4.3.1 Exclusions
We used 18 male Sprague-Dawley rat hearts for the infarct size experiments of which 0 were 
excluded (see section 3.2.3 for exclusion criteria).
4.4.3.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 4.4). Baseline data relating to cardiac function ( assessed by the rate-pressu re-product, 
RPP) and coronary flow before the lethal ischaemic period, were similar in the experimental 
groups (see tables 4.5, 4.6). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
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Table 4.4 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight (g) Risk volume (cm3)
1. Control 6 446±8 1.83±0.06 0.533±0.041
2. 0.5 minute 6 324±5 1.37±0.02 0.568±0.038
Post-Conditioning
3. 1 minute 6 385±28 1.87±0.20 0.562±0.046
Post-Conditioning
Values are mean±SEM.
Table 4.5 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 23.9±3.9 27.4±2.4 17.8±2.3 17.5±5.6 28.1±2.4 13.1±0.1
2. 0.5 minute 21.7±2.0 22.7±2.4 10.3±2.7 14.7±4.3 21.0±1.0 13.0±1.0
Post-Conditioning
3. 1 minute 27.9±2.7 28.4±2.2 13.2±2.1 10.8±2.5 19.0±0.9 14.6±0.6
Post-Conditioning
Values are mean±SEM.
Table 4.6 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 16.0±1.0 16.0±0.6 7.8±0.9 7.0±0.6 12.5±3.5 7.8±1.4
2. 0.5 minute 17.5±1.3 18.0±3.0 6.0±1.2 8.7±2.9 10.5±1.0 5.3±0.3
Post-Conditioning
3. 1 minute 17.2±1.1 17.2±1.3 6.8±0.6 6.2±0.8 10.8±1.9 7.0±0.6
Post-Conditioning
Values are mean±SEM.
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4.4.4.3 Infarct Size Data
Infarct size is presented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. The 0.5 minute and the 1.0 minute post-conditioning protocols did not reduce infarct size 
(41.7±4.8% in control hearts vs 31 .7±4.1% with 0.5 minute post-conditioning and 3 4.4±5.6% 
with 1.0 minute post-conditioning; P=NS; figure 4.5).
Figure 4.5: The Effect of ‘Ischaemic Post-Conditioning1 on Infarct Size. Ischaemic post­
conditioning’ did not reduce infarct size when compared to control hearts. (Values are 
mean±SEM).
0.5 minute 1.0 minute
Post-Conditioning Post-Conditioning
Control
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4.4.4 Discussion
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In this part of the study we demonstrated that in the Langendorff-perfused rat heart ‘ischaemic 
post-conditioning’ with six episodes of either 1 minute alternate ischaemia/reperfusion periods 
or 30 second alternate ischaemia/reperfusion periods produced a non-significant reduction in 
infarct size. The 30 second ‘ischaemic post-conditioning’ protocol was used initially, based on 
that used by Zhao and colleagues in the in vivo canine model of ischaemia-reperfusion 
injury.(611) After determining that this protocol did not provide significant protection, we used a 1 
minute ‘ischaemic post-conditioning’ protocol, but this produced even less protection. Based on 
these findings, we did not perform any further investigation of the phenomenon of ‘ischaemic 
post-conditioning’.
The possible reasons for why we did not observe protection against lethal reperfusion 
injury with ‘ischaemic post-conditioning’ include:
(1) Difference in species and model used-most of the studies that demonstrated this protective 
phenomenon used in vivo models of ischaemia-reperfusion injury in rabbit and dog.(611;615) The 
fact that Zhao and colleagues observed attenuation in neutrophil accumulation in ‘ischaemic 
post-conditionioned’ hearts may suggest the requirement of systemic factors for protection, 
which would not be present in our in vitro model of ischaemia-reperfusion in the rat. Against this 
argument, however, is the fact that Vinten-Johansen recently demonstrated ‘ischaemic post­
conditioning’ in the in vivo rat model(616) as well as in isolated myocytes,(617) suggesting that the 
mechanism of protection may be via a direct effect on the myocyte.
(2) The 30 second and 1 minute ‘ischaemic post-conditioning’ protocols used in our study may 
have been too long. In the in vivo rat model of ‘ischaemic post-conditioning’, three times 10 
second alternate episodes of ischaemia/reperfusion have now been demonstrated to induce 
protection.(616) Interestingly, the extent of protection was not so marked in the rat in vivo model, 
with a reduction infarct size from 52±3% in control to 40±2%, which compares favourably to the 
non-significant reduction in infarct size we observed in the isolated rat heart from 42±5% in 
control hearts to 32±4%. This level of protection observed in the rat heart is in contrast to the 
large reductions in infarct size observed in the in vivo canine and rabbit models of ‘ischaemic 
post-conditioning’, which compared favourably to the protection induced by ischaemic 
preconditioning^6111615)
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Further studies are underway to determine whether shortening the duration of the 
‘ischaemic post-conditioning’ protocol to 10 second episodes of alternate ischaemia/reperfusion 
is protective in the Langendorff-perfused rat heart, and studies are required to elucidate the 
mechanism of protection in this setting. Shorter episodes of ischaemia/reperfusion could 
potentially protect the heart by decreasing the opening probability of the mPTP. Whether the 
requirement for shorter episodes of ischaemia/reperfusion can be explained by the modulation 
of survival kinases such as MEK1/2-Erk1/2, as suggested by Downey’s laboratory, is 
unclear.(615) Other potential mechanisms by which ‘ischaemic post-conditioning’, could protect 
the heart against lethal reperfusion injury include the production of nitric oxide,(615) attenuation 
of ROS production and reduced mitochondrial calcium load,(616;617) all factors which could 
potentially protect the myocardium by inhibiting mPTP opening.
4.5 Conclusion
In this section of the thesis, we have demonstrated that the opening of the mPTP during the first 
15 minutes of reperfusion, following a period of lethal ischaemia, is a critical determinant of cell 
death, as evidenced by the large reduction in infarct size associated with inhibiting mPTP 
opening using the known mPTP inhibitors, CsA or SfA. Interestingly, we demonstrated that 
these drugs were only effective if given for the first 15 minutes of reperfusion when compared to 
their administration after the first 15 minutes of reperfusion had elapsed, suggesting that 
treatment has to be directed to the first few minutes of reperfusion, when mPTP opening has 
been demonstrated to occur. Given the magnitude of the protection associated with inhibiting 
mPTP opening at the time of reperfusion, in the next chapter we explored whether this powerful 
protective mechanism contributed to the protection associated with the phenomenon of 
myocardial preconditioning.
The data from this part of the thesis demonstrating that inhibiting mPTP opening at 
the time of reperfusion results in a reduction in infarct size has been published.(873;874)
160
Derek J Hausenloy Chapter 5: The mPTP in Myocardial Preconditioning
Chapter Five
THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE AS 
A TARGET FOR PROTECTION IN MYOCARDIAL 
PRECONDITIONING
Page
5.1 Introduction 163
5.2 Hypothesis 165
Myocardial preconditioning protects by inhibiting the prolonged (high-conductance) 
mPTP opening which occurs at the time of reperfusion, following a lethal ischaemic 
insult
5.3 Aim (1): Determine whether there is any interplay between 167
the mPTP and the mitochondrial K Atp  channel
5.3.1 Materials 167
5.3.2 Isolated Langendorff-Perfused Rat Heart Model 167
5.3.3 Experimental Protocols for Infarct Studies 167
5.3.4 Results 169
5.3.5 Discussion 173
5.4 Aim (2): Determine whether pharmacologically opening 175
the mPTP at the time of reperfusion abrogates 
classical preconditioning-induced protection
5.4.1 Materials 175
5.4.2 Isolated Langendorff-Perfused Rat Heart Model 175
5.4.3 Experimental Protocols for Infarct Studies 176
5.4.4 Results 178
5.4.5 Discussion 182
5.5 Aim (3): Determine whether pharmacologically opening 184
the mPTP at the time of reperfusion abrogates 
the second window of protection
5.5.1 Materials 184
5.5.2 Isolated Langendorff-Perfused Rat Heart Model 184
5.5.3 Experimental Protocols for Infarct Studies 184
5.5.4 Results 186
5.5.5 Discussion 189
5.6 Aim (4): Determine whether preconditioning inhibits 190
the calcium-induced opening of the mPTP in 
isolated mitochondria
5.6.1 Materials 190
5.6.2 Mitochondrial Model of mPTP Opening 191
5.6.3 Experimental Protocols for Mitochondrial Studies 191
5.6.4 Results 192
5.6.5 Discussion 197
161
Derek J Hausenloy Chapter 5: The mPTP in Myocardial Preconditioning
5.7 Aim (5): Determine whether preconditioning inhibits the 199
oxidative stress-induced opening of the mPTP in 
isolated myocytes
5.7.1 Materials 199
5.7.2 Myocyte Model of mPTP Opening 199
5.7.3 Experimental Protocols for Myocyte Studies 201
5.7.4 Hypoxic Preconditioning Protocol 202
5.7.5 Results 203
5.7.6 Discussion 211
5 .8  Aim (6 ):  Opening the mitochondrial K atp  channel at the 215
time of reperfusion protects against lethal 
reperfusion injury by inhibiting mPTP opening
5.8.1 Materials 215
5.8.2 Isolated Langendorff-Perfused Rat Heart Model 216
5.8.3 Experimental Protocols for Infarct Studies 216
5.8.4 Results 216
5.8.5 Discussion 218
5.9 Aim (7): Determine the effect of preconditioning on 219
mitochondrial redox potential and mitochondrial 
membrane potential
5.9.1 Materials 220
5.9.2 Myocyte studies 220
5.9.3 Results 221
5.9.4 Discussion 225
5.10 Summary and Discussion 227
5.11 Conclusion 233
162
Derek J Hausenloy
5.1 Introduction
Chapter 5: The mPTP in Myocardial Preconditioning
In the previous chapter, it was demonstrated that the opening of the mPTP during the first few 
minutes of reperfusion is a critical determinant of cell death in the setting of ischaemia- 
reperfusion injury. Furthermore, it was shown that inhibiting mPTP opening at the time of 
reperfusion could protect the heart against lethal reperfusion injury as evidenced by a reduction 
in infarct size following an episode of sustained ischaemia. In this chapter, the role of the mPTP 
in the phenomenon of myocardial preconditioning was examined to determine whether mPTP 
opening at the time of reperfusion is modulated in the setting of preconditioning. Specifically, we 
wanted to examine whether the protection associated with myocardial preconditioning is 
mediated by the inhibition of mPTP opening.
Interestingly, many of the factors that act to induce mPTP opening at the time of 
reperfusion are modified in the setting of preconditioning. For example, mitochondrial Ca2+, 
which is a major determinant of mPTP opening at the time of reperfusion, has been 
demonstrated to be reduced in the setting of preconditioning induced by either ischaemia(238;239) 
or opening of the mitochondrial K At p  channel. (52:239;257:258;261=262) |n addition, IPC and 
mitochondrial K At p  channel openers have been demonstrated to preserve mitochondrial function 
and render mitochondria more tolerant to mitochondrial Ca2+ loading^263-265)
Another major determinant of mPTP opening at the time of reperfusion is the oxidative 
stress which is generated primarily from the reoxygenation of an ischaemia-mediated reduced 
electron transport chain.(79:276;277) Interesting, preconditioning induced by ischaemia,(278) 
hypoxia,(79) adenosine,(77;79) or the K ATp  channel openers (diazoxide and nicorandil)(78) have all 
been demonstrated to reduce the production of oxidative stress at the time of reperfusion.
Preserving mitochondrial energy production during ischaemia-reperfusion is critical for 
the survival and recovery of myocytes following an episode of ischaemia-reperfusion injury, and 
IPC has been demonstrated to preserve mitochondrial energy production during ischaemia- 
reperfusion injury.f228'231* 31'234) In addition, the opening of the mitochondrial KATP channel has 
been demonstrated to increase ATP synthesis,(234), preserve mitochondrial energy 
production^267) decrease ATP hydrolysis,(159) and improve energy transfer at reperfusion.(159)
Therefore protecting the heart against lethal reperfusion injury can be mediated by 
attenuating mitochondrial Ca2+ loading, reducing oxidative stress at the time of reperfusion, and
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preserving mitochondrial energy production, during ischaemia-reperfusion, such that mPTP 
opening is suppressed at the time of reperfusion. In this section of the study we wanted to 
investigate whether myocardial preconditioning protects the hearts by inhibiting the mPTP 
opening that occurs in the first few minutes of reperfusion. At the time these experiments were 
performed the only published study directly related to this research area was a study by 
Ashrafs group(251) in which they demonstrated using neonatal rat myocytes that the mPTP 
opener, atractyloside could reverse the protection associated with Ca2+-preconditioning. 
However, in that study the effect of Ca2+-preconditioning on mPTP opening was not examined. 
Therefore, the aim of this part of the study was to determine whether myocardial preconditioning 
protects the heart by inhibiting the mPTP opening that occurs at the time of reperfusion.
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5.2 Hypothesis
Chapter 5: The mPTP in Myocardial Preconditioning
Myocardial preconditioning protects by inhibiting the prolonged (high-conductance) mPTP 
opening at the time of reperfusion, following the tethal ischaemic insult
The first part of the study (section 5.3) was to determine whether there existed any interplay 
between the mitochondrial K Atp  channel (a proposed mediator/effector of preconditioning) and 
the mPTP. Both are constituents of the inner mitochondrial membrane and are therefore 
subjected to the same ionic and metabolic changes during ischaemia-reperfusion injury. Having 
demonstrated in chapter 4, that inhibiting mPTP opening at the time of reperfusion, using CsA, 
could protect the heart against lethal reperfusion injury, we wanted to next determine whether 
modulating the mitochondrial KATP channel could influence the protection associated with CsA.
In the next part of the study (section 5.4), we adopted an approach similar to that used 
by Ashrafs group,(251) in that we administered the mPTP opener atractyloside, to induce the 
opening the mPTP during the first 15 minutes of reperfusion, to determine whether we could 
abrogate the protection associated with ischaemic and pharmacological classical 
preconditioning, assuming that myocardial preconditioning had resulted in the suppression of 
mPTP opening. Because atractyloside is an inhibitor of ANT, which would interfere with the 
mitochondrial exchange of adenine nucleotides at the time of reperfusion, we also investigated 
an alternative mPTP opener, phenylarsenine oxide. The same approach was used to 
investigate the role of the mPTP in the second window of protection induced by the adenosine 
A1-receptor agonist, CCPA (section 5.5). Of course, these initial experiments do not examine 
mPTP opening d irectly, and they only suggest the involvement. The next objective therefore 
was to examine the effect of preconditioning on mPTP opening directly, using two different 
models for assessing mPTP opening.
In section 5.6 we examined the effect of pharmacological preconditioning using 
diazoxide on the mPTP-opening induced by Ca2+, in adult rat mitochondria. Following this set of 
experiments, we examined the effect of hypoxic and pharmacological preconditioning on the 
mPTP opening-induced by oxidative stress in adult rat myocytes (section 5.7). In section 5.8, 
we explore the role of mitochondrial K ATp  channel opening at the time of reperfusion, which has 
been demonstrated to protect the heart against lethal reperfusion injury, to determine whether 
protection is mediated by inhibition of mPTP opening.
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In the final section of this chapter (section 5.9), we investigate how myocardial 
preconditioning might modulate mPTP opening by examining the effects of the preconditioning 
mimetic, diazoxide, on mitochondrial function.
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5.3 Aim (1)
Chapter 5: The mPTP in Myocardial Preconditioning
Determine whether there is any interplay between the mPTP and the mitochondrial K Atp  
channel
5.3.1 Materials
Cyclosporin-A (Sigma Chemicals, Poole, Dorset) was dissolved in 50% ethanol and added to 
the Krebs-Henseleit buffer such that the final ethanol concentration was less than 0.005%. 
Glibenclamide (Sigma Chemicals, Poole, Dorset) and glimepiride (Sigma Chemicals, Poole, 
Dorset) were dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset) and 
added to the Krebs-Henseleit buffer such that the final DMSO concentration was less than 
0.01%. 5-Hydroxydecanoic acid (5-HD, Sigma Chemicals, Poole, Dorset) and HMR 1098 (gift 
courtesy of Dr Jim Downey) were dissolved in distilled H20. All other reagents were of standard 
analytical grade.
5.3.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
5.3.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in figure 5.1. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts were perfused with 0.01% DMSO (n=3) or Krebs-Henseleit buffer alone (n=6) 
throughout stabilisation and ischaemia up until the point of reperfusion;
(2) CsA-treatment: hearts (n=6) were perfused with cyclosporin-A (0.2 pmol/L) for the first 15 
minutes of reperfusion. This concentration of CsA has been demonstrated to inhibit mPTP 
opening in the isolated perfused rat heart.(780)
(3) 5-HD + CsA-treatment hearts (n=6) were perfused with 5-HD (100 pmol/l) throughout 
stabilisation and ischaemia up until the point of reperfusion and cyclosporin-A (0.2 pmol/L) was
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given for the first 15 minutes of reperfusion. This concentration of 5-HD has been used to close 
the mitochondrial K Atp  channel in the isolated perfused rat heart;(104)
(4) Glibenclamide + CsA-treatment: hearts (n=6) were perfused with glibenclamide (10 pmol/l) 
throughout stabilisation and ischaemia up until the point of reperfusion and cyclosporin-A (0.2 
pmol/L) was given for the first 15 minutes of reperfusion. This concentration of glibenclamide 
has been used to close the K Atp  channel in the isolated perfused rat heart;(875)
(5) Glimepiride + CsA-treatment: hearts (n=6) were perfused with glimepiride (10 pmol/l) 
throughout stabilisation and ischaemia up until the point of reperfusion and cyclosporin-A (0.2 
pmol/L) was given for the first 15 minutes of reperfusion. This concentration of glimepiride has 
been used to close the K ATp  channel in the isolated perfused rat heart;(875)
(6) HMR 1098 + CsA-treatment: hearts (n=6) were perfused with HMR 1098 (10 pmol/l) 
throughout stabilisation and ischaemia up until the point of reperfusion and cyclosporin-A (0.2 
pmol/L) was given for the first 15 minutes of reperfusion. This concentration of HMR 1098 has 
been used to close the sarcolemmal K ATp channel in the isolated perfused rat heart;(876)
(7-10) 5-HD/Glibenclamide/Glimepiride/HMR 1098-treatment: hearts were perfused with 
either 5-HD (100 pmol/l, n=4), glibenclamide (10 pmol/l, n=5), glimepiride (10 pmol/l, n=4) or 
HMR 1098 (10 pmol/l, n=4) throughout stabilisation and ischaemia up until the point of 
reperfusion;
Figure 5.1: Experimental Protocols Investigating the Interplay Between the mPTP and
the Mitochondrial KATP Channel. 5-HD-5-hydroxydecanoic acid, Glib-glibenclamide, Glim- 
Glimepiride, HMR-HMR 1098, TTC-tetrazolium.
Time (min) 0 10 20 30 65 80
30 min 35 min 120 min 
stabilisation ischaemia reperfusion
Group 1: Control
Group 2: CsA for the
first 15 min of reperfusion
with CsA at reperfusion
Groups 7-10: 5-HD/Glib/Glim/HMR
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5.3.4 Results
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5.3.4.1 Exclusions
We used 56 male Sprague-Dawley rat hearts for the infarct size experiments of which 3 were 
excluded owing to poor function during stabilisation (see section 3.2.3 for exclusion criteria).
5.3.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 5.1). Baseline data relating to cardiac function (assessed by the rate-pressure-product, 
RPP) a nd coronary flow b efore the I ethal ischaemic period, were s imilar i n t he e xperimental 
groups (see table 5.2, 5.3). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
Table 5.1 Characteristics o f Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight
(g)
Risk volume 
(cm3)
1. Control 6 359±19 1.90±0.06 0.41110.017
2. CsA 6 387±20 1.98±0.07 0.55510.037
3. 5-HD + CsA 6 358±2 1.82±0.06 0.53310.059
4. Glib + CsA 6 331±10 1.67±0.09 0.46210.048
5. Glim + CsA 6 338±12 1.77±0.22 0.49010.063
6. HMR +CsA 6 333±5 1.84±0.10 0.48110.034
7. 5-HD 4 368±6 1.89±0.22 0.51710.063
8. Glib 5 349±9 1.72±0.09 0.50810.023
9. Glim 4 362±25 2.01±0.21 0.51310.019
10. HMR 4 328±6 1.7210.11 0.43910.053
Values are meamSEM.
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Table 5.2 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation 
5-Min 30-Min
Ischaemia 
5-Min 30-Min
Reperfusion 
15-Min 120-Min
1. Control 29.8±2.0 27.4±2.3 13.3±1.7 13.812.2 12.812.1 10.111.3
2. CsA 36.4±1.0 32.1±2.1 12.512.0 18.911.4 12.110.9 10.811.6
3. 5-HD + CsA 37.4±1.7 32.8±3.2 9.111.0 14.410.9 16.212.0 13.011.7
4. Glib + CsA 25.6±0.9 25.5±1.8 9.210.8 11.912.0 13.911.3 9.710.4
5. Glim + CsA 19.3±0.9* 27.0±1.8 8.310.3 13.611.8 12.711.3 12.310.8
6. HMR +CsA 28.4±2.7 31.6±2.5 9.412.5 13.613.7 12.712.9 15.710.6
7. 5-HD 28.8±0.5 27.8±4.3 10.911.2 10.411.8 13.512.0 9.310.6
8. Glib 25.0±1.3 21.3±1.8 9.011.0 13.111.4 12.712.1 9.910.5
9. Glim 22.9±3.1 21.9±6.8 14.010.8 12.310.3 16.013.5 14.312.6
10. HMR 32.6±4.0 30.6±4.4 11.211.3 12.412.2 11.310.2 10.111.1
Values are mean±SEM. *P<0.05 compared with control.
Table 5.3 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 14.611.1 12.611.2 7.210.9 6.010.8 8.811.4 5.210.7
2. CsA 15.811.4 13.610.7 7.210.9 6.010.5 7.011.0 5.010.6
3. 5-HD + CsA 16.010.6 14.710.9 8.010.6 6.710.3 8.010.8 6.310.3
4. Glib + CsA 11.810.7 11.210.4 6.210.7 5.610.5 8.010.6 6.011.0
5. Glim + CsA 15.211.0 14.611.2 6.410.5 5.810.6 9.511.3 6.310.9
6. HMR +CsA 15.510.6 15.010.7 10.8+2.8 8.510.3 9.510.3 5.810.5
7. 5-HD 15.310.8 14.011.4 8.310.3 5.310.3 7.710.9 5.010.6
8. Glib 12.511.3 12.511.2 6.810.5 6.010.7 8.311.7 5.010.6
9. Glim 15.311.1 13.011.5 6.811.0 6.511.2 9.311.6 6.011.0
10. HMR 15.312.7 14.712.4 5.710.9 4.710.7 8.011.5 5.710.3
Values are meaniSEM.
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5.3.4.3 Infarct Size Data
Infarct size is presented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. The protection induced by inhibiting the prolonged mPTP opening that occurs at 
reperfusion, using CsA, was abolished in the presence of the mitochondrial selective KATp 
channel blocker, 5-HD (24.6±1.9% with CsA vs 47.1±3.5% with CsA and 5-HD; P0.001; figure 
5.2), the non-selective KAtp channel blocker glibenclamide (24.6±1.9% with CsA vs 52.6±1.8% 
with CsA and glibenclamide; P0.001; figure 5.2), the KATP channel blocker glimepiride 
(24.6±1.9% with CsA vs 41.7±3.0% with CsA and glimepiride; P<0.001; figure 5.2). However, 
the protection induced by CsA was maintained in the presence of the specific sarcolemmal KATP 
channel blocker, HMR 1098 (24.6±1.9% with CsA vs 29.4±0.5% with CsA and HMR 1098; 
P=NS; figure 5.2). The KATP channel blockers alone did not influence infarct size (49.3±4.1% 
with 5-HD, 47.1 ±4.2% with glibenclamide, 41.7±3.0% with glimepiride, 47.9±3.1% with HMR 
1098 vs 44.8±3.2% in control; P=NS; figure 5.3).
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Figure 5.2: Closing the KATP Channel Abrogates CsA-lnduced Cardio Protection.
Pharmacologically closing the K ATp channel using 5-hydroxydecanoic acid (5-HD), 
glibenclamide (Glib) or glimepiride (Glim) during stabilisation and ischaemia abrogates the 
protection mediated by cyclosporin-A (CsA)-induced inhibition of mPTP opening at reperfusion. 
Pharmacologically closing the sarcolemmal K Atp  channel using HMR 1098 (HMR) had no effect 
on CsA-induced protection.*P<0.001 compared with control.
Control Glib+
CsA
Glim+
CsA
Figure 5.3: Closing the KATP Channel Does not Influence Infarct Size.
Pharmacologically closing the mitochondrial KATP channel using 5-hydroxydecanoic acid (5-HD), 
glibenclamide (Glib) or glimepiride (Glim) or closing the sarcolemmal K ATp channel using HMR 
1098 (HMR) during stabilisation and ischaemia has no effect on infarct size. *P<0.001 
compared with control.
Control
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The results from this section of the study, suggest that there exists an interplay between the 
mitochondrial KATP channel and the mPTP such that the closing of the former during stabilisation 
and the index ischaemic period appeared to antagonise CsA-induced protection at the time of 
reperfusion. We demonstrated that the presence of glibenclamide or 5-HD (presumed 
mitochondrial KATP channel blockers) during the pre-ischaemic and ischaemic period abrogated 
the CsA-mediated reduction in infarct size. However, the sarcolemmal KATP channel blocker did 
not influence the CsA-mediated reduction in infarct size, suggesting that there is no apparent 
interplay between the sarcolemmal KATP channel and the mPTP.
However, the results with glimepiride are surprising. According to a recent study by 
Yellon’s group,(875) this KATP channel blocker does not target the mitochondria, as it did not 
block IPC or diazoxide-induced cardio-protection. Furthermore, glimepiride was not 
demonstrated to antagonise mitochondrial KATP channel opening as evidenced by the fact that it 
did not block the GTP-induced mitochondrial membrane depolarisation in isolated 
mitochondria.(875) The finding that glimepiride does not abolish preconditioning has been 
demonstrated in rabbit hearts,(877) preconditioning at the time of PTCA,(878) and in diabetic 
rats.(879) Therefore, why glimepiride should abrogate CsA-induced protection is unknown if the 
mitochondrial KATP channel is supposed to be the mediator.
The mechanism by which these KATP channel blockers abrogate CsA-mediated 
inhibition of mPTP opening at the time of reperfusion is unclear. We can speculate on several 
possibilities: (1) It may represent a drug interaction between the KATP channel blockers and CsA 
and the abrogation of CsA-induced cardio-protection or else a non-specific effect of the KATP 
channel blockers on mitochondrial function.(107:158) Either way the observed effect may be 
independent of any effect on the KATP channel. This may explain the discrepancy with 
glimepiride also blocking CsA-induced protection, when it is believed to not influence the 
mitochondrial KATP channel; (2) The capacity of CsA to induce inhibition of mPTP opening 
depends on its ability to bind to cyclophilin D and prevents its interaction with the ANT.(666) 
Therefore, factors which act to facilitate the binding of cyclophilin D to ANT, may overcome the 
inhibitory effect of CsA on mPTP opening. In this regard, Halestrap’s group have demonstrated 
that the binding of cyclophilin D to ANT was facilitated by chaotropic agents (substances, 
usually ions [e.g., SCN-, CI04-, guanidinium], which disrupt the structure of water and thereby
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promote the solubility of non-polar substances in polar solvents [e.g., water], and promote the 
unfolding of proteins) and mitochondrial swelling.(671) Intriguingly, the KAtp channel blocker, 5- 
HD, has been demonstrated to induce mitochondrial matrix swelling,(149) and so potentially it 
could enhance the binding of cyclophilin D to ANT, thereby overcoming the inhibitory effect of 
CsA on mPTP opening. Glibenclamide has been demonstrated to induce K+ influx into 
mitochondria,(819) which would be expected to increase matrix volume.
This part of the study suggested that there may be an interaction between the 
mitochondrial K At p  channel (which has been implicated in preconditioning) and the mPTP 
(which has been implicated in ischaemia-reperfusion injury). Therefore, our next objective was 
to determine whether mPTP opening in the setting of ischaemia-reperfusion injury can be 
modulated by preconditioning.
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5.4 Aim (2)
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Determine whether pharmacologically opening the mPTP at the time of reperfusion 
abrogates classical preconditioning-induced protection
In this section we examined the effect of pharmacologically opening the mPTP for the first 15 
minutes of reperfusion, using either atractyloside or phenylarsenine oxide, on the protection 
induced by both ischaemic and pharmacological preconditioning, based on the assumption that 
preconditioning protects by inhibiting mPTP opening at the time of reperfusion. Atractyloside is 
an ANT inhibitor which has been demonstrated to induce mPTP opening. Ashrafs group 
demonstrated that at 20 pmol/l, this drug reversed the protection associated with calcium 
preconditioning^251) Phenylarsenine oxide (PAO) induces mPTP opening by cross-linking 
critical thiol groups on the ANT,(655:658) a component of the mPTP. This drug has been used in 
isolated myocytes to induce mPTP opening as detected by the movement of the fluorescent dye, 
calcein out of the mitochondria.(857)
In this part of the study we also wanted to confirm that the protection associated with 
IPC and diazoxide could be abolished by the mitochondrial KAtp channel blocker, 5- 
hydroxydecanoate.
5.4.1 Materials
Diazoxide (Sigma Chemicals, Poole, Dorset) was dissolved in dimethyl sulfoxide (DMSO) and 
added to the Krebs-Henseleit buffer such that the final DMSO concentration was less than 
0.02%. 2 chloro-N6-cyclopentyl-adenosine (CCPA, Sigma Chemicals, Poole, Dorset), 
atractyloside (Atr, Sigma Chemicals, Poole, Dorset), and 5-hydroxydecanoic acid (5-HD, Sigma 
Chemicals, Poole, Dorset) were dissolved in distilled water and added to the Krebs-Henseleit 
buffer. All other reagents were of standard analytical grade.
5.4.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
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5.4.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in figure 5.4. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts were perfused with 0.02% DMSO (n=3) or Krebs-Henseleit buffer alone (n=6) 
for 10 minutes prior to lethal ischaemia;
(2) Ischaemic preconditioning (IPC)-treated hearts (n=6)were treated with 2 periods of 5 
minutes each of global ischaemia with a 10-minute intervening reperfusion before the lethal 
ischemia;
(3) Diazoxide-treatment: hearts (n=6) were perfused with diazoxide (30 pmol/l) for 10 minutes 
followed by 10 minutes washout with Krebs-Henseleit buffer prior to lethal ischemia. This 
concentration of diazoxide has been previously shown to pharmacologically precondition the 
isolated perfused rat heart;(104)
(4) CCPA-treatment: hearts (n=7) were perfused with CCPA (200 nmol/l) for 10 minutes 
(during which time the hearts were paced at 300 beats per minute due to CCPA-induced 
bradycardia) followed by 10 minutes washout with Krebs-Henseleit buffer prior to lethal 
ischemia. This concentration of CCPA has been shown to precondition the isolated perfused rat 
heart;(880)
(5) IPC + atractyloside-treatment: hearts (n=6) underwent IPC (as in group 2) and were then 
perfused with atractyloside (20 pmol/l, a known opener of the mPTP)(8'10) for the first 15 minutes 
of reperfusion. This concentration of atractyloside has been previously demonstrated to reverse 
the effects of calcium-preconditioning in adult rat myocytes;(251)
(6) Diazoxide + atractyloside-treatment: hearts (n=6) were pre-treated with diazoxide (as in 
group 3) and were then perfused with atractyloside for the first 15 minutes of reperfusion;
(7) CCPA + atractyloside-treatment: hearts (n=6) were pre-treated with CCPA (as in group 4) 
and were then perfused with atractyloside for the first 15 minutes of reperfusion;
(8) Atractyloside-treatment: hearts (n=6) were perfused with atractyloside for the first 15 
minutes of reperfusion;
(9) IPC + phenylarsenine oxide-treatment: Hearts (n=6) underwent IPC (as in group 2) and 
were perfused with phenylarsenine oxide (PAO, 2 pmol/l, n=3), for the first 15 minutes of 
reperfusion. PAO is another opener of the mPTP and was used here to induce prolonged 
opening of the mPTP for the first 15 minutes of reperfusion. A PAO concentration of 20 pM had
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been shown to induce mPTP opening in myocytes.(857) At this concentration the hearts in our 
study went into immediate irreversible hypercontracture. Hence, we used the lower 
concentration of 2 pmol/l.
(10) Phenylarsenine oxide-treatment: Hearts (n=3) were perfused with phenylarsenine oxide 
(PAO, 2 pmol/l, n=3), for the first 15 minutes of reperfusion.
(11) IPC + 5-HD-treatment: hearts (n=6) underwent IPC (as in group 2) in the presence of 5- 
HD (100 pmol/L) prior to and during regional ischaemia. This concentration of 5-HD has been 
shown to block preconditioning in the isolated perfused rat heart;(104)
(12) Diazoxide + 5-HD-treatment: hearts (n=6) were preconditioned with diazoxide (as in group 
3) in the presence of 5-HD (100 mol/L) which was perfused throughout ischaemia.
(13) 5-HD-treatment: hearts (n=4) were perfused with 1 00 pmol/L 5-HD prior to  and during 
regional ischaemia.
Figure 5.4: Experimental Protocols Investigating the Effect of Opening the mPTP at
the Time of Reperfusion in Preconditioned Hearts. 5-HD-5-hydroxydecanoic 
acid, Atr-Atractyloside, Dzx-Diazoxide, TTC-tetrazolium, CCPA-2 chloro-N6- 
cyclopentyl-adenosine. PAO- phenylarsenine oxide.
Time (min) [■
Group 1: Control 
Group 2: IPC
Groups 3,4: Diazoxide or CCPA
Group 5,9: IPC + Atr or PAO 
Groups 6,7: Diazoxide/CCPA+Atr
Group 8,10: Atr or PAO
Group 11: IPC + 5-HD
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5.4.4.1 Exclusions
We used 82 male Sprague-Dawley rat hearts for the infarct size experiments of which 8 were 
excluded owing to poor function during stabilisation (see section 3.2.3 for exclusion criteria), 
including 3 which were excluded due to phenylarsenine oxide-induced irreversible 
hypercontracture at the concentration of 20 pmol/l.
5.4.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 5.4). Baseline data relating to cardiac function (assessed by the rate-pressure-product, 
RPP) a nd c oronary f low b efore t he I ethal ischaemic period, were s imilar i n t he e xperimental 
groups (see table 5.5, 5.6). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
Table 5.4 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight (g) Risk volume (cm3)
1. Control 6 419±2 1.93±0.08 0.605±0.030
2. IPC 6 405±10 2.06±0.05 0.504±0.051
3. Dzx 6 395±7.1 2.11±0.01 0.565±0.046
4. CCPA 7 374±8.9 2.20±0.21 0.562±0.030
5. IPC + Atr 6 358±37 2.08±0.15 0.578±0.030
6. Dzx + Atr 6 399±18 2.20±0.21 0.559±0.046
7. CCPA + Atr 6 368±13 1.94±0.13 0.530±0.029
8. Atr 6 363±11 2.00±0.13 0.528±0.027
9. IPC + PAO 6 398±9 1.62±0.06 0.474±0.022
10. PAO 3 372±2 2.12±0.03 0.513±0.078
11. IPC + 5-HD 6 343±10 1.77±0.07 0.513±0.078
12. Dzx + 5-HD 6 338±10 1.72±0.05 0.508±0.029
13. 5-HD 4 368±6 1.89±0.22 0.517±0.063
Values are mean±SEM. *P<0.001 compared with control.
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Table 5.5 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 26.5±1.8 25.3±2.8 7.2±1.5 14.0±2.6 17.212.8 9.911.5
2. IPC 28.1±4.1 26.4±1.2 8.1±1.3 15.3±0.8 9.312.3 9.011.5
3. Dzx 26.3±1.7 24.7±1.4 5.1±0.6 12.1±1.8 13.7+2.3 9.411.8
4. CCPA 26.313=3 24.9±4.6 7.1±0.8 15.512.0 18.613.3 6.411.2
5. IPC + Atr 25.6±2.2 25.9±0.8 7.8±1.2 8.9+0.8 10.210.4 6.510.6
6. Dzx + Atr 23.3±1.6 23.3±1.4 6.1±0.8 8.911.6 9.211.4 3.911.0
7. CCPA + Atr 26.4±2.4 26.8±2.6 7.8±1.5 10.011.5 10.610.7 6.411.2
8. Atr 23.0±1.2 27.0±2.5 8.4±1.4 13.0+2.2 9.613.1 6.511.2
9. IPC + PAO 25.5±5.4 26.0±3.0 7.1±2.2 16.410.4 19.310.4 8.111.1
10. PAO 21.6±2.8 28.1±2.0 8.7±1.7 13.410.6 11.314.3 4.410.4
11. IPC + 5-HD 27.9±3.2 29.8±8.8 8.8±1.9 14.913.2 19.711.1 13.411.7
12. Dzx + 5-HD 33.811.9* 31.8±1.2 5.8±0.8 13.1+2.4 21.413.2 18.012.1
13. 5-HD 37.4±1.7* 32.813.2* 9.1±1.0 14.410.9 16.212.0 13.011.7
Table 5.6 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 18.210.5 17.610.5 7.410.2 7.410.2 10.011.0 6.610.7
2. IPC 17.312.4 16.012.1 7.310.7 7.310.7 11.510.5 8.511.5
3. Dzx 17.011.1 15.811.0 6.210.4 5.810.2 9.210.9 4.810.5
4. CCPA 15.411.7 16.311.9 5.510.3 5.510.3 9.311.0 5.310.6
5. IPC + Atr 15.210.7 14.810.6 6.610.7 5.610.5 8.010.6 5.010.3
6. Dzx + Atr 15.511.2 14.311.1 5.310.6 5.310.8 9.011.8 5.811.4
7. CCPA + Atr 14.510.9 14.011.2 5.010.6 4.8+0.5 7.010.4 4.310.3
8. Atr 15.811.3 15.011.7 5.810.3 5.310.3 8.510.6 4.310.3
9. IPC + PAO 19.311.7 19.710.3 8.710.3 8.010.3 16.011.1 8.511.5
10. PAO 17.013.0 17.013.0 9.511.5 10.011.0 14.012.0 8.511.5
11. IPC + 5-HD 18.711.0 19.510.5 8.510.2 7.810.6 12.210.6 8.610.8
12. Dzx + 5-HD 20.310.3 20.010.8 6.5+0.5 6.8+0.5 12.811.1 8.011.4
13. 5-HD 15.310.8 14.011.4 8.3+0.3 5.310.3 7.710.9 5.010.6
Values are mean±SEM. *P<0.05 compared with control.
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5.4.4.3 Infarct Size Data
Infarct size is represented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. IPC significantly reduced infarct size compared with control hearts (19.9±2.6% with IPC 
vs 44.7±2.0% in control, P <0.0001; figure 5.5), as did pharmacological preconditioning using 
diazoxide (18.0±1.7% with diazoxide vs 44.7±2.0% in control, P<0.0001; figure 5.5) or the 
adenosine A1-receptor agonist, CCPA (20.4±3.3% with CCPA vs 44.7±2.0% in control, 
P<0.0001; figure 5.5). However, when atractyloside (the mPTP opener) was administered after 
35 minutes ischaemia and immediately at reperfusion for 15 minutes, it abolished the protective 
effects of IPC (47.7±1.8% with IPC + Atr vs 19.9±2.6% with IPC, P<0.0001; figure 5.5), 
diazoxide (42.3±3.2% with diazoxide + Atr vs 18.0±1.7% with diazoxide, P<0.0001; figure 5.5) 
and CCPA (51.2±1.6% with CCPA + Atr vs 20.4±3.3% with CCPA, P<0.0001; figure 5.5). 
Atractyloside given alone for the first 15 minutes of reperfusion d id not influence infarct size 
(43.9±1.5% vs 44.7±2.0% with control; P=NS; figure 5.5).
Opening the mPTP for the first 15 minutes of reperfusion using phenylarsenine oxide 
(PAO) also abrogated the protection induced by IPC (45.9±4.6% in IPC+PAO vs 19.9±2.6% in 
IPC; N=3; P<0.001; figure 5.5). PAO given alone for the first 15 minutes of reperfusion did not 
influence infarct size (48.3±3.2% vs 44.7±2.0% with control; P=NS; figure 5.5).
The presence of the mitochondrial K At p  channel blocker, 5-HD prior to and during the 
lethal ischaemic period abolished the cardio-protective effects of both IPC (45.8±3.7% with IPC 
+ 5-HD vs 19.9±2.6% with IPC, P<0.0001; figure 5.6) and diazoxide (46.6±2.5% with diazoxide 
+ 5-HD vs 18.0±1.7% with diazoxide, P0.0001; figure 5.6). 5-HD given alone prior to and 
during the lethal ischaemic period did not influence infarct size (49.3±4.1% with 5-HD vs 
44.7±2.0% with control; P=NS; figure 5.6).
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Figure 5.5: Pharmacologically Opening the mPTP at Reperfusion Abrogates
Preconditioning-Induced Protection. Pharmacologically opening the mPTP 
using atractyloside (Atr) abrogated the protection associated with ischaemic 
preconditioning (IPC), diazoxide (Dzx), and 2 chloro-N6-cyclopentyl-adenosine 
(CCPA). Pharmacologically opening the mPTP using phenylarsenine oxide 
(PAO) also abrogated the protection associated with ischaemic preconditioning 
(IPC) *P<0.001 compared with control.
Control IPC IPC+ Dzx Dzx+ CCPA CCPA+ IPC+ PAO Atr
Atr Atr Atr PAO 1
Figure 5.6: Pharmacologically Closing the Mitochondrial KATP Channel Abrogates
Preconditioning Induced Protection: Closing the mitochondrial K Atp  Channel 
using 5-hydroxydecanoic acid (5-HD) abolishes both ischaemic preconditioning 
(IPC) and diazoxide (Dzx)-induced protection.*P<0.001.
Control IPC
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5.4.5 Discussion
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In this part of the study, we demonstrated that opening the mPTP during the first 15 minutes of 
reperfusion, following a period of lethal ischaemia, abrogated the protection induced by 
ischaemic preconditioning and pharmacological preconditioning using either diazoxide or the 
adenosine A1 receptor agonist, CCPA. It was important to demonstrate that two different mPTP 
openers were able to abolish the protection induced by IPC, especially since atractyloside, an 
inhibitor of ANT, would therefore be expected to inhibit the mitochondrial transfer of ATP to the 
cytosol during the first few minutes of reperfusion.
Interestingly, the opening the mPTP for the first 15 minutes of reperfusion increased the 
infarct size in hearts which had been preconditioned to a level comparable with control hearts, 
which would suggest that these drugs do not appear to non-specifically induce mPTP opening. 
In support of this, is the fact that the presence of either Atr or PAO during the first 15 minutes of 
reperfusion in control hearts did not influence infarct size. If these drugs were non-specifically 
inducing mPTP opening, one may have expected to have obtained an increase in infarct size 
compared to the control hearts. Interestingly, a study by Baines and colleagues also 
demonstrated that atractyloside did not increase the infarct size when compared to control 
hearts,(881) as did a study by Rajesh and colleagues.(882) In addition, the latter study found no 
increase in infarct size with isolated perfused rats heart given another mPTP opener 
lonidamine.(882)
This may suggest that these mPTP openers have been targeting the mPTP’s that had 
been i nhibited b y t he p rocess of p reconditioning. O f c ourse t his i s pure s peculation a nd t he 
abrogation of preconditioning-induced protection observed with the mPTP openers, Atr and 
PAO may solely be due to the fact that by opening the mPTP one causes necrotic cell death. 
However, we found that perfusing isolated rat hearts not subjected to ischaemia, with 
atractyloside did not produce any infarction, as measured by tetrazolium staining, suggesting 
the explanation may not be quite so simple. Interestingly, a study by Pastorino and 
colleagues(755) using isolated mitochondria, observed that atractyloside only induced mPTP 
opening i n t he p resence o f t he a poptotic p rotein, B ax ( which t ranslocates t o m itochondria i n 
response to an apoptotic stimulus such as ischaemia-reperfusion).
The finding that opening the mPTP using atractyloside abrogates IPC-induced 
protection has been confirmed in the isolated mouse heart by Baines and colleagues.(881)
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However, a study by Rajesh and co-workers failed to block IPC-induced protection, using the 
open-chest rat model,(882) yet they were able to block the effects of the SWOP (see section 5.5).
The reason for the discrepancy between their results and our in unclear but may relate to a 
difference in the treatment protocols and the model used.
We used an isolated perfused rat heart and gave the mPTP openers, atractyloside or 
PAO at the time of reperfusion, as this is the time period when mPTP opening has been 
demonstrated to occur in the setting of ischaemia-reperfusion injury. In contrast, the study by 
Rajesh and colleagues used the open chest rat model and they gave the mPTP openers 
atractyloside and lonidamine prior to the index ischaemic episode.(882)
In our set of experiments we also demonstrated that IPC and diazoxide induced 
protection could be inhibited by 5-hydroxydecanoic acid, the putative mitochondrial K At p  channel 
blocker, supporting the findings of Schultz and colleagues.(883)
Having demonstrated that classical preconditioning may modulate the mPTP, our next 
objective was to examine whether the mPTP was modulated in the second window of protection.
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5.5 Aim (3)
Chapter 5: The mPTP in Myocardial Preconditioning
Determine whether pharmacologically opening the mPTP at the time of reperfusion 
abrogates the Second Window of Protection
In this part of the study, we investigated whether mPTP opening is modulated in the second 
window of protection (SWOP). SWOP was induced by giving the adenosine A1-receptor agonist 
CCPA, 24 hours before subjecting isolated perfused rats hearts to ischaemia-reperfusion. Again 
the drug atractyloside was given for the first 15 minutes of reperfusion to open the mPTP.
5.5.1 Materials
2 chloro-N6-cyclopentyl-adenosine (CCPA, Sigma Chemicals, Poole, Dorset), was dissolved in 
normal saline. Atractyloside (Atr, Sigma Chemicals, Poole, Dorset) was dissolved in distilled 
water. All other reagents were of standard analytical grade.
5.5.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
5.5.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in figure 5.7. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts: Rats (n=6) received a tail-vein injection of saline vehicle and 24 hours later 
the hearts were excised and Langendorff-perfused and subjected to 35 minutes lethal 
ischaemia and 120 minutes reperfusion;
(2) CCPA-lnduced SWOP: Rats received a tail-vein injection of CCPA (75 |jg/kg) and 24 hours 
later the hearts were excised and Langendorff-perfused and subjected to 35 minutes lethal 
ischaemia and 120 minutes reperfusion;
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(3) CCPA-lnduced SWOP+Atr: Rats received a tail-vein injection of CCPA (75 pg/kg) and 24 
hours later the hearts were excised and Langendorff-perfused and subjected to 35 minutes 
lethal ischaemia and 120 minutes reperfusion, and were perfused with atractyloside (20 pmol/l, 
a known opener of the mPTP)(8'10) for the first 15 minutes of reperfusion. This concentration of 
atractyloside has been previously demonstrated to reverse the effects of calcium- 
preconditioning in adult rat myocytes;(251)
(4) Atr controls: Rats (n=6) received a tail-vein injection of saline vehicle and 24 hours later the 
hearts were excised and Langendorff-perfused and subjected to 35 minutes lethai ischaemia 
and 120 minutes reperfusion, and were perfused with atractyloside (20 pmol/l) for the first 15 
minutes of reperfusion.
Figure 5.7: Experimental protocols Investigating the Effect of Opening the mPTP at
the Time of Reperfusion in Hearts Treated with CCPA-lnduced Second 
Window of Protection (SWOP). Atr-Atractyloside, TTC-tetrazolium, CCPA-2 
chloro-N6-cyclopentyl-adenosine.
Group 1: Saline vehicle control
Group 2: CCPA-SWOP
Group 3: CCPA-SWOP +
Atr at reperfusion
24 hours
1— 1 //
35 min 120 min 
ischaemia reperfusion
1
TTC
staining
Group 4: Saline vehicle + l— I // ' ■ n Atr
Atr at reperfusion
□  Ischaemia ■  Drug
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5.5.4 Results
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5.5.4.1 Exclusions
We used 24 male Sprague-Dawley rat hearts for the infarct size experiments of which 0 were 
excluded (see section 3.2.3 for exclusion criteria).
5.5.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 5.7). Baseline data relating to cardiac function (assessed by the rate-pressure-product, 
RPP) and coronary flow before the lethal ischaemic period, were similar in the experimental 
groups (see table 5.8, 5.9). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
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Table 5.7 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight (g) Risk volume (cmJ)
1. Control 6 440±16 2.3±0.07 0.638±0.029
2. CCPA 6 397±12 2.1 ±0.02 0.615±0.026
3. CCPA + Atr 6 422±24 2.0±0.09 0.561 ±0.029
4. Atr 6 428±21 2.3±0.07 0.653±0.041
Values are mean±SEM. *P<0.001 compared with control.
Table 5.8 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 26.8±2.0 31.8±1.5 8.6±1.8 19.6±1.0 24.4±2.1 19.8±2.9
2. CCPA 26.6±1.6 29.1±2.3 8.2±2.2 17.9±1.7 18.2±2.7 13.8±2.4
3. CCPA + Atr 27.5±1.9 33.8±2.4 7.5±0.4 22.0±2.3 23.0±4.0 18.4±0.9
4. Atr 23.6±3.1 32.0±1.6 10.9±2.6 16.2±3.4 20.8±2.6 11.7±2.0
Values are mean±SEM. *P<0.005 compared with control.
Table 5.9 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 21.2±1.1 21.2±1.1 10.0±0.5 9.5±0.6 16.5±1.1 12.2±0.7
2. CCPA 18.2±0.8 17.8±0.7 8.8±0.4 8.5±0.3 13.0±0.8 8.8±1.6
3. CCPA + Atr 18.0±0.8 17.6±0.9 8.2±0.6 8.8±0.7 11,0±0.9 9.4±1.1
4. Atr 18.3±0.8 18.0±0.9 9.7±0.8 9.3±0.8 14.8±1.9 9.3±1.0
Values are mean±SEM. *P<0.005 compared with control.
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5.5.4.3 Infarct Size Data
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Infarct size is represented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. CCPA-induced SWOP reduced infarct size from 43.9±3.1% in control to 22.7±1.9% with 
CCPA (P<0.001; figure 5.8). When atractyloside was administered for the first 15 minutes of 
reperfusion to open the mPTP, CCPA-induced protection was completely abolished (22.7±1.9% 
with CCPA vs 44.6±3.5% with CCPA+Atr; P<0.001; figure 5.8). Atractyloside given alone at 
reperfusion did not influence infarct size (39.8±4.6% with Atr vs 43.9±3.1% in control; P=NS; 
figure 5.8).
Figure 5.8: Pharmacologically Opening the mPTP at Reperfusion Abrogates the
Protection Associated with CCPA-lnduced SWOP. Pharmacologically 
opening the mPTP for the first 15 minutes of reperfusion using atractyloside (Atr) 
abrogated the protection associated with CCPA-induced second window of 
protection (SWOP). 2 chloro-N6-cyclopentyl-adenosine (CCPA). *P<0.001 
compared with control.
Control CCPA CCPA 
+ Atr
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5.5.4 Discussion
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In this part of the study we have shown that pharmacologically opening the mPTP at the time of 
reperfusion, using atractyloside, abrogates the protection associated with the second window of 
protection induced by the adenosine A1-receptor agonist, CCPA, suggesting that SWOP may 
also modulate mPTP opening. A recent study by Rajesh and colleagues using ischaemia- 
induced delayed preconditioning has confirmed our findings.(882) They demonstrated, that 
ischaemic preconditioning protected the isolated perfused rat heart 24 hours later, as evidenced 
by a reduction in infarct size, increased expression of the anti-apoptotic protein Bcl-2, 
attenuation of apoptotic cell death and mitochondrial swelling and cytochrome C release. The 
mPTP openers lonidamine or atractyloside, when given prior to the index ischaemic episode 
were shown to abolish the protective effect associated with ischaemic preconditioning^882) 
However, they did not demonstrate directly that the SWOP actually inhibits mPTP opening, but 
have implied it based on the effects of mPTP opener, much like we have done in this part of the 
study.
Interestingly, we did not observe an increase in infarct size with control hearts given 
atractyloside at the time of reperfusion, a finding supported by Rajesh and colleagues, who 
found no difference in infarct size with either of the mPTP openers atractyloside or lonidamine 
when compared to control hearts.(882)
The findings from this section and section 5.4 provide only indirect evidence that the 
mPTP is modulated in myocardial preconditioning. Therefore, the next objective was to 
determine whether preconditioning inhibits mPTP opening directly.
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5.6 Aim (4)
Chapter 5: The mPTP in Myocardial Preconditioning
Determine whether preconditioning inhibits calcium-induced opening of the mPTP in 
isolated mitochondria
In this part of the study we examined the effect of preconditioning on mPTP opening directly. 
We used a method for inducing and detecting mPTP opening in adult rat mitochondria, in which 
mitochondria were loaded with the fluorescent, calcein. Opening of the mPTP was induced by 
calcium loading and was detected as a reduction in mitochondrial calcein fluorescence, which 
was measured using a flow cytometer. As such, the method was adapted from that used by 
Pastorino and colleagues(755) who loaded mitochondria with calcein and detected the reduction 
in mitochondrial fluorescence due to mPTP opening, using a fluorescence spectrophotometer. 
As mitochondrial Ca2+ loading during ischaemia-reperfusion is a key determinant of mPTP 
opening at the time of reperfusion, this model is relevant to examining the effect of 
preconditioning on the mPTP opening-induced by mitochondrial Ca2+. In this regard, the effect 
of the preconditioning-mimetics diazoxide and CCPA (the adenosine A1-receptor agonist) on 
Ca 2+-induced mPTP opening was examined.
5.6.1 Materials
Diazoxide was dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset), 
giving a final concentration of <0.1% DMSO. Cyclosporin-A (Sigma Chemicals, Poole, Dorset) 
was dissolved in 50% ethanol, giving a final concentration of 0.05% ethanol. Atractyloside 
(Sigma Chemicals, Poole, Dorset), 5-Hydroxydecanoic acid (5-HD, Sigma Chemicals, Poole, 
Dorset) and 2 chloro-N6-cyclopentyl-adenosine (CCPA, Sigma Chemicals, Poole, Dorset), were 
dissolved in distilled H20 . The fluorescent dyes calcein-AM (calcein-acetoxymethyl ester, 
Molecular Probes Inc., Leiden, The Netherlands) and tetramethyl rhodamine methyl ester 
(TMRM, Molecular Probes Inc., Leiden, The Netherlands) were dissolved in dimethyl sulphoxide 
(DMSO, Sigma Chemicals, Poole, Dorset). All other reagents were of standard analytical grade.
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5.6.2 Mitochondrial Model of mPTP Opening
In this study, mPTP opening was induced and detected in isolated adult rat mitochondria, which 
involved following the movement of a membrane-impermeant fluorescent dye, calcein- 
acetoxymethyl ester (calcein-AM) out of the mitochondria on mPTP opening. The reduction in 
mitochondrial calcein fluorescence was measured using a flow cytometer.
Mitochondria were isolated from male Sprague-Dawley rats according to the method 
described in section 3.3. Aliquots of the mitochondrial sample (0.5 mg/ml) were incubated with 
the fluorescent dye, calcein-AM (1 pmol/L) for 15 minutes at room temperature. The ester form 
of calcein, termed calcein-AM is membrane permeable, unlike free calcein which is membrane 
impermeable. Therefore calcein-AM readily enters the mitochondria and once within the 
mitochondrial matrix it is de-esterified (by mitochondrial esterases), releasing the free 
fluorescent calcein which is trapped in the mitochondrial matrix as it is membrane impermeable. 
Therefore, calcein (which has a molecular weight of 620 Da) can only exit the mitochondria via 
the mPTP, which allows solutes <1500 Da to pass through.(9:848) Therefore, in this model mPTP 
opening is indicated by the reduction in calcein fluorescence, which was measured using flow 
cytometry (see section 3.4). For calcein-fluorescence, the signal was analysed in the FL1 
detector channel equipped with a band-pass filter at 520 nm; the photo-multiplier value of the 
detector was 631 V. In this model, mPTP opening was induced using either calcium or 
atractyloside (both known inducers of mPTP opening).(8'10) Using this model, the effect of the 
preconditioning-mimetic diazoxide on Ca2+-induced mPTP opening was examined.
The mitochondria were then washed twice with KCI buffer containing (in mmol/l) KCI 
120.0, TES 5.0, and MgCI20.1, with added ATP 0.2 and sodium succinate 10. To confirm that 
the observed reduction in mitochondrial calcein fluorescence was due to mPTP opening it was 
essential to demonstrate that it was sensitive to the mPTP inhibitor, cyclosporin-A.
5.6.3 Experimental Protocols for Mitochondrial Studies
Calcein-loaded mitochondria in KCI buffer were incubated for 10 minutes at room temperature 
with the following treatments:
(1) Control: 0.1 pmol/l Ca2+ in the presence or absence of 0.05% ethanol or 0.1% DMSO;
(2) Calcium-induced mPTP opening: 500 pmol/l Ca2+;
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(3) Atractyloside-induced mPTP opening: 0.1 pmol/l Ca2+ + atractyloside (5 mmol/l). This 
concentration of atractyloside has been used to induce mPTP opening in isolated 
mitochondria;(884)
(4) Calcium and CsA: 500 pmol/L Ca2+ in the presence of cyclosporine-A (0.2 pmol/l). This 
concentration of CsA confers potent inhibition of mPTP opening;(780)
(4) Atractyloside and CsA: 0.1 pmol/l Ca2+ + atractyloside (5 mmol/l) in the presence of 
cyclosporine-A (0.2 pmol/l);
(5) C alcium a nd diazoxide. 500 pmol/l Ca2+ in the presence of the preconditioning-mimetic 
diazoxide (30 pmol/l). This concentration of diazoxide has been used as a preconditioning- 
mimetic;(104)
(6) Calcium, diazoxide and 5-HD: 500 pmol/l Ca2+ in the presence of diazoxide (30 pmol/l) and 
5-HD (100 pmol/l). This concentration of 5-HD has been used to close the mitochondrial K At p  
channel;(104)
(7) Calcium and CCPA: 500 pmol/l Ca2+ in the presence of the adenosine A1-receptor agonist, 
CCPA (200 nmol/l). This concentration of CCPA has been used as a preconditioning 
mimetic;(880) and
(8) Calcium and 5-HD: 500 pmol/l Ca2+ in the presence of 5-HD (100 pmol/L).
Following incubation with the above treatments, mitochondrial calcein fluorescence was 
measured using the flow cytometer (see section 3.4). Experiments were performed on 
mitochondria isolated from 6 individual rats.
5.6.4 Results
5.6.4.1 Exclusions
We used 14 male Sprague-Dawley rat hearts for mitochondrial isolation of which 2 were 
excluded owing to poor mitochondrial function (see section 3.2.3 for exclusion criteria).
5.6.4.2 Mitochondrial Calcein Fluorescence Data
Arithmetic mean values of the median mitochondrial calcein fluorescence intensities were 
determined for each sample for graphic representation. Figure 5.9 (a-h) shows representative
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flow cytometric profiles following various treatment protocols. The Y scale denotes the number 
of events which corresponds to the number of mitochondria emitting a calcein fluorescence 
signal portrayed on the X axis. A shift to the left in the profile signifies a reduction in the median 
mitochondrial fluorescence for the population of mitochondria, due to opening of the mPTP.
The mitochondrial calcein fluorescence values after treatment with Ca2+ (0.1 pmol/l) 
plus or minus the treatment drug were taken as the values from which any reduction in 
fluorescence was measured. Exposure of mitochondria to Ca2+ (500 pmol/l) induced a reduction 
in calcein fluorescence of 41.9±3.5% (figure 5.10a), indicating mPTP opening. This Ca2+- 
induced reduction in calcein fluorescence was abolished in the presence of the mPTP inhibitor, 
cyclosporin-A (0.7±0.7% with 500 pmol/l Ca2+ + CsA vs 41.9±3.5% with 500 pmol/l Ca2+ alone, 
P0.0001; figure 5.10a), indicating that the calcium-induced reduction in calcein fluorescence 
was due to opening of the mPTP. The mPTP opener, atractyloside induced a reduction in 
calcein fluorescence of 40.3±3.1% (figure 5.10a), indicating mPTP opening, which was also 
sensitive to cyclosporin-A (7.0±2.0% with atractyloside + CsA vs 40.3±3.1% with atractyloside 
alone, P<0.0001; figure 5.10a), indicating that the atractyloside-induced reduction in calcein 
fluorescence was due to opening of the mPTP.
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Figure 5.9 (a-h): Flow Cytometric Profiles of Mitochondrial Calcein Fluorescence.
Treatment (green profiles) with either (a) 500 pmol/l Ca2+ or (c) Atractyloside induces a 
reduction in mitochondrial calcein fluorescence, indicating mPTP opening, compared to the red 
control profiles. The presence of the mPTP inhibitor, cyclosporin-A (CsA) prevents the reduction 
in calcein fluorescence induced by (b) 500 pmol/l Ca + or (d) Atractyloside, indicating inhibition 
of mPTP opening. The presence of the preconditioning-mimetic, diazoxide, attenuates the 
reduction in calcein fluorescence induced by (e) 500 pmol/l Ca2+, indicating inhibition of mPTP 
opening. This effect of diazoxide on mPTP opening is abolished in the presence of the 
mitochondrial Katp channel blocker, 5-HD (f). The adenosine A1-receptor agonist, CCPA and 
5HD do not have any effect on mPTP opening (h, i).
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The presence of the preconditioning-mimetic, diazoxide attenuated the calcium-induced 
reduction in calcein fluorescence (18.4±4.1% with 500 pmol/l Ca2+ + diazoxide vs 41.9±3.5% 
with 500 pmol/l Ca2+ alone, P<0.0001; Figure 5.10b), which is equivalent to a 52.5±8.0% 
reduction, indicating that pharmacological preconditioning using diazoxide inhibits calcium- 
induced mPTP opening. This effect of diazoxide was abolished in the presence of the 
mitochondrial K At p  channel blocker, 5-HD (41.5±2.4% with 500 pmol/l Ca2+ + diazoxide + 5-HD 
vs 18.4±4.1% with 500 pmol/l Ca2+ + diazoxide, P<0.0001; figure 5.10b). 5-HD alone did not 
influence the reduction in calcein fluorescence (44.5±3.7% with 500 pmol/l Ca2+ + 5-HD vs 
41.9±3.5% with 500 pmol/L Ca2+ alone; figure 5.10b). C CPA had no effect on the calcium- 
induced reduction in calcein fluorescence (44.9±10.2% vs 41.9±3.5% with 500 pmol/L Ca2+ 
alone; figure 5.10b).
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Figure 5.10 (a-b): Changes in Mitochondrial Calcein Fluorescence, (a) Treatment with 
either 500 pmol/l Ca2+ or atractyloside induces a reduction in mitochondrial calcein fluorescence, 
indicating mPTP opening. The presence of the mPTP inhibitor, cyclosporin-A (CsA) prevents 
the reduction in calcein fluorescence induced by 500 pmol/l Ca2+ or atractyloside, indicating 
inhibition of mPTP opening, (b) The presence of the preconditioning-mimetic, diazoxide, 
attenuates the reduction in calcein fluorescence induced by 500 pmol/l Ca +, indicating inhibition 
of mPTP opening. This effect of diazoxide on mPTP opening is abolished in the presence of the 
mitochondrial K Atp  channel blocker, 5-HD. The adenosine A1-receptor agonist, CCPA and 5HD 
do not have any effect on mPTP opening. Values are means of the median mitochondrial 
calcein fluorescence for that group ±SEM expressed as a % of the baseline 
fluorescence.*P<0.0001 compared to control.
(a)
Calcium Calcium Atractyloside Atractyloside
control + CsA + CsA
-50
(b)
Calcium Calcium + Calcium + Calcium + Calcium +
control diazoxide diazoxide+ 5-HD CCPA
-60
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The results demonstrate that the treatment with the preconditioning mimetic, diazoxide, inhibits 
the mPTP opening induced by mitochondrial Ca2+ loading. The inhibitory effect of diazoxide on 
mPTP opening was abolished in the presence of the mitochondrial K Atp  channel blocker, 5-HD, 
suggesting that this effect of diazoxide can be antagonised by 5-HD, whether it be due to the 
closing of the mitochondrial K Atp  channel or independent of the mitochondrial K ATp channel. As 
expected the adenosine-A1 receptor agonist had no effect on Ca2+-induced mPTP opening, 
since this drug exerts its effect by activating a cell-surface G-protein coupled receptor, not 
present in a mitochondrial preparation.
This effect of diazoxide on mPTP opening has been confirmed in a study by Weiss and 
colleagues,(846) who demonstrated that diazoxide inhibited the mPTP opening induced by 
mitochondrial Ca2+ loading, using the reduction in mitochondrial calcein fluorescence to indicate 
mPTP opening. In addition, an agonist of PKC (implicated as a mediator of IPC) was 
demonstrated to inhibit Ca2+-induced mPTP opening in their model.(846) However, in their study 
they used a very high concentration of calcein of 10 pmol/l, which was ten times greater than 
the concentration used in our study. At this higher concentration, calcein would be expected to 
generate mitochondrial oxidative stress.(885;886)
The results from this part of the study suggests that the preconditioning mimetic 
diazoxide may be able to protect the heart by inhibiting the Ca2+-induced mPTP opening that 
occurs in the setting of ischaemia-reperfusion. However, t he m echanism by which d iazoxide 
inhibits Ca2+-induced mPTP opening is unclear, though it could relate to the effect of diazoxide 
on mitochondrial [Ca2+]. The mitochondrial entry of Ca2+into occurs via the Ca2+-uniporter and is 
determined by the mitochondrial membrane potential. Several studies have suggested 
diazoxide can attenuate mitochondrial Ca2+ loading by reducing the mitochondrial membrane 
potential. (257;258) However, these studies have attracted controversy because of the high 
concentrations of diazoxide and pinacidil u sed and over whether m itochondrial KATP channel 
opening actually induces a significant mitochondrial membrane depolarisation.(109;159:160;259) At 
high concentrations, diazoxide and pinacidil can uncouple mitochondria, independent of 
mitochondrial K ATp channel opening.(160:26°) Subsequent studies in other laboratories however, 
have noted that diazoxide can protect against ischaemia-reperfusion injury by causing reduction 
in mitochondrial Ca2+ load;(52:239:261;262)
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It may well transpire that the conditions in which diazoxide induces a significant 
mitochondrial membrane depolarisation are: (1) if high concentrations of diazoxide (>100 pmol/l) 
are used in which case uncoupling occurs independent of the mitochondrial K Atp  channel;(160:260) 
or (2) if the mitochondria are de-energised, such that a K+ influx induced by diazoxide is 
sufficient to uncouple the already compromised mitochondrial respiratory function. This is 
supported by a study by Weiss’ group who demonstrated significant diazoxide-induced 
mitochondrial membrane depolarisation in de-energised but not energised mitochondria.(846) 
Further evidence is provided by the revelation that the diazoxide-induced flavoprotein oxidation 
(secondary to mitochondrial uncoupling), used by Marban’s group to indicate opening of the 
mitochondrial K Atp  channel, was only observed in de-energised cells-i.e. cells which had been 
kept in substrate-free medium overnight.(108:11°)
Another major determinant of mPTP opening in the setting of ischaemia-reperfusion is 
oxidative stress, which is generated on the reperfusion of ischaemic myocardium.(79;276:277) 
Therefore, in the next section of the study, we investigated the effects of preconditioning on the 
mPTP opening induced by oxidative stress.
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Determine whether preconditioning inhibits oxidative stress-induced opening of the 
mPTP in isolated myocytes
Having demonstrated in the previous section that the preconditioning mimetic, diazoxide can 
inhibit mPTP opening induced by mitochondrial Ca2+ loading, our next objective was to 
determine whether preconditioning could inhibit the mPTP opening induced by oxidative stress. 
Together with the mitochondrial [Ca2+], oxidative stress is a major determinant of mPTP opening 
at the time of reperfusion. Using a model which allowed us to induce and detect mPTP opening 
both accurately and reproducibly, we investigated the effects of hypoxic preconditioning (HP) 
and pharmacological preconditioning using diazoxide or nicorandil on the mPTP opening 
induced by oxidative stress.
5.7.1 Materials
Diazoxide (Sigma Chemicals, Poole, Dorset), glibenclamide (Sigma Chemicals, Poole, Dorset) 
and sanglifehrin-A (SfA, Novartis Pharm AG, Basel, Switzerland) were dissolved in 
dimethylsulphoxide (DMSO), giving a final concentration of <0.1% DMSO. Cyclosporin-A (CsA, 
Sigma Chemicals, Poole, Dorset) and N-methyl 4-valine CsA (Novartis Pharm AG, Basel, 
Switzerland) were dissolved in 50% ethanol, giving a final concentration of 0.05% ethanol. HMR 
1098 (gift of Dr J. Downey) and 5-hydroxydecanoate (5-HD, Sigma Chemicals, Poole, Dorset) 
were dissolved in distilled water. Nicorandil (Nic, Chugai Pharmaceuticals, Tokyo, Japan) was 
dissolved in normal saline. Tetramethylrhodamine methyl ester (TMRM, Molecular Probes 
Europe BV, Leiden, The Netherlands) was dissolved in DMSO. All other agents were of 
standard analytical grade and quality.
5.7.2 Myocyte Model of mPTP Opening
Adult rat myocytes were isolated from male Sprague-Dawley rats according to the method in 
described in section 3.5. Isolated myocytes were seeded onto 25-mm round cover-slips 
according to the method in described in section 3.6.
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Opening of the mPTP in adult rat myocytes was induced and detected using a cellular 
model of oxidative stress. (647;768:827‘830) Seeded myocytes, in restoration buffer, were incubated 
with the fluorescent dye, TMRM (3 ^mol/l) for 15 minutes at 37°C, washed and visualised using 
confocal fluorescence microscopy, as described in section 3.7.
TMRM, a lipophilic cation, accumulates selectively into mitochondria according to the 
mitochondrial membrane potential(845) (figure 5.11 shows an adult rat myocyte loaded with 
TMRM). In this figure, NADH fluorescence (representing autofluorescence) is also shown to 
demonstrate the co-localisation of the fluorescence signal, verifying that the TMRM localises to 
the mitochondria.
Figure 5.11: TMRM and NADH Fluorescence of an Adult Rat Myocyte. Representative 
image of adult rat myocytes demonstrating: (a) TMRM fluorescence localised to the 
mitochondria as bands of yellow-orange fluorescence (b) NADH fluorescence indicating 
mitochondrial autofluorescence as bands of blue fluorescence. Note how the TMRM and NADH 
fluorescent signals are co-localised to the mitochondria, confirming that TMRM localises to the 
mitochondria.
(A) TMRM Fluorescence (B) NADH Fluorescence 
\
Laser-illumination of the TMRM dye contained within the mitochondria, photosensitises 
the TMRM, generating reactive oxygen species (ROS) from within the mitochondria,(887) which 
induce opening of the mPTP. Opening of the mPTP, permeates the normally impermeable inner
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mitochondrial membrane, which results in uncoupling of oxidative phosphorylation and 
subsequent collapse of the mitochondrial membrane potential. In this model, the opening of the 
mPTP is represented by the collapse in mitochondrial membrane potential.(825:829) Oxidative 
stress generated on reperfusing ischaemic myocardium also involves the excess production of 
ROS from within the mitochondria,(276;277:45°) and this model therefore simulates the events 
associated with lethal reperfusion injury. This model represents a widely reported and reliable 
way to reproducibly induce the loss of mitochondrial membrane potential, which has been 
unequivocally identified as mPTP opening.(768:818:825,827'830)
The relatively high concentration of TMRM in the mitochondria causes auto-quenching 
of fluorescence, such that the fluorescence signal becomes a non-linear function of dye 
concentration; therefore in this model, mitochondrial membrane depolarisation results in the 
loss of dye into the cytosol where the signal increases.{BB7,BBB) Laser-induced oxidative stress 
was applied until mPTP opening had been induced (indicated by collapse of the mitochondrial 
potential) and continued until rigour contracture occurred. We measured the duration of time 
taken to induce mPTP opening, which corresponds to the burden of ROS required to induce 
mPTP opening. Following the induction of mPTP opening, the additional duration of time taken 
to induce rigour contracture (signalling ATP depletion) was also measured.
For all photo-sensitisation experiments, the conditions of the confocal imaging system 
(laser power, confocal pinhole - set to give an optical slice of 1 micron - pixel dwell time, and 
detector sensitivity) were identical to ensure comparability between experiments.
5.7.3 Experimental Protocols for Myocyte Studies
After loading with TMRM in the restoration buffer, cells were randomly assigned to one of the 
following treatment groups. Cells were incubated for 20 minutes with the drug(s) at 37°C and 
were then subjected to the TMRM-oxidative stress protocol.
1 Confro/-incubation with restoration buffer alone (n=18), with 0.05% ethanol (n=6), or 0.1% 
DMSO vehicle control (n=6);
2 Cyclosporin-A (0.2 pmol/l, an inhibitor of mPTP opening, n=12);
3 N-methyl 4-valine-CsA (0.4 pmol/l, an inhibitor of mPTP opening, n=12). This 
concentration of N-methyl 4-valine-CsA has been use to inhibit mPTP opening;(830)
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4 Sangliefehrin-A (1.0 pmol/l, n=12). This concentration of sangliefehrin-A has been 
demonstrated to be a potent mPTP inhibitor^676)
5 Hypoxic preconditioning (HP) (n=12)-see section 5.7.4;
6 HP + 5-HD: HP in the presence of 5-HD (100 pmol/l, a mitochondrial K Atp  channel blocker, 
n=6). This concentration of 5-HD has been shown to block the mitochondrial K Atp  
channel;(104)
7 HP + glibenclamide: HP in the presence of glibenclamide (10 pM, n=6). This concentration 
of glibenclamide has been shown to block the mitochondrial KATP channel;(875)
8 Diazoxide (30 pmol/l, n=12). After incubation of the cells with diazoxide the cells were 
washed with restoration buffer prior to the oxidative stress protocol. This concentration of 
diazoxide has been shown to act as a preconditioning mimetic;(104)
9 Diazoxide + 5-HD (n=6);
10 Diazoxide + glibenclamide (n=6);
11 Diazoxide + HMR 1098 (10 pmol/l, n=6).
12 Nicorandil (100 pmol/l, n=12). After incubation of the cells with nicorandil the cells were 
washed with restoration buffer prior to the oxidative stress protocol. This concentration of 
nicorandil has been shown to act as a preconditioning mimetic;(889)
13 Nicorandil + 5-HD (n=6);
14 Nicorandil + glibenclamide (n=6);
15 5-HD alone (n=6);
16 Glibenclamide alone (n=6);
17 HMR 1098 alone (n=6).
5.7.4 Hypoxic Preconditioning Protocol
Cells were incubated in a hypoxic (Pa02 < 3 KPa) incubator (Heraeus, Kendro Laboratory 
Products, Germany) for 2 periods of 10 minutes at 37°C in anoxic buffer comprising (in mmol/l):
137.0 NaCI, 12.0 KCI, 0.49 MgCI2> 4.0 HEPES, 0.9 CaCI2, 1.0 Na dithionite, 20.0 2- 
deoxyglucose, 20.0 lactate (pH 6.5) with an intervening 30 minutes reoxygenation in restoration 
buffer prior to undergoing the TMRM-induced oxidative stress protocol. The anoxic buffer is a 
modification of that described by Esumi and colleagues.(89°)
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5.7.4.1 Exclusions
We used 25 male Sprague-Dawley rat hearts for myocyte isolation of which 3 were excluded 
owing to poor myocyte isolation (see section 3.5 for exclusion criteria).
5.7.4.2 Myocyte Model of mPTP Opening
Confocal fluorescence imaging of adult rat ventricular myocytes loaded with TMRM, revealed 
mitochondria as fluorescent bands orientated with the longitudinal axis of the cell (see figure 
5.12a). TMRM localises selectively to the mitochondria according to the mitochondrial 
membrane potential. Figure 5.12 (a-e) shows representative images extracted from a time 
sequence in which a myocyte was loaded with TMRM and subjected to laser-induced oxidative 
stress, and demonstrates the sequential changes that take place in mitochondrial membrane 
potential over time. Laser illumination induces firstly occasional and reversible local 
depolarisation of either clusters of mitochondria or individual mitochondria (which appear as 
areas in which TMRM fluorescence suddenly disappears, see arrows in figure 5.12b). With 
continued laser-induced oxidative stress, global mitochondrial membrane depolarisation occurs, 
seen as a ‘wave’ of increased TMRM fluorescence which propagates from one end of the cell to 
the other (a process which takes about 100 seconds), reflecting progression of irreversible 
mPTP opening (see arrow, figure 5.12c and figure 5.13a,b), until all the mitochondria have 
undergone mPTP opening (figure 5.12d). Following the depolarisation, mitochondria consume 
ATP ultimately leading to rigour contracture (figure 5.12e).
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Figure 5.12: Confocal Images of TMRM-loaded Myocytes. Confocal fluorescent images are 
extracted from two separate time sequences in which a control myocyte (images on left) and a 
diazoxide-preconditioned myocyte (images on right) were subjected to laser-induced oxidative 
stress. They demonstrate the typical changes in mitochondrial membrane potential that occur in 
response to oxidative stress: (a) Prior to oxidative stress, (b) Localised areas devoid of TMRM 
fluorescence appear (see arrows), (c) A wave’ of global mitochondrial membrane depolarisation 
(which indicates opening of the mPTP) begins at one end of the myocyte (see arrows), and 
propagates across the whole cell as a wave’ of increase fluorescence, (d) The whole myocyte 
has now undergone global mitochondrial depolarisation (as mPTP opening has taken place in 
all the mitochondria), (e) Following the opening of the mPTP and the resultant collapse in 
mitochondrial membrane potential, the uncoupling of oxidative phosphorylation leads to ATP 
depletion and rigour contracture Note that the time taken to induce mPTP opening and rigour 
contracture is increased in the diazoxide -preconditioned cell.
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Figure 5.13: The Wave of Mitochondrial Depolarisation, (a) Representative confocal 
fluorescence image of a myocyte loaded with TMRM showing the ‘wave’ of global mitochondrial 
depolarisation (indicating the opening of the mPTP), demonstrated by a ‘wave’ of increased 
TMRM fluorescence propagating across the cell from left to right across five regions of interest 
(ROI). (b) Graph showing intensity of TMRM fluorescence in arbitrary units (a.u.) in the 5 
regions of interest over time.
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The times taken to induce global mitochondrial membrane depolarisation and rigour 
contracture were noted and in the control group, m PTP opening was routinely induced after 
252.0±18.1 seconds of laser-induced oxidative stress (see figure 5.14a). A further 384 seconds 
were required for the progression to irreversible contraction, with rigour contracture occurring 
after a total of 636.1±26.4 seconds of laser-induced oxidative stress (figure 5.14b).
To verify that the observed global mitochondrial membrane depolarisation induced by 
laser induced oxidative stress, actually represents opening of the mPTP, it is essential to 
demonstrate that it is sensitive to cyclosporin-A (CsA), the most reliable inhibitor of mPTP 
opening.(664) CsA was shown to extend the time required to induce opening of the mPTP more 
than two-fold, from 252.0±18.1 seconds to 450.7±26.1 seconds (P<0.001, figures 5.14b) and it 
also extended the time required to induce rigour contracture from 636.1 ±26.4 seconds to 
945.4±69.7 seconds, (P<0.001, figures 5.14b). However, as well as inhibiting mPTP opening,
CsA inhibits the phosphatase, calcineurin. To exclude the effect of CsA-induced inhibition of 
calcineurin i n this m odel, we tested the n on-immunosuppressive C sA analogue, N -methyl 4 - 
valine CsA, as this drug has been shown to inhibit mPTP opening without inhibiting 
calcineurin.(674) This mPTP inhibitor also increased the time taken to induce both mPTP 
opening and rigour contracture to 605.8±74.5 seconds and 1055.3±79.4 seconds, respectively 
(P<0.001, figure 5.14a,b). Furthermore, in this model, N-methyl 4-valine CsA was shown to be a 
more potent inhibitor of mPTP opening than CsA, extending the time taken to induce mPTP 
opening even further than CsA (605.8±74.5 seconds with N-methyl 4-valine CsA vs 450.7±26.1 
with CsA, P<0.005, figure 5.14a), although there was no significant difference with respect to 
the times taken to induce rigour contracture (figure 5.14b).
The recently described mPTP inhibitor, sanglifehrin-A,(676) which does not inhibit 
calcineurin, also significantly prolonged the time taken to induce both mPTP opening and rigour 
contracture to 777.4±100.7 and 1329.0±129.0 seconds (P<0.001) respectively (figure 5.14a,b). 
Furthermore, s anglifehrin-A was s hown to be a m ore p otent inhibitor of m PTP o pening t han 
CsA, extending the time taken to induce mPTP opening even further than CsA (777.4±100.7 
seconds with sanglifehrin-A vs 450.7±26.1 with CsA; P<0.005; figure 5.14a), and extending the 
time taken to induce rigour contracture even further than CsA (1329.0±129.0 seconds with 
sanglifehrin-A vs 945.4±69.7 seconds with CsA; P<0.005; figure 5.14b).
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5.7.4.3 Hypoxic Preconditioning Protects the Myocyte from Oxidative Stress by
inhibiting mPTP Opening 
Hypoxic preconditioning increased the illumination time required to induce global mitochondrial 
membrane depolarisation from 252.0±18.1 seconds in control to 464.1 ±53.8 seconds in hypoxic 
preconditioned cells, (P<0.001, figure 5.14a). The times taken to induce rigour was also 
extended from 636.1±26.4 seconds in control to 1140.7±84.0 seconds (P<0.001, figure 5.14b). 
These results suggest that hypoxic preconditioning acts to inhibit the opening of the mPTP 
induced by oxidative stress, resulting in protection from oxidative stress-induced rigour 
contracture.
The mitochondrial K Atp  channel blockers, glibenclamide and 5-HD abrogated the 
inhibitory effect of hypoxic preconditioning on mPTP opening and abolished the protective effect 
of preconditioning. HP in the presence of either glibenclamide or 5-HD abolished both the delay 
in the time taken to induce mPTP opening (464.1 ±53.8 seconds with HP vs 256.6±27.0 seconds 
with HP+glibenclamide and 247.4±7.0 seconds with HP+5-HD; P<0.001; figure 5.14a) and the 
delay in the time taken to induce rigour contracture (1140.7±84.0 seconds with HP vs 
692.3±68.0 seconds with HP+glibenclamide and 687.8±30.1 seconds with HP+5-HD; P<0.001; 
figure 5.14b).
207
Derek J Hausenloy Chapter 5: The mPTP in Myocardial Preconditioning
Figure 5.14: Effect of Hypoxic Preconditioning on mPTP Opening. Hypoxic preconditioning 
(HP) prolonged the duration of laser-induced oxidative stress required to cause both (a) mPTP 
opening and (b) rigour contracture in TMRM-loaded myocytes, an effect abolished in the 
presence of the mitochondrial KAjp  channel blockers, 5-hydroxydecanoate (5-HD) and 
glibenclamide (Glib). The m PTP inhibitors, cyclosporin-A (CsA), N-methyl 4-valine CsA and 
sanglifehrin-A (SfA), also prolonged the duration of laser-induced oxidative stress required to 
cause both (a) mPTP opening and (b) rigour contracture. (Values are MeaniSEM. *P<0.001 
compared to control. #P<0.005 compared to CsA)
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5.7.4.4 Pharmacological Preconditioning Protects the Myocyte From Oxidative Stress by
Inhibiting mPTP Opening 
Pharmacological preconditioning using either diazoxide or nicorandil also increased the 
illumination time required to induce global mitochondrial membrane depolarisation from 
252.0±18.1 seconds in control to 528.5±28.5 seconds after diazoxide treatment, and 386.1 ±33.4 
seconds after nicorandil treatment (P<0.001, 5.15a). The times taken to induce rigour were also 
extended from 636.1±26.4 seconds in control to 1095.6±102.4 seconds, and 967.6±61.8 
seconds, respectively (P<0.001, 5.15b). These results suggest that pharmacological 
preconditioning using either diazoxide or nicorandil act to inhibit the opening of the mPTP 
induced by oxidative stress, resulting in protection from oxidative stress-induced rigour 
contracture.
The mitochondrial K Atp  channel blockers, glibenclamide and 5-HD abrogated the 
inhibitory effect of pharmacological preconditioning on mPTP opening and abolished the 
protective effect of preconditioning. Therefore, diazoxide in the presence of either glibenclamide 
or 5-HD abolished both the delay in the time taken to induce mPTP opening (528.3±28.5 
seconds with diazoxide vs 261.7±24.1 seconds with diazoxide+glibenclamide and 283.3±14.4 
seconds with diazoxide+5-HD; P<0.001; figure 5.15a) and the delay in the time taken to induce 
rigour contracture (1095.6±102.4 seconds with diazoxide vs 543.4±47.1 seconds with 
diazoxide+glibenclamide and 664.0±48.3 seconds with diazoxide+5-HD; P<0.001; figure 5.15b). 
Furthermore, nicorandil in the presence of either glibenclamide or 5-HD also abolished both the 
delay in the time taken to induce mPTP opening (386.1 ±33.4 seconds with nicorandil vs 
256.1±25.6 seconds with nicorandil+glibenclamide and 249.1±36.1 seconds with nicorandil+5- 
HD; P0.001; figure 5.15a) and the delay in the time taken to induce rigour contracture 
(967.6±61.8 seconds with nicorandil vs 482.3±48.1 seconds with nicorandil+glibenclamide and 
661.0±77.4 seconds with nicorandil+5-HD; P<0.001; figure 5.15b).
However, the specific sarcolemmal K Atp  channel blocker, HMR 1098, did not abolish 
the effects of diazoxide on either the time taken to induce mPTP opening (528.5±28.5 seconds 
with diazoxide vs 485.9±11.5 seconds with diazoxide+HMR 1098; P=NS; figure 5.15a) or the 
time taken to induce rigour contracture (1095.6±102.4 seconds with diazoxide vs 1076.8±30.3 
seconds with diazoxide+HMR 1098; P=NS; figure 5.15b).
Given alone the KATP channel blockers did not influence either the time required to 
induce mPTP opening (252.0±18.1 seconds in control vs 239.4±22.3 seconds with
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glibenclamide, 197.3±11.2 seconds with 5-HD and 216.3±13.5 seconds with HMR 1098; P=NS; 
figure 5.15a) or the time taken to induce rigour contracture (636.1 ±26.4 seconds in control vs 
732.6±77.3 seconds with glibenclamide, 496.4±28.2 seconds with 5-HD and 729.4±18.8 
seconds with HMR 1098; P=NS; figure 5.15b).
Figure 5.15: Effect of Pharmacological Preconditioning on mPTP Opening.
Pharmacological preconditioning using either diazoxide (Dzx) or nicorandil (Nic) prolonged the 
duration of laser-induced oxidative stress required to cause both (a) mPTP opening and (b) 
rigour contracture in TMRM-loaded myocytes, an effect abolished in the presence of the 
mitochondrial K At p  channel blockers, 5-hydroxydecanoate (5-HD) and glibenclamide (Glib) but 
not the sarcolemmal K Atp  channel blocker, HMR 1098 (HMR). The K ATp channel blockers, 5- 
hydroxydecanoate, glibenclamide, and HMR 1098 had no effect on the time taken to induce 
either (a) mPTP opening or (b) rigour contracture. (Values are Mean±SEM. *P<0.001)
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This study shows for the first time that both hypoxic and pharmacological preconditioning, using 
diazoxide and nicorandil, protect the myocyte against oxidative stress by suppressing reactive 
oxygen species (ROS)-induced mPTP opening. Myocytes subjected to preconditioning were 
demonstrated to be more resistant to laser-induced oxidative stress, indicated by the fact that 
preconditioning treatment increased the threshold of ROS required to induce mPTP opening. 
The prolonged time taken to induce rigour contracture in preconditioned cells was shown to 
relate directly to suppression of mPTP opening, confirming the importance of the latter, in 
mediating cellular protection.
5.7.6.1 The Model for mPTP Opening
We used an established model for both inducing and detecting mPTP opening in the intact cell, 
in which laser-illumination of TMRM generates oxidative stress from within mitochondria, 
inducing mPTP opening, which is detected by global mitochondrial membrane 
depolarisation.(768;818;825;827'830) Following the induction of mPTP opening, continued oxidative 
stress results in ATP depletion indicated by rigour contracture. The laser-induced collapse in 
mitochondrial membrane potential, as detected by increased TMRM fluorescence, was 
demonstrated to be sensitive to the potent mPTP inhibitor, cyclosporin-A (CsA),(664) validating 
the use of this model for assessing mPTP opening in the intact cell. To exclude the effect of 
CsA-mediated inhibition of calcineurin, we also demonstrated that the observed mitochondrial 
membrane depolarisation was sensitive to the CsA analogue, N-methyl 4-valine CsA, an agent 
which inhibits mPTP opening without affecting calcineurin.(674) Furthermore, the newly 
described mPTP inhibitor, sanglifehrin-A,(676) which does not inhibit calcineurin, was also 
demonstrated to prolong the time taken to induce both mPTP opening and rigour contracture.
In the current model used to investigate mPTP opening, oxidative stress was continued 
until mPTP opening was induced in both control and CsA-treated cells. One would not expect 
CsA to completely suppress mPTP opening under these extreme conditions of oxidative stress 
and presumed mitochondrial Ca2+ overload, especially since oxidative stress can induce direct 
mitochondrial membrane damage by lipid peroxidation. If we had exposed control and CsA- 
treated cells to equal burdens of oxidative stress, it would be clear that under these conditions, 
CsA inhibits mPTP opening compared to the control group. From the current data it is clear that
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CsA increases the tolerance to oxidative stress compared to control suggesting that CsA is 
inhibiting mPTP opening in this model.
The reperfusion of ischaemic myocardium, re-oxygenates the reduced mitochondrial 
respiratory chain,(276) generating ROS, which in turn induces opening of the mPTP.(453) 
Therefore, by contributing to the induction of mPTP opening in the first few minutes of 
reperfusion, ROS assume a pivotal role in mediating reperfusion-induced cell death. It was for 
this reason, that we investigated whether preconditioning protects the heart against ischemia- 
reperfusion injury by suppressing the mPTP opening that occurs in response to the oxidative 
stress, that is generated in the first few minutes of post-ischemic reperfusion. The findings of the 
current study substantiated the role of oxidative stress in mediating irreversible myocyte injury 
and demonstrated that preconditioning can protect the myocyte by inhibiting the mPTP opening 
that would ordinarily occur in response to oxidative stress.
5.7.6.2 The Role of the Mitochondrial KATp Channel
The effects of hypoxic and pharmacological preconditioning (using diazoxide or nicorandil, 
purported openers of the mitochondrial K Atp  channel) on suppressing mPTP opening and 
protecting against rigour contracture in the face of oxidative stress, were abrogated in the 
presence of 5-HD and glibenclamide, agents that have been shown to antagonize the putative 
mitochondrial K Atp  channel.(104) This finding suggests that the observed effect of 
preconditioning on mPTP opening may be mediated via activation of the mitochondrial KATP 
channel, although controversy surrounds the nature of protection associated with agents such 
as diazoxide, which are reported to act via the mitochondrial K ATp channel, in that they have 
been demonstrated to exert non-specific effects on mitochondrial function which include 
inhibiting mitochondrial respiration.(107;148:149;161)
5.7.6.3 Other Studies
The results of our study have been recently confirmed by a study from Marban’s group, in which 
they demonstrated that diazoxide, nicorandil or pinacidil delayed the mitochondrial membrane 
depolarisation (signifying mPTP opening) induced by exogenous hydrogen peroxide, in 
neonatal rat myocytes.(859) In our study we examined the effect of hypoxic preconditioning in 
addition to diazoxide and nicorandil on mPTP opening. Furthermore, in our model the oxidative
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stress used to induce m PTP opening, was generated within m itochondria, which reproduces 
more closely the situation that occurs at time of reperfusion.
5.7.6.4 The Wave ’ of Mitochondrial Depolarisation
Interestingly, the ROS-induced opening of the mPTP, which was represented as a collapse in 
mitochondrial membrane potential, occurred as a ‘wave’ of mitochondrial membrane 
depolarisation, travelling from one end of the cell to the other in about 100 seconds. The basis 
for the propagation of this ‘wave’ of global mitochondrial depolarisation is not known, but it may 
represent a self-propagating wave of mitochondria undergoing mPTP opening, with calcium 
and/or ROS released from one mitochondria on mPTP opening, initiating mPTP opening in the 
adjacent mitochondria and so on,(647;89i) until the whole cell has undergone global mitochondrial 
depolarisation. Several other studies have described mPTP-induced m itochondrial ‘waves’ of 
depolarisation, with the suggestion that they contribute to cellular Ca^-signallingf6471839) or 
propagation of the apoptotic signal.(842)
In contrast, a recent study by O’Rourke’s group documented oscillatory waves of 
mitochondrial membrane depolarisation and repolarisation, in response to the laser-induced 
local release of ROS in a small volume of the cell.(862) They demonstrated that the oscillatory 
‘waves’ of mitochondrial depolarisation/repolarisation were mediated by ROS-induced ROS 
release from the mitochondrial electron transport chain, and that they were insensitive to CsA 
(and were not associated with mitochondrial calcein efflux), suggesting that they occurred 
independent of the mPTP. However, they were blocked by the inner membrane anion channel 
(IMAC) inhibitor, DIDS (4’-chlorodiazepam), and a mitochondrial benzodiazepine receptor 
antagonist, which interestingly has been suggested to be a component of the mPTP.(719) 
However, t he i nvestigators p ostulated t hat R OS ( superoxide anion) e xited via t he I MAC a nd 
propagated the oscillatory mitochondrial waves of depolarisation/repolarisation.(862) Interestingly, 
Vanden Hoek and colleagues when investigating the role of ROS as a trigger/mediator of 
hypoxic preconditioning, observed that the mitochondrial release of ROS was inhibited by the 
IMAC inhibitor, DIDS, suggesting that the IMAC was acting as an exit channel for mitochondrial 
generated ROS.(49)
The model used by Marban’s group(862) differs from the one in our study in that we 
subjected the whole cell to a much greater quantity of oxidative stress in order to induce mPTP 
opening and rigour contracture, and the ‘wave’ of mitochondrial depolarisation we observed
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occurred as a single non-oscillatory wave that propagated from one end of the cell to the other, 
until the whole cell had undergone mitochondrial membrane depolarisation. As such the ‘wave’ 
of mitochondrial depolarisation, we observed constituted part of the process of mPTP opening.
5.7.6.5 The mechanism by which preconditioning inhibits mPTP opening 
The mechanism by which preconditioning results in the inhibition of mPTP opening is unclear 
but it is probably due to a direct effect of preconditioning on mitochondrial function, such that 
preconditioned-mitochondria are rendered more resistant to the insult of ischaemia-reperfusion 
injury (discussed in section 5.10). The mechanism by which diazoxide inhibits the mPTP 
opening induced by oxidative stress is investigated in section 5.9.
214
Derek J Hausenloy
5.8 Aim (6):
Chapter 5: The mPTP in Myocardial Preconditioning
Determine whether opening the mitochondrial K Atp  channel at the time of reperfusion 
protects against lethal reperfusion injury by inhibiting mPTP opening
Pharmacological opening of the mitochondrial K Atp  channel at the time of reperfusion, following 
an episode of lethal ischaemia has been shown in the in vivo canine(268:269) and swine(636) 
models of ischaemia-reperfusion injury to be cardio-protective, though not in the in vivo rabbit 
model.(256:270,271) In addition, Toyoda et al observed that 5-HD (the mitochondrial K Atp  channel 
blocker) administered at the time of reperfusion increased infarct size in IPC-treated hearts, 
suggesting that the mitochondrial KATP channel must be open during the reperfusion phase for 
preconditioning-induced protection^169) Using chick neonatal myocytes, Vanden Hoek and 
colleagues observed that hypoxic preconditioning reduced the production of ROS at the time of 
reoxygenation and that this effect could be blocked by 5-HD and mimicked by the KATP channel 
opener, pinacidil, suggesting that the opening of the mitochondrial KATP channel at the time of 
reperfusion may protect against lethal reperfusion injury by attenuating oxidative stress.(79)
Other studies however, have failed to show cardio-protection with the pharmacological 
activation of the mitochondrial KATP channel using either diazoxide(256) or nicorandil.(270;27i)
Having demonstrated in sections 5.4 and 5.5 that opening of the mKATP channel as part 
of a preconditioning protocol may protect the heart by inhibiting mPTP opening, we 
hypothesised that opening of the mKATP channel by administering diazoxide for the first 15 
minutes of reperfusion protects the Langendorff-perfused rat heart by inhibiting mPTP opening.
5.8.1 Materials
Diazoxide (Sigma Chemicals, Poole, Dorset) was dissolved in dimethyl sulphoxide (DMSO) and 
added to the Krebs-Henseleit buffer such that the final DMSO concentration was less than
0.01%. All other reagents were of standard analytical grade.
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5.8.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
5.8.3 Experimental Protocols for Infarct Studies
The hearts were randomly assigned to one of the following treatment groups:
(1) Control hearts were perfused with 0.01% DMSO (n=6) or Krebs-Henseleit buffer alone (n=6) 
at reperfusion for 15 minutes;
(2) Dzx-treatment: hearts (n=6) were perfused with diazoxide (30 pmol/l) for the first 15 minutes 
of reperfusion. This concentration of diazoxide has been demonstrated to cardio-protect the 
isolated perfused rat heart.(104)
5.8.4 Results
5.8.4.1 Exclusions
We used 14 male Sprague-Dawley rat hearts for the infarct size experiments of which 0 were 
excluded (see section 3.2.2 for exclusion criteria).
5.8.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 5.10). Baseline data relating to cardiac function (assessed by the rate-pressure-product, 
RPP) a nd c oronary f low b efore t he I ethal ischaemic period, were s imilar i n t he e xperimental 
groups (see tables 5.11, 5.12). During regional ischaemia, coronary flow and RPP decreased to 
a similar extent in both groups.
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Table 5.10 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight (g) Risk volume (cmJ)
1. Control 6 445±8.7 1.83±0.06 0.533±0.041
2. Diazoxide at 8 403±18.1 2.38±0.13 0.517±0.016
reperfusion
Values are mean±SEM. *P<0.001 compared with control.
Table 5.11 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation 
5-Min 30-Min
Ischaemia 
5-Min 30-Min
Reperfusion 
15-Min 120-Min
1. Control
2. Diazoxide at 
reperfusion
23.9±3.9 27.4±2.4 
22.4±1.6 24.4±2.0
17.8±2.3
13.8±2.6
17.5±5.6
12.5±1.3
28.1 ±2.4 13.1±0.1 
14.4±1.5 13.1±1.6
Values are mean±SEM. *P<0.005 compared with control.
Table 5.12 Coronary Flow Rate (ml/min)
Groups Stabilisation 
5-Min 30-Min
Ischaemia 
5-Min 30-Min
Reperfusion 
15-Min 120-Min
1. Control
2. Diazoxide at 
reperfusion
16.0±1.0 16.0±0.6 
19.7±1.3 19.7±1.3
7.8±0.9
8.7±0.4
7.0±0.6
8.5±0.5
12.5±3.5 7.8±1.4 
11.2±0.7 6.3±0.3
Values are mean±SEM. *P<0.005 compared with control.
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5.8.4.3 Infarct Size Data
Infarct size is represented as the percentage of tetrazolium-negative tissue in the ischaemic risk 
zone. Pharmacologically opening the i t iK a tp  channel by giving diazoxide for the first 15 minutes 
of reperfusion reduced infarct size from 44.8±3.2% in control hearts to 30.4±4.5% (P<0.001).
5.8.5 Discussion
In this section of the study, we demonstrated that the presence of diazoxide (a putative 
mitochondrial K Atp  channel) for the first 15 minutes of reperfusion protected the heart against 
lethal reperfusion injury, as evidenced by a reduction in infarct size. Our findings are in close 
agreement with studies in the open chest dog(268:269) and swine,(636) demonstrating a cardio­
protective effect from activating the mitochondrial K Atp  channel at the time of reperfusion. 
Further studies are required to confirm the involvement of the mitochondrial K ATp channel, and 
to determine whether diazoxide is protecting via the inhibition of the mPTP opening that occurs 
at the time of reperfusion. Diazoxide has been demonstrated to decrease oxidative stress at the 
time of reperfusion,(78) which may be one possible mechanism by which diazoxide inhibits 
mPTP opening at the time of reperfusion. In addition, Garlid’s group have proposed that 
mitochondrial K ATp channel opening at the time of reperfusion would increase rapid energy 
conversion to phosphocreatine, with the effect that mitochondria do not produce a burst of ROS 
at reperfusion, such that opening of the mPTP does not occur.(110)
Having demonstrated from the previous sections that preconditioning may protect the 
heart by inhibiting m PTP o pening a 11 he t ime o f r eperfusion a nd t hat t he m echanism I inking 
preconditioning with mPTP inhibition may be the modulation of mitochondrial function, our next 
objective was to examine the effects of the preconditioning mimetic, diazoxide, on mitochondrial 
function.
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5.9 Aim (7):
Chapter 5: The mPTP in Myocardial Preconditioning
Determine the effect of preconditioning on mitochondrial redox potential and 
mitochondrial membrane potential.
Studies have implicated the modulation of mitochondrial function as an important mechanism in 
preconditioning-induced protection. IPC or preconditioning via the opening of the mitochondrial 
Katp channel have been demonstrated to confer beneficial effects on mitochondrial function 
which render the mitochondria and therefore the cell more resistant to the insult of ischaemia- 
reperfusion injury. These beneficial effects on mitochondrial function may also protect the heart 
against ischaemia-reperfusion injury by inhibiting the mPTP opening that occurs at the time of 
reperfusion. The mitochondrial effects of preconditioning include: (1) the attenuation of 
mitochondrial Ca2+ loading:(52;239;257;258;261;262) (2) rendering the mitochondria more resistant to 
mitochondrial Ca2+ loading;(263'265) (3) maintaining mitochondrial energy production;(159;234;267) (3) 
reducing the production of oxidative stress at the time of reperfusion;(77'79;278) (4) mitochondrial 
uncoupling.(150:236:237)
However, several aspects concerning the effects of IPC or mitochondrial K Atp  channel 
opening on mitochondrial function are shrouded with controversy. For example, the issue of 
whether the opening of the mitochondrial K Atp  channel actually induces mitochondrial 
membrane depolarisation is currently under debate. Several studies have demonstrated 
mitochondrial membrane depolarisation in response to diazoxide,(52:239:257;258:846) but some 
studies have failed to observe this effect of diazoxide(109:159:16°) and attribute it to a non-specific 
effect of the drug due to the use of high concentrations^60:26°) or else the fact that the cells or 
mitochondrial under examination were de-energised.(110:846)
A further controversial area is the use by Marban’s group, of flavoprotein oxidation, that 
occurs as a consequence of mitochondrial membrane depolarisation, to indicate opening of the 
mitochondrial KATP channel.(108;143) Other studies have failed to demonstrate either 
mitochondrial membrane depolarisation(109;159:16°) or flavoprotein oxidation(109) with 
mitochondrial KATP channel activation.
On this background, we examined the effect of diazoxide on mitochondrial redox 
potential and mitochondrial membrane potential.
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5.9.1 Materials
Diazoxide (Sigma Chemicals, Poole, Dorset) was dissolved in dimethylsulphoxide (DMSO), 
giving a final concentration of <0.1% DMSO. Tetramethylrhodamine methyl ester (TMRM, 
Molecular Probes Europe BV, Leiden, The Netherlands) was dissolved in DMSO. All other 
agents were of standard analytical grade and quality.
5.9.2 Myocyte studies
Adult rat myocytes were isolated from male Sprague-Dawley rats according to the method in 
described in section 3.5. Isolated myocytes were seeded onto 25-mm round cover-slips 
according to the method in described in section 3.6.
5.9.2.1 Effect of Preconditioning on Mitochondrial Redox Potential
The effect of the preconditioning mimetic, diazoxide on the mitochondrial redox potential 
(assessed by measuring FAD+ or NADH autofluorescence, using confocal microscopy) in 
quiescent cells was determined using two treatment protocols:
(a) Acute effect micropipetting diazoxide (30 pmol/l) onto the myocyte over 5 minutes. This 
concentration of diazoxide has been shown to as a preconditioning mimetic;(104) and
(b) Sub-acute effect cells were either incubated with diazoxide (30 pmol/l) or 0.1% DMSO for 
30 minutes at 37°C.
Mitochondrial NADH and FAD+ fluorescence were measured from 20 cells in each treatment 
group.
Next the effect of the preconditioning mimetic, diazoxide on the mitochondrial redox 
potential (assessed by measuring NADH autofluorescence, using confocal microscopy-see 
section 3.7) in cells subjected to the TMRM oxidative stress protocol described in section 5.6.2 
was determined. After loading with TMRM in the restoration buffer, cells were randomly 
assigned to one of the following treatment groups. Cells were incubated for 20 minutes with the 
drug(s) and were then washed with restoration buffer and subjected to the TMRM-oxidative 
stress protocol at 37°C.
1. ConfroZ-incubation with restoration buffer alone (n=18), or 0.1% DMSO vehicle control (n=6);
2. Diazoxide (30 pmol/l, n=6). This concentration of diazoxide has been shown to act as a 
preconditioning mimetic;(104)
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NADH auto-fluorescence was elicited using the 351 laser line of the Zeiss 510 CLSM after 
careful pinhole alignment of the microscope so that images could be acquired with minimal 
illumination intensities for prolonged period with no apparent adverse effects and no photo- 
bleaching. The NADH fluorescence signal was collected using a band-pass filter between 375 
and 488 nm. A configuration using multi-tracking (switching between configurations from frame 
to frame) to allow simultaneous measurements of flavoprotein and NADH fluorescence. The 
flavoprotein (FAD) signals were excited using the 458 line of an argon laser and were measured 
at >505 nm. Flavo-protein signals increase with oxidation and decrease with reduction, while 
NADH signals show opposite changes. The signals were ‘calibrated’ in terms of maximally 
oxidised and maximally reduced by using cyanide (2 mmol/l) to promote maximal reduction and 
FCCP (1 mmol/l) for maximal oxidation.
5.9.2.2 Effect of Preconditioning on Mitochondrial Membrane Potential
The effect of the preconditioning mimetic, diazoxide on the mitochondrial membrane potential 
(assessed by TMRM fluorescence, using confocal microscopy-see section 3.7) in quiescent 
cells were determined using two treatment protocols:
(a) Acute effect: Cells were incubated with 3 pmol/l of TMRM for 30 minutes, to allow the 
TMRM in the bathing solution to equilibrate with the mitochondria. Diazoxide (30 pmol/l) was 
then micropipetted onto the myocyte over 5 minutes. This concentration of diazoxide has been 
shown to act as a preconditioning mimetic;(104) and
(b) Sub-acute effect Cells were incubated with 50 nmol/l of TMRM for 30 minutes, to allow the 
TMRM in the bathing solution to equilibrate with the mitochondria. Cells were either incubated 
with diazoxide (30 pmol/l) or 0.1% DMSO for 30 minutes at 37°C.
5.9.3 Results
5.9.3.1 Effect of Preconditioning on Mitochondrial Redox Potential
5.9.3.1.a The Acute Effect of Diazoxide on Quiescent Cells
Micro-pipetting diazoxide over 5 minutes onto a myocyte had no acute effect on either FAD+ or 
NADH autofluorescence (figure 5.16a,b). Cyanide as expected increased NADH fluorescence 
and decreased FAD+ fluorescence, whereas FCCP reduced NADH fluorescence and increased 
FAD+ fluorescence (figure 5.16a,b).
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5.9.3.1.b The Sub-Acute Effect of Diazoxide on Quiescent Cells
There was no change in NADH autofluorescence in cells incubated with diazoxide (30 pmol/l) 
for 30 minutes (148.3±8.1 arbitrary units [a.u] after incubating with DMSO 0.1% for 30 minutes 
compared to 164.1 ±7.7 a.u after incubating with diazoxide for 30 minutes; N=20; P=NS). 
However, there was a small but significant increase in FAD+ autofluorescence in cells incubated 
with diazoxide (30 pmol/l) for 30 minutes (178.8±3.5 arbitrary units [a.u] after incubating with 
DMSO 0.1% for 30 minutes compared to 197.9±4.7 a.u after incubating with diazoxide for 30 
minutes; N=20; P<0.05).
Figure 5.16: The Acute Effect of Diazoxide on Mitochondrial Redox Potential Diazoxide 
micropipetted onto myocytes (over 5 minutes) followed by cyanide (2 mmol/l) and FCCP (1 
mmol/l) on NADH and FAD+ fluorescence in a representative myocyte (a) Confocal images; (b) 
Graph showing changes in NADH and FAD+fluorescence signal over time.
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5.9.3.1c The Effect of Diazoxide on Cells Subjected to Oxidative Stress
Diazoxide treatment of cells prior to the TMRM-induced oxidative stress protocol not only
delayed the time taken to induce mPTP opening and rigour contracture, but also appeared to
attenuate the drop in NADH auto-fluorescence associated with the oxidative stress (figure 5.17
a,b).
Figure 5.17 a,b: The Effect of Diazoxide on NADH Autofluorescence in Cells Subjected to 
Oxidative Stress, (a) In the control ceil there was a sharp decline in NADH autofluorescence 
with oxidative stress, which slowly rises after mPTP opening has occurred, (b) Diazoxide 
treatment of cells delays the time taken to induce mPTP opening and rigour contracture, and 
also appeared to attenuate the drop in NADH auto-fluorescence associated with the oxidative 
stress. However, after mPTP opening, the NADH fluorescence slowly rises.
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5.9.3.2 Effect of Preconditioning on Mitochondrial Membrane Potential
Acute administration of diazoxide micro-pipetted onto the myocyte had no immediate effect on 
mitochondrial membrane potential, as assessed by TMRM fluorescence (N=10, figure 5.18a), 
even though complete mitochondrial depolarisation occurred with FCCP (1 mmol/l). However, 
after incubation with diazoxide for 30 minutes, there was a significant reduction in TMRM 
fluorescence (from 2149.4±100.7 in control to 1498.0±74.5 arbitrary units of fluorescence; 
N=20; P<0.001; figure 5.18b), suggesting significant mitochondrial membrane potential 
depolarisation.
Figure 5.18 a,b: The Effect of Diazoxide on Mitochondrial Membrane Potential, (a)
Diazoxide had no acute effect on mitochondrial membrane potential when given over 5 minutes, 
whereas the uncoupler FCCP induces a complete collapse in mitochondrial membrane potential, 
as evidenced by an increase in TMRM signal signifying dequenching. (b) However, when the 
cells were incubated with diazoxide for 30 minutes there was a significant reduction in TMRM 
fluorescence, indicating mitochondrial membrane depolarisation.*P<0.001 compared to control.
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5.9.4 Discussion
Chapter 5: The mPTP in Myocardial Preconditioning
5.9.4.1 The Effect of Diazoxide on Mitochondrial Redox Potential in Quiescent Cells
We demonstrated in this part of the study that the acute administration (over 5 minutes) of 
diazoxide (at a concentration associated with cardio-protection)(104) had no effect on 
mitochondrial redox potential, asm  easured by N ADH a nd F AD+ a utofluorescence. H owever, 
when diazoxide was administered sub-acutely (incubation for 30 minutes) there was a small but 
significant increase i n FAD+ autofluorescence, though no change in NADH autofluorescence. 
Marban’s group have demonstrated a rapid (within 5 minutes) flavoprotein oxidation with 
diazoxide (at comparable concentrations), and they have used this effect to indicate 
mitochondrial K Atp  channel opening.(108:143;889) However, we only observed flavoprotein 
oxidation after incubating the cells with diazoxide for 30 minutes. In contrast, Standen’s 
group,(109) have demonstrated no change in flavoprotein oxidation with a comparable 
concentration of diazoxide given over 15 minutes. The reason for the difference probably relates 
to the fact that the effect of diazoxide on mitochondrial flavoprotein oxidation may be only 
observed in de-energised myocytes, that had been kept overnight in substrate-free medium.(11°)
5.9.4.2 The Effect of Diazoxide on Mitochondrial Redox Potential in Cells Subjected to 
Oxidative Stress
In order to investigate the effect of the preconditioning mimetic diazoxide on mPTP opening, we 
used a model in which mPTP opening in myocytes was induced by laser-induced oxidative 
stress (see section 5.7). We demonstrated that diazoxide pre-treatment prolonged the time 
taken to induce both mPTP opening and rigour contracture, suggesting that diazoxide protects 
the cell against oxidative stress by inhibiting mPTP opening. In this part of the study, we 
examined the effect of diazoxide on NADH autofluorescence in the setting of oxidative stress. In 
control cells, there was a rapid decline in NADH autofluorescence, due to oxidation of NADH, 
followed by the opening of the mPTP (indicated by mitochondrial membrane depolarisation). We 
found that diazoxide appeared to attenuate the drop in NADH auto-fluorescence associated with 
oxidative stress, when compared to control cells. The delay in the decline of the NADH 
autofluorescence in the presence of diazoxide appears to correlate with the delay in inducing 
mPTP opening. This finding suggests that diazoxide was preserving NADH autofluorescence 
via a possible free-radical scavenging effect. The oxidation of NADH is a critical determinant of
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mPTP opening, and the reduction in NADH oxidation, may be a possible mechanism by which 
diazoxide inhibits mPTP opening. Interestingly, several studies have demonstrated that 
diazoxide can reduce the production of oxidative stress.(77'79;120:121:278)
5.9.4.3 The Effect of Diazoxide on Mitochondrial Membrane Potential
A possible mechanism for diazoxide-induced protection against ischaemia-reperfusion injury, is 
that it reduces the mitochondrial membrane potential that drives the influx of Ca2+ into the 
mitochondria, thereby attenuating Ca2+ mitochondrial loading during ischaemia- 
reperfusion^52'1081239,257’258’846) However, whether diazoxide induces mitochondrial membrane 
depolarisation is in dispute.(109:159;160:259)
Interestingly, we demonstrated that acutely (over 5 minutes), diazoxide had no effect on 
mitochondrial membrane potential. However, after 30 minutes incubation with diazoxide we did 
observe a significant reduction in mitochondrial membrane potential. The reason why we 
observed mitochondrial membrane depolarisation after a prolonged incubation is not clear, but it 
may be related to the inhibitory effect of diazoxide on mitochondrial respiration. Diazoxide has 
been demonstrated to inhibit succinate dehydrogenase, which forms part of the FADH-linked 
electron transport carrjer,(107;121:135;136:148;149) the effect of which after a prolonged period of time, 
would be expected to depolarise the mitochondrial membrane potential. The question remains 
as to whether the observed depolarisation in mitochondrial membrane potential we observed in 
our model is of patho-physiological importance with respect to mitochondrial Ca2+ loading during 
ischaemia-reperfusion, as suggested by several studies.(52;108;239:257:258:846).
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5.10 Summary and Discussion
In this chapter, we have demonstrated that both ischaemic preconditioning (IPC) and 
pharmacological preconditioning using diazoxide, nicorandil and CCPA protect the heart against 
lethal reperfusion injury by inhibiting mPTP opening at the time of reperfusion. In sections 5.4 
and 5.5, we demonstrated that pharmacologically opening the mPTP during the first 15 minutes 
of reperfusion, abrogated the protective effect associated with IPC, pharmacological 
preconditioning using diazoxide, nicorandil and CCPA, as well as CCPA-induced delayed 
preconditioning. In sections 5.6 and 5.7, we demonstrated that preconditioning protected by 
inhibiting the mPTP opening induced by mitochondrial Ca2+ loading and oxidative stress, two 
major determinants of mPTP opening at the time of reperfusion.
An important interpretation of the findings from this study is that preconditioning protects 
by modifying events which occur during the first few minutes of reperfusion, a theme which is 
explored further in the next chapter. Specifically, preconditioning appears to protect the heart 
against lethal reperfusion injury by rendering mitochondria more resistant to the crucial first few 
minutes of reperfusion, when the prevailing conditions predispose to mPTP opening and 
subsequent cell death. The scheme portrayed in figure 5.19 demonstrates in terms of infarct 
size the individual effects of lethal reperfusion injury, inhibition of mPTP opening at the time of 
reperfusion, and preconditioning. Importantly, the interpretation of the results from this chapter, 
could be that the volume of infarction reduced by preconditioning may be due to the inhibition of 
mPTP opening, which in turn protects the heart against lethal reperfusion injury.
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Figure 5.19: Hypothetical Scheme Relating Lethal Reperfusion Injury, Inhibition of mPTP 
Opening and Preconditioning in Terms of Protection From Infarction. The protection 
against lethal reperfusion injury obtained from inhibiting mPTP opening at the time of 
reperfusion, may be the mechanism by which preconditioning protects the heart against 
ischaemia-reperfusion injury.
100 - Ischaemia-Reperfusion Inhibiting mPTP Preconditioningopening
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§ 5 0 -
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5.10.1 Evidence From Other Studies Supporting a Role for the mPTP in Preconditioning
Several studies have since been published confirming the findings in our study that the 
inhibition of mPTP opening is critical to preconditioning-induced protection (see table 5.13).
Table 5.13: Table Listing Studies Which Have Implicated the mPTP in Preconditioning
Group Model PC stimulus Note
Ashraf 2001 (251) Rat myocytes Calcium Atr abrogates protection
Weiss 2002(846) Rabbit mitochondria Diazoxide Inhibition of mPTP
Dos Santos 2002(159) Rat mitochondria Diazoxide Reduced mitochondrial 
Cytochrome C release
Baines 2003(881) Mice mitochondria IPC Inhibition of mPTP
Halestrap 2003(803) Rat heart IPC Inhibition of mPTP
Lemasters 2003(892) Rat mitochondria Heat shock Inhibition of mPTP
Akao 2003(859) Myocytes it iKatp Delayed mPTP opening
Rajesh 2003(882) Rat mitochondria SWOP Inhibition of mPTP
The first study by Ashraf’s group,(251) demonstrated that opening the mPTP using atractyloside, 
in neonatal rat myocytes subjected to anoxia-reoxygenation injury, reversed the protective 
effects of calcium-preconditioning. However, in this study, a direct inhibitory effect of calcium- 
preconditioning on mPTP opening was not demonstrated^251)
A subsequent study by Weiss’ group(846) demonstrated, using isolated rabbit 
mitochondria, that both diazoxide and a PKC agonist could inhibit calcium-induced mPTP 
opening (detected by the mitochondrial efflux of calcein), which confirms our findings from 
section 5.6, in which we demonstrated diazoxide-induced inhibition of calcium-induced mPTP 
opening.
Garlid’s group(159) demonstrated that diazoxide preserved the permeability of the outer 
mitochondrial membrane during ischaemia-reperfusion such that cytochrome C release was 
prevented. One potential mechanism for cytochrome C release is mPTP opening, and therefore 
this study was indirectly demonstrating that diazoxide can induce mPTP opening. In the same
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vein other studies reporting reduced mitochondrial cytochrome C release may have indirectly 
implicated the mPTP in preconditioning^2511274)
This was followed by a study from Baines and colleagues(881) demonstrating the 
inhibition of m PTP opening (detected by the mitochondrial swelling) in preconditioned mice 
hearts. Importantly, this study addressed the issue of how preconditioning mediates the 
inhibition of mPTP opening (see later). Halestrap’s group(803) demonstrated in the isolated 
perfused rat heart that IPC result in the inhibition of mPTP opening (detected by the 
mitochondrial 2-deoxyglucose entrapment technique) at the time of reperfusion, though the 
mitochondria isolated from IPC-treated hearts were found to be more sensitive to calcium- 
induced mPTP opening than control hearts (see section 5.10.2). Akao and colleagues(859) 
demonstrated using neonatal rat myocytes, that diazoxide, nicorandil and pinacidil delays the 
onset of mPTP opening (detected as mitochondrial membrane depolarisation) induced by 
administered hydrogen peroxide.
The second window of protection has been investigated by Rajesh and colleagues(882) 
who demonstrated that the protective effects present 24 hours after an IPC protocol, were 
abrogated if the mPTP was opened just prior to the index ischaemic period. However, in this 
study, the direct effect of the SWOP on mPTP opening was not examined. Finally, Lemaster’s 
group(892) examined the role of the mPTP in heat shock, which is known to induce a SWOP.(44) 
They demonstrated that mitochondria isolated from rat livers that had been subjected to heat 
shock were less sensitive to calcium-induced mPTP opening. (892)
Therefore, the role of the mPTP in myocardial preconditioning is becoming more 
apparent, though the question still remains as to how preconditioning inhibits mPTP opening.
5.10.2 Mechanisms by Which Preconditioning inhibits mPTP Opening
The most obvious mechanism by which preconditioning leads to inhibition of mPTP opening at 
the time of reperfusion is an indirect effect (see figure 5.20), in which preconditioning confers a 
beneficial effect on mitochondrial function such that at the time of reperfusion, the mitochondria 
are more resistant to mPTP opening.
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Figure 5.20: Hypothetical Scheme Depicting the Potential Mechanisms by Which 
Preconditioning may Inhibit mPTP Opening. Preconditioning-mediated inhibition of mPTP 
opening could be a mediated by an indirect effect whereby preconditioning reduces mPTP 
inducing factors such that mPTP opening at the time of reperfusion is inhibited. Alternatively the 
preconditioning-mediated inhibition of mPTP opening could be a direct effect whereby a 
component of preconditioning inhibits mPTP opening directly (see text for details).
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The fact that preconditioning can modify the same factors that predispose to mPTP opening 
during the first few minutes of reperfusion supports this mechanism. In this regard, the major 
determinants of mPTP opening at the time of reperfusion are: (1) the mitochondrial Ca2+ load, 
which is attenuated in the setting of preconditioning.(52:239:257;258:261;262) In addition, 
preconditioning renders the mitochondria more resistant to mitochondrial Ca2+ loading^263-265) (2) 
ATP depletion. Preconditioning has been demonstrated to improve mitochondrial energy 
production;(159:234:267) (3) Oxidative stress which induces mPTP opening via cross-linking of thiol 
group and the oxidation of NADH. Preconditioning has been demonstrated to attenuate the 
production of oxidative stress at the time of reperfusion.(77'79:278) We have also demonstrated 
that diazoxide appears to attenuate the oxidation of NADH in the setting of oxidative-stress- 
induced mPTP opening (see section 5.9).
In apparent support for an indirect effect of preconditioning on mPTP opening, 
Halestrap’s group(803) demonstrated that mitochondria isolated from I PC-treated hearts that had 
demonstrated inhibition of mPTP opening in situ, were paradoxically more sensitive to mPTP
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opening when isolated, suggesting that the factor (s) mediating the inhibition of mPTP opening 
were lost in the isolation procedure.(803)
However, an alternative mechanism through which preconditioning inhibits mPTP 
opening, may be a direct effect on the mPTP (see figure 5.20). In this scenario, a component of 
preconditioning appears to target and inhibit mPTP opening directly. There are three possible 
candidates in this scenario:
5.10.2.1 Protein Kinase C
Baines and colleagues(881) have demonstrated that PKC-e (which has been implicated as a 
mediator of preconditioning-induced protection) co-immuno-precipitated with components of the 
mPTP, including the VDAC and ANT. Using isolated mitochondria, they demonstrated that 
exogenous PKC-e inhibited calcium-induced mPTP opening in isolated mouse mitochondria.
This suggests that a known component of preconditioning, PKC, can interact with and inhibit 
mPTP opening. Whether, this actually happens in the setting of ischaemia-reperfusion is 
unknown and remains to be tested. Several other components have been demonstrated to 
associate with components of the mPTP and regulate the function of the VDAC-ANT complex, 
including the mitochondrial benzodiazepine receptor,(719) glycerol kinase,(893) hexokinase(714) 
and creatine kinase.(714;717)
Interestingly, the PKC-5 isoform, which has been recently implicated as a mediator of 
lethal reperfusion injury in an open chest pig model,(184;185) may act by inducing mPTP opening. 
Therefore, preconditioning may inhibit m PTP opening by down-regulating PKC-6, suggesting 
that the ratio between the PKC-e/PKC-5, may determine the effect of preconditioning on mPTP 
opening. Furthermore, Mochly-Rosen’s group have demonstrated that the protection in the 
isolated perfused rat heart associated with the inhibition of PKC-6 and the activation of PKC-e 
was additive.(185) Another pairing that is modified by preconditioning and may influence mPTP 
opening in the setting of ischaemia-reperfusion injury, is that between the pro- and anti- 
apoptotic members of the Bcl-2 family.
5.10.2.2 The Bcl-2 Family
The ratio between certain pro-apoptotic members (Bax/Bak/Bad/BNIP3) and anti-apoptotic 
members (Bcl-2/BclXL) of the Bcl-2 family have been demonstrated to be a major determinant of 
mPTP opening and apoptotic cell death (see section 1.5.4.2.a).(755'758) Importantly, the anti-
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apoptotic members, have been demonstrated to inhibit mPTP opening, and the pro-apoptotic 
members Bax, Bak and BNIP3 have been demonstrated by some investigators to induce mPTP 
opening.(755'762;762;763) Interestingly, preconditioning has been demonstrated to protect the heart 
by up-regulating the anti-apoptotic proteins and down-regulating the pro-apoptotic proteins. 
(243;244;882;894j j  herefore p reconditioning m ay i nhibit m PTP o pening b y m odulating t he r atio o f 
pro- and anti-apoptotic proteins of the Bcl-2 family.
5.10.2.3 The Pro-Survival Kinases
The pro-survival kinases PI3K-Akt and MEK1/2-Erk1/2 as a potential link between 
preconditioning and the inhibition of mPTP opening at the time of reperfusion is examined in the 
next chapter.
5.11 Conclusion
In this section of the study we have demonstrated that myocardial preconditioning protects the 
heart against ischaemia-reperfusion injury by inhibiting the mPTP opening that occurs in the first 
few minutes of reperfusion. The findings suggest that preconditioning protects the heart by 
modifying crucial events such as mPTP opening, which take place at reperfusion. This may be 
because preconditioned-mitochondria are more resistant to ischaemia-reperfusion injury, such 
that at the time of reperfusion, mPTP opening is suppressed. This view is supported by the fact 
that many of the factors that induce mPTP opening at the time of reperfusion can be neutralised 
by preconditioning. An alternative explanation could be that a component of preconditioning 
such as PKC or the Bcl-2 family, inhibits mPTP opening directly. In this regard the next chapter
investigates the role of the pro-survival kinase cascades, PI3K-Akt and M EK1/2-Erk1/2 as a
potential component of preconditioning which mediates protection by inhibiting mPTP opening.
The data from the infarct studies and mitochondrial experiments presented in this 
section have been published.(873)
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6.1 Introduction
Chapter 6: Kinases and Myocardial Preconditioning
The findings from chapter 5 demonstrated that myocardial preconditioning protects the heart by 
inhibiting the mPTP opening which occurs at the time of reperfusion. However, the mechanism 
by which preconditioning inhibits mPTP opening is unclear although several mechanisms have 
been postulated (see section 5.10.2). At the end of the last chapter we speculated that a 
potential candidate in this scheme could be the pro-survival phosphatidylinositol 3-OH kinase 
(PI3K)-Akt, and possibly the mitogen activated protein kinase (MAPK), p42/p44 extra-cellular 
signal-regulated kinases (Erk1/2) cascades. Therefore, in this chapter we investigated the role 
of the PI3K-Akt and MEK1/2-Erk1/2 kinase cascades at the time of reperfusion in hearts that 
have undergone ischaemic preconditioning (IPC), to determine whether these kinases are 
required for IPC-induced protection and if they are, do they protect the heart by inhibiting mPTP 
opening.
The PI3K-Akt and MEK1/2-Erk1/2 kinase cascades are activated in the setting of 
ischaemia-reperfusion and mediate cellular protection by recruiting anti-apoptotic mechanisms 
outlined in section 1.4.3. Recent studies have suggested that the activation of either the PI3K- 
Akt^80-82) ancj possibly the Erk1/2 cascades,(82;194) relays the ischemic and pharmacological 
preconditioning signal to downstream mediators of preconditioning such as PKC(81) and 
reactive oxygen species (ROS).(80) In this scenario, these kinase cascades are activated in 
response to an IPC stimulus during the preconditioning phase, prior to the lethal ischaemic 
episode. We were interested in the role of these kinases at the time of reperfusion, following the 
lethal ischaemic episode in the setting of IPC.
The roles of the PI3K-Akt and MEK1/2-Erk1/2 kinase cascades at the time of 
reperfusion in the context of mediating protection against lethal reperfusion injury have been 
investigated extensively by Yellon’s group.(519) They have previously shown that 
pharmacologically activating these kinases at the time of reperfusion, by administering growth 
factors (such as insulin,(530;895) TGF-P1,(534) CT-1,(525) and urocortin(535;536)) or other agents 
(such as atorvastatin(522) and bradykinin(524)) during the first few minutes of reperfusion, 
protects the heart by limiting both the apoptotic and necrotic components of cell death (see 
section 1.4.3.1), through the phosphorylation of BAD, p70S6K(530) and eNOS.(524) This 
suggests that activating these pro-survival kinase cascades at the time of reperfusion, which
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together comprise the Reperfusion Injury Salvage Kinase (RISK)-Pathway, can protect the heart 
against lethal reperfusion injury (see section 1.4.3).
Whether these kinase cascades are activated at the time of reperfusion in response to 
an IPC stimulus, and whether their activation at this time contributes to IPC-induced protection 
is unknown. Therefore the initial aim of this part of the study was to determine whether IPC 
results in the activation of the PI3K-Akt and M EK1/2-Erk1/2 kinase cascades, at the time of 
reperfusion, following the lethal ischaemic insult, and whether the activation of these pro­
survival kinases at reperfusion are essential for IPC-induced protection. The second part of the 
study was to determine whether these kinase cascades protect the heart by inhibiting mPTP 
opening.
6.2 Hypothesis
Myocardial preconditioning protects by inhibiting the prolonged (high-conductance) mPTP 
opening at the time of reperfusion, following the lethal ischaemic insult, via the activation of the 
pro-survival kinases Akt and Erk1/2.
The first part of the study (section 6.3) was to determine, using an isolated perfused rat heart, 
whether IPC results in the activation of the PI3K-Akt and MEK1/2-Erk1/2 kinase cascades at the 
time of reperfusion, following the lethal ischaemic insult, and if it did, to determine whether these 
kinases are essential for IPC-induced protection. The next part of the study (section 6.4) was to 
determine if these kinase cascades protect the heart by inhibiting mPTP opening.
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6.3 Aim (1):
Determine whether myocardial preconditioning activates the pro-survival kinases Akt 
and Erk1/2 at the time of reperfusion, following the lethal ischaemic insult, and whether 
they are required for protection.
6.3.1 Materials
LY294002 (LY, Tocris, Bristol, UK), PD98059 (PD, Tocris, Bristol, UK), rapamycin (RAPA, 
Tocris, Bristol, UK) and chelerythrine (Chel, Sigma Chemicals, Poole, Dorset) were dissolved in 
dimethylsulphoxide (DMSO, Sigma Chemicals, Poole, Dorset) and added to the Krebs- 
Henseleit buffer such that the final DMSO concentration was less than 0.01%, which did not 
influence either infarct size or kinase phosphorylation. All other reagents were of standard 
analytical grade.
6.3.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
6.3.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in Figure 6.1. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts were given 0.01% DMSO (n=6) or Krebs-Henseleit buffer alone (n=6) for the 
first 15 minutes of reperfusion;
(2) IPC hearts (n=6) were treated with two-5 minute periods of global ischaemia/10 minute 
reperfusion periods prior to the lethal ischaemic insult;
(3) IPC + LY: IPC-treated hearts (n=6) were given LY 294002 (15 pmol/L, a specific PI3K 
inhibitor)(896) for the first 15 minutes of reperfusion following the lethal ischaemic period. This 
concentration of LY 294002 has been shown to inhibit Akt phosphorylation in the isolated 
perfused rat heart;(82)
(4) IPC + PD: IPC-treated hearts (n=6) were given PD 98059 (10 pmol/L, a specific MEK1/2 
inhibitor)(897) for the first 15 minutes of reperfusion following the lethal ischaemic period. This
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concentration of P D 9 8059 h as b een s hown t o i nhibit Erk1 /2 p hosphorylation i n t he i solated 
perfused rat heart;(82)
(5) IPC + RAPA: IPC-treated hearts (n=6) were given rapamycin (0.5 nmol/L, a p70S6K 
inhibitor) for the first 15 minutes of reperfusion following the lethal ischaemic period. This 
concentration of rapamycin has been shown to inhibit p70S6K phosphorylation in the isolated 
perfused rat heart;(530)
(6) IPC + Chel: IPC-treated hearts (n=6) were given chelerythrine (5 pmol/L, a PKC inhibitor) for 
the first 15 minutes of reperfusion following the lethal ischaemic period. This concentration of 
chelerythrine has been shown to inhibit PKC phosphorylation in the isolated perfused rat 
heart;(898)
(7) LY. Hearts (n=6) were given LY 294008 for the first 15 minutes of reperfusion;
(8) PD: Hearts were given PD 98059 for the first 15 minutes of reperfusion;
(9) RAPA: Hearts were given rapamycin for the first 15 minutes of reperfusion;
(10) Chel: Hearts were given chelerythrine for the first 15 minutes of reperfusion;
Figure 6.1: Experimental Protocols Investigating the Role of Kinases at the Time of
Reperfusion in Preconditioning-lnduced Protection. LY-LY 294008, PD-PD 
98059, RAPA-Rapamycin, Chel- chelerythrine, TTC-tetrazolium.
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Ischaemic preconditioning + 
LY at reperfusion
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Ischaemic preconditioning + 
Chel at reperfusion
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at reperfusion
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238
Derek J Hausenloy Chapter 6: Kinases and Myocardial Preconditioning
Figure 6.2: Experimental Protocols Outlining the Time-Points for Obtaining Tissue
Samples for Determination of Akt and Erk1/2 Phosphorylation
Time (min) 0 10 20 30 65 80
30 min 35 min 15 min 
stabilisation ischaemia reperfusion
Control ♦ 4 4  4
Ischaemic Preconditioning mt 4 4 4 4
Samples taken for 
Western Blotting for 
AKT and Erk1/2
■  Ischaemia
6.3.4 Measuring Akt/Erk1/2/p70S6K phosphorylation using Western blotting
6.3.4.1 Time-Course of Akt and Erk1/2 Phosphorylation Induced by IPC
Control hearts and IPC-treated hearts were subjected to ischaemia-reperfusion and tissue 
samples were taken from the region-at-risk and collected as outlined in section 3.8.1 at the 
following four time-points (n=6 at each time-point) for subsequent Western blot analysis for Akt 
and Erk1/2 phosphorylation (see figure 6.2):
(1) following the period of stabilisation or the IPC-treatment protocol;
(2) after 15 minutes of lethal ischaemia;
(3) at the end of the 35 minute ischaemic period, and
(4) after 15 minutes of reperfusion,
6.3.4.2 Akt, Erk1/2, and p70S6K Phosphorylation at Time of Reperfusion Induced by
Ischaemic Preconditioning
Tissue samples were collected after 15 minutes of reperfusion, from hearts undergoing the 
experimental protocols as outlined in figure 6.1, according to the method described in section 
3.8.1. Following protein extraction as outlined in section 3.8.2, protein samples were electro- 
phoresed and probed using antibodies for phospho-Erk1/2 (Thr202/Thr204), phospho-Akt 
(Ser473), phospho-p70S6 kinase (Thr389) and phospho-p70S6 kinase (Thr421/Ser424), and 
were used in accordance with the instructions issued by the manufacturer, Cell Signalling 
(Hitchin, Kent), according to the method employed in section 3.8.5.
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6.3.5.1 Exclusions
We used 56 male Sprague-Dawley rat hearts for the infarct size experiments of which 4 were 
excluded owing to poor function during stabilisation (see section 3.2.2 for exclusion criteria).
6.3.5.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 6.1). Baseline data relating to cardiac function ( assessed by the rate-pressure-product, 
RPP) a nd c oronary f low b efore t he I ethal ischaemic period, were s imilar i n t he e xperimental 
groups (see tables 6.2, 6.3). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
Table 6.1 Characteristics of Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight
(g)
Risk volume 
(cm3)
1. Control 6 380±7 2.32±0.08 0.56810.062
2. IPC 6 340±10 1.87±0.06 0.39510.026
3. IPC + LY 6 338±12 1.79±0.16 0.47710.048
4. IPC + PD 6 355±10 1.95±0.12 0.43310.023
5. IPC + RAPA 6 333±16 1.85±0.13 0.50310.032
6. IPC + Chel 6 337±7 1.87±0.03 0.42310.044
7.LY 4 335±10 1.83±0.12 0.53310.031
8. PD 4 346±16 1.84±0.13 0.48010.037
9. RAPA 4 393±3 2.11±0.19 0.55010.039
10. Chel 4 333±3 1.6710.04 0.39110.026
Values are mean±SEM. *P<0.001 compared with control.
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Table 6.2 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation 
5-Min 30-Min
Ischaemia 
5-Min 30-Min
Reperfusion 
15-Min 120-Min
1. Control 23.1±3.5 27.4±1.4 11.8±2.2 13.312.2 16.011.6 10.6+0.6
2. IPC 26.6±2.9 19.3±6.1 10.7±2.6 14.512.8 20.911.6 14.8+1.5
3. IPC + LY 34.9±5.3* 31.4±3.7 12.3±2.2 12.411.8 15.211.7 8.611.5
4. IPC + PD 28.7±3.4 26.5±2.3 13.5±2.4 15.412.3 17.312.2 9.311.4
5. IPC+RAPA 26.5±3.0 20.6±3.2 9.9±1.7 12.812.8 16.0+2.7 11.412.1
6. IPC + Chel 23.5±1.1 18.7±4.4 9.4±2.9 16.413.0 19.814.4 10.612.9
7. LY 29.9±3.8 27.9±3.7 11.1±1.8 15.213.0 12.111.4 13.4+2.5
8. PD 27.2±2.4 25.6±2.3 10.6±1.4 12.412.3 14.411.7 11.412.4
9. RAPA 22.8±3.3 26.4±1.0 10.212.4 9.011.7 14.713.5 8.412.9
10 Chel 33.810.9* 34.413.1* 22.115.7 18.711.8 23.214.0 16.210.3
Values are meaniSEM. *P<0.05 compared with control.
Table 6.3 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 21.211.1 23.510.3 12.011.2 11.610.9 19.811.6 14.213.0
2. IPC 19.511.7 19.011.4 7.010.6 6.510.6 11.511.9 6.810.8
3. IPC + LY 21.311.2 22.811.7 11.210.9 8.811.1 12.310.9 10.512.2
4. IPC + PD 20.311.4 22.412.5 8.411.3 7.511.3 11.411.0 8.411.4
5. IPC+RAPA 19.811.7 21.512.6 9.011.5 10.211.8 12.811.3 8.310.8
6. IPC + Chel 23.010.6 17.313.3 8.311.7 8.112.6 20.311.7 9.310.7
7.LY 23.510.9 22.311.3 12.011.1 11.712.0 16.011.1 12.3+2.6
8. PD 22.311.9 24.312.5 13.412.1 11.311.8 10.211.2 7.411.4
9. RAPA 18.012.0 18.012.0 7.910.2 7.011.0 8.510.5 8.512.5
10 Chel 19.312.4 20.812.0 13.513.2 13.8+4.2 21.211.1 11.511.8
Values are mean±SEM. *P<0.005 compared with control.
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6.3.5.3 Western Blot Data
IPC Induces a Biphasic Response in Akt and Erk1/2 Phosphorylation
The IPC stimulus resulted in an immediate increase in Akt phosphorylation (relative density of 
242.0±31.8 arbitrary units [a.u] in control to 680.7±160.9 a.u with IPC; P<0.05; figure 6.3a), 
which then declined during the lethal ischaemic period, followed by a second increase at the 
time of reperfusion (563.7±74.4 with IPC vs 129.7±33.9 in control; P<0.001; figure 6.3a). IPC 
resulted in a similar biphasic response in Erk1/2 phosphorylation: during the preconditioning 
phase (540.3±130.2 in control to 804.2±165.4 with IPC; P<0.05; figure 6.3b) and at the time of 
reperfusion (834.3±14.1 with IPC vs 275.8±20.8 in control; P<0.001; figure 6.3a).
The Presence of LY 294002 or PD 98059 at the Time of Reperfusion Abrogates the IPC- 
induced Phosphorylation of Akt, Erk1/2 and p70S6K
In addition to inducing the phosphorylation of Akt and Erk1/2 after 15 minutes reperfusion 
(figure 6.4), IPC also resulted in the phosphorylation of p70S6K, the kinase downstream of Akt 
and Erk1/2, at Thr389, the site phosphorylated by Akt-mTOR (2745.0±454.4 with IPC vs 
746.7±219.1 in control; P<0.01; figure 6.4) and at Thr421/Ser424, the sites phosphorylated by 
Erk1/2 (1906.0±110.1 with IPC vs 450.0±34.2 in control; P<0.01; figure 6.5).
The presence of LY (the PI3K inhibitor) during the first 15 minutes of reperfusion 
abrogated the IPC-induced phosphorylation of Akt (115.7±15.6 with IPC+LY vs 891.3±99.2 with 
IPC; P<0.01; figure 6.4), and p70S6K at (Thr389) (472.7+89.8 with IPC+LY vs 2745.0+454.4 
with IPC; P<0.01; figure 6.4). The presence of PD (the Erk1/2 inhibitor) during the first 15 
minutes of reperfusion abrogated the IPC-induced phosphorylation of Erk1/2 (543.0±10.9 in 
IPC+PD vs 1121.8+78.9 in IPC; P<0.01; figure 6.5) and p70S6K at (Thr421/Ser424) 
(556.7+189.7 in IPC+PD vs 1906+110.1 in IPC; P<0.01; figure 6.5). The presence of LY 294002 
in control hearts at the time of reperfusion, did not influence Akt phosphorylation (relative 
density 72.0+43.7 a.u with LY vs 280.7+58.4 a.u in control; P=NS; figure 6.4), although it did 
decrease p70S6K p hosphorylation (at Thr389, relative density 1 49.3+ a .u with LY vs 746.7+
219.1 a.u in control; P<0.05; figure 6.4). The presence of PD 098059 at the time of reperfusion 
in control hearts, did not influence either Erk1/2 phosphorylation (relative density 454.5+143.1 
a.u with PD vs 334.3+67.3 a.u in control; P=NS; figure 6.5) or p70S6K phosphorylation (at
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Thr421, Ser 424, relative density 872.0+309.1 a.u with PD vs 450.0±34.2 a.u in control; P=NS; 
figure 6.5).
Figure 6.3: Time-Course of Akt and Erk1/2 Activation in Ischaemic Preconditioning.
Representative Western blots and relative densitometry, depicting the time-course o f (a) Akt 
and (b) Erk1/2 phosphorylation, in control and ischaemic preconditioned (IPC) rat hearts. IPC 
induces two phases of Akt and Erk1/2 phosphorylation, the first occurring immediately following 
the IPC protocol, and the second occurring at reperfusion. (N=6 at each time-point per 
treatment group.*P<0.05 compared to control)
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Figure 6.4: Western Blots of Akt and p70S6K Phosphorylation. Representative Western 
blots and relative densitometry showing that inhibiting PI3K, using LY 294008, abolishes the 
IPC-induced phosphorylation of Akt and p70S6K at Thr 389 (the site phosphorylated by 
Akt)(N=6 per group.*P<0.05 compared to control).
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Figure 6.5: Western Blots of Erk1/2 and p70S6K Phosphorylation. Representative Western 
blots and relative densitometry showing that inhibiting MEK1/2, using PD 98059, abolishes the 
IPC-induced phosphorylation of Erk1/2 and p70S6K at Thr421/Ser424 (the sites phosphorylated 
by Erk1/2)(N=6 per group.*P<0.05 compared to control).
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‘Cross-talk’ between the PI3K-Akt and MEK1/2-Erk1/2 Kinase Cascades at the Time of 
Reperfusion
This was a surprising and interesting finding of the study, which did not form one of our initial 
objectives of the study. Inhibiting MEK1/2 in control hearts, during the reperfusion phase, using 
PD 98059 alone, resulted in the phosphorylation of Akt (785±78 a.u with PD alone vs 281 ±58 
a.u in control; P<0.01; figure 6.6) and a non-significant increase in phosphorylation of the 
downstream p70S6K at Thr389 (356±52 a.u with PD alone vs 1 63±41 a.u in control; P=NS; 
figure 6.6). Inhibiting MEK1/2 at reperfusion in IPC-treated hearts did not increase Akt 
phosphorylation above that observed in hearts that had only received IPC treatment (914±18
a.u in IPC+PD vs ± 891±99 a.u in IPC; P=NS; figure 6.6).
Conversely, inhibiting PI3K in control hearts, during the reperfusion phase, using LY 
294002, resulted in the phosphorylation of Erk1/2 (913±225 a.u with LY alone vs 334±67 a.u in 
control; P<0.01; figure 6.7) and the downstream p70S6K at Thr421, Ser424 (1260±60 a.u with 
LY alone vs 450±34 a.u in control; P<0.01; figure 6.7). Interestingly, in this case, the inhibition of 
PI3K at the time of reperfusion resulted in the activation of Erk1/2 over and above that induced 
by IPC alone (1442±134 a.u in IPC+LY vs + 1122±79 a.u in IPC; P<0.001; figure 6.7).
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Figure 6.6: ‘Cross-Talk’ Between PI3K-Akt and MEK1/2-Erk1/2. Representative Western 
blots and relative densitometry showing that inhibiting MEK1/2, using PD 98059, results in 
phosphorylation of Akt but not p70S6K at Thr389 (the site phosphorylated by Akt) The lower 
band of the blot represents p70S6K. (N=6/group.*P<0.05 compared to control).
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Figure 6.7: Cross-Talk Between PI3K-Akt and MEK1/2-Erk1/2. Representative Western blots 
and relative densitometry showing that inhibiting Akt, using LY 294008, results in 
phosphorylation of Erk1/2 and p70S6K at Thr421/Ser424 (the sites phosphorylated by 
Erk1/2)(N=6/group.*P<0.05 compared to control).
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6.3.5.4 Infarct Data
Inhibiting Either Akt or Erk1/2 Phosphorylation at the Time of Reperfusion Abrogates the I PC- 
Mediated Reduction in Infarct Size
IPC reduced infarct size (56.9±5.7% in control vs 20.9±3.6% with IPC; P<0.01; figure 6.8). The 
presence of LY (the PI3K inhibitor) or PD (the MEK1/2 inhibitor) for the first 15 minutes of 
reperfusion, abrogated the IPC-induced reduction in infarct size (46.3±5.8% with IPC+LY, 
49.2±4.0% with IPC+PD vs 20.9±3.6% with IPC; P<0.01; figure 6.8), suggesting that 
phosphorylation of Akt and Erk1/2, in the first few minutes of reperfusion, are required for IPC- 
induced protection.
The ‘Cross-talk’ Demonstrated Between the PI3K-Akt and Raf1-MEK1/2-Erk1/2 Kinase 
Cascades is not Associated with Protection
In order to determine whether the PD 98059-induced phosphorylation of Akt and the LY 
294008-induced phosphorylation of Erk1/2 were associated with protection at the time of 
reperfusion, we examined the effect of these kinases on infarct size. Inhibiting PI3K, using LY 
294002 f or t he f irst 15m  inutes o f r eperfusion in c ontrol h earts d id n ot influence i nfarct s ize 
(43.1 ±7.2% with LY vs 46.3±5.8% in control; P=NS; figure 6.8), suggesting that the LY 294002- 
induced Erk1/2 phosphorylation is not sufficient in itself to induce protection. Similarly, inhibiting 
MEK1/2, using PD 98059 for the first 15 minutes of reperfusion in control hearts did not 
influence infarct size (57.7±7.0% in PD vs 46.3±5.8% in control; P=NS; figure 6.8), suggesting 
that the PD 98059-induced Akt phosphorylation is also not sufficient in itself to induce protection.
Inhibiting p70S6K phosphorylation at the time of reperfusion abrogates the I PC-mediated 
reduction in infarct size
The presence of rapamycin (the p70S6K inhibitor) for the first 15 minutes of reperfusion, 
abrogated the IPC-induced reduction in infarct size (46.0±7.7% with IPC+RAPA vs 17.8±2.3% 
with IPC; P<0.01; figure 6.9), implicating the activation of p70S6K as a mediator of IPC-induced 
protection. Rapamycin given alone at time of reperfusion to control hearts did not influence 
infarct size (36.0±5.4% with RAPA vs 46.3±5.8% in control; P=NS; figure 6.9).
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Inhibiting PKC Phosphorylation at the Time of Reperfusion Abrogates the IPC-Mediated 
Reduction in Infarct Size
The presence of chelerythrine (the PKC inhibitor) for the first 15 minutes of reperfusion, also 
abrogated the IPC-induced reduction in infarct size (42.6±5.3% with IPC+Chelvs 17.8±2.3% 
with IPC; P<0.01; figure 6.9). Chelerythrine given alone at time of reperfusion to control hearts 
did not influence infarct size (38.0±1.1% with Chel vs 46.3±5.8% in control; P=NS; figure 6.9).
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Figure 6.8: Inhibiting Either Akt or Erk1/2 Phosphorylation at Reperfusion Abrogates IPC- 
induced Protection. Inhibiting PI3K (using LY294002, LY) or MEK1/2 (using PD98059, PD) for 
the first 15 minutes of post-ischaemic reperfusion, abrogates the ischaemic preconditioned 
(IPC)-induced reduction in infarct-risk volume ratio.(N=6/group.*P<0.01).
Control IPC
Figure 6.9: Inhibiting Either p70S6K or PKC Phosphorylation at Reperfusion Abrogates 
IPC-induced Protection. Inhibiting p70S6K (using rapamycin, RAPA) or PKC (using 
chelerythrine, Chel) for the first 15 minutes of post-ischaemic reperfusion, abrogates the 
ischaemic preconditioned (IPC)-induced reduction in infarct-risk volume 
ratio.(N=6/group.*P<0.01).
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6.3.6 Discussion
Chapter 6: Kinases and Myocardial Preconditioning
The main findings of this section of the study were as follows: (1) We demonstrated for the first 
time that IPC induces the activation of both the PI3K-Akt-p70S6K and the MEK1/2-Erk1/2- 
p70S6K signalling cascades at the time of reperfusion, following a lethal ischaemic period. (2) 
Furthermore, we show that the activation of these kinase cascades at reperfusion are essential 
to mediate IPC-induced protection, as inhibiting their activation at this time, abrogates their IPC- 
mediated infarct-limiting effect.
Several studies have demonstrated that the activation of the PI3K-Akt pathway during 
the preconditioning phase mediates I PC-induced protection^81’82) as well as insulin-mediated 
preconditioning^83) Whether MEK1/2-Erk1/2 activation during the preconditioning phase, 
contributes to IPC-induced protection is less conclusive.(82:193;194;196) In this scenario the kinase 
activation takes place during the preconditioning phase and the kinases act as triggers of 
preconditioning mediating the preconditioning signal to targets situated further downstream the 
signalling pathway such as ROS and PKC. We confirm in our study that IPC produces 
phosphorylation of both Akt and Erk1/2 during the preconditioning phase, prior to the index 
ischaemic period. The absence of kinase activation noted during ischaemia may be due to the 
lack of ATP.
We demonstrated for the first time, that in addition to inducing the phosphorylation of 
the PI3K-Akt cascade during the preconditioning phase, IPC appears to induce a second phase 
of phosphorylation of the PI3K-Akt cascade, at the time of reperfusion, following the lethal 
ischaemic period. However, this second phase of activation noted at reperfusion could be a 
continuation of the signal induced prior to ischaemia, and the kinases are reactivated at 
reperfusion, because ATP is again present.
Furthermore, we demonstrate that IPC induces two phases of Erk1/2 phosphorylation, 
the first one occurring during the preconditioning phase, followed by a second phase taking 
place at reperfusion, confirming the findings of a study by Fryer and colleagues,(194) in which 
they observed that preconditioning with either ischaemia or a 8-opioid receptor agonist resulted 
in two phases of Erk1/2 phosphorylation. However, in that study, these authors did not 
determine whether the IPC-induced Erk1/2 phosphorylation that occurred at reperfusion, was 
required to mediate IPC-induced protection.
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Previous studies have demonstrated that, activating the PI3K-Akt and MEK1/2-Erk1/2 
cascades, which together comprise the Reperfusion Injury Salvage Kinase (RISK)-pathway, at 
the t ime of reperfusion, p rotects the heart, with n umerous g rowth factors i nitiating protection 
when given at reperfusion, through the up-regulation of this pathway.(519) The intriguing 
implication of the present study, is that IPC may also recruit the PI3K-Akt and MEK1/2-Erk1/2 
cascades, during the reperfusion phase to mediate its protection.
Further studies are required to ascertain, why an IPC stimulus should result in the 
activation of these pro-survival kinases cascades at the time of reperfusion. We propose that 
PKC and reactive oxygen species (ROS) may be important candidates in this scheme, as they 
have both been implicated as early mediators of the preconditioning signal,(72;173) and both have 
been demonstrated to activate these kinase cascades.(223:327:899)
In support of PKC as a mediator of kinase activation at the time of reperfusion, we 
found that inhibiting PKC activation at the time of reperfusion also abolished IPC-induced 
protection suggesting the role of PKC as a mediator of IPC-induced protection at the time of 
reperfusion. However, further studies are required to determine whether the phosphorylation of 
Akt and Erk1/2 are dependent on PKC, before one can implicate the latter as a mediator of 
kinase activation at the time of reperfusion in the setting of IPC.
In support of ROS as a mediator of kinase activation at the time of reperfusion, it is 
interesting to note that, the phosphorylation of Akt and Erk1/2, that was observed to occur 
during the preconditioning phase, declined to control levels during the ischaemic phase, and 
increased again during the reperfusion phase. This finding suggests that the act of ‘reperfusion’ 
itself may be important in mediating the phosphorylation of Akt and Erk1/2. Reactive oxygen 
species (ROS) may contribute to the activation of these kinase cascades that occur following 
the IPC treatment and at time of reperfusion, based on the fact that: (1) ROS have been shown 
to be produced during the preconditioning and reperfusion phases, but not during the lethal 
ischaemic period;(900) and (2) ROS have been shown to activate the kinase cascades at the 
time of reperfusion.(223)
We were also intrigued by the temporal relationship between the two observed phases 
of Akt and Erk1/2 kinase phosphorylation induced by an IPC stimulus. We propose that the first 
phase of IPC-induced kinase phosphorylation observed prior to ischaemia, may either ‘prime’ 
the kinase cascade o r change the intracellular distribution of these kinases, such that at the 
time of reperfusion, the second phase of kinase phosphorylation is amplified and mediates the
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protection against lethal reperfusion-induced injury. In this regard, Fujio and colleagues 
observed in mouse hearts that the increased Akt activity induced by IGF-1 over-expression, was 
amplified at the time of reperfusion.(542)
Therefore, both the phases of kinase phosphorylation appear to be required to mediate 
IPC-induced protection, as inhibiting the kinase cascades either during the preconditioning 
phase,(81;194) or at the time of reperfusion, as demonstrated in the current study, abolishes IPC- 
induced protection.
‘Cross-talk’ Between the PI3K-Akt and MEK1/2-Erk1/2 Kinase Cascades and the Role of 
p70S6K
A surprising finding from this part of the study, was the observation that the PI3K-Akt and Raf- 
MEK1/2-Erk1/2 kinase cascades, which are activated at the time of reperfusion in response to 
ischaemic preconditioning, exhibit ‘cross-talk’.
Cross-talk between these kinase cascades had not been investigated in the setting of 
myocardial ischemia-reperfusion. We found that, inhibiting PI3K, using LY 294002, at the time 
of reperfusion resulted in the activation of the MEK1/2-Erk1/2-p70S6K kinase cascade, and that 
the inhibition of MEK1/2 with PD 98059 at the time of reperfusion resulted in the activation of 
the PI3K-Akt kinase cascade, but not p70S6K. Interestingly, this ‘cross-talk’ between the kinase 
cascades was not associated with protection, in terms of a reduction in infarct size, which 
suggests that the PI3K-Akt phosphorylation induced by PD 98059 (the MEK1/2 inhibitor) and 
the MEK1/2-Erk1/2-p70S6K phosphorylation induced by LY294008 (the PI3K inhibitor) were 
insufficient in themselves to induce protection, and indicates that both the kinase cascades may 
be required to be activated at the time of reperfusion to mediate IPC-induced protection.
The previous data had demonstrated that inhibiting either the Akt or the Erk1/2 
activation that occurred at the time of reperfusion, using LY 294008 or PD 98059, respectively, 
completely abrogated IPC-induced protection, also indicating the requirement for both kinase 
cascades to mediate protection. The fact that both cascades appear to work in concert to 
mediate IPC-induced protection at reperfusion, suggests they may converge on a common 
distal signalling moiety. A potential candidate in this scheme may be the downstream p70S6K, 
which is phosphorylated at different sites by the PI3K-Akt and MEK1/2-Erk1/2 cascades.(591;90i) 
One can postulate that IPC-induced protection may require phosphorylation at both sites of the
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p70S6K in order to execute protection^902) In this scenario therefore, inhibiting one of the kinase 
cascades may be able to completely abolish IPC-induced protection.
Activation of the p70S6K may mediate IPC-induced protection via an anti-apoptotic 
mechanism, in which it phosphorylates and inactivates the pro-apoptotic protein BAD.(581) In this 
regard, Jonassen and colleagues have demonstrated that the protection induced by insulin at 
the time of reperfusion is mediated by activation of the Akt-p70S6K-BAD pathway.(530) Studies 
in haematopoietic cells, have also observed the requirement for both kinases cascades to be 
activated to induce cellular protection^903) and interestingly, a study by Muscarella & Bloom 
suggested that the kinase cascades appeared to converge on p90S6 kinase (RSK).(904) In the 
present study, we demonstrated that IPC results in the activation of p70S6K at phosphorylation 
sites specific for Akt (at Thr 389) and Erk1/2 (at Thr421, Ser424), at the time of 
reperfusion.(591:901)
We found that the presence of the known p70S6K inhibitor, rapamycin, at the time of 
reperfusion completely abrogated IPC-induced protection, suggesting that p70S6K may act as 
the point of convergence for these kinase cascades. However, without including data actually 
demonstrating rapamycin-mediated inhibition of the IPC-induced phosphorylation of p70S6K, 
we cannot categorically state that p70S6K is implicated in IPC-induced protection. We 
speculate that the activation of p70S6K requires the phosphorylation at both Thr 389 (the site 
phosphorylated by Akt-mTOR) and Thr421, Ser424 (the sites phosphorylated by Erk1/2), which 
would necessitate the activation of both the PI3K-Akt and MEK1/2-Erk1/2 pathways to mediate 
IPC-induced protection. Previous studies have demonstrated that signalling through these 
kinase cascades can converge on another distal target, the pro-apoptotic protein, BAD, the 
phosphorylation and inactivation of which would mediate cellular survival by an anti-apoptotic 
mechanism.(574;607;608)
The phenomenon of ‘cross-talk’ observed between the kinase cascades, in which the 
inhibition of one kinase cascade results in the activation of the other and vice versa, has been 
observed in other organ tissue, including the lens(609) and neuronal cells^603) In previous 
studies, using immortal cell lines, it has been demonstrated that Akt inhibits the Raf-MEK1/2- 
Erk1/2 kinase cascade by phosphorylation and inactivation of Raf at ser259^ 6001601) and this 
inhibitory pathway may be recruited at different stages of cell development^600) or vary 
according to the concentration and type of ligand exposure.(604) Therefore, the inhibition of the 
PI3K-Akt pathway may activate the Raf-MEK1/2-Erk1/2 cascade, providing a form of
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‘compensatory regulation’. This would explain, why the inhibition of PI3K at the time of 
reperfusion induces the activation of MEK1/2-Erk1/2, as the inhibitory pathway from Akt to Raf- 
MEK1/2-Erk1/2 is removed.
Whether the corollary occurs, in which the activation of Akt occurring in response to the 
inhibition of the Raf-MEK1/2-Erk1/2 cascade is the result of the removal of an inhibitory pathway 
from Erk1/2 on the PI3K-Akt pathway, is unclear at present. We did not find any evidence to 
suggest that the PI3k-Akt cascade facilitates the Raf-MEK1/2-Erk1/2 kinase cascade as has 
been shown in previous studies^602-604) Nor did we find evidence that MEK1 activation activates 
the PI3K-Akt-p70S6K pathway as been suggested by several studies.(605:606) The disparity in 
findings may rest with the different experimental models used and vary with the experimental 
conditions.(602)
Interestingly, the ‘cross-talk’ observed between the two kinase cascades did not appear 
to be equal in that inhibiting MEK1/2 at the time of reperfusion in control hearts resulted in the 
phosphorylation of Akt but not p70S6K (at Thr389). Furthermore, inhibiting MEK1/2 at the time 
of reperfusion in IPC-treated hearts did not result in the phosphorylation of either Akt or p70S6K 
(at Thr389) to a greater level than that observed in hearts undergoing IPC-alone. In direct 
contrast, we found that inhibiting PI3K at the time of reperfusion in control hearts resulted in the 
phosphorylation of Erk1/2 and its downstream p70S6K (at Thr421/Ser424). Furthermore, 
inhibiting PI3K at the time of reperfusion in IPC-treated hearts resulted in the phosphorylation of 
Erk1/2 but not p70S6K (at Thr421/Ser424) to a greater level than that observed in hearts 
undergoing IPC-alone. These findings would suggest that the cross-talk between the two kinase 
cascades is not balanced and that in the scenario of cellular survival, the PI3K-Akt cascade is 
the more dominant cascade, with the MEK1/2-Erk1/2 cascade playing a more significant role in 
mediating growth and hypertrophy.
In conclusion, we report that the activation of the PI3K-Akt and MEK1/2-Erk1/2 kinase 
cascades that occurs at the time of reperfusion, in response to ischaemic preconditioning, 
occurs in parallel and that both kinase cascades are required to act in concert to mediate IPC- 
induced protection. The downstream kinase, p70S6K may be a point of convergence for the 
PI3K-Akt and MEK1/2-Erk1/2 kinase cascades in mediating IPC-induced protection, a Ithough 
further studies are required to confirm this. These two pathways appear to interact in such a 
way, that inhibiting one kinase cascade up-regulates the activity of the other pathway, thereby 
acting as a compensatory safe-guard, ensuring the signal for cellular protection is executed.
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Further work is needed to explore the intricate interactions between these two kinase cascades 
at the time of reperfusion, in the setting of IPC-induced protection.
In this section, we have demonstrated that IPC protects the heart by activating the 
PI3K-Akt and MEK1/2-Erk1/2 kinase cascades at the time of reperfusion. Interestingly, we also 
found that these kinase cascades exhibit ‘cross-talk’ at the time of reperfusion such that 
inhibiting one kinase cascade up-regulates the other. In addition, it appears that both kinases 
are activated in response to an IPC stimulus and both are required to mediate protection. 
However, how these kinases mediate protection at the time of reperfusion is unclear and is the 
subject of the next section of the study.
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6.4 Aim (2):
Chapter 6: Kinases and Myocardial Preconditioning
Determine whether the pro-survival kinases Akt and Erk1/2 protect by inhibiting the 
prolonged (high-conductance) mPTP opening at the time of reperfusion.
The previous section demonstrated that IPC protects the heart by activating the PI3K-Akt and 
MEK1/2-Erk1/2 kinase cascades at the time of reperfusion. Previous studies by Yellon’s group 
have demonstrated that activating these kinase cascades at the time of reperfusion protects the 
heart against lethal reperfusion injury (reviewed in reference (519)). This part of the study 
presents provisional data investigating whether these kinases protect the heart by inhibiting 
mPTP opening at the time of reperfusion.
In this section of the study, we studied the effect of insulin on mPTP opening in the 
adult rat myocyte using the oxidative stress model of mPTP opening used in section 5.7. Insulin 
has been demonstrated to protect the heart against lethal reperfusion injury by activating the 
PI3K-Akt cascade.(530:895) Importantly, to mediate protection insulin has to be present in the first 
few minutes of reperfusion,(53°) the time period, when mPTP opening has been demonstrated to 
occur. Therefore, the insulin-mediated activation of the kinase cascades was used as a 
surrogate model for the I PC-mediated activation of the kinase cascades.
6.4.1 Materials
Insulin was dissolved in distilled water (Actrapid, Novo Nordisk Pharmaceuticals, Crawley, West 
Sussex). Tetramethyl rhodamine methyl ester (TMRM, Molecular Probes Inc., Leiden, The 
Netherlands) were dissolved in dimethyl sulphoxide (DMSO). All other reagents were of 
standard analytical grade.
6.4.2 Myocyte Model of mPTP Opening
Adult rat myocytes were isolated from male Sprague-Dawley rats according to the method in 
described in section 3.5. Isolated myocytes were seeded onto 25-mm round cover-slips 
according to the method in described in section 3.6. Opening of the mPTP in adult rat myocytes 
was induced and detected using a cellular model of oxidative stress, as described in section 5.7.
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6.4.3 Experimental Protocols for Myocyte Studies
After loading with TMRM in the restoration buffer, cells were randomly assigned to one of the 
following treatment groups. Cells were incubated for 20 minutes with insulin at 37°C and then 
subjected to the TMRM-oxidative stress protocol: (1) Control-incubation with restoration buffer 
alone (n=18) and (2) Insulin (0.3 mU/ml, n=12). This concentration of insulin has been shown 
to be cardio-protective in the rat heart;(530)
6.4.4 Results
Insulin treatment increased the illumination time required to induce global mitochondrial 
membrane depolarization from 181.9±14.7 seconds in control to 294.5±15.8 seconds in insulin- 
treated cells, (P<0.001, figure 6.10). The times taken to induce rigour was also extended from 
473.3.±21.2 seconds in control to 688.2±28.4 seconds (P<0.001, figure 6.10). These results 
suggest that insulin treatment acts to inhibit the opening of the mPTP induced by oxidative 
stress, resulting in protection from oxidative stress-induced rigour contracture.
Figure 6.10: The Effect of Insulin on mPTP Opening. Insulin treatment prolongs the duration 
of laser-induced oxidative stress required to cause both mPTP opening and rigour contracture 
in TMRM-loaded myocytes. (Values are Mean±SEM. *P<0.001 compared to control)
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6.4.5 Discussion
Chapter 6: Kinases and Myocardial Preconditioning
In this section, we have demonstrated that insulin treatment protects myocytes against oxidative 
stress by inhibiting mPTP opening. Insulin has previously been demonstrated to protect the 
heart by activating the PI3K-Akt kinase cascade.(530) This forms provisional data suggesting that 
activation of the kinase cascades may protect the heart by inhibiting mPTP opening at the time 
of reperfusion. These results are preliminary and further studies are required to directly 
demonstrate that IPC inhibits mPTP opening at the time of reperfusion by activating these 
kinase cascades.
Interestingly, there are two possible mechanisms through which the PI3K-Akt pathway 
could potentially mediate inhibition of mPTP opening: (1) Activation of the PI3K-Akt kinase 
cascade has been demonstrated to activate eNOS.(585) Gao and colleagues have demonstrated 
that insulin protects at reperfusion by activating the PI3K-Akt-eNOS cascade.(531) Nitric oxide 
has been demonstrated to inhibit mPTP opening,(489) and data from Lemaster’s group suggests 
that the nitric oxide donor, SNAP, given at the time of reoxygenation can protect myocytes 
against anoxia-reoxygenation injury by inhibiting mPTP opening (unpublished data, 2003). (2) 
The pro-apoptotic factors, Bax and BAD have been demonstrated to execute apoptosis by 
opening the mPTP.(751) Activation of Akt results in the phosphorylation of Bax which prevents its 
translocation to the mitochondria(575;576) and the phosphorylation of BAD, which prevents it from 
translocating to the mitochondria.(574) Therefore, activation of Akt could potentially inhibit mPTP 
opening by neutralising the effect of pro-apoptotic factors.
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6.5 Discussion and Conclusion
In this section, we have shown for the first time that IPC results in the activation of the P13K- 
Akt-p70S6K and MEK1/2-Erk1/2-p70S6K kinase cascades during the early reperfusion phase, 
following a lethal ischaemic insult, and we demonstrated that the activation of these kinase 
cascades at this time are essential to mediate I PC-induced protection. Importantly, we have 
demonstrated the importance of the reperfusion phase for IPC-induced protection and show that 
by activating the pro-survival PI3K-Akt and MEK1/2-Erk1/2 kinase cascades at the time of 
reperfusion, IPC is able to modify events that occur at reperfusion, and protect the heart against 
lethal reperfusion injury. Preliminary data suggests that PKC activation at the time of 
reperfusion is also required for IPC-induced protection. Further studies are required to 
determine whether PKC is the potential up-stream activator of these kinase cascades at the 
time of reperfusion in the setting of IPC.
Interestingly, we find that the activation of the PI3K-Akt and MEK1/2-Erk1/2 kinase 
cascades that occurs at the time of reperfusion, in response to ischaemic preconditioning, 
occurs in parallel and that both are required to act in concert by convergence on p70S6K to 
induce IPC-induced protection. Furthermore, these two pathways appear to interact in such a 
way, that inhibiting one kinase cascade up-regulates the activity of the other pathway, thereby 
acting as a compensatory safe-guard, ensuring the signal for cellular protection is executed.
We have preliminary data to suggest that activating the kinase cascades using insulin 
may protect the heart by inhibiting mPTP opening. However, further studies are required to 
demonstrate directly that IPC inhibits mPTP opening at the time of reperfusion via the activation 
of PI3K-Akt and MEK1/2-Erk1/2. Figure 6.11 depicts the biphasic activation of these kinase 
cascades in the setting of IPC and demonstrates the possible interaction between the two 
kinase cascades in mediating their cardio-protective effect.
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Figure 6.11 (a-b): Biphasic Activation of the PI3K-Akt MEK1/2-Erk1/2 Kinase Cascades in 
Ischaemic Preconditioning, (a) The kinase cascades are first activated during the 
preconditioning phase where they act as preconditioning ‘triggers’ relaying the preconditioning 
signal to downstream signalling components such as ROS and PKC. (b) At reperfusion, the 
kinase cascades are re-activated possibly by ROS and PKC. The kinase cascades then recruit 
several anti-apoptotic mechanisms such as the inactivation of the pro-apoptotic protein, BAD 
and the inhibition of mPTP opening which mediate cellular protection. The existence of 
inhibitory pathways between the kinase cascades, may explain why the inhibition of one 
cascade using either LY294008 or PD98059 results in the activation of the other and vice versa. 
Convergence on the downstream kinase p70S6K and the pro-apoptotic factor, BAD, may 
explain the requirement for both kinase cascades to be activated to mediate IPC-induced 
protection.
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This part of the study has focused on the role of the pro-survival PI3K-Akt and Erk1/2 
kinase cascades in mediating protection at the time of reperfusion in the setting of IPC. 
However, it is interesting to note that the same kinase cascades are activated during the 
preconditioning phase,(81;82:194) as we demonstrated in the time course of kinase activation in 
IPC. Therefore, the kinase cascades may constitute a common pathway of cardio-protection, 
mediating the protection associated with both IPC and agents which have been demonstrated to 
protect against lethal reperfusion injury by activating these kinase cascades at the time of 
reperfusion.(519) Evidence in support of this proposition, is provided by the fact that agents 
which precondition, such as bradykinin and AMP579,(596:597) also induce protection when given 
at reperfusion.(494:524). Conversely, agents which have been demonstrated to protect at 
reperfusion by activating the RISK-pathway, such as insulin, urocortin and CT-1 have also been 
shown to precondition the myocardium.(83,391,598) The evidence would tend to suggest that the 
pro-survival kinase cascades may therefore constitute a common pathway, mediating the 
cardio-protection induced by IPC on the one hand, as well as protecting the myocardium 
through their recruitment at the time of reperfusion, on the other hand.
Pharmacological manipulation and up-regulation of the pro-survival kinase cascades, 
during the early reperfusion phase, may therefore provide a novel approach to salvaging viable 
myocardium, and provide new treatment strategies that can be used as an adjunct to 
thrombolytic therapy in the treatment of acute myocardial infarction.
The next part of the thesis examines the mPTP as a potential mediator of 
preconditioning-induced protection.
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7.1 INTRODUCTION
Chapter 7: The mPTP as a Mediator of Preconditioning
Until this point of the thesis, we have been examining the role of the mPTP as a mediator of cell 
death in the setting of ischaemia-reperfusion injury and its modification by myocardial 
preconditioning. In this scenario, the mPTP assumes a prolonged high-conductance, non- 
selective open conformation, which results in apoptotic and necrotic cell death as outlined in 
section 1.5.4. The previous chapters have demonstrated how inhibiting this form of mPTP 
opening at the time of reperfusion using either pharmacological mPTP inhibitors or by 
myocardial preconditioning is a powerful mechanism of protection.
In addition to this form of mPTP opening, which leads to cell death, numerous studies 
describe the existence of a low-conductance (<300 Da) ion-selective (Ca2+, H+ and K+) state of 
mPTP opening (also called transient mPTP opening or ‘mPTP flicker’), which may occur under 
physiological circumstances, and does not lead to cell death (see section 
15  6) (9;10;647;648;692;817;825)
Interestingly, transient (low-conductance) mPTP opening has some features in common 
with the mechanisms implicated in triggering/mediating preconditioning:
(1) Preconditioning has been demonstrated to attenuate mitochondrial Ca2+ 
loading.(52;239:257;258;261;262) This form of mPTP opening may m ediate m itochondrial Ca2+ efflux 
thereby emptying mitochondria of ca2+;(674;834;835)
(2) ROS released by the mitochondria into the cytosol in response to an preconditioning 
stimulus are believed to mediate preconditioning by activating kinases such as PKC.(49:67:72) 
Certain types of ROS such as superoxide are membrane impermeable(905) and may require a 
channel to exit mitochondria into the cytosol. This form of mPTP opening has been 
demonstrated to mediate mitochondrial ROS release into the cytosol;(840) Conversely, oxidation 
of NADH can induce this form of mPTP opening.(659)
(3) Preconditioning using calcium is believed to be mediated by the activation of kinases such 
as p k c .(372;375;378) This form of mPTP opening may contribute to calcium signalling, through the 
phenomenon of mitochondrial Ca2+-induced Ca2+ release (rnCICR) via transitory opening of the 
mPTP.(647;648;815:837'839) Therefore, the release of Ca2+from mitochondria from this form of mPTP 
opening may activate kinases such as PKC; and
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(4) Preconditioning has been demonstrated to protect the heart by uncoupling mitochondrial 
oxidative phosphorylation.(150) Indeed modest mitochondrial uncoupling can mimic 
preconditioning-induced protection.(236;237) Mitochondrial uncoupling can induce transient mPTP 
opening by either depolarising mitochondrial membrane potential,(906) or by producing ROS.(907) 
Conversely this form of mPTP opening would be expected to partially uncouple mitochondrial 
respiration.
(5) Garlid has suggested that the opening of the mitochondrial K At p  channel induces matrix 
a!kanisation.(110;132) The K + influx induced by opening the mitochondrial K At p  channel results in a 
proton efflux which results in matrix alkanisation.(110:132) An increase in matrix pH would be 
expected to favour transient (low-conductance) mPTP opening since mPTP opening is inhibited 
by protons.(686)
On the basis of these common features we postulated that transient (low-conductance) 
mPTP opening prior to the index ischaemic period is required to mediate preconditioning- 
induced protection. In addition, we wanted to determine whether this form of mPTP opening 
contributed to the protection induced by modest mitochondrial uncoupling, a mechanism which 
can mimic preconditioning-induced protection. We were particularly interested in the role of 
ROS as a mediator of both preconditioning and mitochondrial uncoupling-induced protection 
and its relationship to transient (low-conductance) mPTP opening. Specifically, we postulated 
that this form of mPTP opening is required to mediate preconditioning and mitochondrial 
uncoupling-induced protection because it acts as a channel for mitochondrial ROS release.
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7.2 HYPOTHESIS
Chapter 7: The mPTP as a Mediator of Preconditioning
Transient (low-conductance) opening of the mPTP mediates both preconditioning and 
mitochondrial uncoupling-induced protection by acting as a channel for mitochondrial ROS 
release.
In the first part of the study, our objective was to determine whether transient (low-conductance) 
mPTP opening is required to mediate both preconditioning and mitochondrial uncoupling- 
induced protection. Therefore, we subjected the isolated perfused rat heart to IPC, 
pharmacological preconditioning using diazoxide or CCPA (the adenosine A1-receptor agonist), 
or mitochondrial uncoupling using 2,4-dinitrophoenol (DNP). During the preconditioning 
protocols, we gave the known mPTP inhibitors cyclosporin-A(664) or sanglifehrin-A,(676) to inhibit 
mPTP opening, to determine whether preconditioning or mitochondrial uncoupling-induced 
protection would be abrogated.
In the second part of the study, our objective was to determine whether preconditioning 
actually induces transient (low-conductance) mPTP opening. We used a well-established model 
for detecting transient mPTP opening in the intact cell.(832) In the final part of the study, we 
determined whether preconditioning-induced mitochondrial ROS release depends on mPTP 
opening, in order to establish whether transient (low-conductance) mPTP opening acts as a 
channel for mitochondrial ROS release into the cytosol. For this part of the study we used the 
fluorescent dye d ichlorofluorescin ( DCF) to d etect m itochondrial R OS g eneration, which was 
assessed using flow cytometry.
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7.3 Aim (1):
Chapter 7: The mPTP as a Mediator of Preconditioning
Determine whether pharmacologically inhibiting mPTP opening and scavenging ROS, 
during the preconditioning phase, abrogates preconditioning and/or mitochondrial- 
uncoupling induced protection.
7.3.1 Materials
Diazoxide (Dzx, Sigma Chemicals, Poole, Dorset), N-mercaptopropionylglycine ( MPG, Sigma 
Chemicals, Poole, Dorset), sanglifehrin-A (SfA, Novartis Pharma AG, Basel), and 2,4- 
dinitrophoenol (DNP, Sigma Chemicals, Poole, Dorset), were dissolved in dimethyl sulfoxide 
(DMSO, Sigma Chemicals, Poole, Dorset) and added to the Krebs-Henseleit buffer such that 
the final DMSO concentration was less than 0.02%. Cyclosporin-A (CsA, Sigma Chemicals, 
Poole, Dorset) was dissolved in 50% ethanol and added to the Krebs-Henseleit buffer such that 
the final ethanol concentration was less than 0.005%. 2 chloro-N6-cyclopentyl-adenosine (CCPA, 
Sigma Chemicals, Poole, Dorset) was dissolved in distilled water. All other reagents were of 
standard analytical grade.
7.3.2 Isolated Langendorff-Perfused Rat Heart Model
Hearts were excised from male Sprague-Dawley rats and mounted on a Langendorff-perfusion 
apparatus and subjected to 35 minutes regional ischaemia followed by 120 minutes of 
reperfusion (see section 3.2.1). At the end of the reperfusion period, the infarct-risk volume ratio 
was determined using tetrazolium (TTC) staining (see section 3.2.2).
7.3.3 Experimental Protocols for Infarct Studies
The experiment protocols for the infarct studies are presented in figure 7.1. The hearts were 
randomly assigned to one of the following treatment groups:
(1) Control hearts were perfused with 0.02% DMSO (n=6) prior to lethal ischaemia or 0.005% 
ethanol (n=6) or Krebs-Henseleit buffer alone (n=6) during stabilisation.
(2) IPC hearts (n=6)were treated with two 5 minute periods of global ischaemia with a 10- 
minute intervening reperfusion prior to the lethal ischaemic insult.
(3) CsA + IPC: Hearts (n=6) underwent IPC in the presence of the known mPTP inhibitor, 
cyclosporin-A (0.2 pmol/l).(664) This drug was perfused throughout the IPC protocol. This
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concentration of cyclosporin-A has been previously used to inhibit mPTP opening in the isolated 
perfused rat heart.(78°)
(4) SfA + IPC: Hearts (n=6) underwent IPC in the presence of the known mPTP inhibitor, 
sanglifehrin-A (1.0 pmol/l).(676) This drug was perfused throughout the IPC protocol. This 
concentration of sanglifehrin-A has been previously used to inhibit mPTP opening in the isolated 
perfused rat heart.(676)
(5) MPG + IPC: Hearts (n=6) underwent IPC in the presence of the free radical scavenger, MPG 
(1 m mol/l). M PG was p erfused t hroughout t he I PC protocol. This concentration of M PG h as 
been previously used to scavenge free radicals in the isolated perfused rat heart.(908)
(6) Dzx treatment: Hearts (n=6) were perfused with diazoxide (30 pmol/l) for 10 minutes 
followed by 10 minutes wash-out with Krebs-Henseleit buffer prior to the lethal ischaemic insult.
This concentration of diazoxide has been previously shown to precondition the isolated 
perfused rat heart.(104)
(7) CsA + Dzx: Hearts (n=6) were preconditioned with diazoxide in the presence of cyclosporin- 
A.
(8) SfA + Dzx: Hearts (n=6) were preconditioned with diazoxide in the presence of sanglifehrin- 
A.
(9) MPG + Dzx: Hearts (n=6) were preconditioned with diazoxide in the presence of MPG.
(10) CCPA treatment: Hearts (n=6) were perfused with the adenosine A1-receptor agonist,
CCPA (200 nmol/l) for 10 minutes (during which time the hearts were paced at 300 beats per 
minute due to CCPA-induced bradycardia) followed by 10 minutes wash-out with Krebs- 
Henseleit buffer prior to the lethal ischaemic insult. This concentration of CCPA has been 
previously shown to precondition the isolated perfused rat heart.(880)
(11) CsA + CCPA: Hearts (n=6) were preconditioned with CCPA in the presence of cyclosporin- 
A.
(12) SfA + CCPA: Hearts (n=6) were preconditioned with CCPA in the presence of sanglifehrin- 
A.
(13) MPG + CCPA: Hearts (n=6) were preconditioned with CCPA in the presence of MPG.
(14) DNP treatment: Hearts (n=9) were perfused with 2,4-dinitrophoenol (50 nmol/l) for 5 
minutes followed by 10 minutes wash-out with Krebs-Henseleit buffer prior to the lethal 
ischaemic insult. This concentration of DNP has been previously shown to precondition the 
isolated perfused rat heart.(236)
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(15) CsA + DNP: Hearts (n=6) were perfused with DNP in the presence of CsA.
(16) SfA + DNP: Hearts (n=6) were perfused with DNP in the presence of SfA.
(17) MPG + DNP: Hearts (n=6) were perfused with DNP in the presence of MPG.
(18-20) Hearts (n=6 per group) were perfused with either CsA, SfA or MPG throughout 
stabilisation.
Figure 7.1: Experimental Protocols for Investigating the Role of the mPTP as a Mediator 
of Preconditioning-Induced Protection. TTC, triphenyltetrazolium chloride. IPC, ischaemic 
preconditioning. CsA, cyclosporin-A. SfA, sanglifehrin-A. MPG, 3-mercaptopropionylglycine. Dzx, 
diazoxide. 2 chloro-N6-cyclopentyl-adenosine , CCPA. DNP, 2,4-dinitrophoenol.
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7.3.4 Results
7.3.4.1 Exclusions
We used 158 male Sprague-Dawley rat hearts for the infarct size experiments of which 11 were 
excluded owing to poor function during stabilisation (see section 3.2.3 for exclusion criteria).
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7.3.4.2 Animal and Haemodynamic Data
Animal and heart weights and risk zone volumes were similar in the experimental groups (see 
table 7.1). Baseline data relating to cardiac function ( assessed by the rate-pressure-product,
RPP) a nd coronary flow b efore the I ethal ischaemic period, were s imilar i n the experimental 
groups (see table 7.2, 7.3). During regional ischaemia, coronary flow and RPP decreased to a 
similar extent in both groups. An increase in cardiac function and coronary flow upon 
reperfusion was indicative of successful re-flow.
Table 7.1 Characteristics o f Animals in Treatment Groups
Groups Number Body Weight (g) Heart Weight
(g)
Risk volume 
(cm3)
1. Control 12 363±12 1.86±0.10 0.527±0.021
DMSO 3 360±9 1.98±0.05 0.614±0.053
Ethanol 3 365±4 1.83±0.08 0.538±0.014
2. IPC 10 330±11 1.87±0.08 0.481 ±0.024
3. CsA + IPC 6 337±10 1.84±0.13 0.473±0.044
4. SfA + IPC 6 337±3 1.81 ±0.04 0.525±0.035
5. MPG + IPC 6 302±13 1.64±0.07 0.449±0.032
6. Dzx 6 381±12 1.95±0.05 0.543±0.033
7. CsA + Dzx 6 374±10 1.87±0.06 0.516±0.026
8. SfA + Dzx 7 421±16 2.10±0.08 0.543±0.027
9. MPG + Dzx 6 349±8 1.60±0.05 0.522±0.027
10. CCPA g 384±7 1.94±0.09 0.495±0.021
11. CsA + CCPA 6 409±11 1.90±0.08 0.506±0.034
12. SfA + CCPA 6 388±19 2.22±0.12 0.548±0.036
13. MPG + CCPA 6 361 ±5 1.68±0.07 0.513±0.025
14. DNP 11 397±22 2.00±0.09 0.508±0.023
15. CsA + DNP 7 427±29 2.09±0.12 0.487±0.039
16. SfA + DNP 6 463±27 2.30±0 17 0.512±0.044
17. MPG + DNP 6 354±27 1.89±0.18 0.416±0.028
18. CsA 6 425±38 2.16±0.17 0.534±0.028
19. SfA 6 389±29 2.07±0.13 0.515±0.036
20. MPG 7 372±16 1.77±0.11 0.436±0.033
Values are mean±SEM. *P<0.001 compared with control.
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Table 7.2 Rate Pressure Product (x 103mmHg/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 28.7±3.0 27.5±2.5 11.9±1.7 20.8±1.5 23.2±2.5 14.8±1.7
DMSO 30.8±2.2 28.6±3.0 7.2±1.1 20.7±1.9 21.1 ±1.2 16.8±2.8
Ethanol 36.1±8.6 28.6±7.0 8.8±2.1 18.4±1.9 25.5±3.1 19.2±2.0
2. IPC 26.7±3.5 23.1±2.4 13.4±2.7 19.7±2.0 25.4±2.7 18.3±2.5
3. CsA + IPC 24.3±2.6 24.1 ±3.7 10.8±3.0 12.8±1.4 17.6±2.6 12.3±3.0
4. SfA + IPC 26.5±9.2 24.0±6.8 12.9±1.8 22.1±8.1 21.0±1.8 11.4±3.2
5. MPG + IPC 39.8±2.4 34.1 ±2.5 14.9±2.2 20.5±1.3 20.9±2.9 14.5±1.4
6. Dzx 26.3±3.0 27.3±3.1 13.1 ±3.2 19.6±3.0 30.3±1.4 21.3±2.9
7. CsA + Dzx 29.7±4.2 33.7±3.8 15.3±2.7 22.0±2.2 27.3±2.3 18.0±1.6
8. SfA + Dzx 29.5±5.7 27.5±2.0 11.3±2.5 18.7±1.9 26.7±1.2 16.0±1.6
9. MPG + Dzx 29.7±2.7 37.2±2.4* 16.8±1.7 20.7±2.1 17.5±3.3 10.1 ±2.8
10.CCPA 30.5±1.5 22.6±2.3 9.4±1.4 19.8±2.3 21.1±2.0 11.2±1.1
11 .CsA+CCPA 48.3±2.9* 26.3±6.2 10.9±0.9 23.6±1.2 24.3±3.3 13.2±2.5
12.SfA+ CCPA 47.3±4.1* 22.1±4.5 7.9±1.4 22.0±3.6 22.1±3.5 12.5±1.8
13.MPG +CCPA 36.2±4.6 35.0±4.4 20.1±1.8 22.9±1.1 32.3±3.2 18.7±1.2
14.DNP 27.4±2.4 23.6±2.0 12.3±1.3 20.4±1.3 26.1 ±1.9 19.1 ±1.4
15. CsA + DNP 26.6±3.3 22.4±2.5 9.2±1.3 18.8±2.0 22.5±1.9 16.2±1.4
16.SfA + DNP 30.7±2.8 16.5±2.3* 10.8±1.9 21.6±1.1 23.1±2.9 18.8±2.2
17.MPG + DNP 26.0±5.2 27.5±2.1 17.9±3.8 21.4±2.0 20.1±1.4 9.5±2.0
18. CsA 27.5±4.7 33.4±2.0 10.4±1.4 19.6±2.3 26.4±1.5 19.1±0.7
19. SfA 24.4±2.3 31.6±3.5 10.7±1.8 18.4±1.8 22.8±2.1 14.8±3.6
20. MPG 29.2±2.9 32.5±3.3 16.5±2.2 16.4±2.8 32.4±3.2 18.7±1.2
Values are mean±SEM. *P<0.05 compared with control.
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Table 7.3 Coronary Flow Rate (ml/min)
Groups Stabilisation Ischaemia Reperfusion
5-Min 30-Min 5-Min 30-Min 15-Min 120-Min
1. Control 17.8±1.3 17.711.5 10.811.7 11.911.8 16.911.8 12.412.0
DMSO 17.0±1.0 15.311.2 8.010.6 9.710.3 14.7+1.3 9.710.3
Ethanol 18.0±1.2 17.311.2 7.710.3 8.710.9 16.0+0.6 10.010.6
2. IPC 14.711.0 16.210.8 7.4+0.6 7.710.7 14.2+0.6 9.310.7
3. CsA + IPC 21.712.0 19.013.1 6.510.3 7.611.0 12.611.4 7.510.6
4. SfA + IPC 24.011.0* 24.012.3* 11.512.4 19.9+0.1 24.0+2.0 12.012.5
5. MPG + IPC 17.011.6 19.211.7 9.711.1 9.510.9 17.211.5 10.711.6
6. Dzx 18.811.6 18.011.8 8.810.9 10.311.4 17.812.7 12.811.9
7. CsA + Dzx 16.311.0 18.311.7 8.710.7 9.010.8 14.711.3 9.010.9
8. SfA + Dzx 18.411.8 17.011.4 8.010.6 9.010.6 16.510.7 10.010.6
9. MPG + Dzx 21.411.1 22.511.3* 11.510.6 12.511.6 20.012.1 11.711.9
10.CCPA 21.010.7 20.411.2 9.810.4 11.210.8 15.8+0.5 10.010.5
11 .CsA+CCPA 22.312.0* 20.010.8 8.810.7 10.010.9 17.310.7 10.811.2
12.SfA+ CCPA 23.011.0* 22.3+1.7* 9.411.5 11.211.4 19.3+0.8 11.8+1.5
13.MPG +CCPA 25.011.7* 26.010.9* 11.810.6 13.2+0.4 21.811.5 14.7+1.8
14.DNP 19.611.5 19.511.1 8.910.3 10.910.6 19.710.9 12.810.8
15.CsA +DNP 18.511.3 17.611.0 8.910.7 10.811.0 17.211.2 11.911.4
16. SfA + DNP 19.010.9 19.211.4 9.210.4 11.010.8 16.810.8 10.310.7
17.MPG + DNP 17.713.2 19.311.8 10.010.6 11.710.9 18.011.7 10.011.0
18. CsA 19.312.3 20.012.2 8.710.7 10.211.0 18.512.5 13.011.9
19. SfA 16.311.1 16.310.9 8.511.1 9.711.2 14.810.7 9.310.8
20. MPG 20.911.9 20.411.2 11.110.9 9.110.7 15.911.1 8.610.7
Values are mean+SEM. *P<0.05 compared with control.
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Inhibiting mPTP Opening Abrogates Preconditioning-Induced Protection 
Ischaemic preconditioning (IPC) reduced infarct size from 49.9±3.8% in control to 20.2±3.6% 
with IPC (P<0.001; figure 7.2a). Inhibiting mPTP opening during the preconditioning protocol, 
using either of the known mPTP inhibitors CsA or SfA, abolished the protection associated with 
IPC (20.2±3.6% vs 45.9±2.5% with CsA, 49.0±7.1% with SfA; P<0.001; figure 7.2a), suggesting 
that mPTP opening is required to mediate the protection in this setting.
Pharmacological preconditioning using either diazoxide or CCPA reduced infarct size 
from 49.9±3.8% in control to 22.1±2.7% with diazoxide, 24.9±4.5% with CCPA (P<0.001; figures 
7.2b, 7.3a). Inhibiting mPTP opening during the preconditioning protocol, using either of the 
known mPTP inhibitors CsA or SfA, abolished the protection associated with diazoxide 
(22.1 ±2.7% vs 46.3±3.0% with CsA, 48.4±5.5% with SfA; P<0.001; figure 7.2a) and CCPA 
(24.9±4.5% vs 54.4±6.6% with CsA, 42.6±9.0% with SfA; P<0.001; figure 7.3a), suggesting that 
mPTP opening is required to mediate the protection in this setting.
Treatment with the mitochondrial-uncoupler, DNP reduced infarct size from 49.9±3.8% 
in control to 15.7±2.7% with DNP (P<0.001; figure 7.3b). Inhibiting mPTP opening during the 
preconditioning protocol, using either of the known mPTP inhibitors CsA or SfA, also abolished 
the protection associated with DNP (15.7±2.7% vs 40.8±5.5% with CsA, 34.3±3.1% with SfA; 
P<0.001; figure 7.3b), suggesting that mPTP opening is required to mediate the protection in 
this setting.
Scavenging Reactive Oxygen Species and Preconditioning-Induced Protection 
The presence of the ROS scavenger, MPG, during the preconditioning protocols abolished the 
protection associated with IPC (20.2±3.6% vs 47.1±3.8% with MPG; P<0.001; figure 7.2a), 
diazoxide (22.1±2.7% vs 56.3±3.8% with MPG; P<0.001; figure 7.2b), implicating ROS as a 
mediator of protection in these settings. However, MPG did not abolish the protection 
associated with CCPA (24.9±4.5% vs 26.5±8.4% with MPG; P<0.001; figure 7.3a). The 
presence of the ROS scavenger, MPG, during the preconditioning protocols abolished the 
protection associated with DNP (15.7±2.7% vs 50.7±6.6% with MPG; P<0.001; figure 7.3b)
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Given alone during stabilisation, neither cyclosporin-A, sanglifehrin-A nor MPG 
influenced infarct size (43.9±1.4% in control vs 42.8±3.5% with CsA, 48.0±4.2% with SfA, 
47.8±6.4% with MPG; P=NS; figure 7.4).
Figure 7.2 (a-b): Inhibiting mPTP Opening and Scavenging ROS Abrogates
Preconditioning-Induced Protection: Inhibiting mitochondrial permeability transition pore 
(mPTP) opening using either cyclosporin-A (CsA) or sanglifehrin-A (SfA) or scavenging ROS 
using 3-mercaptopropionylglycine (MPG) during the preconditioning phase abolishes the 
protection associated with (a) ischaemic preconditioning (IPC) and (b) diazoxide (Dzx).
Values are Mean±SEM.*P<0.01.
(a) 60 -r
SfA+ MPG+Control
IPC IPC IPC
<b >70
SfA+ MPG+Control
Dzx Dzx Dzx
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Figure 7.3 (a-b): Inhibiting mPTP Opening and Scavenging ROS Abrogates 
Preconditioning-Induced Protection: Inhibiting mitochondrial permeability transition pore 
(mPTP) opening using either cyclosporin-A (CsA) or sanglifehrin-A (SfA) during the 
preconditioning phase abolishes the protection associated with (a) 2 chloro-N6-cyclopentyl- 
adenosine (CCPA) and (b) 2,4-dinitrophoenol (DNP). However, scavenging ROS using 3- 
mercaptopropionylglycine (MPG) abolishes the protection associated with DNP but not CCPA.
Values are Mean±SEM.*P<0.01.
Control CCPA CsA+ SfA+ MPG+
CCPA CCPA CCPA
MPG+Control
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Figure 7.4: The Effect of CsA, SfA and MPG Alone: The presence of either cyclosporin-A 
(CsA), sanglifehrin-A (SfA) or 3-mercaptopropionylglycine (MPG) during stabilisation did not 
influence infarct size. Values are Mean±SEM.*P<0.01.
Control
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7.3.5 Discussion
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In this part of the study, we demonstrated for the first time that transient (low-conductance) 
opening of the mPTP during the preconditioning phase, is required to mediate the protection 
associated with both ischaemic and pharmacological preconditioning and mitochondrial- 
uncoupling. We demonstrated that pharmacologically inhibiting mPTP opening during the 
preconditioning phase, completely abrogated the protection associated with IPC, diazoxide, and 
CCPA, indicating that mPTP opening is required for protection in these settings. This suggests 
that preconditioning using these different approaches induces mPTP opening during the 
preconditioning phase. The possible mechanisms which may explain how preconditioning- 
induces transient (low-conductance) mPTP opening are discussed in section 7.4.5.
We also showed for the first time that mitochondrial-uncoupling induced protection is 
mediated by ROS, as evidenced by the abrogation of protection in this setting in the presence of 
the free radical scavenger, MPG. We confirm that IPC and diazoxide-induced protection is 
ROS-dependent,(67;72;116) and demonstrate that CCPA-induced preconditioning is ROS- 
independent, supporting the findings of Cohen and colleagues.(73)
7.3.5.1 The Role of the mPTP and ROS in Mitochondrial Uncoupling-lnduced Protection 
It is has been previously demonstrated that ischaemic preconditioning and diazoxide induce 
mitochondrial uncoupling.(108;150;257) Furthermore, modest m itochondrial u ncoupling can m imic 
preconditioning-induced protection.(236;237) The mechanism by which mitochondrial uncoupling 
protects the heart against ischaemia-reperfusion injury is not clear but it may in part be due to 
an attenuation in mitochondrial Ca2+ load.(52:108:258) In the present study, we confirm that modest 
mitochondrial uncoupling can mimic preconditioning-induced protection as evidenced by a 
reduction in infarct size with pre-treatment with dinitrophoenol. We show for the first time that 
mitochondrial uncoupling-induced protection is mediated by both mPTP opening and ROS, 
suggesting that both transient (low-conductance) mPTP opening and ROS occur as a 
consequence of mitochondrial-uncoupling. Mitochondrial uncoupling can induce transient (low- 
conductance) m PTP o pening b y m itochondrial m embrane d epolarisation.(906) Vercesi’s g roup 
have also demonstrated that mitochondrial-uncoupling induces the production of mitochondrial 
hydrogen peroxide, which then induced mPTP opening.(907) This finding may explain why we 
observed that the protection induced by mitochondrial-uncoupling to be dependent on ROS.
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Therefore, we can postulate that mitochondrial-uncoupling mimics preconditioning-induced 
protection by generating mitochondrial ROS, which then activate kinases implicated in 
preconditioning-induced protection.
7.3.5.2 The Mechanism by Which Transient mPTP Opening Mediates Protection
Transient (low-conductance) mPTP opening during the preconditioning phase, induced by the 
preconditioning stimulus or mitochondrial uncoupling, may mediate protection by: (1) Reducing 
mitochondrial Ca2+ load.(647) In this regard, Katoh and colleagues have demonstrated that 
diazoxide at a very high concentration (200 pmol/l) can induce mitochondrial calcium-efflux via 
mPTP opening.(266) Interestingly, in an earlier study, Holmuhamedov and colleagues,(257:258) 
demonstrated using isolated mitochondria that diazoxide at a very high concentration (IC50 96 
pmol/l) induced both mitochondrial Ca2+ and cytochrome C release, which were both sensitive 
to cyclosporin-A, suggesting the involvement of mPTP opening; (2) Mediating mitochondrial 
ROS release/signalling.(840) Whether preconditioning-induced mitochondrial ROS release 
occurs via mPTP opening was investigated in section 7.5; (3) Facilitating Ca2+ signalling and 
subsequent kinase activation. Preconditioning using calcium has been demonstrated to be 
mediated by the activation of kinases such as p k c .(372;375:378) One might expect the transient 
intracellular increase in Ca2+ to induce transient (low-conductance) mPTP opening which in turn 
would cause mitochondrial Ca2+ efflux. But whether, the released Ca2+ activates kinases 
implicated in preconditioning is unknown.
To implicate mPTP opening as a mediator of protection it was essential to investigate 
the effects of two different mPTP inhibitors. SfA has the advantage over CsA in that it does not 
inhibit the protein phosphatase, calcineurin.(677:678) However, the infarct studies do not 
demonstrate directly that transient (low-conductance) mPTP opening actually occurs in the 
setting of preconditioning. Its occurrence is only implicated with the use of pharmacological 
inhibitors, which may be sufficient to infer the involvement of the mPTP. To demonstrate directly, 
that p reconditioning induces t ransient ( low-conductance) m PTP o pening, we i nvestigated t he 
effect of diazoxide on mPTP opening in myocytes.
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7.4 Aim (2):
Chapter 7: The mPTP as a Preconditioning Mediator
Determine whether myocardial preconditioning causes transient (low-conductance) 
opening of the mPTP
In order to determine whether preconditioning induces transient (low-conductance) mPTP 
opening during the preconditioning phase, we investigated the effect of the preconditioning 
mimetic, diazoxide on mPTP opening in adult rat myocytes, using a model which was devised 
by Di Lisa’s group for detecting transient (low-conductance) mPTP opening.(832)
7.4.1 Materials
Diazoxide was dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset), 
giving a final concentration of <0.1% DMSO. Cyclosporin-A (Sigma Chemicals, Poole, Dorset) 
was dissolved in 50% ethanol, giving a final concentration of 0.05% ethanol. 5-Hydroxydecanoic 
acid (5-HD, Sigma Chemicals, Poole, Dorset) was dissolved in distilled H20. The fluorescent 
dye, calcein-AM (calcein-acetoxymethyl ester, Molecular Probes Inc., Leiden, The Netherlands) 
was dissolved in dimethyl sulphoxide (DMSO). All other reagents were of standard analytical 
grade.
7.4.2 Myocyte Model of Transient (Low-Conductance) mPTP Opening
Adult rat myocytes were isolated from male Sprague-Dawley rats according to the method 
described in section 3.5. Isolated myocytes were seeded onto 25-mm round cover-slips 
according to the method described in section 3.6.
For this part of the study, a well-established reproducible method for detecting transient 
(low-conductance) opening of the mPTP in the intact cell was used.(266;832) Petronilli and 
colleagues observed that under steady state conditions there was a slow loss of mitochondrial 
calcein, which was inhibited by CsA, suggesting transient mPTP opening under physiological 
conditions.(832) Using this model we examined whether diazoxide (at a cardio-protective 
concentration)^04) induced transient mPTP opening.
Myocytes were incubated with the fluorescent dye calcein-AM (1 pmol/l) and cobalt 
chloride (CoCI2, 1 mmol/l) for 30 minutes at 37°C. Intracellular esterases remove the 
acetoxymethyl ester group, releasing free calcein which because it is membrane-impermeable,
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becomes trapped within the cytosol and mitochondria. The cytosolic calcein signal is then 
quenched by the CoCI2, leaving the calcein signal localised to the mitochondria, which can then 
be visualised by confocal microscopy (see figure 7.5b). Figure 7.5a depicts a representative 
myocyte loaded with calcein-AM in the absence of CoCI2 and demonstrates homogenous 
calcein fluorescence, with localisation of mitochondria impossible. With the calcein trapped 
within the mitochondrial matrix, the calcein can only exit if the mPTP opens. Therefore, in this 
model, transient (low-conductance) mPTP opening is represented by a reduction in 
mitochondrial calcein fluorescence, which can be measured using confocal microscopy.
Mitochondrial calcein fluorescence intensity was measured over six randomly chosen 
regions of interest (ROI’s) in 3 different cells every 5 minutes for a total of 25 minutes. The 
mean mitochondrial calcein fluorescence intensity was expressed as the percentage of the 
baseline value.
Figure 7.5: Myocyte Model of mPTP Opening. Representative confocal image of adult rat 
myocyte loaded with calcein-AM alone (a) or with both calcein and cobalt chloride (b). In the 
absence of cobalt chloride, the myocyte displays an homogenous calcein fluorescence. 
However, in the presence of cobalt chloride, which quenches the cytosolic and nuclear calcein 
fluorescence signal, the calcein localises to the mitochondria, and appears as green stripes 
(see arrow). The trapped calcein within the mitochondria can only exit if the mPTP opens. 
Therefore, opening of the mPTP is indicated by a reduction in mitochondrial calcein 
fluorescence.
(b) Calcein + CoCI
7.4.3 Experimental Protocols for Myocyte Studies
After incubating with calcein-AM/CoCI2 in the restoration buffer, cells were randomly assigned to 
the following treatment groups:
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(1) Control (n=18), or incubation with 0.05% ethanol vehicle (n=6), or 0.1% DMSO vehicle 
(n=6).
(2) Diazoxide (30 pmol/l, n=18).
(3) Diazoxide and CsA (0.2 pmol/l, a known inhibitor of the mPTP, n=18).
(4) Diazoxide and 5-HD (100 pmol/l, a purported mitochondrial KATP channel blocker, n=18).
(5) CsA (n=18), and (6) 5-HD (n=18).
7.4.4 Results
Treatment with diazoxide was shown to induce transient opening of the mPTP as shown by a 
reduction in mitochondrial calcein fluorescence to 72±3% of baseline values (figure 7.6). 
Importantly, mPTP opening did not result in cell death suggesting that it was of the transient 
non-lethal type. Diazoxide-induced transient opening of the mPTP was abrogated in the 
presence of cyclosporin-A (the known mPTP inhibitor), confirming that the reduction in 
mitochondrial calcein fluorescence actually indicates opening of the mPTP. Furthermore, 
diazoxide-induced transient opening o f the mPTP was also abolished in the presence of the 
purported mitochondrial K Atp  channel blocker, 5-HD.
Figure 7.6: The Effect of Diazoxide on Transient (Low-Conductance) mPTP Opening.
Change in mitochondrial calcein fluorescence (expressed as a percentage of the baseline 
fluorescence), demonstrating a diazoxide (Dzx)-induced reduction in mitochondrial calcein 
fluorescence, representing transient (low-conductance) opening of the mPTP, which is 
abolished in the presence of either 5-hydroxydecanoate (5-HD, a mitochondrial K ATp channel 
blocker) or cyclosporine-A (CsA, an inhibitor of mPTP opening). Values are Mean±SEM. N= 36 
per group. *P<0.05.
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In this section of the study, we demonstrated that the preconditioning-mimetic, diazoxide can 
induce transient (low-conductance) mPTP opening in myocytes under steady state conditions. 
The reduction in mitochondrial calcein fluorescence was used to indicate diazoxide-induced 
mPTP opening, and was demonstrated to be sensitive to the archetypal mPTP inhibitor CsA, 
confirming that the reduction in mitochondrial calcein fluorescence was actually due to mPTP 
opening. In addition, the effect of diazoxide on mPTP opening was blocked by 5-HD, the 
putative mitochondrial K At p  channel blocker, suggesting that the effect of diazoxide on mPTP 
opening may be dependent on the mitochondrial K At p  channel.
The mechanism by which diazoxide induces transient (low-conductance) mPTP 
opening is unknown but possible mechanisms include: (1) As mitochondrial KATp channel 
opening induces matrix alkanisation,(110:132) and an increase in matrix pH would be expected to 
favour m PTP o pening,(686) t his m ay b e t he p otential m echanism b y which diazoxide-induces 
transient (low-conductance) mPTP opening; (2) Oxidation of NADH has been demonstrated to 
induce transient (low-conductance) mPTP opening in isolated liver mitochondria,(659) and 
diazoxide has been shown to generate mitochondrial ROS.(72;116) Therefore, diazoxide-induced 
ROS may induce transient (low-conductance) mPTP opening by oxidising NADH; (3) diazoxide 
has been demonstrated to induce mitochondrial uncoupling.(108;150:257;846) Mitochondrial 
uncoupling by either inducing mitochondrial membrane depolarisation(906) or via ROS 
release(907) may cause transient (low-conductance) mPTP opening.
The question remains as to how transient (low-conductance) mPTP opening mediates 
the protection associated with preconditioning and mitochondrial uncoupling. We have 
demonstrated that both forms of protection are dependent on ROS (except for CCPA-induced 
preconditioning). In the next section, we examined whether transient (low-conductance) mPTP 
opening is required to mediate the preconditioning-induced ROS release from mitochondria.
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7.5 Aim (3)
Chapter 7: The mPTP as a Preconditioning Mediator
Determine whether transient (low-conductance) opening of the mPTP acts as a channel 
for the release of ROS generated in response to preconditioning
In order to investigate a possible mechanism to explain why transient (low-conductance) 
opening of the mPTP is required for preconditioning-induced protection, this section of the study 
examines the role of this form of mPTP opening in mediating the mitochondrial ROS release 
that occurs in response to a preconditioning stimulus. Certain types of mitochondrial generated 
ROS such as superoxide are membrane impermeable and therefore require a channel to enter 
the cytosol.(905) Marban's(862) and Vanden Hoek’s(49) groups have suggested that the inner 
membrane anion channel (IMAC) may act as a channel for mitochondrial ROS release into the 
cytosol.
Because we have demonstrated that both ROS and transient (low-conductance) 
opening of the mPTP are required for preconditioning-induced protection and Zorov and 
colleagues(840) have demonstrated that ROS generated within the mitochondrial matrix can 
induce the mitochondrial release of ROS via transient (low-conductance) opening of the mPTP, 
we postulated that the mPTP acts as a channel for the release of ROS generated in response to 
a preconditioning stimulus.
In order to investigate this proposition we determined whether inhibiting mPTP opening 
using CsA could block the mitochondrial ROS release induced by the preconditioning mimetic 
diazoxide, using isolated adult rat m itochondria. These studies are preliminary investigations 
and require further confirmatory studies.
7.5.1 Materials
Diazoxide was dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset), 
giving a final concentration of <0.1% DMSO. Cyclosporin-A (Sigma Chemicals, Poole, Dorset) 
was dissolved in 50% ethanol, giving a final concentration of 0.05% ethanol. 5-Hydroxydecanoic 
acid (5-HD, Sigma Chemicals, Poole, Dorset) and 2 chloro-N6-cyclopentyl-adenosine (CCPA, 
Sigma C hemicals, Poole, Dorset), were d issolved in distilled H20. The fluorescent dye 2’,7’- 
dichlorofluorescein diacetate (DCFH-DA, Molecular Probes Inc., Leiden, The Netherlands) was
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dissolved in dimethyl sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset) such that the final 
DMSO concentration was less than 0.1%. All other reagents were of standard analytical grade.
7.5.2 Mitochondrial ROS Release
In this study, mitochondrial ROS release was detected using DCF fluorescence and was 
measured by flow cytometry. Mitochondria were isolated from male Sprague-Dawley rats 
according to the method described in section 3.3. Aliquots of the mitochondrial sample (0.5 
mg/ml) were incubated with the fluorescent dye, DCFH-DA (10 pmol/L) for 15 minutes at 37°C.
This concentration of DCFH-DA has been previously used to detect diazoxide-induced ROS 
release in adult rat myocytes.(116) Once within the matrix, the acetate group in DCFH-DA is 
removed by esterases, resulting in a non-fluorescent product DCFH.(116) Oxidation of DCFH by 
ROS generates the fluorescent product DCF, which can be measured by flow cytometry. The 
mitochondria were then washed twice with KCI buffer containing (in mmol/l) KCI 120.0, TES 5.0, 
and MgCI20.1, with added ATP 0.2 and sodium succinate 10.
7.5.3 Experimental Protocols for Mitochondrial Studies
DCF-loaded mitochondria in KCI buffer were incubated for 30 minutes at room temperature with 
the following treatments:
(1) Control: DMSO 0.1%
(2) Dzx: Diazoxide (30 pmol/l). This concentration of diazoxide has been demonstrated to be 
cardio-protective.(104)
(3) Dzx+CsA: Diazoxide (30 pmol/l) was incubated with CsA (0.2 pmol/l). This concentration of 
CsA has been demonstrated to inhibit mPTP opening.(779:780)
(4) CsA
Mitochondrial DCF fluorescence was determined using the flow cytometer (see section 3.4) 
before adding the treatment and was then re-measured 30 minutes later. For DCF-fluorescence, 
the signal was analysed in the FL1 detector channel equipped with a band-pass filter at 520 nm; 
the photo-multiplier value of the detector was 631 V. Experiments were performed on 
mitochondria isolated from 2 individual rats, and were repeated three times for each isolation.
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7.5.4.1 Exclusions
We used 2 male Sprague-Dawley rat hearts for mitochondrial isolation of which 0 were 
excluded (see section 3.3 for exclusion criteria).
7.5.4.2 Mitochondrial DCF Fluorescence Data
Arithmetic mean values of the median mitochondrial DCF fluorescence intensities were 
determined for each sample, and were expressed as a percentage of the baseline. The 
mitochondrial DCF fluorescence values in the control group increased over 30 minutes by 
35.9±1.1%, whereas in the presence of diazoxide it increased by 283.9±3.1%. The diazoxide- 
induced increase in DCF fluorescence was abolished in the presence of themPTP inhibitor, 
CsA, as the mitochondrial DCF fluorescence only increased by 104.0±1.7% over 30 minutes. In 
the presence of CsA alone, the mitochondrial DCF fluorescence increased by 40.3±2.2%.
Figure 7.7: Changes in Mitochondrial DCF Fluorescence. In control, the mitochondrial DCF 
fluorescence increased by 36% over the 30 minute period. Treatment with either diazoxide (30 
pmol/l) induced an increase in mitochondrial DCF fluorescence, indicating the generation of 
reactive oxygen species (ROS). The presence of the mPTP inhibitor, cyclosporin-A (CsA) 
prevents the increases in mitochondrial DCF fluorescence, suggesting that the diazoxide- 
induced increase in ROS requires mPTP opening. CsA alone does not differ from control. 
Values are means of the median mitochondrial DCF fluorescence for that group ±SEM 
expressed as a % of the baseline fluorescence.*P<0.001 compared to control. . P<0.001 
compared to diazoxide treatment.
350
Diazoxide DiazoxideControl
+
CsA
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In this part of the study we confirm the findings of previous studies demonstrating that diazoxide 
induces an increase in mitochondrial ROS.(72;116) We show for the first time that the diazoxide- 
induced production of ROS requires mPTP opening since it was attenuated in the presence of 
the mPTP inhibitor, CsA. Importantly, CsA alone did not influence DCF fluorescence, 
suggesting that CsA does not exert a free radical scavenging effect. We postulate that it is 
transient (low-conductance) mPTP opening which is required to mediate the diazoxide-induced 
mitochondrial ROS release. The findings from this part of the study provide one possible 
mechanism by which transient (low-conductance) mPTP opening mediate the protection of 
diazoxide, in that it acts as a channel for mitochondrial ROS release. Therefore, in the infarct 
studies, we observed that the diazoxide-induced reduction in infarct size was abrogated in the 
presence of CsA. We can postulate that the protection was blocked because CsA prevented to 
release of mitochondrial ROS into the cytosol to activate the kinases required for protection. 
Further studies a re required to determine whether mPTP opening is required to mediate the 
mitochondrial ROS release induced by IPC and mitochondrial uncoupling.
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7.6 Discussion and Conclusion
In this section of the study, we demonstrated that transient (low-conductance) mPTP opening is 
induced during the preconditioning phase and is required for the protection associated with 
preconditioning and mitochondrial uncoupling. Our provisional data suggests that transient (low- 
conductance) mPTP opening acts as a channel for the release into the cytosol of mitochondrial 
ROS generated in response to the preconditioning stimulus.
The mechanism by which preconditioning induces transient (low-conductance) mPTP 
opening has not been examined in this study and forms the basis of further study. However, 
several mechanisms can be postulated (see figure 7.8). Preconditioning may induce transient 
(low-conductance) mPTP opening by: (1) inducing matrix alkanisation;(110;132) (2) generating 
mitochondrial ROS(72:116) which oxidises NADH; and/or (3) inducing mitochondrial 
uncoupling.(108:150;257:846) All these effects would act to induce transient (low-conductance) mPTP 
opening, which can be induced by matrix alkanisation,(686) the oxidation of NADH,(659) and 
mitochondrial uncoupling.(906:907)
Other mechanisms by which transient (low-conductance) mPTP opening mediates 
preconditioning-induced protection include (see figure 7.8): (1) Reducing mitochondrial Ca2+ 
load, as demonstrated by Katoh and colleagues(266) who demonstrated that diazoxide (albeit at 
a h igh concentration) i nduces mitochondrial Ca2+ efflux via m PTP opening i n myocytes, and 
Holmuhamedov and colleagues,(257;258) who demonstrated that diazoxide (albeit at a high 
concentration) induces mitochondrial Ca2+ efflux via mPTP opening in mitochondria; and (2) 
Facilitating Ca2+ signalling and subsequent kinase activation, although the evidence for this is 
not available, except for the fact that calcium preconditioning(372;375;378) (in which a transitory 
increase in intracellular Ca2+) triggers preconditioning-induced protection by activating PKC, 
may induce transient (low-conductance) mPTP opening.
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Figure 7.8: Hypothetical Scheme Depicting the Role of Transient mPTP Opening in 
Preconditioning. The preconditioning signal induces transient (low conductance) mPTP 
opening by: (1) Uncoupling mitochondria which induces transient mPTP opening by 
mitochondrial membrane depolarisation or ROS release; (2) Generating ROS which induces 
transient mPTP opening by oxidising NADH; and (3) Increasing matrix pH. Transient (low 
conductance) mPTP opening protects the heart by inducing the release of mitochondrial ROS 
and Ca2+ which activate kinases implicated in preconditioning such as PKC. In addition, 
mitochondrial Ca2+ release renders the mitochondria more resistant to ischaemia-reperfusion 
injury.
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The findings from this study add to the amounting evidence that the modulation of mitochondrial 
function is pivotal to preconditioning-induced protection. Interestingly, transient (low- 
conductance) mPTP opening may be considered the mitochondrial response to a brief amount 
of stress, such as that induced by a preconditioning stimulus. Transient (low-conductance) 
mPTP opening then triggers downstream mediators of preconditioning such as PKC by 
mediating mitochondrial ROS release.
287
Derek J Hausenloy Chapter 8: Summary and Discussion
Chapter Eight: SUMMARY AND DISCUSSION
Novel therapeutic approaches are required to improve upon the current treatment strategies 
employed for coronary artery disease, in order to reduce the mortality and morbidity from this 
common condition. Current advances in the areas of primary prevention (HMG-CoA reductase 
inhibitors, lifestyle changes, anti-platelet agents, ACE-inhibitors) and secondary prevention 
(anti-platelet agents, thrombolytic agents, primary PTCA, drug-eluting stents, and anti­
thrombotic therapy) have made and will continue to make a significant impact on patient 
mortality and morbidity.
The phenomenon of myocardial preconditioning has the potential to deliver a powerful 
cardio-protective effect against ischaemia-reperfusion injury, but by definition, it necessitates 
intervening before the index ischaemic episode, which in the setting of an acute myocardial 
infarction, is beyond the control of the operator. Therefore, the role for agents which cardio- 
protect by preconditioning the heart, will be in targeting patient populations, that are either at 
high-risk of a major coronary occlusive event (such as patients presenting with an unstable 
coronary artery syndrome) or in those patients undergoing cardiac surgery.
An alternative cardio-protective strategy which intervenes, after the index ischaemic 
event as an adjunct to current reperfusion treatment strategies (whether that be by thrombolysis 
or primary PTCA), offers a powerful protective approach, and importantly it is under the control 
of the operator. The opening of the mitochondrial permeability transition pore (mPTP) during the 
first few minutes of reperfusion, that follows the index ischaemic period is a critical determinant 
of cell death, and therefore presents a potential target for cardio-protection.
This thesis examined the role of the mPTP as a target for cardio-protection against 
ischaemic-reperfusion injury. We found that inhibiting the mPTP opening which takes place at 
reperfusion is a common target for cardio-protection, irrespective of whether the protection was 
mediated by interventions applied solely at the time of reperfusion or by myocardial 
preconditioning. In addition, we presented evidence that, prior to the index ischaemic period, 
transient (low-conductance) opening of the mPTP may paradoxically, act as a mediator of 
preconditioning-induced protection.
The main f indings o f t his t hesis were: (1) T he m PTP i s a c ritical d eterminant o f c ell 
death in the setting of ischaemia-reperfusion injury, and pharmacologically inhibiting its opening, 
solely at the time of reperfusion, protects the heart against lethal reperfusion injury, as
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evidenced by a reduction in infarct size; (2) Myocardial preconditioning induced by either 
ischaemia or pharmacological agents, protects the heart by inhibiting the opening of the mPTP, 
which occurs during the first few minutes of reperfusion; (3) Ischaemic preconditioning induces 
the activation of the pro-survival kinase cascades, PI3K-Akt and MEK1/2-Erk1/2, during the first 
few minutes of post-ischaemic-reperfusion, and these kinase cascades may protect the heart by 
inhibiting the mPTP opening; (4) Transient (low-conductance) opening of the mPTP during the 
preconditioning phase, may mediate the protection associated with ischaemic and 
pharmacological preconditioning and mitochondrial uncoupling, by acting as a channel for the 
mitochondrial release of reactive oxygen species (ROS), enabling the activation of kinases 
implicated in protection such as PKC.
The mPTP as a Mediator of Lethal Reperfusion Injury
In chapter 4, we demonstrated, using the isolated perfused rat heart model, that the presence of 
the pharmacological mPTP inhibitors, cyclosporin-A or sanglifehrin-A during the first few 
minutes of reperfusion, protected the heart against lethal reperfusion injury, as evidenced by a 
near 50% reduction in infarct size. Importantly, we demonstrated that targeting the first few 
minutes of reperfusion was critical to the protective effect of these mPTP inhibitors, which 
supports the experimental findings that the mPTP opens during the first few minutes of post- 
ischaemic reperfusion.(52;470;776;777) The findings from this part of the study suggested that the 
opening of the mPTP during the first few minutes of reperfusion is a critical determinant of cell 
death, and that inhibiting its opening provide a potential target of cardio-protection.
The mPTP as a Target for Cardio-Protection in Myocardial Preconditioning 
In chapter 5, we demonstrated, using several different methodological approaches, that the 
protection associated with the phenomenon of myocardial preconditioning was mediated by the 
inhibition of mPTP opening at the time of reperfusion, suggesting that the mPTP is a common 
target for cardio-protection, irrespective of whether the protection is mediated by interventions 
applied solely at the time of reperfusion or by myocardial preconditioning. Several studies have 
since been published, which confirm that inhibiting mPTP opening is critical to the protection 
associated with myocardial preconditioning.(803;846;859;881;882;892)
In the initial infarct studies, we demonstrated that pharmacologically opening the mPTP 
during the first few minutes could abrogate the protection induced by both ischaemic and
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pharmacological preconditioning, suggesting that preconditioning protects by inhibiting the 
mPTP opening at the time of reperfusion. Halestrap’s group have confirmed that IPC protects 
the heart by inhibiting the mPTP opening that occurs in the first few minutes of reperfusion.(803) 
Using a similar approach, we demonstrated that the protection associated with delayed 
preconditioning could also be abrogated by pharmacologically opening the mPTP at the time of 
reperfusion. This finding has been confirmed in a study by Rajesh and colleagues using a 
similar methodological approach.(882) Lemaster’s group have subsequently demonstrated that 
heat shock (which protects by a delayed preconditioning effect) suppresses mPTP opening in 
isolated liver mitochondria.(892)
We demonstrated that the preconditioning mimetic, diazoxide could inhibit the mPTP 
opening induced by mitochondrial Ca2+ loading, a finding which was confirmed by Korge and 
colleagues.(846) In addition they demonstrated that a PKC agonist had the same inhibitory effect 
on mPTP opening. Using a model for inducing and detecting mPTP opening in the intact cell, 
we demonstrated that hypoxic and pharmacological preconditioning protected myocytes against 
oxidative stress by inhibiting mPTP opening, a finding which has been confirmed in a recent 
study by Akao and colleagues.(859)
Preconditioning may inhibit mPTP opening at the time of reperfusion by several 
possible mechanisms including an indirect effect, in which known inducing factors of mPTP 
opening, such as mitochondrial Ca2+ l o a d ^ ^ s r ^ e i ^  AJp depletjont and
oxidative stress(77'79,278) are counteracted by the effects of preconditioning, such that mPTP 
opening does not occur during the first few minutes of reperfusion. In this regard, we 
demonstrated that diazoxide appeared to attenuate the oxidation of NADH in the setting of 
oxidative-stress-induced mPTP opening. Additionally diazoxide appeared to depolarise 
mitochondrial m embrane p otential and i nduce f lavo-protein oxidation a Ibeit after a prolonged 
incubation, which may support the role for preconditioning in attenuating mitochondrial Ca2+ 
load.
Alternatively, a component of preconditioning may target and inhibit mPTP opening 
directly. In this regard, Baines and colleagues demonstrated that PKC-e, may interact with and 
inhibit mPTP opening.(881) Preconditioning may also inhibit mPTP opening by modulating the 
ratio of pro- and anti-apoptotic proteins of the Bcl-2 family. (243;244;882:894) |n chapter 6, we 
examined the role of the pro-survival kinases as a potential candidate for mediating the 
inhibition of mPTP opening, as the mechanism for preconditioning-induced protection.
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The Pro-Survival Kinases as a Target for Cardio-Protection in Myocardial Preconditioning 
In chapter 6, we examined the role of the pro-survival kinases PI3K-Akt and MEK1/2-Erk1/2, at 
the time of reperfusion, as a mediator of preconditioning protection. Previous studies had 
demonstrated that the activation of these kinase cascades prior to the index ischaemic episode 
was required for protection as a preconditioning trigger^80-82) We demonstrated that IPC 
protects the heart by activating these kinases at the time of reperfusion, and we provided 
preliminary data that these kinase cascades may protect by inhibiting mPTP opening. In the 
next part of the thesis, we examined the role of the mPTP as a potential mediator of 
preconditioning-induced protection.
The mPTP as a Mediator for Cardio-Protection in Myocardial Preconditioning 
In chapter 7, we examined the role of transient (low-conductance) mPTP opening, which does 
not lead to cell death and may be beneficial to the cell, as a potential mediator of 
preconditioning-induced protection. Previous studies have suggested that this form of m PTP 
opening shares some features with preconditioning. For example, (1) Both 
preconditioning(52;239;257:258;261:262) and transient (low-conductance) mPTP opening(266;674:835) 
have been demonstrated to attenuate mitochondrial Ca2+ loading; (2) Both 
preconditioning.(49;67:72) and transient (low-conductance) mPTP opening,(84°) may induce the 
release of mitochondrial ROS (3) Mitochondrial uncoupling is a critical process in both 
precond ition ing(150:236;237) and transient (low-conductance) mPTP opening.(907) Using the 
isolated perfused rat heart we demonstrated that pharmacologically i nhibiting m PTP opening 
during the preconditioning phase abrogated the protection associated with both ischaemic and 
pharmacological preconditioning. Using a myocyte model for detecting transient mPTP opening, 
we demonstrated that diazoxide induces transient (low-conductance) mPTP opening, confirming 
the findings of Katoh and colleagues.(266) Finally, using isolated mitochondria, we demonstrated 
that the diazoxide-induced generation of mitochondrial ROS requires mPTP opening. Therefore, 
the findings from this part of the study suggest that transient (low-conductance) opening of the 
mPTP mediates both preconditioning and mitochondrial uncoupling-induced protection by acting 
as a channel for mitochondrial ROS release. Evidence in the literature suggest that diazoxide 
can induce mPTP opening and promote mitochondrial Ca2+ efflux.(257;258;266)
Given that we have demonstrated that transient (low-conductance) opening of the 
mPTP prior to the index ischaemic episode mediates preconditioning-induced protection, and
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the recent suggestion that the adenine nucleotide translocase, which is believed to be a 
component of both the mPTP,(909) may also form part of the mitochondrial K Atp  channel,(146) it is 
intriguing to speculate on the possibility that the mPTP may be masquerading as the 
mitochondrial K Atp  channel, such that preconditioning-induced protection is mediated by 
transient (low-conductance) opening of the mPTP rather than opening of the mitochondrial KATP 
channel.
A Dichotomous Role for the mPTP in Myocardial Protection
Interestingly, the findings from this thesis which suggest that the mPTP may mediate 
preconditioning-induced protection implicate a dichotomous role for mPTP opening in 
myocardial preconditioning. On the one hand the prolonged high-conductance mPTP opening 
which occurs during the first few minutes of reperfusion mediates cell death and is inhibited by 
preconditioning, whereas on the other hand, the transient (low-conductance) form of mPTP 
opening which occurs physiologically is activated prior to the index ischaemic period and may 
mediate preconditioning-induced protection by acting as a channel for mitochondrial ROS 
release. Combining these two effects of preconditioning, one can conclude that preconditioning 
protects the heart by inducing the transient (low-conductance) mPTP opening during the 
preconditioning phase, which sets into motion mechanisms which protect the mitochondria 
against the insult of ischaemia-reperfusion injury, such that at the time of reperfusion, the 
prolonged high-conductance mPTP opening is suppressed.
Interestingly, in the context of myocardial preconditioning other factors have been 
demonstrated to play a dichotomous role. For example, ROS have been implicated as 
trigger/mediators of preconditioning-induced protection when released in small amounts during 
the preconditioning phase.(49:67) However, at the time of post-ischaemic reperfusion, ROS are a 
major determinant of lethal reperfusion injury and studies have demonstrated that 
preconditioning can attenuate the production of ROS at the time of reperfusion.(78:79) These 
examples of dichotomy in cardio-protection echo the phenomenon of ischaemic preconditioning 
as originally described by Murry and colleagues in 1986,(5) in which a brief episode of 
ischaemia and reperfusion, paradoxically protected the heart against a subsequent lethal 
episode of ischaemia. Therefore, whether it be a brief episode of ischaemia, a small burst of 
ROS or transient (low-conductance) opening of the mPTP opening, these examples of cellular 
stress are able to trigger a cellular innate adaptive response to further episode of cellular stress.
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Chapter Nine: CONCLUSION
9.1 Summary of Findings
This thesis has examined the role of the mitochondrial permeability transition pore (mPTP) in 
myocardial protection. We have demonstrated that the opening of the mPTP during the first few 
minutes of reperfusion is a critical determinant of cell death in the setting of ischaemia- 
reperfusion injury, and therefore inhibiting its opening by either myocardial preconditioning or 
the administration of agents solely at the time of reperfusion, is an effective cardio-protective 
strategy. Importantly we demonstrated that the mPTP appears to be a common target of 
myocardial protection, irrespective of whether the protection was mediated by interventions 
applied solely at the time of reperfusion or by myocardial preconditioning. In addition, we 
present evidence that, prior to the index ischaemic period, the transient (low-conductance) 
opening of the mPTP may paradoxically, act as a mediator of preconditioning-induced 
protection, by acting as a mitochondrial channel for ROS release. The findings from this study 
suggest a dual role for the mPTP in the setting of myocardial protection, and importantly, 
suggest that myocardial preconditioning can protect the heart by modifying crucial events which 
take place during the first few minutes of reperfusion.
9.2 Clinical Implications
A significant finding from this study, is that the powerful cardio-protective phenomenon that is 
myocardial preconditioning appears to protect the heart by modifying events which occurs 
during the first few minutes of post-ischaemic reperfusion. In this thesis, we have provided 
evidence that preconditioning protects the heart by inhibiting the mPTP opening which occurs 
during the first few minutes of reperfusion. In addition, preconditioning activates cellular innate 
pro-survival mechanisms, such as thePI3K-Akt and MEK1/2-Erk1/2 kinase cascades, during 
the first few minutes of reperfusion. Therefore, the first few minutes of reperfusion offer a 
potential target for cardio-protection which would be under the control of the operator and from 
the findings of this thesis, targeting the mPTP opening which occurs at the time of reperfusion, 
can offer protection that is comparable to myocardial preconditioning.
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Targeting mPTP Opening at the Time of Reperfusion
Importantly, we demonstrated that the opening of the mPTP during the first few minutes of 
reperfusion was a major determinant of lethal reperfusion injury and was responsible for up to 
50% of the infarct size sustained following an episode of lethal ischaemia. We demonstrated 
that inhibiting mPTP opening during the first few minutes of reperfusion, by either administering 
pharmacological mPTP inhibitors or by preconditioning the myocardium produced significant 
protection.
Suitable pharmacological agents need to be developed which specifically inhibit the 
mPTP opening, that are safe and can achieve therapeutic levels rapidly, for use at the time of 
reperfusion, in the clinical settings of ischaemia-reperfusion injury, such as at the time of 
reperfusion (by either thrombolysis or primary PTCA) following an acute myocardial infarction 
and at the time of cardiac surgery. However, the drug would have to be administered as an 
adjunct to the reperfusion treatment strategy to be effective, as we have demonstrated in this 
thesis, that targeting the first few minutes of post-ischaemic reperfusion is critical to protection. 
Pharmacological agents we have used in this thesis to inhibit mPTP opening such as 
cyclosporin-A, which is used clinically as an immunosuppressant following transplant surgery, 
can p roduce s erious s ide effects, a nd i n a ddition t he u se of t his agent r equires 2 -3 d ays to 
achieve steady state serum levels. Therefore, the local intra-coronary delivery of a small 
concentration of CsA, at the time of primary angioplasty for an AMI, may provide a potential 
approach for harnessing the protection gained from inhibiting mPTP opening at the time of 
reperfusion. An alternative approach would be to administer pharmacological agents, which are 
safe for clinical use, and have been demonstrated to activate the cells own pro-survival 
pathways.
Targeting the Pro-Survival Kinase Pathway at the Time of Reperfusion
The findings from this thesis suggest that ischaemic preconditioning protects the heart by 
activating the pro-survival kinase pathways, PI3K-Akt and MEK1/2-Erk1/2 during the first few 
minutes of reperfusion. We also provided preliminary data suggesting that these kinase 
cascades m ay p rotect a 11 he t ime o f r eperfusion b y inhibiting m PTP o pening. Therefore, t he 
cardio-protective benefits of inhibiting mPTP opening during the first few minutes of reperfusion 
may be achieved by administering pharmacological agents which activate these pro-survival 
kinase pathways, termed the Reperfusion Injury Salvage Kinase (RISK)-Pathway. Suitable
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pharmacological agents, which have been demonstrated to activate these kinase cascades, that 
could be administered during the first few minutes of reperfusion, as an adjunct to current 
reperfusion therapy are, H MG-CoA reductase i nhibitors,(522) ACE-inhibitors,(524) insulin(530) or 
several other growth factors.(519) These agents may provide a potential approach to salvaging 
viable myocardium and limiting infarct size in patients presenting with an acute myocardial 
infarction.
Despite clinical studies reporting benefit from the early administration of HMG-CoA 
reductase inhibitors following an acute myocardial infarction,(910;9i1) as yet no study has been 
undertaken which examines whether these drugs offer cardio-protection when given during the 
first few minutes of reperfusion following an acute myocardial infarction, as an adjunct to 
thrombolysis or primary PTCA.
It would be interesting to speculate whether the benefits reported in the clinical trials 
(such as the DIGAMI(620) and ECLA(621) and other trials(622)), reporting benefits from the 
treatment of glucose, insulin and potassium (GIK) therapy at the time of reperfusion, following 
an acute myocardial infarction, were due to inhibition of mPTP opening. Already, a large 
randomised control clinical study (named GIK II) is underway, examining the benefits of glucose 
insulin therapy (GIK) given at time of reperfusion in patients presenting with an acute 
myocardial infarction.(626)
Recent studies have shown that fluoroscopic-guided intramyocardial injection in the pig 
model is a feasible and safe procedure for targeting the delivery of therapeutic agents to the 
area of myocardium at risk from ischaemia-reperfusion injury.(912) Therefore the local delivery of 
growth factors themselves or the adenoviral vectors (carrying mutated genes which over­
express growth factors) may provide a potential method for targeting and up-regulating the 
RISK-pathway in the clinical setting of reperfusion. Alternatively for patients undergoing an 
anticipated episode of ischaemia-reperfusion injury, such as during CABG surgery or elective 
coronary angioplasty, gene transfer may be a possible method of delivering growth factors to 
myocardium at risk of lethal reperfusion-induced injury.
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9.3 Future Directions
Chapter 9: Conclusion
The mPTP as a Mediator of Lethal Reperfusion Injury
We have demonstrated that the opening of the mPTP during the first few minutes of reperfusion 
is a critical determinant of cell death and that inhibiting its opening offers a powerful target for 
myocardial protection. Further experimental studies are required to investigate newer classes of 
drugs which inhibit mPTP opening and which can be demonstrated to offer protection against 
lethal reperfusion injury by inhibiting mPTP opening. In this regard, the new class of m PTP 
inhibitors,(682) which appear to interact and inhibit mPTP opening by targeting the VDAC, a 
presumed outer membrane component of the mPTP, may provide a potential approach.
Furthermore, it would be interesting to determine whether other interventions which 
have been demonstrated to protect the heart against lethal reperfusion injury, when applied 
solely at reperfusion, such as the phenomenon of ‘ischaemic post-conditioning’ or the opening 
of the mitochondrial K Atp  channel, do so by inhibiting mPTP opening.
The mPTP as a Target for Cardio-Protection in Myocardial Preconditioning 
In this thesis, we have demonstrated that inhibiting mPTP opening at the time of reperfusion, is 
critical to the protection induced by both ischaemic and pharmacological preconditioning. 
Further studies are required to elucidate the mechanisms that mediate the inhibition of mPTP 
opening, especially in light of previous studies which suggest that certain components of 
preconditioning such as PKC can interact with and inhibit mPTP opening directly.(881) However, 
most evidence would support the proposition that the inhibition of mPTP opening is due to the 
beneficial effects on mitochondrial function (such as mitochondrial Ca2+ load, mitochondrial 
energy production, and reduced production of oxidative stress) which are induced by a 
preconditioning stimulus, and these factors then act in concert to reduce the opening probability 
of the mPTP at the time of reperfusion.
The Pro-Survival Kinases as a Target for Cardio-Protection in Myocardial Preconditioning 
It would be both important to demonstrate that agents which protect at reperfusion by activating 
the pro-survival kinases (such as insulin,(53°) HMG-CoA reductase inhibitors(522) and ACE- 
inhibitors(524)), PI3K-Akt and MEK1/2-Erk1/2 actually protect the heart against lethal reperfusion
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injury by inhibiting the mPTP opening during the first few minutes of reperfusion. Our 
preliminary data (chapter 6) demonstrated that insulin (which activates the PI3K-Akt kinase 
cascades) can protect myocytes against oxidative stress (a major determinant of lethal 
reperfusion injury), by inhibiting the mPTP opening.
The mPTP as a Mediator for Cardio-Protection in Myocardial Preconditioning 
The findings that the mPTP can act as a mediator of preconditioning-induced protection prior to 
the index ischaemic episode (chapter 7), underscores the importance of modulating 
mitochondrial function in preconditioning-induced protection. Further work is required to 
determine the contribution of transient (low-conductance) mPTP opening to preconditioning- 
induced protection, and to confirm the role of this form of mPTP opening in mediating the 
mitochondrial release of ROS, in response to a preconditioning stimulus.
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